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PRELIMINARIES  
Abstract  
 
The aim of this PhD thesis was to produce research that could inform and benefit clinical 
practice by exploring the application of basic science and clinical research methodologies to 
disorders in obstetrics and gynaecology. Chapter 1’s investigation of endometriosis is the 
first to 1) report detailed genetic mapping of endometriosis-associated ovarian cancer, 2) 
report the existence of micro-LOH (loss of heterozygosity)  in ovarian endometriosis through 
a SNP 100K DNA array. Chapter 2 explores the efficacy of interventions to treat menstrual 
abnormalities using clinical cohort studies.  Furthermore, Chapter 2 highlights how 
negligence in female sterilization failure may be mathematically (Bayesian) modelled. 
Chapter 3 explores the value of systematic reviews for preventing preterm delivery and use 
of LNG-IUS (Mirena coil). The clinical guidelines published in Chapter 4 include: vaginal 
birth after previous caesarean, ectopic pregnancy, safe laparoscopic entry and minimising risk 
of sterilisation failure. The thesis concludes (Chapter 5) by suggesting strategies to augment 
the research methodological approaches evaluated in this thesis in order fulfill the aim of 
benefitting clinical practice. Work included in this PhD thesis has been orally presented at 
international conferences, published in peer-reviewed journals, and published as a national 
clinical guideline by the Royal College of Obstetricians and Gynaecologists, UK (RCOG). 
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Introduction to Thesis 
 
Clinical research, although a commonly used term, is actually difficult to achieve a 
consensus definition for. A definition stated by Department of Health (United Kingdom) is 
that research is ―the attempt to derive generalisable new knowledge by addressing clearly 
defined questions with systematic and rigorous methods‖. This definition includes studies that 
aim to generate hypotheses as well as studies that aim to test them 
1
 . The Medical Research 
Council (United Kingdom) aims to support research that is aimed at ― maintaining and 
improving human health” 2; a commitment endorsed by all other research funding bodies, 
professional medical colleges and National Health Service (UK).  
There are numerous basic science and clinical research methodologies employed in clinical 
research. I suggest that these may be depicted as components of a ‗research pyramid‘ (Figure 
A).  For research to ultimately translate to clinical benefit, there needs to be ascension of the 
pyramid to its peak through appropriate selection of the ‗next level‖ research methodology. 
The graphical depiction is useful as it highlights methodologies existing within the context  of 
a particular level that corresponds to the level of evidence that is considered during guideline 
development (Table A).  Furthermore, the pyramid shape mirrors the typical frequency of 
publications on disease, with several existing at the base, and fewer identified as the pyramid 
is ascended. 
 
Multiple components are necessary to ensure that research is relevant, effective, efficient, 
ethical, and will ultimately translate to health gain.  The aim of this PhD thesis was to 
produce research that could inform and benefit clinical practice. The chapters have been 
ordered to follow a stepwise ascension of the research methodology pyramid (Figure A). 
Introduction to Thesis 
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Each chapter illustrates the use of a specific research methodology by considering selected 
disorders in obstetrics and gynaecology.  In Chapter 1, the thesis explores the molecular 
aetiology of endometriosis and tests whether it behaves as a neoplastic precursor to ovarian 
cancer. Maintaining a gynaecological theme, Chapter 2 explores the efficacy and 
effectiveness of interventions to treat menstrual abnormalities using clinical cohort studies; 
this work also led to the production of a RCOG educational module for specialist trainees in 
abnormal uterine bleeding 
3
.  Furthermore, Chapter 2 highlights how rare outcome measures, 
such as failed sterilisation, may be adequately explored using cohort study design and 
Bayesian mathematical modelling. Chapter 3 explores the clinical value and potential 
drawbacks of systematic review by assessing screening-preventative interventions to reduce 
the risk of preterm delivery.  In addition, the chapter includes a systematic review of the non-
contraceptive uses of Levonorgestrel-releasing hormone system. The publications of the 
clinical guidelines in Chapter 4 are likely to have immediate and maximal benefit on clinical 
practice. The production of clinical guidelines adopted a structured approach and considered 
all levels of research evidence, not just systematic reviews or RCTs, to generate 
recommendations for best medical practice. The guidelines included: vaginal birth after 
previous caesarean (RCOG national guideline), ectopic pregnancy (BMJ Clinical evidence), 
safe gynaecological laparoscopic entry, and minimising the risk of sterilisation failure.  The 
thesis concludes (Chapter 5) by summarising the benefits to clinical practice for each 
research methodology. The chapter also suggests future research themes that may augment 
the research methodological approaches evaluated in this thesis in order to benefit clinical 
practice. 
Introduction to Thesis 
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Table A Classification of evidence used by RCOG guideline development 
Classification of Evidence Levels  
Ia Evidence obtained from meta-analysis of randomised controlled trials.  
Ib Evidence obtained from at least one randomised controlled trial.  
IIa Evidence obtained from at least one well-designed controlled study without 
randomisation.  
IIb Evidence obtained from at least one other type of well-designed quasi-experimental study.  
III Evidence obtained from well-designed non-experimental descriptive studies, such as 
comparative studies, correlation studies and case studies.  
IV Evidence obtained from expert committee reports or opinions and/or clinical experience of 
respected authorities.  
Grades of Recommendations  
 
Requires at least one randomised controlled trial as part of a body of literature of 
overall good quality and consistency addressing the specific recommendation. 
(Evidence levels Ia, Ib) 
 
Requires the availability of well controlled clinical studies but no randomised 
clinical trials on the topic of recommendations. (Evidence levels IIa, IIb, III) 
 
Requires evidence obtained from expert committee reports or opinions and/or 
clinical experiences of respected authorities. Indicates an absence of directly 
applicable clinical studies of good quality. (Evidence level IV) 
Good Practice Point    
 
Recommended best practice based on the clinical experience of the guideline  
development group 
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Figure A. Ascension of research pyramid 
Audit
Clinical 
Guidelines
Systematic 
reviews & RCTs
Cohort studies
Descriptive studies 
Elucidating aetiopathogenesis
molecular  in vitro &  in vivo models
Molecular & epidemiological associations
 
Footnotes 
RCT randomised controlled clinical trials 
Audit refers to clinical audit to assess impact of clinical guidelines 
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CHAPTER 1: INVESTIGATING THE GENETIC AND MOLECULAR 
AETIOLOGY OF ENDOMETRIOSIS 
 
Introduction 
 
Endometriosis is a gynaecological disorder affecting 10-15% of women of reproductive age. 
The condition often presents with infertility and pelvic pain, causing significant impairment 
of quality of life.  The precise aetiology of endometriosis is unclear, but is considered to 
involve multiple genetic, environmental, immunological, angiogenic and endocrine 
processes. Although endometriosis is a benign disorder, recent studies suggest endometriosis 
could be viewed as a neoplastic process. This chapter presents a basic science investigation of 
the genetic and molecular aetiology of endometriosis. The similarities between endometriosis 
and neoplasia have been used to investigate endometriosis using techniques normally applied 
in cancer biology. Initially, the chapter presents the epidemiological, genetic and molecular 
evidence that justifies the rationale for using a cancer biology model to study endometriosis. 
Thereafter, the chapter discusses various genetic and immunohistochemistry techniques used 
in the investigation. Traditional approaches (such as microsatellite genetic marker genetic 
mapping) are contrasted with newer technologies (laser capture microdissection and 
Affymetrix SNP 100K DNA microarray). The aim was to identify the key genes involved in 
the initiation, proliferation and malignant transformation of endometriosis to enable 
development of improved screening-preventative therapies for both endometriosis and 
ovarian cancer.
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1.1: Exploring the hypothesis that endometriosis is a neoplastic precursor 
to ovarian cancer 
 
Introduction 
Endometriosis is defined as the implantation of endometrium-like glandular and stromal cells 
outside their normal location in the uterus. Endometriotic lesions are usually identified at 
laparoscopy localised to ovaries and the Pouch of Douglas (Figure 1.1). Endometriosis is 
diagnosed in 30% of cases referred for infertility investigation 
1
 and in 10%-70% of women 
with pelvic pain 
1
 . Overall, studies estimate that endometriosis may affect around 7-15% of 
women of reproductive age, thus making this a common condition. 
Endometriosis has been considered a ‗disease‘ because it is often identified when 
investigating women with infertility, pelvic pain, dyspareunia (pain on intercourse) and 
dysmenorrhoea (painful periods). Traditionally the classification of endometriosis has been 
made by anatomical (surgical staging by revised American Fertility Society score) and 
histopathological (atypical and non-atypical endometriosis) criteria 
2
. However, this 
combined approach of classification does not correlate closely with pelvic pain or 
reproductive outcome, and is prone to inter-observer error. Furthermore, the emphasis of 
targeting the endometriotic lesion, by surgical removal or hypo-oestrogenic inactivation, does 
not necessarily correct the aberrant underlying molecular mechanism(s). This explains why 
current endometriosis treatment does not alleviate clinical symptoms in all cases, and 
recurrence is common 
3
.  
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Figure 1.1. Image of an endometriotic lesion surrounded by adhesions  
 
These disparities suggest that endometriosis may not be a true ‗disease‘ but a heterogeneous 
entity with differing subtypes. One subtype may be capable of causing symptomatic disease 
directly consequent to endometriotic pathology (e.g. ovarian endometriomas, pelvic 
adhesions), whereas, another subtype, may be associated with symptoms without obvious 
endometriotic-lesion basis.  Another subtype may be clinically asymptomatic and its presence 
be considered a normal ‗non-pathogenic‘ phenomena. Consequently the current focus on 
treating the endometriotic lesion should be reconsidered, and efforts to understand the 
pathogenesis of endometriosis, and its temporo-spatial relationship to symptomology, should 
be increased. 
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Traditionally, endometriosis research has focused on the lesion itself and comparing 
molecular processes between ectopic and eutopic endometrium
4
. This has identified multiple 
anomalies in genetic, environment, angiogenic, endocrine, metabolic, and immunological 
mechanisms. Some of these correlate with the severity of endometriosis and/or associated 
clinical sequelae implying a causative rather than simply associative role. However, the major 
obstacle has been the difficulty in discriminating between processes fundamental to 
endometriosis aetiopathogenesis and epiphenomena. Importantly, these physiological 
differences are multi-compartment (endometrium, peritoneal fluid, follicular fluid and blood) 
and not just localised to the site of the endometriotic lesion, implying a fundamental 
widespread alteration in reproductive tract function. This multifactorial multi-compartment 
pathogenesis, coupled with the clinical heterogeneity, has created a confusion of data, with 
little consensus on a unifying mechanism. Nevertheless, since Sampson first reported in 
1925
5
 that endometriosis may give rise to malignant change, and proposed criteria for 
diagnosis of malignancy arising in endometriosis, extensive evidence for an association 
between endometriosis and cancer (especially ovarian) has now accumulated.  
 
Aim To evaluate the hypothesis that endometriosis is a neoplastic precursor to the 
development of ovarian cancer based on systematic literature search and critical appraisal of 
clinical and basic science data  
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Methods All observational and experimental studies examining the relationship between 
endometriosis and ovarian cancer were retrieved from MEDLINE (1966-2004) and EMBASE 
(1980-2004) medical databases using combination of specific keywords and MeSH terms. 
The following search terms and word variants were used: ‗endometriosis‘, ‗endometriotic‘, or 
‗endometrio$‘ combined with ―AND‖ to ‗ovarian neoplasms‘, ‗neoplasms‘, ‗carcinoma‘ 
‗genital neoplasms, female‘, ‗carcinogens‘, ‗carcinogen$‘, ‗carcinogens, enivronmental‘, 
‗tumo$‘, ‗malignan$‘, ‗cancer$‘, or ‗neoplas$‘. In addition, bibliographies of retrieved 
articles were examined to identify further relevant studies. The search was completed in April 
2004. At the time of submission of this PhD thesis, a further search of the medical databases 
was performed and specific key articles have been included where they substantially alter the 
evidence-base. The hypothesis was examined by examining by considering the following 
methodological approaches: 
A. Clinico-pathological epidemiological data 
B. Genetic and molecular data of endometriosis and cancer. In particular, considering 
how endometriosis demonstrates a molecular cancer phenotype according to 
Hanahan’s  ‘Hallmarks of Cancer6‘ criteria for a cancer cell [defined as seven 
critical features of the cancer phenotype (Tables 1.1 and 1.2)] 
C. Testing association vs. causality of endometriosis and cancer using Bradford-Hill 
(1965) epidemiological causality criteria
7
 (Table 1.3). 
D. Summary of the published evidence that supports or refutes the hypothesis that 
endometriosis is a neoplastic precursor to the development of ovarian cancer. 
 Chapter 1.1. Hypothesis that endometriosis is a neoplastic precursor to ovarian cancer 
 12 
Table 1.1 Hanahan’s criteria of properties exhibited by a cancer cell: ‘the hallmarks of 
cancer’ 6 
1 Self-sufficiency in growth 
signals 
Mitotic growth signals are needed for cells to move from a quiescent 
state into active proliferative state. These signals are transmitted into 
the cell by transmembrane cell-surface receptors that bind to: 
diffusible growth factors, ECM components, cell-to-cell adhesion 
interaction molecules 
2 Insensitivity to 
antiproliferative signals 
Growth inhibitory signals (soluble or immobilized in ECM and on 
surfaces of nearby cells) are received by transmembrane cell-surface 
receptors coupled to intracellular signaling circuits 
3 Resistance to Apoptosis Evasion mechanisms of programmed cell death 
4 Limitless replicative 
potential 
Disruption of intrinsic cell-autonomous program that limits their 
multiplication. This program operates independently of the cell-to-cell 
signaling pathways described above 
5 Sustained angiogenesis Virtually all cells in a tissue are obligated to reside within 100um of a 
capillary blood vessel to allow adequate permeation of oxygen and 
nutrients crucial for cell survival The cells within aberrant 
proliferative lesions initially lack angiogenic ability, but in order to 
progress, incipient neoplasias must develop angiogenic ability 
6 Tissue invasion and 
metastasis 
This enables cancer cells to escape the primary tumour mass and 
colonise new sites where, at least initially, nutrients and space are not 
limited 
7 Genomic instability Mutations or inactivation/activation of tumour suppressor genes, 
oncogenes, DNA monitoring and repair enzymes, checkpoint systems 
at mitosis. These are carried out by intragene (e.g. mutation, deletion) 
and epigenetic (e.g. promoter hypermethylation) mechanisms 
Footnotes 
The listed capabilities are mostly acquired directly, or indirectly, through changes in the 
genomes of cancer cells. 
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Table 1.2 How endometriosis displays the ‘Hallmarks  of cancer’6 
Hallmarks of cancer How endometriosis demonstrates the signified hallmark 
1 Self-sufficiency in 
growth signals 
Increased local production of estrogen and responsiveness to estrogen
8
 
Inherited genetic polymorphisms in drug-metabolizing enzymes (CYP1A1, 
CYP19, and GSTM1) which predispose to endometriosis
9
 and ovarian 
endometrioid and clear cell cancer
10
 
2 Insensitivity to 
antiproliferative 
signals 
Expression of the inhibitory progesterone receptor isoform PR-A instead of the 
stimulatory isoform PR-B 
11
 
Altered expression of p27Kip1 protein (cdk inhibitor) in active and inactive 
endometriotic lesion, and increased p21 expression in endometriomas compared 
with benign and malignant ovarian tumours 
12;13
 
3 Resistance to 
Apoptosis 
Elevated soluble Fas ligand and IL-8 in endometriotic peritoneal fluid.
14
 
Germline and somatically acquired inactivating mutations of p53 gene 
15;16
 
Up-regulation of survivin, matrix metalloproteinases, and bcl-2, and decreased 
BAX 
17-19
 
4 Limitless 
replicative 
potential 
No studies examining telomerase function in endometriosis, but it is noted 
estrogen and progesterone stimulate, whilst tamoxifen and wild-type (normal 
variant) p53 inhibit, telomerase activity in estrogen dependent neoplasms (breast 
and endometrial cancer cells) 
20;21
 which endometriosis represents. 
 
5 Sustained 
angiogenesis 
Pathological angiogenesis, immune cell suppression and immune cell activation 
co-exist in endometriosis
22
 and cancer processes
23
. Mediators of angiogenesis 
exhibit genetic polymorphisms that either predispose to endometriosis (e.g. 
ICAM-1, IL-6 and IL-10 gene promoters)
24-26
 or ovarian cancer (e.g. IL-6, MMP-
1, integrin beta3, TGFBR1 ,IL-1R antagonist)
27-31
 
6 Tissue invasion 
and metastasis 
Endometriosis exhibits invasiveness that is mediated through de-regulation of 
similar cell adherence signaling (such as integrins, beta-catenin, cadherins and 
matrix metalloproteinases
17-19;32-34
 to cancer. Beta catenin mutations occur in 
endometrial and ovarian endometrioid cancers 
35;36
 but have not been investigated 
for in endometriosis. 
7 Genomic instability Like cancer, endometriosis is monoclonal
37
 and shows allelic imbalance
38
. 
Mutations of tumour suppressor genes occur in endometriosis
39;40
, which are in 
some cases similar to those ovarian cancers arising directly from the 
endometriosis
41
. 
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Table 1.3  Criteria and fulfillment of Bradford Hill criteria
7
 of causality for 
endometriosis and ovarian cancer 
 
Liste
d 
factor 
 
Causality criteria 
Comments 
 
Strength of supporting 
evidence identified by 
this review 
1 Temporal sequence Did exposure precede outcome? 
 
Weak 
2 Strength of association  How strong is the effect, measured as relative 
risk or odds ratio? 
 
Moderate 
3 Consistency of 
association 
Has the effect been seen by others? 
 
Strong 
4 Biological gradient  
 
Does increased exposure result in more of the 
outcome (dose-dependency)? 
 
None 
5 Specificity of 
association 
Does exposure lead only to outcome? 
 
Weak 
6 Biological plausibility Does the association make pathophysiological 
sense? 
 
Moderate 
7 Coherence with 
existing knowledge 
 
Is the association consistent with available 
evidence? 
Weak 
8 Experimental evidence Has a randomized controlled trial been done? 
 
Human-Weak 
Animal-Strong 
 
9 Analogy Is the association similar to others? 
 
Weak 
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 A) Clinico-pathological AND epidemiological data 
 
1.Histopathology. Like malignancy, endometriosis displays features of atypia, adherence, 
invasion and metastases. Atypical endometriosis is characterized histologically by 
endometrial glands with cytological or architectural atypia 
42
, and has been observed in 12%- 
35% of ovarian endometriosis 
43-45
. Around 60%-80% of cases of endometriosis-associated 
ovarian cancer (EAOC) occur in the presence of atypical ovarian endometriosis
46-48
. Of these 
cases, 25% showed direct continuity of the atypical ovarian endometriosis with ovarian 
cancer
49
 , underlying a potential ‗premalignant‘ transition spectrum of non-atypical to 
atypical and malignant variants. 
 
2. Nuclear morphometry This involves a structured histological approach to grading mitotic 
activity using nuclear size and pleomorphism.  Morphometric analysis of cancer has been 
shown to correlate to clinical prognosis 
50;51
. There is published data on nuclear 
morphometric analysis of endometriosis (and related adenomyosis), albeit most limited to 
mainly non-prognostic correlations
52-61
.  Morphometric analysis of non-atypical 
endometriosis showed no difference between active (red lesions) and inactive (black or white 
lesions) lesions; it is yet to be studied in atypical endometriosis
62
 . Nonetheless, mild 
cytological atypia in the glandular epithelium of endometriotic cysts has been associated with 
normal DNA diploid patterns, whereas severe atypia may be associated with aneuploidy
63
 . 
Furthermore, the existence of morphometric differences between  peritoneal, ovarian and 
rectovaginal endometriosis supports the earlier stated hypothesis that endometriosis at 
different anatomical locations are likely to be molecularly diverse entities
53;55;56
. 
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3.Ovarian malignancy may arise directly from ovarian endometriosis Around 60% of 
EAOC occurs with the cancer adjacent to endometriosis or arising directly from ovarian 
endometriosis, with the remaining 40% occurring with distant endometriotic disease 
64;65
. 
Clear cell and endometrioid carcinomas are the commonest EAOCs with ovarian 
endometriosis, while clear cell adenocarcinoma and adenosarcoma the commonest EAOCs in 
extraovarian endometriosis
66-70
. The risk of direct malignant transformation of ovarian 
endometriosis has been estimated as 0.7% to 1.6% over an average of eight years 
43;44
. 
Interestingly, there is a common unexplained left-sided predominance for endometriotic 
cysts, and ovarian endometrioid and clear-cell cancers
71
.
72
 
 
4. Increased risk of ovarian cancer in women with endometriosis, irrespective if 
endometriosis is distant or adjacent to ovarian tumour. The age standardised incidence of 
ovarian cancer in women in the UK is 21.9 per 100,000 (0.02%), with around 75% of cases 
diagnosed in postmenopausal women 
73
. If there were no association between cancer and 
endometriosis then the incidence of endometriosis in women with ovarian cancer would be 
similar to that in the general population. However, the incidence of endometriosis in women 
with ovarian cancer is 8%-30% 
46;74;75
. This compares to a background incidence of 
endometriosis of 7-15% in women of reproductive age, and less than 2% in postmenopausal 
women 
1
. This data correlates with the finding from a Swedish population study, where the 
risk of ovarian cancer was increased 4.2-fold (95% confidence interval 2.0 to 7.7) in the 
presence of endometriosis 
76
.  Furthermore, the histology of EAOC (40-55% clear cell , 20-
40% endometrioid and <10% serous and mucinous subtypes)
77-79
 differs considerably from 
that seen in all ovarian cancers (FIGO 1998 annual report 55% serous, 13% mucinous, 14% 
endometrioid, 6% clear cell) 
80
.  
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5.Increased risk of synchronous endometrial and ovarian cancers, especially 
endometrioid type, in presence of endometriosis. Simultaneously detected endometrial and 
ovarian carcinomas are most often associated with endometrioid subtypes, and ovarian 
endometriosis was identified in around 30% of these cases
68;70;81
. 
 
6.Clinical behavior and prognosis of endometriosis associated ovarian cancer (EAOC) 
differs from matched ovarian cancer subtypes not associated with endometriosis. EAOC 
compared to ovarian cancer without endometriosis presents at a less advanced stage, lower 
grade, predominantly endometrioid and clear cell type, and has a better overall survival 
82;83
. 
 
7.Increased risk of extra-ovarian cancers. Around 80% of intraperitoneal cancers 
associated with endometriosis relate to ovarian cancer, with the remainder extra-ovarian
84
.  A 
separate study showed an increased risk of extra-pelvic cancers (breast and non-Hodgkin‘s 
lymphoma) in women with endometriosis 
85
. 
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B) Genetic and molecular data  
 
These have been considered according the SEVEN listed criteria that a cancer cell possess 
according to Hanahan and Weinberg (2000)
6
 (Tables 1.1 and 1.2). 
1.Self-sufficiency in growth signals:  Like uterine and breast cancer, endometriosis behaves 
as an oestrogen dependent neoplasm. Endometriosis has specifically adapted to oestrogen-
induced signaling by: 
 Increased local production of oestrogen through increased expression of aromatase 
cytochrome P450 expression but deficient 17B-hydroxysteroid dehydrogenase (17B-
HSD) type 2 expression (which impairs inactivation of potent oestradiol E2 to less potent 
oestrone E1) 
86
. 
 Increased responsiveness to oestrogen. There is increased oestrogen receptor (ER-alpha) 
expression in active (red lesions) than inactive (black lesions) endometriosis 
87
.  
 Inherited genetic polymorphisms in oestrogen and progesterone receptors, which 
predispose to endometriosis
88;89
 
 Inherited genetic polymorphisms in drug-metabolizing enzymes (CYP1A1, CYP19, and 
GSTM1) which predispose to endometriosis
9;90-92
 and ovarian endometrioid and clear cell 
cancers 
93
. These alterations may induce endometriosis or cancer by altering a dioxin-
induced oestrogen growth signal. Dioxins have been shown to induce endometriosis-like 
and oestrogen-dependent tumours in animal models 
94
. Of importance, there is a doubled 
risk of developing endometriosis amongst women with high serum dioxin levels 
95
 . 
Activation of oestrogen receptors in endometriosis may occur indirectly through 
upregulated CYP1A1 activity, which causes increased aromatase P450 and oestrogen 
production 
96
, or directly by dioxin activated aryl hydrocarbon receptor 
97
.  
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Other growth factors, such as transforming growth factor alpha (TGF-alpha) and insulin-like 
growth factor-1 (IGF-1) have also been implicated in endometriosis and cancer 
development
98
. IGF-1 signaling is required for cell cycle progression and appears to be a pre-
requisite for malignant transformation and implantation. A higher risk for cervical, ovarian 
and endometrial cancer is related to high IGF-1 levels in post- and premenopausal women. 
Plasma IGF-1 levels are higher in cases of severe endometriosis; however, in endometriosis 
IGF-1 levels locally in the endometrium are reduced 
99
. 
 
2.Insensitivity to antiproliferative signals 
Cell division relies on the activation of Cyclins (e.g. Cyclin D1), which bind to cyclin-
dependent kinases (cdk) to induce cell-cycle progression towards S phase and later to initiate 
mitosis. Since uncontrolled cdk activity is often the cause of human cancer, their function is 
tightly regulated by cdk inhibitors (e.g. p21 and p27 Cip/Kip proteins). For example, 
increased expression of Cyclin D1 and cdk occurs in breast cancer and is associated with 
poor outcome.  At the cellular level, differences in expression of p27Kip1 protein (cdk 
inhibitor) in active and inactive endometriotic lesions
13
, coupled with increased p21 
expression in endometriomas compared with benign and malignant ovarian tumours 
12
, 
suggests a role for increased cyclin-dependent kinase activity through reduced cell-cycle 
inhibitor activity; which is an imbalance frequently seen in cancer.  At the tissue level, 
endometriosis may resist the anti-proliferative effect of progesterone by the predominant 
expression of the inhibitory progesterone receptor isoform PR-A instead of the stimulatory 
isoform PR-B 
11
.  
3.Resistance to Apoptosis 
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Malignancy commonly displays overexpression of anti-apoptotic (Bcl-2), under-expression 
of pro-apoptotic (BAX) factors, and inactivation of p53 gene (p53 is a tumour suppressor 
gene whose protein is pro-apoptotic) through mutation. Similarly, endometriotic lesions have 
also evolved strategies to evade apoptosis by: 
 Increased bcl-2, and decreased BAX100. 
 Up-regulation of survivin and matrix metalloproteinases (MMPs)17-19. 
 Elevated soluble Fas ligand and IL-8 in endometriotic peritoneal fluid. The increased 
FasL expression by IL-8 may induce apoptosis of T lymphocytes and thus enable 
endometriosis to evade immune mediated cell death
14
. 
 Germline 16 and somatically acquired 101 inactivating mutations of p53 gene. 
 
4.Limitless replicative potential 
With each replicative cycle, telomeres (repetitive DNA sequences capping each 
chromosome) become progressively shorter, eventually resulting in cell senescence and cell 
death. Tumours commonly express the enzyme telomerase, which protects the telomeres 
from shortening and thus preventing ‗cell ageing‘. Oestrogen and progesterone stimulate, 
whilst tamoxifen and wild-type (normal variant) p53 inhibit, telomerase activity in breast and 
endometrial cancer cells
20;21
. Although there are no published studies examining telomerase 
function in endometriosis, it is notable that oestrogen dependent neoplasms are potentially 
susceptible to telomerase control. 
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5.Sustained angiogenesis 
Pathological angiogenesis, immune cell suppression and immune cell activation co-exist in 
endometriosis and cancer processes 
22;23
. Genetically transmitted or environmentally induced 
(e.g. exposure to dioxins) alterations in the angiogenic and/or immune response may 
predispose women to the ectopic implantation of endometrial cells, transported into the 
peritoneal cavity by retrograde menstruation which thereby lead to endometriosis. 
Significantly, both cancer and endometriosis share some of the mediators implicated in this 
‗inflammatory angiogenesis‘ model. Furthermore, the genes of these mediators exhibit 
genetic polymorphisms that either predispose to endometriosis (e.g. ICAM-1, IL-6 and IL-10 
gene promoters) 
102-104
 or cancer (e.g. IL6, IL8, TNF-alpha, NFKB1, and PPAR-gamma 
genes) 
105-109
. 
 
Anti-angiogenic therapy involves the inhibition of pro-angiogenic factors (e.g. anti-vascular 
endothelial growth factor VEGF monoclonal antibodies) or activation of endogenous 
inhibitors of angiogenesis (e.g. endostatin and angiostatin). Pre-clinical studies have shown 
that endostatin effectively inhibits tumor growth and shrinks existing tumor blood vessels. 
Phase 1 clinical cancer trials of endostatin and angiostatin are ongoing, and preliminary 
results show minimal toxicities. Similarly, anti-angiogenic strategies for treating 
endometriosis exist, but are still at the experimental phase
110
.  Soluble truncated receptor (flt-
1) and an affinity-purified antibody to human VEGF-A, significantly inhibited the growth of 
endometrial explants in a mouse in vivo model of endometriosis by disrupting the vascular 
supply. Gene transfection (using a replication-deficient adenovirus vector Ad-Angiostatin) of 
the endogenous angiogenesis inhibitor angiostatin to the peritoneum of a mouse was 
successful in treating a mouse in vivo model of endometriosis
111
. 
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6.Tissue invasion and metastasis  
The ability to invade through the basement membranes characterizes the transition from non-
invasive to invasive cancer. Tumours secret proteases (e.g. matrix metalloproteinases MMPs) 
to degrade the basement membrane and surrounding stroma. Expression of MMP-2 and 
MMP-9 is correlated to grade and stage of many cancers. Likewise, MMP activity is 
upregulated in endometriotic lesions 
112
. De-regulation of cell adherence signaling involving 
integrins, beta-catenin, E-Cadherin and P-Cadherin has been demonstrated in the genesis of a 
number of malignancies
113
, and has also been implicated in endometriosis aetiopathogenesis 
32;33;114
. Beta-catenin mutations have been identified in endometrial and ovarian endometrioid 
cancers
35;36
but have not been invesitgated in endometriosis. Cytokeratin-positive and E-
Cadherin-negative endometriotic cells have an invasive phenotype in an in vitro collagen 
invasion assay similar to metastatic carcinoma cells 
115
. 
7.Genomic Instability  
The classical model of malignant transformation of the cell involves the stepwise acquisition 
of multiple genetic alterations, which confers a clonal selective advantage at each step 
predisposing to the next step (Fearon and Vogelstein 
116;117
, Figure 1.2). This is often 
accompanied by activation of proto-oncogenes to oncogenes (transformation of normal 
cellular growth, proliferation and differentiation genes) and inactivation of tumour suppressor 
genes (TSG) (genes that encode for proteins which inhibit excess cellular proliferation and 
malignant transformation). The genetic alterations can occur at different levels and include 
single nucleotides, small stretches of DNA [microsatellites], whole genes, chromosomal 
components or whole chromosomes. The genetic alterations can be intragene or epigenetic 
(e.g. gene silencing by promoter hypermethylation).  
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Figure 1.2, Acquired stepwise genetic somatic mutations that predispose to development 
of cancer (Fearon and Vogelstein 1990
116;117
) 
Stepwise genetic alterations create cancer
Genetic model of colorectal carcinogenesis 
[Fearon and Vogelstein (1990)] 
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Six principle genetic mechanisms have been identified to contribute to genomic instability 
in cancer, but only the first three have been examined for in endometriosis: 
 Gain in oncogenic activity.  
 Inactivation of TSG (loss of both gene copies of allele confers functional loss), or 
inactivation of haploinsufficient TSG (loss of only a single gene copy of allele confers 
functional loss) 
 Anomalies in DNA mismatch repair enzymes, identified by microsatellite instability 
 Inactivation of genes that monitor genomic instability at cell cycling (e.g. mitotic 
spindle assembly checkpoint genes) 
 Telomere dysfunction (provokes chromosomal aberrations initiating carcinogenesis) and 
telomerase-mediated telomere maintenance  (enables cells to achieve a fully malignant 
endpoint and metastasis).  
 Hypermethylation. These mechanisms often act in synergy to promote genomic 
instability and tumour cell proliferation. For example, deficiency of the TSG p53  alters 
the cellular response to DNA damage, in that it leaves cells with attenuated DNA damage 
checkpoint controls and a reduced propensity for apoptotic cell death. Thus, although the 
DNA repair capacity of these cells is reduced, survival is increased. This promotes 
genomic instability and contributes to the resistance of p53-deficient cells to cytotoxic 
agents.  
Importantly, pre-malignant lesions display similar genetic aberrations to established cancer. 
Loss of mismatch repair enzyme activity, and loss of PTEN (phosphatase and tensin homolog 
gene) and p53 TSGs frequently occurs in premalignant and malignant stages of breast, 
endometrial and ovarian carcinomas 
118;119
. Furthermore, epithelial-stromal interactions are 
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important in tumour microenvironment and tumour development. In a similar manner, 
endometriosis demonstrates somatically acquired genetic alterations analogous to those found 
in cancer, resulting in the clonal expansion of genetically abnormal cells. The genetic 
evidence supporting the ‗pre-neoplastic‘ state of endometriosis involves:  
 Monoclonality. Most neoplasms are monoclonal in origin and evidence for 
monoclonality of endometriosis has been demonstrated in several studies 
120-122
, although 
these findings have been challenged recently 
123
. 
 Comparative genomic hybridization (CGH) has shown over-representation (increased 
copy-number) of chromosomes 1, 2, 3, 5, 6p, 7, 16, 17q, 20, 21q and 22q in an 
endometriosis cell culture line FbEM-1, while chromosomes 5p, 6q, 9q, 11p, 12, 13q, 18 
and X were under-represented. CGH repeated in endometriotic tissue revealed loss of 
DNA copy number on 1p, 22q and chromosome X, while gain on 6p and 17q. FISH 
analysis confirmed that the gain at 17q includes amplification of the proto-oncogene 
HER-2/neu
124;125
. 
 Fluorescent in situ hybridization (FISH) analysis of late stage endometriotic lesions 
showed monosomy of chromosome 17, and loss of TP53 (17p13.1) locus. Because not all 
endometriotic cells displayed this genetic alteration it was suggested that this was a 
somatically acquired mutation, perhaps occurring in mainly advanced endometriosis 
states
126;127
.  
 Loss of heterozygosity (LOH) commonly indicates regions of TSG inactivation, and has 
been identified in endometriosis and endometriosis derived cell lines at 5q, 6q, 9p, 10q, 
11q, 22q, p16 (Ink4), GALT, p53, APOA2 
128-133
. Importantly, cases with ovarian cancer 
adjacent to endometriosis or arising from endometriosis showed common genetic LOH 
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alterations in endometriosis and cancer indicating a possible malignant genetic transition 
spectrum between endometriosis and cancer 
134;135
. 
 Microsatellite Instability (MSI) Hypermethylation of hMLH1 (gene product is a 
component of the DNA mismatch repair pathway), with concurrent absence of hMLH1 
protein expression, is noted in 8.6% of endometriotic lesions 
136
.  
 Somatic mutations in TSGs. Mutations of PTEN, a TSG, were identified in 20% of 
ovarian endometrioid carcinomas (EAOC and sporadic) and 20% of solitary endometrial
 
cysts, suggesting that inactivation of the PTEN is an early event in the malignant 
transformation of endometriotic implants
137
.   A separate study identified reduced PTEN 
protein expression in 15% of endometriosis cases 
136
.  
 Germline mutations in Tumour suppressor genes (TSGs). As stated earlier, germline 
and somatically acquired 
138
 inactivating mutations of p53 gene. 
 Activation of oncogene. Both human 139;140  and mouse model141 studies of endometrosis 
have shown that activation of the K-ras oncogene promotes the development of ovarian 
cancer, even though the mutation appears not be present in the adjacent endometriosis. 
 Evidence from endometriosis associated ovarian cancer (EAOC) arising from 
endometriosis. Endometrioid EAOC arising from endometriosis shows higher expression 
of p53 and c-erB-2 oncoproteins than similar ovarian endometrioid cancers without 
endometriosis 
142
. The different pattern of expression in the two groups suggests different 
molecular pathways and could explain variations in cancer subtype and prognosis 
between the two groups 
66;143
. 
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C)  Testing causality of endometriosis and ovarian cancer using Bradford Hill criteria 
 
Causality for aetiological factors is normally assessed using the following study designs: 
randomized controlled clinical trials (RCTs), cohort, case-control, cross-sectional analyses 
and biological models (in vivo, ex vivo, in vitro).  Studies would normally be subjected to 
critical analysis according to established causal inference methods, the most widely used 
being the criteria suggested by Austin Bradford Hill (1965) 
7
 and listed in Table 1.3. The 
strength of the causal relationship between endometriosis and ovarian cancer is assessed 
using such epidemiological causality criteria.  
 
1. Temporal sequence The natural history of the development and progression of 
endometriosis and ovarian carcinoma is not known. No studies have examined women with 
initially normal pelvices, who then develop endometriosis, and prospectively followed them 
with a control cohort to establish the relative risk of developing ovarian cancer; or the need 
for endometriosis as a pre-requisite that precedes the onset of ovarian cancer. However, 
indirect evidence exists that supports this concept. 
Cross sectional studies indicate that the peak age range for endometriosis diagnosis is 25-30 
years 
144
 and for sporadic ovarian cancer, the age range is 50-55 years
80
, thus fulfilling the 
criteria for temporal sequence. However, studies mainly reported estimates of incidence of 
symptomatic endometriosis and ovarian cancer diagnosis rather than their actual incidence of 
onset. There is little evidence to support that endometriosis onset necessarily coincides with 
symptom onset. Furthermore, delays in diagnosis may also exist. The time elapsed from onset 
of symptoms to diagnosis of endometriosis varies from 3-13 years for women mainly 
complaining of pelvic pain, and 2-6 years for infertility 
145;146
 .The time from symptom onset 
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to diagnosis in ovarian cancer is four to six weeks
147
, although the cancer is often at a 
significantly advanced stage at diagnosis. Thus, even taking into account the symptom free 
intervals before the diagnosis of endometriosis and ovarian cancer, the criteria for temporal 
sequence remains valid. One study retrospectively assessed ovarian cancer cases (n=573)  to 
investigate whether ovarian pathology had been identified 12 months previously
148
. This 
study showed that within this limited period approximately half of ovarian carcinomas 
developed secondarily from preexisting benign-appearing cysts or endometriotic cysts, and 
the remainder appeared to develop from an ovary of normal appearance. A case report has 
described the continuous transition from benign endometrioid epithelium through epithelial 
atypia to invasive ovarian carcinoma within a three year period 
149
, again suggesting 
causality. 
 
2. Strength of Association Strong associations imply causality, whereas weak 
associations are more likely to have arisen or been influenced by unsuspected bias. It has 
been suggested that relative risks more than 3 in cohort studies, or odds ratios greater than 4 
in case-control studies, provide strong support for causation
150
. Strong evidence to support 
this component of causality testing was identified by demonstrating:- 
 Increased prevalence of ovarian cancer in women with endometriosis  
Several studies have found an increased ovarian cancer incidence in women with 
endometriosis: the odds ratios range from 0.8 to 4.2 (studies are listed in Table 1.4). 
 Increased prevalence of endometriosis in women with ovarian cancer 
The age standardised incidence of ovarian cancer in women in the UK is 21.9 per 100,000 
(0.02%), with around 75% of cases being diagnosed in postmenopausal women 
73
. If there 
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were no association between cancer and endometriosis then the prevalence of endometriosis 
in women with ovarian cancer would be similar to that in the age-matched general 
population, and would be similar across all ovarian cancer subtypes. However, the prevalence 
of endometriosis is increased in women with ovarian cancer (7.7%-29%)
46;47;67;74;151-158
, in 
comparison to a background prevalence of endometriosis of 5%-15% in women of 
reproductive age and 3%-5% in postmenopausal women
144
 .  Furthermore, endometrioid and 
clear cell ovarian cancer subtypes are more likely in the presence of endometriosis than those 
ovarian cancers occurring in the absence of endometriosis: odds ratios range from 1.87 to 
5.36 for endometrioid, and range from 1.05 to 7.30 for clear cell subtypes, and these are 
shown in Table 1.5. This table also shows increased odds ratios for ‗mixed epithelial‘ and 
‗other types‘ of ovarian cancer, but these tumours are generally uncommon and contain 
mixed varieties of endometrioid, clear cell and adenosquamous cells; the significance of this 
association is unclear. Nonetheless, summarizing comparative and non-comparative studies 
46;152;153;155;156;158-161
, the prevalence of endometriosis for each ovarian cancer subtype is: 0-
8% of serous, 0-6% of mucinous, 8%-74% of clear cell, and 9%-43% of endometrioid 
subtypes.  
 
3. Consistency of association Since Sampson‘s first report in 1925 5, numerous reports 
have described cases of ovarian cancer arising from pre-existing endometriosis or associated 
with ovarian cancer. This observation is consistently repeated in different populations. 
Furthermore, all the studies depicted in Tables 1.4 and 1.5, apart from one, found consistent 
and similar increases in risk of ovarian cancer and distribution of histological subtypes, and 
thus further emphasizing the validity of this association.  
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Table 1.4. Risk of ovarian cancer and other types of cancer in women with 
endometriosis 
Type of study Risk of ovarian 
cancer 
in women with 
endometriosis 
Other cancers in women 
with endometriosis 
 
Reference and 
source of data 
Case control study 
Examining 28,163 
women with 
endometriosis 
OR 1.34  
(95% CL  1.03-1.75) 
Not reported 
162
 
Swedish Hospital 
Discharge Register 
Pooled analysis of 
eight case-control 
studies 
OR 1.73  
(95% CL 1.10-2.71) 
Not reported 
163
 
Studies from US, 
Canada, Australia, 
Denmark 
Cohort study of 
women with 
Self-reported 
endometriosis 
Up to 13 year 
follow up 
RR 0.8 
(95% CL 0.2-2.4) 
 
 
Non Hodgkin‘s 
lymphoma 
RR  1.8 (95% CL 1.0-3.0) 
 
 
164
 Iowa Women‘s 
Health Study 
 
 
Case control study 
examining 20,686 
women with 
endometriosis 
OR 1.9 
(95% CL 1.3-2.8) 
 
OR 4.2 
(95% CL 2.0-7.7) 
for long-standing 
endometriosis 
 
Non-Hodgkin‘s 
lymphoma  
OR 1.8 (95% CL 1.2-2.6) 
 
Breast 
OR 1.3 (95% CL 1.1-1.4) 
 
165
 
Swedish Inpatient 
Register and 
National Swedish 
Cancer Registry 
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Table 1.5. Prevalence of ovarian cancer in women with and without endometriosis  
Subtype of 
epithelial ovarian 
cancer 
Prevalence 
of ovarian cancers 
in association with 
endometriosis 
Prevalence of 
ovarian cancers 
in absence of 
endometriosis  
Odds Ratio 
With  
(95% confidence 
interval) 
Reference Pooled 
epidemiological 
studies of ovarian 
cancer
80
 
(prevalence of 
endometriosis not 
stated) 
Serous 32% (8/25) 
15% (8/52) 
11% (4/37) 
13% (6/48) 
7% (4/58) 
21% (3/14) 
57% (84/147) 
51% (212/414) 
62% (56/90) 
44% (57/131) 
52% (121/232) 
38% (56/146) 
0.35 (0.28-0.42) 
0.17 (0.14-0.21) 
0.07 (0.03-0.12) 
0.19 (0.13-0.24) 
0.07 (0.04-0.10) 
0.44 (0.36-0.52) 
166
 
156
 
46
 
74
 
66
* 
47
 
55% 
Mucinous 4% (1/25) 
11% (6/52) 
0% 
4% (2/48) 
2% (1/58) 
14% (2/14) 
23% (34/147) 
21% (88/414) 
19% (17/90) 
25% (33/131) 
11% (25/232) 
14% (21/146) 
0.14 (0.09-0.19) 
0.48 (0.44-0.53) 
- 
0.13 (0.08-0.18) 
0.15 (0.10-0.19) 
0.99 (0.98-1.01) 
166
 
156
 
46
 
74
  
66
* 
47
 
13% 
Mixed epithelial 0% 
22% (13/58) 
28% (4/14) 
0% 
5% (11/232) 
23% (33/146) 
- 
5.80 (5.2-6.41) 
1.37 (1.26-1.48) 
166
 
66
* 
47
 
3% 
Endometrioid 12% (3/25) 
58% (30/52) 
41% (9/22) 
8% (3/37) 
27% (13/48) 
57% (33/58) 
28% (4/14) 
7% (10/147) 
20% (84/414) 
24% (14/57) 
4% (4/90) 
13% (18/131) 
27% (62/232) 
10% (14/146) 
1.87 (1.68-2.06) 
5.36 (4.92-5.80) 
2.13 (1.79-2.47) 
1.90 (1.67-2.12) 
2.33 (2.07-2.59) 
3.62 (3.26-3.97) 
3.77 (3.27-4.27) 
166
 
156
 
154
 
46
 
74
 
66
* 
47
 
14% 
Clear Cell 52% (13/25) 
15% (8/52) 
13% (19/147) 
7% (30/414) 
7.30 (6.29-8.31) 
2.33 (2.17-2.49) 
166
 
156
 
6% 
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32% (7/22) 
81% (30/37) 
56% (27/48) 
10% (6/58) 
7% (1/14) 
18% (10/57) 
14% (13/90) 
18% (23/131) 
5% (11/232) 
7% (10/146) 
2.19 (1.84-2.55) 
25.38 (21-29) 
6.04 (5.23-6.85) 
2.32 (2.12-2.52) 
1.05 (1.01-1.08) 
154
 
46
 
74
 
66
* 
47
 
Other types 0% 
2% (1/58) 
0% 
0% 
1% (2/232) 
8% (12/146) 
- 
- 
2.02 (1.85-2.18) 
166
 
66
* 
47
 
9% 
 
Footnotes  * Age matched nested case control study 
4. Biological gradient (dose-response relationship) No studies were identified that 
correlated volume and extent of endometriosis with acquisition of ovarian cancer. 
Interestingly, there is a common unexplained left-sided predominance for endometriotic 
cysts, and ovarian endometrioid and clear-cell cancers 
167, which may suggest a ‗spatial‘ 
biological gradient.  
5. Specificity This criterion relates to a specific cause producing a specific effect. 
Importantly, the occurrence of endometriosis need not cause ovarian cancer, pelvic pain or 
infertility. Similarly ovarian cancer, as well as pelvic pain and infertility, may occur without 
endometriosis. 
6. Biological plausibility There is extensive histopathological, molecular and genetic 
evidence showing that endometriosis may be considered a neoplastic process with potential 
for malignant transformation (discussed earlier 
168
). 
7. Coherence with existing knowledge There is strong evidence to support this 
causality component, as several of the risk factors known to increase or decrease 
susceptibility to endometriosis are also common to those of epithelial ovarian cancer. These 
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factors may indicate a common aetiological mechanism for endometriosis and ovarian cancer. 
Alternatively, these factors could act as confounders in the association between endometriosis 
and ovarian cancer. However, data of their presence in endometriosis associated ovarian 
cancers compared to matched (by age, histological subtype, grade and FIGO stage) ovarian 
cancers is unobtainable in most studies, which precludes any analysis of their confounding 
influence. The risk factors currently identified are: 
 Infertility and nulliparity- both of multifactorial aetiology and positively associated 
with endometriosis 
144
 and ovarian cancer
169
. 
 Unopposed estrogen replacement therapy (ERT)-  this is associated with malignant 
transformation of endometriosis 
170;171
 and increased the risk of endometrioid or clear cell 
epithelial ovarian tumours (OR 2.56; 95% CL 1.32-4.94)
172;173
. Importantly, a 
confounding effect is unlikely with ERT as most studies reporting prevalence of 
endometriosis associated ovarian cancer were based on women not taking ERT. 
 Multiple lifetime ovulations- this increases the risk of epithelial ovarian cancer174. 
The combined oral contraceptive pill, which is known to reduce ovulations, has been shown 
to reduce the risk of ovarian cancer
175;176
 and endometriosis. 
 Tubal ligation- this reduces the risk of ovarian cancer177, particularly endometrioid 
and clear cell types
178;179
. No prospective trials exist showing tubal ligation to reduce 
endometriosis occurrence, progression or recurrence, However, assuming retrograde 
menstruation to be a main mechanism for endometriosis, it is plausible that tubal ligation 
suppresses retrograde menstruation and endometriosis which consequently suppresses 
endometriosis associated ovarian cancer development.  
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8. Experimental evidence   Animal models (mice, rat or baboon) of endometriosis may 
be created by surgically implanting host (or human) endometrial cells in to the peritoneal 
cavity and promoting proliferation of the cells by administration of supraphysiological 
estrogens
141;180-186
.  Of these animal models, a sentinel paper by Dinulescu (2005) 
141
 induced 
ovarian lesions with an endometrioid glandular pre-neoplastic morphology by activating an 
oncogenic K-ras allele and deletion of the PTEN tumour suppressor gene; hence, fulfilling 
Fearon and Vogelstein‘s classic stepwise model of cancer development (Figure 1.2)116;117 .  
Human studies demonstrating induction of endometriosis or its malignant transformation are 
highly unlikely as such research would be deemed unethical. 
 
9. Analogy Malignant transformation of endometriosis is not restricted to the ovary. 
Several studies have reported analogous malignant transformation at extra-ovarian locations, 
such as the rectovaginal septum, vulva, and colon
187
. Principle malignancies include 
endometrial stromal sarcoma, endometrioid adenocarcinoma, clear cell carcinoma, with 
histological confirmation of tumour and adjacent endometriosis in all cases. Furthermore, 
malignant transformation of adenomyosis, considered the ‗uterine‘ variant of endometriosis, 
has been observed and results in similar histological subtypes to that found for endometriosis 
related malignancies
188
. 
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D. Summarising the published evidence whether endometriosis is a neoplastic 
precursor to ovarian cancer 
 
Based on the methodological approaches discussed earlier (A: clinicopathological, B: Genetic 
and molecular hallmarks of cancer, C: Bradford-Hill causality criteria) there is inadequate 
evidence to support the hypothesis that ‗ENDOMETRIOSIS IS A NEOPLASTIC 
PRECURSOR TO OVARIAN CANCER‘ (Table 1.6). 
Table 1.6. Summarising the published evidence that supports or refutes the hypothesis 
that endometriosis is a neoplastic precursor to the development of ovarian cancer 
 Supporting evidence for 
endometriosis 
Refuting evidence for 
endometriosis 
Overall strength 
that hypothesis is 
true 
A. Clinico-
pathological 
epidemiological 
data 
 
Cancer arises directly from 
endometriosis 
Increased risk of certain 
ovarian cancer subtypes 
Inconsistency of histological 
observations 
 
Weak association 
Weak 
B. Genetic and 
molecular 
‘Hallmarks of 
Cancer
6’ 
criteria 
Self-sufficiency 
Insensitivity to anti-
proliferative signals 
Resistance to apoptosis 
Angiogenesis 
Genomic instability 
 
Limitless replication 
potential 
Tissue invasion and 
metastasis 
Moderate 
C. Association 
vs. causality 
using 
Bradford-Hill 
(1965) 
epidemiological 
criteria
7
 
Experimental evidence 
(animal model) 
Biological plausibility 
Experimental analogy 
Strength of association  
Specificity of association 
Inconsistency of association 
Temporal sequence 
Biological gradient (dose 
response relationship) 
Experimental evidence 
(humans) 
Weak 
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Nevertheless, the identification of an association between endometriosis and ovarian cancer 
may suggest alternative hypotheses: 
 Only specific endometriotic implants may directly undergo malignant transformation, 
perhaps through environmental exposure via an atypical endometriosis transition phase,  
analogous to the genetic cancer model of colon cancer where colonic epithelium acquires 
stepwise somatic genetic mutations to transform to colonic polyp, adenoma and finally to 
colonic carcinoma (Figure 1.2)
116;117
. Therefore, like most types of sporadic cancer 
189
, 
endometriosis  may be exposed to complex interactions between inherited germline 
polygenic low-penetrance alleles (polymorphisms) 
190;191
, somatically acquired genetic 
alterations 
192
 and  environmental factors 
94
 .  A visual summary of the main pathways of 
this hypothesis is shown in Figure 1.3. 
 Both endometriosis and cancer share common antecedent mechanisms and/or 
predisposing factors (e.g. genetic susceptibility, immune/angiogenic dysregulation, 
environmental toxin exposure), with obvious divergence in molecular pathways 
downstream.  
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Figure 1.3 Proposed genetic and molecular aeitopathogenesis of endometriosis 
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Discussion of methodology used in testing hypothesis 
 
A strength of this work has been the utilization of a systematic literature search and 
combining this with established research methodological approaches. However, it is accepted 
there may still be grounds to challenge our conclusion.  
To some extent, my conclusions may be less certain, as most included studies were of small 
sample size, retrospective design, and suffered from selection bias (incomplete case 
ascertainment and unmatched populations), information bias (varying histological criteria for 
cancer arising from endometriosis and atypical endometriosis) and confounding to varying 
degrees. Such problems of interpreting epidemiological studies involving endometriosis have 
also been observed by others
193;194
. 
Significantly, my research aim of using Bradford-Hill criteria to test causality was adopted by 
another group (Vigano 2007
195
)  investigating the causal link of endometriosis and cancer. 
Their work
195
, which partly included and referenced my work
168
,concluded that there was 
only a weak causal link. However, Vigano‘s group did not perform a systematic literature 
search (and omitted key references that we have included above) and utilised modified 
causality criteria. I therefore believe my conclusion is more likely to be accurate, and in fact, 
has been further validated through the experimental work discussed below and orally 
presented at international conferences
196;197
.
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1.2. Experimental investigation of endometriosis and EAOC 
 
Introduction  
 
Experimental studies on primary endometriotic tissue and endometriotic-cell lines has shown 
endometriosis and cancer to share similar molecular (limitless replicative potential, self-
sufficiency in growth signals, insensitivity to growth-inhibitory signals, sustained 
angiogenesis) and genetic(monoclonality, genetic instability) characteristics
168;198;199
. Allelic 
loss in endometriosis and sporadic ovarian cancer has been demonstrated in similar 
chromosomal regions 1p, 1q21, 5p, 5q, 6q, 7p, 9p , 9q, 11q, 17p13.1, 17q and 22q 
200;201
. 
Furthermore, a recent in vivo mouse model study demonstrated induction of endometriosis-
like and ovarian cancer tissue through introduction of oncogenic K-ras and conditional 
deletion of PTEN 
202
. Endometriosis-associated ovarian cancer (EAOC) (25-35% of all 
ovarian cancers) appears to be a separate entity from sporadic ovarian cancer without 
endometriosis (SOC). Epidemiological studies have shown EAOC tends to present in 
younger aged women, has better survival, and more likely to be a low-grade endometrioid or 
clear cell cancer subtype 
82;203-205
. However, there is only limited data on the genetic 
alterations in EAOC, which to date is mainly confined to the roles of PTEN and K-ras 
139;140
 
and a limited genome-wide (n=14 cases)
206
 LOH screen and CGH analysis (n=4 cases)
207;208
.  
Hypothesis  
 
Although the supporting evidence is weak (Table 1.6), we could assume that, in some cases, 
it is possible that endometriosis behaves as a neoplastic precursor to the development of 
ovarian cancer (Figure 1.3). If this is valid, then we could better understand the genetic 
aetiopathology of both endometriosis by deliberately selecting endometriosis-associated 
ovarian cancer (EAOC) as a model and testing the ovarian cancer and adjacent endometriosis 
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for common or dissimilar genetic abnormalities. Therefore, in this chapter, I will explore 
whether normal ovarian surface epithelium and adjacent endometriosis and adjacent ovarian 
cancer display a stepwise accumulation of LOH events analogous to the stepwise 
accumulation of LOH (due to inactivation of  tumour suppressor genes TSG) observed in 
Fearon and Vogelstein‘s model for colon cancer (Figure 1.2).  The following patterns of 
results may be generated by adopting this approach: 
 LOH is only demonstrated in the ovarian cancer, and not in endometriosis. This would 
suggest acquired somatic genetic events occur, perhaps due to the presence of 
endometriosis, that cause malignant transformation to ovarian cancer.  
 LOH is demonstrated in endometriosis when compared against matched normal ovarian 
surface epithelium. This would suggest that inactivation of particular TSGs were 
responsible for either the initiation or progression of endometriosis. 
 Similar chromosomal regions of LOH occur in endometriosis and ovarian cancer. This 
would suggest that a particular set of TSGs are in involved in both the initiation, 
progression and malignant transformation of endometriosis and ovarian cancer, and that 
endometriosis and ovarian cancer share common antecedent genetic events.  
 Additional LOH events are identified in ovarian cancer compared to LOH events 
identified  in adjacent endometriosis. This would confirm a stepwise accumulation of 
specific inactivating TSG(s) (equating to the additional LOH events) are responsible for 
the malignant transformation of endometriosis. 
Fine mapping the LOH regions would therefore allow us to select candidate TSGs that were 
either responsible for the initiation and progression of endometriosis (pattern B), malignant 
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transformation of endometriosis to ovarian cancer (pattern D), or common to development of 
both endometriosis and ovarian cancer (pattern C). 
Plan of investigation 
 
 Investigate epidemiological and prognostic factors associated with endometriosis 
associated ovarian cancer (EAOC) and sporadic ovarian cancer (SOC), matched for 
endometrioid and clear cell ovarian cancer subtypes. (Tables 1.7, 1.8, 1.9; Figures 1.7, 
1.8,  1.9) 
 Loss of heterozygosity (LOH) mapping of EAOC and SOC-fine mapping of 
chromosomes 9 and 11 using multiple microsatellite genetic markers to identify candidate 
tumour suppressor genetic loci. (Tables 1.10, 1.11; Figure 1.4-LOH mapping output; 
Figures 1.10 and 1.11).  
 Analyse survival prognostic significance of LOH at chromosomes 9 and 11. Combine 
information narrowed fine-mapped genetic region of LOH, frequency of LOH and 
prognostic significance of loci, to select candidate tumour suppressor genes for further 
investigation (Figure 1.12). 
 Laser Capture Microdissection of endometriosis adjacent to ovarian cancer and perform 
LOH using candidate genetic microsatellite markers.  Compare findings to similar study 
by collaborators (we have donated our samples to their unit). (Figure 1.5-importance of 
LCM; Table 1.12). 
 Immunohistochemical investigation of candidate disease-modifying genes in 
endometriosis adjacent to and distant from  EAOC. Selected gene products are 
Glycodelin (9q34.3) and Progesterone receptor (11q22). (Table 1.13; Figures 1.13, 
1.14, 1.15). Correlation of immunohistochemical expression to disease development . 
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 Preliminary nuclear morphometry analysis of transition zone between endometriosis, 
atypical endometriosis and ovarian cancer that exist in direct continuum. (Figure 1.16). 
 Single nucleotide polymorphism genome wide analysis of endometriosis using 
Affymetrix 100K SNP microarray (Figure 1.6-SNP microarray advantages; Figures 1.17, 
1.18, 1.19, 1.20). 
 
Experimental Methods 
 
Ethics: South Birmingham Local Research Ethics Committee has given full approval to all 
work included in this thesis chapter (LREC reference No: 2002/057, August 2002). 
 
Clinical material   Cases of EAOC and SOC of endometrioid and clear cell subtype were 
identified by interrogation of a computerized histopathological database at Birmingham 
Women‘s Hospital. All cases were gynaecological cancers operated on from 1995-2001 at 
Birmingham Women‘s Hospital. Five micron thick paraffin embedded slides were used for 
DNA extraction and three micron thick slides were cut from selected cases for 
immunohistochemical analysis. Realising that molecular genetic alterations of ovarian cancer 
vary according to histological subtype 
209
, we ensured our comparative analysis of allelic loss 
between EAOC and SOC were matched for endometrioid and clear cell subtypes of ovarian 
cancer. Chromosomal regions showing greatest frequency of LOH in EAOC and SOC and 
that appeared to reside within a consistent minimal region of LOH loss were prioritized for 
further study. 
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DNA Extraction 
Cancer and matched normal DNA were extracted from five micron glass slides using one of 
two methods depending on slide content and composition. Needle microdissection was used 
to collect histologically labeled endometriosis and cancer. DNA was extracted from micro-
dissected material held in an eppendorf  using a microwave-based method as previously 
described 
210
 . Briefly, retrieved tissue material was placed in an eppendorf containing 400μl 
TrisT-EDTA buffer and heated in a 600W microwave for one minute in 15 second bursts. 
Following centrifugation the upper paraffin layer was discarded and the supernatant 
incubated for 48 hours with 4μl of proteinase K 20mg/ml (Sigma-Genosys) with continuous 
gentle agitation. Proteinase K was inactivated by heating to 95ºC for ten minutes and the 
supernatant aliquoted for DNA studies.  
 
LOH Analysis 
Highly polymorphic microsatellite markers spanning the full length of chromosomes 9 and 11 
at approximately 20cM intervals (Wellcome Trust) were kindly provided by Oxford Group, 
Dr. Stephen Kennedy. Detailed genetic fine mapping was performed using customised 
microsatellite markers (Sigma) spaced approximately 10cM apart and in between the 
previous Wellcome markers. The forward primers were 5' end-labeled with FAM. A  25-µl
 
PCR reaction volume containing 1xAB Gene Buffer (ABGene), Magnesium Chloride 
(ABGene),  100 µM each of dATP, dCTP, dGTP, and dTTP; 0.5 unit of DNA Taq 
polymerase
 
(AB Gene); sterile DNAse and RNAse free water (Sigma), and 2 pmol of reverse 
primer, 2ul (approximately 100 ng) of genomic DNA.  PCR
 
cycling conditions were as 
follows: (a) 5 min at 94°C; (b)
 
30 cycles of 30 s at 94°C, 30 s at the appropriate annealing
 
temperature (usually 55°C), and 30 s at 72°C; and a final step of 72°C
 
for 10 min. The 
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reaction products were then diluted 1:15 with sterile water. One microlitre of the diluted PCR 
product was added to 10ul of 95% formamide, and 0.02ul of LIZ dye and subsequently 
denatured for 5 minutes at 95°C and snap frozen with ice. PCR products were run on ABI 
377 gel electrophoresis analyser and fragment sizes were recorded using GeneScan software 
analysis. LOH was scored based on the absence of alleles in tumour-derived
 
DNA compared 
to normal DNA or a loss of at least 70%  in the relative size of alleles in
 
the tumour-derived 
DNA compared to
 
normal tissue; examples of GeneScan  images are shown in Figure 1.4  
 
Figure 1.4. Genetic allelic products images observed following microsatellite 
amplification of target DNA and analysis on ABI Prism analyser 
Microsatellite marker mapping of LOH 
regions
Normal
EAOC
cancer
Endometriosis
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Immunohistochemistry and nuclear morphometry 
Monoclonal antibodies were obtained for p53, CD10 (Santa Cruz), Progesterone receptor 
(isoforms A and B) (AbCAM) and Glycodelin (AbCAM). Immunohistochemistry was 
performed according to standardised protocols using the Dako Chem Mate antigen detection 
kit. Briefly, 3 micron slides were deparaffinised through stepwise Xylene, ethanol, water and 
methanol washes; endogenous peroxidase was subsequently blocked by 20 minutes 
incubation with 0.5% hydrogen peroxide/methanol mixture. Antigen exposure was achieved 
by pressure cooker boiling for 5 to 7 minutes with pH 6 citric acid buffer.  Primary antibodies 
were diluted to concentrations of 1 in 200 to 1 in 1000 in TBS Tris buffered saline (pH 7.6) 
and 200 microlitres were applied to each slide. The Dako Chem Mate protocol (yellow and 
red antibody washes) followed by DAB chromagen/substrate then copper sulphate solution 
staining was performed. Brief dips in Haemotoxylin, acid-alcohol dip and Scott‘s Media 
followed by tap water wash allowed final ascending alcohol/xylene and coverslip slide 
creation. 
 
Laser Capture microdissection 
A PALM microlaser was used. EAOC paraffin 3micron thick cut slides were de-waxed and 
suspended in aqueous buffer. Endometriotic epithelium was separated ‗purely‘ using laser 
blot and line cutting according to the manufacturer‘s guidance (Figure 1.5). Particles were 
catapaulted on to the inside lid surface of a single PALM 1cm
3
 opaque lid eppendorf. 
QUIAGEN mini-DNA prep kit buffer was placed in the conical base of the eppendorf and the 
lid closed after particle deposition and eppendorf was then inverted. DNA was extracted and 
cleaned according to the QUIAGEN mini-columns and centrifuge protocol. 
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Figure 1.5. Importance of Laser capture microdissection of target disease (such as 
endometriosis epithelium glandular lining) from surrounding tissue (such as 
endometriosis stroma) 
 
Heterogeneity in tissue sample
The importance of laser capture microdissection to 
obtain “pure cells”
 
 
Affymetrix SNP 100K Microarray 
Ovarian endometriosis and matched normal ovarian surface epithelium were needle micro-
dissected immediately at the time of surgical extraction from the patients with their 
documented informed consent, and then promptly snap frozen in liquid nitrogen and held at -
77°C. DNA was extracted by crushing the tissue in PureGene extraction buffer and following 
the PureGene centrifugation and incubation protocol. The quality and concentration of 
extracted DNA was determined by spectrophotometry at A260/280. The Affymetrix 
GeneChip® Mapping Assay, in conjunction with the GeneChip Human Mapping 100K Set, 
is designed to detect > 100,000 Single Nucleotide Polymorphisms (SNPs) in samples of 
genomic DNA. The Mapping 100K Set is comprised of two arrays (Mapping 50K Array Xba 
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240 and Mapping 50K Array Hind 240) and two assay kits (containing either Hind III, XbA 1 
restriction enzymes). Each array and its corresponding assay kit are processed independently 
from the second enzyme. The protocol starts with 250 ng of genomic DNA per array and will 
generate SNP genotype calls for more than 50,000 SNPs for each array of a two array set. 
The assay first digests the genomic DNA with the Xba I or Hind III restriction; an overview 
of the remainder of the assay protocol is shown in Figure 1.6. The final PCR products 
(amplicons) are fragmented, end-labelled, and hybridized to either the Xba 1 or Hind III 
GeneChip array. Scanned images obtained from the GeneChip Mapping 50K Array Xba 240 
and the GeneChip Mapping 50K Array Hind 240 are digitally combined and displayed by 
GeneChip Operating Software (GCOS). 
 
Statistical analysis 
Statistical data were analysed with the use of SPSS version 13 (SPSS Inc, USA). Continuous 
variables were analysed by T-test, Mann-Whitney U and ANOVA tests . Categorical 
variables were analysed by Chi-square. Survival regression was analysed using either the 
Kaplan-Meier or Cox proportional Hazards model, depending on the parameters employed. A 
p-value less than 0.05 was considered statistically significant, although a Bonferonni 
correction was considered (p value<0.001) when multiple testing (>10) may have led to 
increased risk of type 1 error. 
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Figure 1.6. Increased genetic resolution of Affymetrix Single Nucleotide Polymoprhism 
DNA microarray compared to ‘traditional’ multiple microsatellite marker genome wide 
mapping 
Genome Wide Screening:
SNP Array vs. Microsatellite markers 
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1.3 Investigation of epidemiological factors associated with EAOC and SOC 
 
At total of 62 cases were identified from the histopathological database; their epidemiological 
characteristics are shown in Table 1.7. Of these, paraffin tissue blocks were retrieved for 50 
cases, and these were subjected to genetic investigation; the epidemiological characteristics 
are shown in Table 1.8.  
Ovarian cancer survival was statistically significantly associated with clear cell or 
endometrioid subtype, cancer stage and the presence of synchronous endometrial and ovarian 
cancer [regression model Chi-sq 14.1, p=0.003).  Clear cell compared to endometrioid 
subtype of cancer increases the odds of dying earlier by 2.2 (i.e. the probability of dying 
earlier is 69%).  An advanced cancer stage increases the odds of dying earlier by 1.6 (i.e. the 
probability of dying earlier is 62%). Synchronous cancers compared to solitary ovarian 
cancers decreases the odds of dying earlier by 0.13 (i.e. the probability of dying earlier is 
12%). The presence or absence of endometriosis did not influence survival, as did other 
factors as listed in Table 1.9. These observations are graphically depicted by the survival 
curves (Figures 1.7, 1.8, 1.9). 
Odds=Prob/1-Prob 
Prob= Odds/1+Odds 
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 Table 1.7. Characteristics of endometriosis associated ovarian cancer (EAOC) and 
sporadic ovarian cancer (SOC), matched for endometrioid and clear cell histologies,  
used in epidemiological analysis (N=62) 
 EAOC  N=34  SOC  N=28  P value  
Clear cell  18  9   
Endometrioid  16  19   
Age  mean [range]  57.7 [32-79]  60.4 [32-84]  n.s.  
Cancer stage:                   1  
                  2  
                  3  
                  4  
                         Mean  
21  
7  
5  
1  
1.59  
13  
5  
9  
1  
1.93  
0.150  
Sidedness:       Left  
                         Right  
                         Bilateral  
14  
18  
2  
8  
8  
12  
0.002  
Endometriosis proximity to tumour:                                        
   Distant  
   Adjacent  
   Tumour arising from endometriosis  
11 (32%)  
12 (35%)  
11 (32%)  
Not relevant   
Synchronous uterine & ovary cancer  5  0  0.034  
Uterine hyperplasia  11  8  n.s  
Leiomyoma  25  17  n.s  
Adenomyosis  14  11  n.s  
Tumour in lymph nodes  2  3  n.s  
Tumour in omentum  4  6   n.s.  
Ascites  12  10   n.s.  
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Table 1.8. Characteristics of endometriosis associated ovarian cancer (EAOC) and 
sporadic ovarian cancer (SOC), matched for endometrioid and clear cell histologies,  
used in genetic analysis(N=50) 
 EAOC 
Clear cell 
EAOC 
Endometrioid 
SOC 
Clear 
cell 
SOC 
Endometrioid 
Statistical 
Testing 
P value 
Number of cases 15 12 7 16  
Mean Age 57.2 59.9 61.6 59.2 0.865** 
Age:lower to 
upper quartile 
51-65 56-66 45-72 51-67  
Staging of  
ovarian cancer 
Stage 1 
Stage 2 
Stage 3  
Stage 4 
 
9 
3 
3 
0 
 
8 
3 
0 
1 
 
3 
0 
3 
1 
 
9 
3 
3 
1 
 
0.486 
Ascites 5 4 4 5 0.660 
Synchronous 
endometrial and 
ovarian cancer 
0 5 
(cases 
17,19,36,37,38) 
0 1 0.222 
Presence of 
endometriosis  
directly adjacent 
to ovarian cancer 
7/15 
(cases 2, 3, 
4,5,10,11,13) 
5/12 
(cases 
17,18,19,24, 26) 
N/A N/A  
Surviving  
>48 months 
>36 months 
>24 months 
>12 months 
<12 months 
 
3 
3 
6 
10 
5 
 
4 
7 
9 
10 
2 
 
0 
0 
3 
5 
2 
 
5 
8 
12 
13 
3 
 
0.337 
0.023 
0.112 
0.707 
0.707 
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Table 1.9. Multivariate survival regression analysis (N=62 combined cases of EAOC and 
SOC) 
Variables included in multivariable Cox 
regression analysis  
P-value 
of  
variable  
Odds of dying earlier  
Expressed as  
Hazard Ratio  
Clear cell vs. Endometrioid subtype  0.019  2.16 (95% CI 1.14 - 
4.10)  
Advancing cancer stage  0.016  1.56 (95% CI 1.09 - 
2.24)  
Synchronous cancer vs. ovarian cancer  0.012  0.13 (95% CI 0.03 - 
0.64)  
Endometriosis presence  0.80  not significant  
Age  0.72  not significant  
CA125  0.43  not significant  
Tumour in Lymph nodes  0.65  not significant  
Tumour in omentum  0.92  not significant  
Ascites  0.70  not significant  
Sidedness of tumour  0.56  not significant  
Proximity of endometriosis to tumour  **   
Footnotes 
Probability corresponds to HR/1+HR 
Interpreting Hazard Ratio results: when all variables are combined in a survival regression analysis, only 
histological subtype, cancer stage and presence of synchronous uterine and ovarian cancer statistically 
significantly impact on cancer survival [ Chi-sq 14.1, p=0.003) : 
Clear cell compared to endometrioid subtype of cancer increases the odds of dying earlier by 2.2:1 (i.e. 
probability of dying earlier is 69%) 
An advanced cancer stage increases the odds of dying earlier by 1.6:1 (i.e. probability of dying earlier is 62%). 
Synchronous cancers compared to solitary ovarian cancers increases the odds of dying earlier by 0.13:1 (i.e. 
probability of dying earlier is 12%) 
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Figure 1.7    Survival differences between subtypes of ovarian cancer 
There is no statistically significant association between the four individual cancer subtypes 
and survival. However, there is a statistically significant association for clear cell vs. 
endometroid types of ovarian cancer (Hazard Ratio 2.16 (95% CI 1.14-4.10)), as depicted in 
the figure i.e.  Clear cell compared to endometrioid subtype of cancer increases the odds of 
dying earlier by 2.2:1 (i.e. probability of dying earlier is 69%).(Hazard analysis results are 
depicted in Table 1.9). 
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Figure 1.8.  Survival analysis according to stage of ovarian cancer. 
There is a statistical significant association between ovarian cancer staging and cancer 
survival (Hazard Ratio 1.56 (95% CI 1.09-2.24)) i.e. an advanced cancer stage increases the 
odds of dying earlier by 1.6:1 (i.e. probability of dying earlier is 62%).(Hazard analysis 
results are depicted in Table 1.9). 
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Figure 1.9. Survival analysis according to presence of endometriosis 
There is no statistical association between the presence of endometriosis and survival for all 
cancers (Log Rank Mantel Cox p=0.80). (Hazard analysis results are depicted in Table 1.9). 
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1.4. Loss of heterozygosity (LOH) fine mapping of EAOC and SOC at 
chromosomes 9 and 11 using multiple microsatellite genetic markers and 
their prognostic significance. 
 
Based on previous published research, chromosomes 9 and 11 were selected for LOH 
mapping as chromosomes most likely to harbor tumour suppressor genes (TSG) for either 
endometriosis or ovarian cancer
201;211
.  
Preliminary microsatellite markers demonstrated LOH at chromosomes 9 and 11 for both 
EAOC and SOC. Microsatellite markers that mapped to genetic loci no greater than 10cM 
apart,  were selected and used to create a fine map of LOH at chromosomes 9 (Table 1.10) 
and chromosome 11 (Table 1.11).  The background frequency of genome-wide LOH 
observed was 30-40% for chromosome 9 (Figure 1.10) and 20-40% for chromosome 
11(Figure 1.11). High frequency LOH was observed at 9q32 (65%), 9q34.3 (78%), 11q22.1 
(57%), 11q24.1 (60%), and 11q25 (64%). There were no significant differences in the 
patterns of LOH between EAOC and SOC (Figures 1.10 and 1.11). 
 
Survival analysis showed LOH at 9q34.3 correlated to poorer survival , suggesting that this 
region of high frequency LOH may harbor a candidate TSG (Figure 1.12). Conversely, 
survival analysis showed LOH at 11q 23.3 correlated to improved survival, suggesting that 
this region of high frequency LOH may harbor a candidate oncogene (Figure 1.12).  
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Table 1.10. Allelic Loss at chromosome 9  
Gene
tic 
Mar
ker 
DeC
ODE 
CM 
Cytoge
netic 
EAOC 
CLEAR CELL 
EAOC 
ENDOMETRIOI
D 
SOC 
CLEAR 
CELL 
SOC 
ENDOMETRIOID 
OVERA
LL 
LOH 
FREQU
ENCY 
   0
1 
0
2 
0
3 
0
4 
0
5 
0
6 
0
7 
0
8 
0
9 
1
0 
1
1 
1
2 
1
3 
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
2
1 
2
2 
2
3 
2
4 
2
5 
2
6 
2
7 
2
8 
2
9 
3
0 
3
1 
3
2 
3
3 
3
4 
3
5 
3
6 
3
7 
3
8 
3
9 
4
0 
4
1 
4
2 
4
3 
4
4 
4
5 
4
6 
4
7 
4
8 
4
9 
5
0 
 
D9S1
71 
45.57 9p21.3 U U U I U I U U I U U I I U I I I I I U I I █ U I █ █ I U █ U U █ I U █ I U I U █ U █ U U I U █ U I 32% 
D9S2
73 
66.75 9q21.1
1 
U I I U U I I █ U U I I █ U I I I I I I I █ U U U U █ I I █ U I █ █ █ U █ U I I █ U I █ I I U I U I 32% 
D9S9
33 
78.26 9q21.3
1 
U I I U I I I I U █ █ I I I U I █ U I █ U I U U U U █ I I █ I I █ █ U U I █ █ I █ I I I █ U U U I █ 37% 
D9S2
83 
94.85 9q22.2 U U U █ U U U U U U █ █ U I █ U I I U U U I U U U U █ U █ U U U U ▓ U I U █ U I █ U I I █ I I █ I U 50% 
D9S1
816 
101.8 9q22.3
2 
U ▓ U U U ▓ I █ U U U U I U U U U U I I █ U U ▓ U U U I U I █ I I ▓ ▓ U U I I U █ █ U U U U U U U I 48% 
D9S2
87 
98.7 9q22.3
2 
I I I U I U U U U U █ █ I █ U I U I I █ U ▓ U U U U U █ I █ █ I █ U U U U █ I I U ▓ I U U U U U █ U 48% 
D9S1
690 
104.0
8 
9q31.1 I █ U U U U U U U U █ █ I █ █ I U I U █ U █ U U U U U U I █ █ I U █ U U U █ I I U █ I U U █ U █ █ █ 64% 
D9S1
677 
112.8
5 
9q31.3 I █ I U U U █ █ ▓ U █ █ U █ I U U I I I U ▓ U U U U I █ U █ U U U █ █ U █ █ I U U U U U █ █ U █ U U 68% 
D9S9
30 
116.7
5 
9q32 I █ U U I I U U U U █ █ I U I I I I I █ I U U U U U █ I U █ █ █ U █ █ U █ U I U █ I I I U I U U █ I 43% 
D9S1
776 
121.6
2 
9q32 I U I U U I U U U █ █ █ I █ █ U ▓ █ U U U U █ █ I █ █ █ U █ █ I █ █ █ U I █ U I █ I I █ █ U █ █ █ █ 71% 
D9S9
34 
126 9q33.1 █ I I I I U I I I U I █ I I I I I █ I U I U U U I U █ I U █ █ U █ U █ U I █ I U █ I I █ U I U U █ U 35% 
D9S1
685 
132 9q33.2 █ U I U U I U U U I █ U U U U U U U U U █ U U ▓ I █ U █ U U U U █ █ █ I I █ I U U I I U I U U U U I 48% 
D9S1
682 
128.7
7 
9q33.2 U I I U U U U U U U █ U █ I I I ▓ I U █ U U █ █ I █ █ █ █ █ █ █ █ █ █ I I █ U █ █ █ U █ U I I █ █ I 66% 
D9S2
90 
136.4 9q34.1
1 
U U █ U U U I U U U I U I I U I U I U I U U U U U U U U U █ █ I █ █ █ U I █ I █ █ I I U █ U U I █ U 46% 
D9S2
60 
141 9q34.1
1 
█ I I U I █ █ U U U █ U U I I U I I █ U U U U U U U █ U U U █ U U █ U U U U U U █ I U U U I U █ U U 53% 
D9S1
830 
145.6
5 
9q34.1
3 
I I I U I █ U U █ █ █ █ U I I I ▓ I █ █ I ▓ █ ▓ I █ U U █ U █ I █ U █ U U █ I I U I I U I I U █ █ I 51% 
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D9S2
157 
146.5
4 
9q34.2 I █ █ U █ █ U █ █ U █ I U █ I I ▓ I I █ █ I U U U █ █ U U █ █ I █ █ █ U I █ I U U I I I I I U █ █ I 57% 
D9S1
826 
157.7
3 
9q34.3 U █ I I █ U U I U U █ U I █ I I ▓ U U U U U U U U █ U I U U █ I U █ █ U U █ U I U I ▓ U U I U █ █ I 52% 
D9S1
58 
161.7
1 
9q34.3 U █ U U I █ I U U U U █ U U U U █ █ ▓ U U ▓ U U I █ U U I U █ U U ▓ U U U █ I U █ U █ █ I U █ U █ █ 74% 
D9S1
838 
164 9q34.3 I I █ U I █ I █ U I I U I U I I █ U U U U ▓ █ U I █ U U U █ █ I U U U U I █ I I █ I U I I I U U U I 37% 
 
Footnotes  
█ indicates informative loci that showed LOH 
▓ indicates MSI 
I indicates informative loci, but no LOH 
U indicates uninformative loci, therefore unable to determine absence or presence of LOH 
Last column refers to overall frequency of LOH and MSI combined at informative loci. 
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Table 1.11  Allelic loss at chromosome 11 
Gen
etic 
Mar
ker 
De
CO
DE 
cM 
Cyto
genet
ic 
EAOC  
CLEAR CELL 
EAOC  
ENDOMETRIOID 
SOC  
CLEAR 
CELL 
SOC  
ENDOMETRIOID 
OVER
ALL 
LOH 
FREQ
UENC
Y 
   0
1 
0
2 
0
3 
0
4 
0
5 
0
6 
0
7 
0
8 
0
9 
1
0 
1
1 
1
2 
1
3 
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
2
1 
2
2 
2
3 
2
4 
2
5 
2
6 
2
7 
2
8 
2
9 
3
0 
3
1 
3
2 
3
3 
3
4 
3
5 
3
6 
3
7 
3
8 
3
9 
4
0 
4
1 
4
2 
4
3 
4
4 
4
5 
4
6 
4
7 
4
8 
4
9 
5
0 
 
D11
S13
38 
9.77 11p1
5.4 
I █ I I I I U U I U █ I I U I U ▓ I I █ U █ █ U █ █ █ I █ U █ █ U U U U U █ I U I U I U I I █ █ U U 47% 
D11
S90
2 
25.6
9 
11p1
5.1 
I U U U █ I U U I U I U U I I U U I I U U U ▓ U U U █ I I U U █ █ U █ U U U I I U I U U █ I U U U I 32% 
D11
S42
04 
43.1
2 
11p1
4.2 
I █ I █ █ I U I █ U U U I I U █ I █ U █ U I U U U U I U U █ █ █ █ █ U U I I I I █ I I I █ I I I I I 40% 
D11
S93
5 
52.9
4 
11p1
3 
I U I █ █ U █ I █ U █ I █ I I I I U I U █ ▓ U U █ U █ U I █ U █ █ █ U I U I U U U U I U U U U U U U 52% 
D11
S19
93 
59.2
1 
11p1
1.2 
I █ U U I U █ I I █ I ▓ U I U I ▓ I █ █ ▓ U I I █ ▓ U I ▓ U █ U █ U █ I I I I I I I I █ I I █ U █ I 44% 
D11
S41
91 
64.9
6 
11q1
2.1 
I █ I U U I █ █ U I U I I U U I ▓ U I █ █ I ▓ U ▓ █ █ U I U █ I U I ▓ I █ I █ I █ I I I I I U U I I 41% 
D11
S98
7 
72.1
7 
11q1
3.2 
I U U I I U U U I U U I I I I I ▓ I I U I I U U █ █ U I I █ I U █ █ U I U I I I I U U █ U U U U U I 24% 
D11
S97
1 
76.7
6 
11q1
3.4 
U █ U U U I U U U U U I U U I U ▓ I U █ I U U U U █ U I I █ U U █ U U █ U I U I U U U █ U U U U I I 42% 
D11
S93
7 
83.7
3 
11q1
4.1 
I █ I I I I I I U I I I U I I █ ▓ I I █ U ▓ U U █ █ █ I I █ I U █ U U U I U I I I I I █ █ I U █ U I 34% 
D11
S20
02 
87.2
5 
11q1
4.1 
I █ I I U I I I █ U U U I I █ I ▓ I I █ I I U U I █ █ U I █ I █ █ I U U I █ I I I U I █ I U I ▓ I U 34% 
D11
S91
9 
98.3
1 
11q2
1 
U U I U I I U U ▓ U U U U I U U U U U U U U U U U █ █ I U █ U U █ U █ █ U █ I I I I I █ U █ █ U I I 48% 
D11
S89
8 
103.
59 
11q2
2.1 
I █ U I I I U I █ U █ U I █ I U █ I I █ █ █ █ ▓ █ █ █ U U █ I U █ U █ U █ █ I I I I █ ▓ █ U █ I █ I 59% 
D11
S20
00 
106 11q2
2.3 
I █ I I U █ █ I ▓ U U U I I █ I █ I I U U █ U U I U █ █ I █ █ █ █ █ █ U I █ I █ I U I █ █ U U U I U 54% 
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D11
S19
86 
110 11q2
3.1 
I █ I I █ █ ▓ I █ I █ █ I I I I █ █ I █ I █ I ▓ █ █ ▓ I I I █ U █ █ █ █ I █ I I I I I █ █ █ █ I I I 51% 
D11
S31
79 
112.
7 
11q2
3.1 
I █ I I U U U U U █ U U U I U U ▓ I U █ U █ █ █ I U █ I U U U U █ I U U U U I I U U U U U U U U U U 47% 
D11
S90
8 
116.
46 
11q2
3.3 
I U I U U U █ U ▓ U U I I I █ U █ U U █ ▓ █ ▓ U ▓ █ U U █ █ U █ █ █ █ I U U I █ U U U █ U █ U U █ I 71% 
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99 
11q2
3.3 
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89 
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37 
11q2
3.3 
I █ I U U I █ U U U I I U I I I ▓ █ █ █ █ U I U █ █ █ I I █ I U █ █ █ █ U U U I I I U U █ U █ █ █ I 54% 
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S44
64 
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43 
11q2
4.1 
U █ U I U █ I I U U U █ █ I I U █ I I █ █ █ U U U ▓ █ I I U █ U U I █ I I █ I U U I I █ U █ █ U █ I 52% 
D11
S93
3 
131.
38 
11q2
4.2 
I U I U I U U U I U U U U I I I █ U U I U U U U U U █ U ▓ U I U U I █ U I █ I █ I U U █ █ █ U U U I 39% 
D11
S41
50 
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95 
11q2
4.3 
I █ U █ U I I I U U U U I I U U U U I I U I U U U U U U U █ I █ █ U U U I U I U I U U █ I I █ █ █ I 36% 
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S20
18 
142 11q2
4.3 
U U U █ █ I I I I I U I I U I I U I █ I █ I █ I I I I I U █ U I I █ I I I U █ █ I I U █ I I █ U U I 29% 
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11q2
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I █ I U U I U U I U U I I I I U ▓ U █ U U █ U U U █ █ I I █ U U U █ I I U U I U I U I █ U U U █ █ I 41% 
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S13
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52 
11q2
5 
U █ I U U I I U U U I U U I I █ ▓ I I U █ █ U U █ █ U I █ U I U U U I U U I U U I U █ █ U U U U █ █ 48% 
D11
S96
9 
151.
02 
11q2
5 
I █ U U I U U U U █ I U U █ I I U I I █ █ █ █ U U █ U I ▓ █ █ █ █ U I █ U I I I U █ U █ █ █ █ █ U U 63% 
D11
S41
25 
152.
45 
11q2
5 
I █ I U I U █ U U U U I █ █ I I U I I █ U ▓ U U U █ █ U █ █ █ U U █ █ U U U U I I I I █ █ I █ █ █ U 58% 
D11
S96
8 
152.
45 
11q2
5 
█ █ I █ I I I I U U U I I U I █ ▓ █ I █ █ ▓ U U U █ █ I I █ █ █ █ I █ I U U U I U U I U I U U U I U 48% 
Footnotes  
█ indicates informative loci that showed LOH 
▓ indicates MSI 
I indicates informative loci, but no LOH 
U indicates uninformative loci, therefore unable to determine absence or presence of LOH 
Last column refers to overall frequency of LOH and MSI combined at informative loci.
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Figure 1.10. Contribution to allelic loss at chromosome 9 by each cancer subtype 
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Figure 1.11. Contribution to allelic loss at chromosome 11  by each cancer subtype 
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Figure 1.12.  Significant association of LOH at 9q34.3 and 11q 23.3 on survival of all 
ovarian cancers according to Cox Proportional Hazards survival analysis 
 
Cox survival analysis for LOH at 9q34.3
P=0.003
 
Cox survival analysis for LOH at 11q23.3
P=0.034
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Rationale for selecting Glycodelin and Progesterone Receptor as candidate 
disease-modifying  genes 
 
A bioinformatic search was performed to examine the published data on genetic expression 
and functional taxonomy of genes at these two genetic loci to select candidate disease-
modifying genes. Previous work had identified glycodelin (9q34) expression to be 
significantly altered in endometriosis and it had also been implicated in tumourigenesis
212-215
. 
Progesterone had been implicated in both endometriosis proliferation and anti-proliferation 
and ovarian cancer
11;211;216-218
; mutations of the Progesterone receptor (PROGINS)(11q22) 
had been associated with development of endometriosis
219
. 
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1.5. Laser Capture Microdissection (LCM) of endometriosis and selected 
LOH mapping 
 
Endometriosis adjacent to EAOC was extracted by LCM and its DNA subjected to LOH 
mapping using the 4 microsatellite markers at chromosome 9 and 11. LOH was identified in 
1/7 cases at 9q34 and 1/7 cases for LOH 11q23.3. Our results did not show strong evidence 
that LOH events occurred in endometriosis. However, our research collaborators, who 
utilised our Birmingham Women‘s EAOC/SOC samples we had donated, showed LOH to 
occur more frequently when they microsatellite mapped their LCM endometriosis, 
particularly when the endometriosis LOH corresponded to an adjacent ovarian cancer LOH 
event (see Table 1.12). 
 
Table. 1.12. Genome wide microsatellite analysis of  endometriosis adjacent to ovarian 
cancer (Prowse, Varma 2006) 
220
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1.6 Immunohistochemical investigation of EAOC using Glycodelin (9q34.3) 
and Progesterone receptor (11q22)    
A summary collation of the immunohistochemical staining for 6 EAOC cases (3 
endometrioid, 3 clear cell) is depicted in table 1.13 and images are depicted (Figure 1.13, 
Figure 1.14, Figure 1.15). Glyocdelin staining was absent in the ovarian cancer and present 
in the endometriosis distant to the ovarian cancer, but not so strongly expressed in 
endometriosis adjacent to ovarian cancer; this is weak evidence that endometriosis adjacent 
may be a differing molecular entity to distant endometriosis, and that glycodelin is possibly 
involved in causing this difference. No significant differences were observed for PR-A or PR-
B staining. 
Table 1.13. Summary of immunohistochemistry findings 
 Endometrioid  EAOC 
patient 
Clear Cell EAOC 
patient 
Endometriosis distant 
from ovarian cancer 
Moderate Glycodelin 
Strong PR-A,PR-B 
Moderate glycodelin 
Strong PR-A,PR-B 
Endometriosis 
adjacent to ovarian 
cancer 
Weak Glycodelin 
Strong PR-A, PR-B 
Weak Glycodelin 
Strong PR-A,PR-B 
Ovarian cancer Absent Glycodelin 
Absent PR-A,  
Patchy positive PR-B 
Absent Glycodelin 
Absent PR-A 
PR-B 
Footnotes 
CD10 used as a positive control for identification of endometriosis
221
-see Figure 1.13 
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Figure 1.13. Immunohistochemistry images of endometriosis and ovarian cancer using 
Glycodelin and CD10  
Glycodelin (9q34.3) and endometriosis distant from cancer
Glycodelin CD10
  
  
Glycodelin (9q34.3) and endometriosis adjacent to cancer
Glycodelin CD10
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Figure 1.13 continued. Immunohistochemistry images of endometriosis and ovarian 
cancer using Glycodelin and CD10  
Glycodelin (9q34.3) negative in cancer
Endometrioid Clear Cell
 
Figure 1.14. Immunohistochemistry images of endometriosis and ovarian cancer using 
Progesterone receptor subtypes A and B  (individually labeled) 
Progesterone Receptor (11q22)
PR-B PR-A
Normal 
endometrium
Endometriosis
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Figure 1.15. Immunohistochemistry: patchy positive staining of PR-B in endometrioid 
cancer  
 
PR-B patchy positive in endometrioid cancer 
Figure 0.1 Immunohistochemistry of PR-B in endometrioid cancer 
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1.7. Preliminary nuclear morphometric analysis of endometriosis adjacent 
to ovarian cancer   
 In the single case identified, there was increasing nuclear diameter and pleomorphism in the 
direct continuum transition between endometriosis, atypical endometriosis and EAOC 
(Figure 1.16). 
Figure 1.16. Nuclear morphometric analysis of endometriosis, atypical endometriosis 
and ovarian cancer that appear as one continuum on the histology slide 
Endometriosis
Transition state 
(Atypical endometriosis)
Ovarian 
endometrioid cancer
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1.8.  Affymetrix SNP DNA microarray genotyping of ovarian endometriosis    
DNA from 10 patients,  5 matched ovarian endometriosis and ovarian surface epithelium and 
5 only ovarian endometriosis DNA,  were subjected to SNP microarray analysis. Multiple, 
extremely small genetic distance areas of LOH were observed in ovarian endometriosis when 
compared to its matched ovarian surface epithelium control, without alteration of the DNA 
copy number at that genetic locus. There was no genome-wide consistency of the 
chromosome or chromosomal region affected by this ‗micro-LOH‘ (summarized in Table 
1.14). However, regions on chromosome 11 (Figure 1.17), 15 (Figure 1.18), 21 (Figure 
1.19), 6 and X (Figure 1.20) showed considerable LOH prominence. These regions of LOH 
need to be validated by confirmatory microsatellite marker analysis. 
 
Table 1.14. Summarising genome-wide LOH regions identified in ovarian endometriosis 
through SNP Affymetrix microarray analysis 
Chromosomal region where 
LOH identified 
Number of ovarian 
endometriosis cases (N= 5) 
Proximity to regions of LOH 
identified in ovarian cancer 
1q One case  
2q One case  
3q One case  
6p One case  
9q No cases 9q32 
9q34.3 
11q Two cases 11q23.3   YES 
11q222    YES 
11q25      NO 
15p One case  
21p Two cases  
Xp Two cases  
Xq One case  
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Figure 1.17. Selected images of chromosomal abnormality (chrom 11) in ovarian 
endometriosis (patient 3) compared to their matched normal ovarian surface epithelium 
(patient 2)  
Chrom 11 pat3
 
 
Chrom 11 pat2
 
Ovarian 
endometriosis 
LOH at 11q 
Matched 
normal ovary 
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Figure 1.18. Selected images of chromosomal abnormality (chrom 15) in ovarian 
endometriosis (patient 5) compared to their matched normal ovarian surface epithelium 
(patient 3)  
Chrom 15 pat5
 
 
Chrom 15 pat3
 
 
Ovarian 
endometriosis 
LOH at 15p 
Matched 
normal ovary 
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Figure 1.19. Selected images of chromosomal abnormality (chrom 21) in ovarian 
endometriosis (patient 6) compared to their matched normal ovarian surface epithelium 
(patient 9)  
Chrom 21 pat6
 
 
Chrom 21 pat9
Matched 
normal ovary 
Ovarian 
endometriosis 
LOH at 21p 
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Figure 1.20. Selected images of chromosomal abnormality (chrom 6 and chrom 11 and 
chrom X) in ovarian endometriosis for patient 2 and patent 3 and patient 6,  
respectively. 
Chrom 6 pat2
 
Chrom 11 pat3
Ovarian 
endometriosis 
LOH at 6p 
Ovarian 
endometriosis 
LOH at 11q 
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Figure 1.20 continued. Selected images of chromosomal abnormality (chrom 6 and 
chrom 11 and chrom X) in ovarian endometriosis for patient 2 and patent 3 and patient 
6,  respectively. 
 
Chrom X pat6
 
 
 
Ovarian 
endometriosis 
LOH at Xp, Xq 
Chapter 2 Analytical observational studies 
76 
 
Chapter 2. ANALYTICAL OBSERVATIONAL STUDIES 
 
Introduction The use of cohort and case-control studies to benefit clinical practice. 
Appraising the clinical value of cohort and case-control studies. 
Results Examination of methodology through five topics in gynaecology 
Chapter  Title 
2.1 Predicting negligence in female sterilization failure using time interval to 
sterilization failure: analysis of 131 cases 
2.2 The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-
IUS) in the treatment of endometrial hyperplasia – a long-term follow-up 
study. 
2.3 Hospital recovery following Thermachoice ablation is not dependent on 
setting (outpatient or daycase) or rescue analgesia: unexpected result 
2.4 Outpatient Thermachoice endometrial balloon ablation: long term, 
prognostic and quality of life measures 
2.5 Long term outcomes following hysteroscopic myomectomy for abnormal 
uterine bleeding                                                                                                                      
 
Chapter 2 Analytical observational studies 
77 
 
 Introduction 
 
Cohort and case-control study methodologies are the main types of analytical observational 
study. Randomised controlled clinical trials are considered a superior methodology in the 
hierarchy of evidence, because they limit the potential for selection bias and minimise the 
influence of confounding due to differences between the two comparison groups (Table 2A). 
However, it is either impractical or unethical to perform RCTs to answer all clinical 
scenarios. Furthermore, cohort studies may provide important preliminary evidence to 
suggest whether a RCT is actually warranted or not. Both Cohort and RCT studies are able to 
determine relative risk as both measure incidence. The differences between cohort and RCT 
design are depicted in the table below. There are many famous longstanding cohort studies in 
medicine (e.g. Framingham in Heart Study) and obstetrics (e.g. UK Confidential enquiry into 
maternal and perinatal mortalities coordinated by CEMACH). 
The aim of this chapter was to assess the effectiveness of menstrual treatments (Outpatient 
Thermachoice endometrial balloon ablation and Hysteroscopic myomectomy) over a long 
time period in a pragmatic clinical setting (rather than highly selected population). It was felt 
that the best study design would be a prospective cohort analysis. The chapter discusses the 
findings in applying the cohort study design to this situation, how reliable data interpretation 
can be given the study design, and the practical beneficial clinical impact the study has 
achieved. Furthermore, the cohort study design is applied to a rare outcome measure that 
tends to occur after considerable time (failed female sterilisation). The cohort study design is 
chosen to test a mathematical (Bayesian) hypothesis that time interval to sterilisation failure 
is predictive of negligence rather than non-negligence. The publication of this work has 
clarified the medico-legal probability of negligence in those cases where the failure 
mechanism is unknown, and has therefore had profound medico-legal impact.
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Furthermore, in our end of thesis conclusion (chapter 5), we suggest that the cohort design 
may be under-utilised, and ways to address this. For example, provided the cohort design 
adopts strict case ascertainment and selection criteria (i.e.  minimises selection bias), is 
sufficiently powered to identify and correct for known confounders in comparison groups,
 
and utilises sophisticated statistical techniques in the analysis, then the results of the cohort 
analysis may be at least (if not more) as reliable as those obtained by a suitably powered 
RCT. To achieve this, robust large scale all inclusive prospective cohort databases are 
needed-akin to the electronic Patient Medical Records database envisaged for both USA and 
UK. 
Table 2A.Advantages and Disadvantages as displayed by Centre for Evidence-Based 
Medicine (Oxford, UK; www.cebm.net ) 
Cohort Study Randomised Controlled Clinical Trial 
Advantages: 
ethically safe 
subjects can be matched 
can establish timing and directionality of events 
eligibility criteria and outcome assessments can 
be standardised 
administratively easier and cheaper than RCT  
Advantages 
unbiased distribution of confounders 
blinding more likely 
randomisation facilitates statistical analysis. 
Disadvantages: 
controls may be difficult to identify 
exposure may be linked to a hidden confounder 
blinding is difficult 
randomisation not present 
for rare disease, large sample sizes or long 
follow-up necessary 
Disadvantages: 
expensive: time and money 
volunteer bias 
ethically problematic at times 
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2.1. Predicting negligence in female sterilization failure using time interval 
to sterilization failure: analysis of 131 cases 
 
BACKGROUND: Sterilization failure due to ‗tubal non-occlusion‘ or ‗wrong structure 
sterilization‘ is considered negligent, whereas ‗spontaneous tubal recanalization‘ or ‗fistula 
formation‘ is considered non-negligent. We examined whether interval to pregnancy failure 
was predictive of a negligent rather non-negligent failure mechanism. We aim to test this 
hypothesis in a selected population series of known mechanisms of sterilization failure and 
their time interval to failure.  
METHODS: Analyses of 131 failed sterilizations pooled from UK (NHS Litigation 
Authority, Medical Protection Society and our hospital), Australia and a qualitative 
systematic review.  
RESULTS: We identified 88 negligent and 43 non-negligent sterilization failures. Filshie 
and ring methods failed earlier than diathermy and Pomeroy methods. Sterilization failure 
occurred significantly earlier in negligent than non-negligent failure mechanisms [median 
failure intervals 7.0 versus 12.0 months; Hazard ratio (2.35 95% CI 1.31–4.21)]. Knowing 
that sterilization failure occurred early, increased the probability that the failure mechanism 
was likely to be negligent rather than non-negligent.  
CONCLUSIONS: A short interval to failure is suggestive of a negligent failure mechanism. 
There is less certainty in the predictive value of longer time intervals on the mechanism of 
failure due to a paucity of cases. A national register of failed sterilizations that have been 
systematically investigated is needed to improve our understanding of negligent and non-
negligent failure mechanisms. 
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INTRODUCTION  
Female sterilization is one of the commonest procedures performed worldwide. In 1999 
around 50,000 female sterilisations were performed in England in the NHS and charitable 
sectors 
1
 .  The procedure is performed on mainly healthy women at their request. Where 
resources permit, the preference is to use a laparoscopic technique that occludes tubal patency 
through tubal application of a mechanical device (e.g. Filshie, Hulka clip or Fallope ring) or 
electrocautery. Tubal excision and separation and related techniques (e.g. Pomeroy 
procedure) are preferred if sterilisation is performed at caesarean delivery. Conception that 
occurs after sterilisation is termed failed sterilisation and can occur several years after the 
procedure. Two large population-wide studies have reported the ten-year cumulative 
probability of pregnancy of 18.5 per 1000 procedures  (US CREST study) 
2
 and 8 per 1000 
procedures (Canada) 
3
 (Table 2.1). Differences in sterilisation failure rates arise due to 
variation in: the characteristics of the women undergoing sterilisation; operator experience; 
operating centre; sterilisation method chosen, and the time interval to resuming sexual 
activity post sterilisation and its frequency. However, neither of these studies reported on the 
precise mechanism of sterilisation failure. In the UK, the RCOG 
1
 recommends laparoscopic 
sterilisation by either Filshie clip or ring. The 10-year sterilisation failure rate for Filshie clip 
has been reported by studies as 2-3 per 1000 procedures (Table 2.1). 
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Table 2.1.  Filshie Clip sterilisation failure rates  
Study Period 
data are 
collected 
from 
Sterilisations  
Performed 
Sterilisation 
method 
Outcome Type of  
study 
Peterson
2
 
US Collaborative 
review of Sterilisation 
(CREST) 
1978-1986 
 
10,685 
 
Various methods. 
Hulka spring clip 
(1595) 
Silicone Rubber 
band (3329) 
Overall 18.5 per 1000 
over 10 years 
Hulka 36.5 per 1000 
Silicone rubber band 
17.7 per 1000 
Prospective 
cohort 
multicentre 
Trussell 
3
 1980-1999 311,960 Mainly 
Laparoscopic 
Filshie clip  
8 per 1000 
[2496 failures] 
Retrospective 
multicentre  
Kovacs 
6
 1994-1998 30,000 
(estimate) 
All Filshie 2.4 per 1000 
[73 failures]
a
 
Retrospective 
multicentre 
Filshie 
7
 1982-1992 First 202 
responders 
from a series 
of 434 
All Filshie 2.3 per 1000  
[1 failure at 6 months] 
Case series 
Birdsall 
8
 1988-1989 1094  Mainly 
Laparoscopic 
Filshie clip  
12 per 1000 at 12 
months 
b 
 
Case series 
Sokal 
9
 1984-1990 2746 Filshie clips vs. 
Rings 
[2 in each group 
became pregnant] 
1.7 per 1000 for both 
Ring and Filshie clip 
groups at 12 months 
RCT 
Dominik 
10
 1984-1990 2126 Filshie clips vs. 
Hulka clips 
[11 pregnancies 
occurred:  
9 Hulka,  
2 Filshie] 
 
At 12 months 
1.1 per 1000 for 
Filshie Clip  
 6.9 per 1000 for 
Hulka Clip group.  
At 24 months, 9.7 per 
1000 for Filshie  
and  
28.1 per 1000 for 
Hulka  
RCT 
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Footnotes to Table 2.1 
a
   Kovacs: Of the 73 failures, 14 cases were due to operator error, 29 were properly applied 
clips and 30 cases had unknown reason for failure. 
b    
Birdsall: Registrars had a 1.3% failure rate, consultants 1.9% and when both a consultant 
and registrar performed the procedure a failure rate was 0.7%. Eighty-six percent (6/7) of 
failed sterilisations were due to operator error (wrong structure, initial non-occlusion). 
 
The psychological and physical morbidity following failed sterilisation often leads to 
litigation 
4
. Women who have undergone sterilisation performed negligently are entitled to 
recover damages according to wrongful conception, negligence, and wrongful birth. Also, 
women are entitled to recover general damages for pain and suffering during pregnancy and 
delivery, and loss of earnings during pregnancy. A recent judgment in the Australian High 
Court 
5
  led the Australian government to amend the Civil Liberty Act to restrict the amount 
of damages that could be awarded in such situations.  
Despite intense medico-legal activity, research into the prevention and causation of 
sterilisation failure is lacking. The mechanism of failure should be identified through a 
systematic assessment of fallopian tube histology, X-ray hysterosalpingography and direct 
pelvic visual inspection. If the mechanism of failure is due to ‗tubal non-occlusion‘ or ‗wrong 
structure sterilisation ‘, these are considered negligent mechanisms, whereas ‗spontaneous 
tubal recanalisation‘ or ‗fistula formation‘ mechanisms of failure are considered non-
negligent. However, in the majority of failed sterilisation cases, even those in the advanced 
stages of litigation, the mechanism of failure remains unknown as there is no uniform 
requirement for such cases to undergo systematic enquiry or to be reported to any supervisory 
national registry. The RCOG should consider this requirement at the time of the sterilisation 
guideline review in 2006. 
1
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Thus, a common scenario in the legal setting is to cast judgment on the likelihood of 
negligence or non-negligence in cases with unknown mechanisms of sterilisation failure. Our 
qualitative systematic review 
4
 pooled 81 cases of sterilisation failure that had documented 
both interval to pregnancy and mechanism of failure. We showed that a greater proportion of 
early (within 12 months from operation) than late (after 12 months from operation) 
sterilisation failures occurred by a negligent mechanism. We therefore propose that interval 
to sterilisation failure may represent a surrogate marker of negligence and non-negligence. 
Our aim was to:- 
1. Determine if sterilisation failure occurred earlier in negligent than non-negligent groups. 
2. Determine if time interval to sterilisation failure was predictive of negligence. 
We aimed to test this hypothesis in a selected population series of known mechanisms of 
sterilisation failure and their time interval to failure.  
 
METHODS  
A written application was made to NHS Litigation Authority (NHSLA), Medical Defence 
Union (MDU) and Medical Protection Society (MPS) requesting anonymised information on 
failed sterilisation cases.  The NHSLA provided 16 cases and the MPS provided 8 cases. 
Similar anonymised failed sterilisation cases that had been subject to litigation proceedings 
were retrieved from our hospital legal services department (n=12) and a series from an 
Australian population (n=14) 
11
.  These cases were pooled with those identified in our 
previously published qualitative systematic review 
4
 (n=81).  A total of 131 failed 
sterilisation cases were identified that reported mechanism of sterilisation failure, interval to 
pregnancy and method used for each case. We have only included cases where the cause of 
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sterilisation failure has been established either by direct pelvic visualization or histology of 
the fallopian tubes or a combination of both. Most of our data series examines Filshie clip 
sterilisation failures as our data set emanates from countries where Filshie clip predominates 
as the preferred sterilisation method (i.e. UK and Australia). The derivation of this set is 
shown in Table 2.2.  
 
STATISTICAL ANALYSES  
Statistical analysis was undertaken using SPSS version 13. Geometric means were derived by 
exponentiating the means from the logarithm transformed interval to pregnancy data. 
Categorical correlations were assessed by Chi-squared analysis. Time-to-event methods 
(Kaplan-Meier and Cox regression) were used to investigate covariates impacting on time 
interval to pregnancy. Graphs of log cumulative hazard for failure against time interval for 
negligent and non-negligent cases were found to be parallel indicating that the proportional 
hazards assumption was true validating the use of the Cox proportional Hazard regression 
model. The probability that a randomly selected case was negligent given sterilisation failure 
before a specified time interval was calculated using Bayes‘ Theorem. 
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Table 2.2. Databases used to acquire failed sterilisation records 
Source of cases NHSLA  MPS BWH Australia
n 
Series 
 
Qualitative 
Systematic 
review 
Used in 
Study  
Dates of sterilisation 
procedure 
1995-
2004 
1990-
2004 
1987- 
1996 
1990- 
2000 
1966- 
2005 
 
Filshie     70 
b
 6 13 31 
b
 17 62+[2] 
Diathermy 
Ring 
Hulka 
b
 
Pomeroy 
0 
1 
0 
0 
 
4 
0 
1 
0 
 
0 
0 
0 
0 
 
0 
0 
0 
0 
 
20 
24 
1 
19 
24 
24 
[2] 
19 
Total included in study 
a
 16 8 12 14 81 131 
 
Footnotes:- 
NHSLA  National Health Service Litigation Authority 
MPS   Medical Protection Society, UK 
BWH   Birmingham Women‘s Hospital 
Australian series  This was published in our qualitative systematic review
4
. 
a
 Only cases that included all three components (mechanism of failure, interval to 
pregnancy and sterilisation method used) were included in the study‘s analysis. 
b
          Individual separate analysis of 2 Hulka clip cases would be extremely limited, 
therefore these were included with the Filshie clip category as both methods utilise similar 
mechanical tubal occlusive devices.  
Chapter 2.1 Predicting negligence in female sterilization failure 
86 
 
RESULTS 
1. Overall interval to pregnancy The mean age for the group was 33.2 years ( SD 4.4;  95% 
CI 31.9-34.4; age range 24-42 years). The arithmetic mean interval to pregnancy was 13.0 
months (SD 14.2; 95% CI 10.6-15.5; range 1 to 102 months). The greatest proportion of 
sterilisation failures occurred by 12 months (72.5%) in a markedly positively skewed 
frequency distribution. The distribution was normalised by natural log transformation of the 
interval to pregnancy times to give a geometric mean interval to pregnancy of 9.3 months 
(SD 2.2 months; 95% CI 8.1-10.6). Unlike the arithmetic mean, the geometric mean is not 
overly influenced by the large values in a skewed distribution, and so gives a better 
representation of the average for the purposes of this study.  
 
2. Negligent and non-negligent failure group compositions and intervals to pregnancy 
Filshie and Ring sterilisation methods failed significantly earlier than diathermy and Pomeroy 
methods (Log Rank p=0.037); the mean and range intervals to pregnancy are shown in Table 
2.3.  Non-occlusion and wrong structure mechanisms of failure occurred significantly earlier 
than fistula and recanalisation methods (Log Rank p=0.001); the mean intervals for negligent 
and non-negligent failure were 7.5 and 14.2 months respectively [Table 2.4]. There is a 
significant association between sterilisation method used and negligent and non-negligent 
mechanism of sterilisation failure (Chi-square, p= 0.001).  The Filshie clip, most often failing 
due to non-occlusion or wrong structure, is the predominant method in negligent failures 
(71% of cases) [Tables 2.3, 2.4]. Whereas, Pomeroy, only failing by recanalisation and 
fistula, is the predominant method in non-negligent failures (44% of cases) [Tables 2.3,2.4]. 
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Table 2.3. Sterilisation method and time interval to pregnancy 
Method of sterilisation Filshie Diathermy Ring Pomeroy 
or related 
surgical 
method 
Overall 
all  
Groups 
P value 
Number in group 64 24 24 19 131  
Interval to pregnancy (months) 
Geometric Mean 
95% confidence interval 
 
7.6 
6.1-9.5 
 
11.9 
8.5-16.6 
 
8.2 
7.6-9.9 
 
14.2 
11.4-17.9 
 
9.3 
8.1-10.6 
 
$
 0.037 
 
Range of time intervals to pregnancy 
(months) for each method 
 
Negligent           Non-occlusion 
                           Wrong structure 
 
Non-negligent   Fistula 
                           Recanalisation  
 
 
 
 
2-38 
1-102 
 
14* 
10* 
 
 
 
3-10 
9* 
 
3-44 
60* 
 
 
 
4-5 
7-20 
 
6-10 
6-13 
 
 
 
No cases 
No cases 
 
10-48 
4-18 
 
 
Footnotes 
$ Kaplan-Meier Log Rank (Mantel-Cox) test for interval to pregnancy difference 
* Single case only, therefore no range 
Chapter 2.1 Predicting negligence in female sterilization failure 
88 
 
Table 2.4. Negligent and Non-negligent failure group compositions and intervals to 
pregnancy 
MECHANISM OF FAILURE NEGLIGENT NON-NEGLIGENT 
 
P value 
Number in group 
 
mean interval to pregnancy and 
95% CI 
 
median interval to pregnancy and 
95% CI 
88 
 
7.5 [6.4-8.8] 
 
7.0 [6.1-8.0] 
43 
 
14.2 [11.8-17.2] 
 
12.0 [10.6-13.5] 
 
 
$ 
0.001 
Composition by method of 
sterilisation 
Number of cases / [%] 
Filshie 
Diathermy 
Ring 
Pomeroy 
62 [71%] 
13 [15%] 
13[15%] 
0 [0%] 
Filshie 
Diathermy 
Ring 
Pomeroy 
2 [5%] 
11 [26%] 
11 [26%] 
19 [44%] 
 
*<0.001 
Composition by mechanism of 
failure 
Mechanism 
 
mean interval to pregnancy and  
95% CI 
 
Mechanism 
 
 
mean interval to pregnancy and  
95% CI 
 
 
Non- occlusion     
45 [51%] 
6.4 [5.2-7.9] 
 
 
Wrong structure   
43 [49%] 
 
8.9 [6.9-11.3] 
 
 
Fistula               
19[44%] 
17.1 [12.1-24.1] 
 
 
Recanalisation   
24[56%] 
 
12.4 [10.2-14.9] 
 
 
 
 
 
$ 
0.001 
 
Footnotes 
* Pearson Chi-Square for category composition difference 
$ Kaplan-Meier Log Rank (Mantel-Cox) test for interval to pregnancy difference 
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3. Regression analysis of interval to failure  
Given that the interval to sterilisation failure was associated with sterilisation method and 
mechanism of failure, and that both of these latter variables may interact with each other, a 
Cox regression analysis was performed. The regression showed that negligence compared to 
non-negligence significantly increased the hazard potential for sterilisation failure, and that 
negligence (p=0.004) was the only statistically significant covariate when adjusting for 
sterilisation method (p=0.237). The unadjusted Hazard Ratio for negligence was 1.91 (95% 
CI 1.31-2.77), and adjusted Hazard Ratio was 2.35 (95% CI 1.31-4.21).  Therefore, interval 
to pregnancy was predictive of a negligent compared to a non-negligent failure mechanism, 
irrespective of the sterilisation method used. Specifically, the earlier the time interval to 
failure the greater the likelihood of negligence than non-negligence. This is graphically 
illustrated in Figure 2.1. 
 
4. Probability of negligence for any case given the interval to pregnancy 
We have assumed that sterilisation failure occurring before time t represents a test of 
negligence. We have calculated the various test positive (failed before or at time t) and test 
negative (failed after time t) likelihood ratios (LR) for negligence at various time intervals 
using Bayes‘ Theorem (Table 2.5). This table shows statistically significantly increasing 
Likelihood Ratios for negligence at successive earlier time interval increments. This is 
consistent with a mathematical trend that negligence is more likely the earlier the sterilisation 
failure occurs. 
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Table 2.5. Empirical probabilities and likelihood ratios at incremental time intervals. 
Time interval 
that 
sterilisation 
failure has 
occurred  
Negligent 
(n=88) 
Non-Negligent 
(n=43) 
 
 
Probability that 
randomly 
selected case is 
negligent from 
the study series 
given failure with 
time interval 
Likelihood Ratio 
of negligence 
given failure 
within time 
interval  
(LR test positive) 
Not stated 88 43 0.67* -n/a- 
0  6 40 4 0.91  4.89 (1.87-12.77) 
0- 9  61 7 0.90 2.48 (1.51-4.10) 
0  12 73 22 0.77 1.62 (1.19-2.20) 
0  18 81 33 0.71 1.20 (1.01-1.43 ) 
0  24 83 34 0.71 1.19 (1.01-1.40) 
0  48 86 42 0.67 1.15 (1.01-1.32) 
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Footnotes to Table 2.5 
* The pretest probability of negligence from our case series is 0.67. This corresponds to the 
probability of a randomly selected case of sterilisation failure being negligent when selected 
from our case series. However, knowledge of the time interval to sterilisation failure either 
increases or decreases the probability of the case being negligent as shown in the table.  
Likelihood ratios (LR) are derived by dividing the cumulative probabilities of sterilisation 
failure occurring at or before a certain time interval (t) according to Bayes‘ Theorem. For 
example, if we consider a test as failure at or before t=10 months then the LR for test positive 
is  
P(Fail |Neg) = 0.7386=2.65 
P(Fail |NonNeg) 0.2791 
 
and, the LR for test negative is 
P(NoFail<10m |Neg) = 1-0.7386 =  0.36 
P(NoFail<10m |NonNeg) 1-0.2791 
Thus, the probability that a randomly selected case is negligent may be calculated by 
knowing the time interval to failure, the Likelihood Ratios at that time interval (as displayed 
in Table 2.5) and the Bayesian equation:  
PRE TEST      X LIKELIHOOD RATIO        = POST TEST 
ODDS   FOR THAT TIME INTERVAL  ODDS 
 
Odds =      Prob.        Prob. = Odds 
          1-Prob.        1+ Odds 
From our case series (88 negligent, 43 non-negligent), the pre-test probability of negligence 
was 0.67 (88/88+43). However, our case series is highly selected. Therefore we suggest using 
a pre-test probability of negligence of 0.5 (Odds=0.5/1-0.5= 1). This pre-test probability 
would correspond to that used in legal proceedings in cases with unknown mechanism of 
failure and therefore derivation of the post-test probability of negligence (using the Bayesian 
equation or Fagan‘s nomogram) would be useful within this medicolegal context.. 
 
Let us suppose that a sterilisation failure occurred at 8 months and the pre-test probability of 
negligence is 0.5. The post-test probability of negligence for a case that fails before or at 8 
months is 0.73 (pre-test odds of 1 x LR 3.70=3.70 post test odds; probability is 3.70/1+3.70= 
0.79). In contrast, the post-test probability of negligence if failure had occurred after 8 
months is 0.32 (pre-test odds of 1 x LR 0.48=0.48 post test odds; probability is 0.48/1+0.48). 
This suggests that failure at 8 months is likely to be negligent because the probability 
distribution is greater in the negligent (0.73) than non-negligent (0.32) direction from a pre-
test probability of 0.5 (see Figure 2.1).  
Chapter 2.1 Predicting negligence in female sterilization failure 
92 
 
Figure 2.1. The probability of sterilisation failure for negligent and non-negligent cases 
against time interval to failure (Cox Regression model) 
Footnotes 
The graph depicts the 1-minus survival function plot of the adjusted Cox regression model 
function i.e. incorporates both sterilisation method and failure mechanism covariates. All 
cases have ultimately failed, therefore for both negligent and non-negligent cases the 
cumulatively probability is 1 at the maximum recorded time interval for each group.The 
hazard ratio corresponds to the odds that a case in the negligent group fails before a case in 
the non-negligent group. Thus, there is a 70% probability (converting Hazard odds of 2.35 to 
probability by 2.35/ (1+2.35)) that sterilisation failure will occur earlier in a negligent case 
than a non-negligent case, irrespective of the sterilisation method used. Furthermore, 
comparing median times (Table 2.3), negligence reduces the time interval to failure by 
approximately 5 months (or 42%) compared to non-negligence.  
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Let us suppose that a sterilisation failure occurred at 18 months and the pre-test probability of 
negligence is 0.5. The post-test probability of negligence for any case that fails before or at 
18 months is 0.55 (pre-test odds 1 x  LR 1.20=1.20 post test odds; probability is 1.20/1+1.20= 
0.79). In contrast, the post-test probability of negligence if failure had occurred after 18 
months is 0.25 (pre-test odds 1 x  LR 0.34=0.34 post test odds; probability is 0.34/1+0.34). 
This suggests that failure at 18 months is likely to be non-negligent because the probability 
distribution is greater in the non-negligent (0.25) than negligent (0.55) direction from a pre-
test probability of 0.5 (see Figure 2.1).  
 
DISCUSSION Analysis of our selected series of failed sterilisations has shown that a 
short interval to failure, and a long interval to failure are suggestive of a negligent and non-
negligent failure mechanism, whilst intervals between the two extremes are less reliable 
indicators of the mechanism of failure.  Negligence compared to non-negligence reduces the 
interval to failure by 5 months. A test of negligence may be applied to any case of 
sterilisation failure having been provided the time interval to pregnancy and the pre-test 
probability, as we have obtained likelihood ratios for the test at various time intervals. Such a 
test may have important medico-legal ramifications in cases with unknown mechanism of 
failure.  
 
Our case series represents the world‘s largest number of failed female sterilisations with 
concurrent knowledge of their mechanism of sterilisation failure and interval to pregnancy.  
Until this study, issues involving mechanism of failure, had not been addressed by the two 
largest studies of sterilisation failure 
2;3
 or the Cochrane review 
12
. We had predicted this 
hypothesis in our earlier qualitative systematic review 
4
. Previous studies had showed 
differences in time interval to failure for different sterilisation methods 
2
and patient age 
3
. 
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We agree there may be caveats when interpreting our results, particularly as our data series is 
selective. Firstly, our data series is composed of cases from 1975 onwards. Advances in 
training in laparoscopic procedures and laparoscopic video imaging may be under-
represented in our data series leading us to overestimate the proportion of negligence 
(operator-fault) that may occur with earlier (1970-1990s) sterilisation failures. Secondly, our 
study sample is not derived from a repository of systematically investigated and recorded 
sterilisation failures. Thirdly, although NHSLA has systematically collected data on litigated 
cases in England since 1995, there are many exclusion criteria allowing hospitals to locally 
manage some failed sterilisation cases thereby limiting case ascertainment. We were unable 
to examine the individual records from the NHSLA and MPS databases to verify the accuracy 
of the failure mechanism reported. Consequently, we are uncertain whether there are 
inconsistencies in the classification of failure mechanism used. Fourthly, we anticipate a 
general under-reporting of non-negligent sterilisation failures in the published literature and 
in the legal databases that we used for the study. Therefore, it is likely that our overall 
estimate of the prevalence of negligence (i.e. pre-test probability of 0.67, 88/88+43) from our 
case series is likely to exceed the upper limit of prevalence that would be obtained from the 
true population of systematically acquired sterilisation failures. 
 
Negligence litigation in the UK is based on the claimant producing the burden of proof 
(prove negligent action has occurred) and the standard of proof is the civil standard (balance 
of probabilities). The claimant has to show that the harm suffered (i.e. failed sterilisation) on 
the balance of probabilities, is more likely than not to be caused by a negligent action than 
non-negligent action. In this legal situation, an unknown mechanism of sterilisation failure 
could be presumed to have a pre-test probability of negligence of 0.5 (legal equivalence). If a 
case had failed at say 8 months, then applying our test of failure before or at 8 months (post 
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test probability of 0.73) and failure after 8 months (post test probability of 0.32) indicates that 
failure at 8 months is more likely to be negligent than non-negligent.  Furthermore, for any 
given interval to pregnancy, the post-test probabilities of negligence for failure before or after 
a specified time interval could be derived using the Bayesian methodology discussed in this 
manuscript. Although our test provides an overall probability of negligence >0.5 or <0.5  and 
therefore satisfies the legal test of negligence or non-negligence, we would always endorse 
that the actual negligent or non-negligent cause of sterilisation failure can only be established 
after a systematic clinical, histopathological and X-ray examination process. 
 
A national register of systematically collected and investigated failed sterilisations, as 
recommended by the RCOG 
1
, would quantify the exact prevalence (pre-test probability) of 
negligent and non-negligent failure mechanisms, and show how this proportion is distributed 
amongst the various sterilisation methods, enabling its use in the legal situation described 
above. Little is known on non-negligent failure mechanisms due to poor case ascertainment, 
but such a registry may show that the probability of a non-negligent sterilisation failure 
equated to the probability of a negligent sterilisation failure for a particular sterilisation 
method, which would then make any legal claim for negligent sterilisation unlikely to 
succeed.  Furthermore, such a registry could identify areas of substandard care that could be 
used as an impetus to improve medical training and design effective clinical risk prevention 
strategies. 
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2.2. The effectiveness of a levonorgestrel-releasing intrauterine system 
(LNG-IUS) in the treatment of endometrial hyperplasia – a long-term 
follow-up study. 
 
OBJECTIVES: Medical treatment of non-atypical endometrial hyperplasia with oral progestogens 
has limited efficacy and poor compliance. A levonorgestrel-releasing intrauterine system (LNG-IUS) 
has been shown to successfully treat hyperplasia in small-sized studies.  Our aim was to examine the 
effectiveness of LNG-IUS in a larger study with long term follow up.  
METHODS: Prospective observational study of 105 women diagnosed with endometrial hyperplasia 
and treated with LNG-IUS between 1999-2004 at a University Teaching hospital. Baseline 
characteristics and outpatient endometrial Pipelle sampling was undertaken at 3 and 6 months post 
LNG-IUS insertion and 6-monthly intervals thereafter in all cases. Outcome included histological data 
derived from both Pipelle and uterine histologies at one and two years LNG-IUS therapy. 
RESULTS:  LNG-IUS achieved endometrial regression in 90% (94/105) of cases by two years, with 
a significant proportion (96%, 90/94) achieving this within one year. Regression occurred in 88/96 
(92%) of non-atypical and 6/9 (67%) of atypical hyperplasias, and in all 22 cases of endometrial 
hyperplasia associated with HRT. Regression rates did not differ between histological types of 
hyperplasia. Twenty-three (22%) underwent hysterectomy of which 13 were indicated and 10 were 
performed at patient request despite regressed endometrium. Two cases of cancer (one uterine and one 
ovarian) were identified.  
CONCLUSION:  LNG-IUS is highly effective at treating endometrial hyperplasia. Beneficial effects 
are observed by the majority within one year. Treatment can be reliably monitored through regular 6-
montly outpatient endometrial Pipelle surveillance. LNG-IUS treatment of non-atypical hyperplasias 
is likely to reduce the number of hysterectomies performed in this subgroup.  
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INTRODUCTION Endometrial hyperplasia may be divided into three principal 
histological categories listed in the order of ascending architectural and cytological 
abnormality: simple, complex and atypical hyperplasia 
13
 . Cytological atypia is the most 
important prognostic factor for progression to carcinoma 
14
. Around 1-3% of non-atypical 
hyperplasias progress to endometrial carcinoma, over a mean duration of 10 years. In 
contrast, 8-30% of atypical hyperplasias progress to carcinoma over a mean duration of 4 
years 
15
. Pooling three observational studies 
16-18
 the rates of spontaneous regression after 
expectant treatment for non-atypical (n=129) and atypical hyperplasia (n=28) are around 72% 
and 54% respectively.  
The objectives of treating women with endometrial hyperplasia are to reduce abnormal 
bleeding symptoms and to prevent progression to endometrial cancer
18-20
. In view of an 
increased oncogenic potential with atypical endometrial hyperplasia, hysterectomy is 
generally recommended unless fertility issues or significant risk factors for surgery preclude 
this. However, for non-atypical endometrial hyperplasia, there is debate as to whether 
hysterectomy is ‗over-treatment‘ given the low risk of malignant transformation, high 
probability of possible spontaneous resolution, low risk of coexistent uterine cancer and high 
therapeutic responsiveness to oral progestogen therapy. Nonetheless, oral progestogens are 
associated with poor compliance and systemic side effects that may limit overall efficacy 
18;19;21
.  Levonorgestrel-releasing intrauterine system (LNG-IUS) may be used to successfully 
treat endometrial hyperplasia without incurring the disadvantages of oral progestogens. This 
finding has been demonstrated in two recently published observational studies 
22;23
, together 
with a systematic review 
24
 that included four limited sized studies
25-28
. Our objective was to 
examine the effectiveness of LNG-IUS to treat endometrial hyperplasia in a larger 
prospective observational study with a long-term follow-up period. 
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METHODS All women participating in this study had presented to our hospital 
(Birmingham Women‘s Hospital, England) for the investigation of abnormal uterine 
bleeding. Their reasons for referral included: women aged 40 years and over with heavy 
menstrual bleeding or intermenstrual bleeding aged unresponsive to medical therapies (such 
as tranexamic acid, combined oral contraceptive or oral progestins), post-menopausal 
bleeding and unscheduled bleeding whilst on hormone replacement therapy or tamoxifen. 
Natural menopause was recognised to have occurred if there had been at least 12 consecutive 
months of amenorrhoea, for which there was no other obvious pathological or physiological 
cause. Clinical investigation involved transvaginal pelvic sonography, outpatient endometrial 
Pipelle sampling (Laboratoire C.C.D, Paris, France) and outpatient hysteroscopy in all cases. 
Intrauterine polyps that were identified at hysteroscopy were removed using outpatient local 
anaesthetic Versapoint® (Gynecare, Ethicon Inc. USA) polyp resection or blind polypectomy 
techniques. 
Endometrial hyperplasia was subdivided into three categories: simple, complex and atypical. 
For the purposes of this study, we grouped simple atypical and complex atypical hyperplasias 
as one atypical hyperplasia group. The criteria for diagnosing endometrial hyperplasia and 
endometrial regression of hyperplasia following LNG-IUS use was as we
29
 and others 
13;30-32
 
have previously described. Typically, LNG-IUS resulted in atrophy of glands separated by 
plump, polygonal, pseudodecidualised stromal cells. These were accompanied by varying 
degrees of secretory glandular changes and Metaplasia of the lining epithelium. These 
changes have been collectively and loosely termed as ―regression‖ of hyperplasia in this 
article. This is not a defined histological entity except in the context of follow up of 
endometrial hyperplasia. Similar morphology can be seen with both oral progestogens and 
intrauterine progestogen (LNG-IUS) when used for other clinical indications. 
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Our study included cases where hyperplasia was only present in the endometrial polyp but 
not the background endometrium, a phenomenon also described by a previous study 
33
.All 
histopathological diagnoses were undertaken by two experienced consultant histopathologists 
(TR, RG) working independently; referral to the other pathologist for a second opinion was 
made in cases where there was diagnostic doubt, and a mutual consensus was then achieved.  
 
Throughout the study period (January 1999-January 2004) there were 114 women diagnosed 
with non-atypical hyperplasia. All were offered oral progestogens, LNG-IUS insertion 
(Mirena®,  Schering Health Care, Burgess Hill, UK) or hysterectomy as part of our routine 
practice; those opting for LNG-IUS (n=105) were included in our study cohort.  Women 
diagnosed with atypical endometrial hyperplasia were recommended to undergo 
hysterectomy. Women who declined surgery or who were medically unfit to undergo surgery 
were offered oral progestogens or LNG-IUS insertion; the latter LNG-IUS treated group 
(n=9) were included our study cohort. Women diagnosed with non-atypical endometrial 
hyperplasia whilst using hormone replacement therapy (HRT) were offered either withdrawal 
of HRT and LNG-IUS, withdrawal of HRT and oral progestagens, or HRT (either estrogen 
replacement therapy or continuous combined preparations) and LNG-IUS; those opting for 
combinations involving LNG-IUS (n=22) were included in our study cohort. 
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Baseline data and study design  
Insertion of LNG-IUS took place between January 1999 and January 2004. For all women in 
the study (n=105) anonymised baseline data was recorded on: histological subtype, 
sociodemographic characteristics [with emphasis on risk factors for endometrial hyperplasia 
such as parity, body mass index, diabetes, hypertension], use of exogenous hormones (e.g. 
hormone replacement therapy, tamoxifen), and presenting with abnormal bleeding symptoms.  
Study participants underwent regular outpatient clinic review and endometrial histological 
surveillance by outpatient Pipelle sampling. Histological surveillance was performed at 3-
months and 6-months following LNG-IUS insertion, and continued thereafter at 6-monthly 
intervals in all cases (n=105). We present the outcome for participants at 1 and 2 years post 
LNG-IUS insertion, however, in clinical practice, we are continuing to prospectively record 
outcome beyond this time, even in cases that show endometrial regression.  LNG-IUS 
treatment was abandoned and hysterectomy recommended if:- 
1. There was no histological evidence of partial or complete regression of the hyperplasia by 12 
months of LNG-IUS use. 
2. There was histological evidence of endometrial cancer or progression of endometrial hyperplasia 
to atypia. 
3. There was reversion to the original endometrial histology showing hyperplasia following a period 
of endometrial regression. 
4. The primary outcome was the proportion of women with complete regression of the endometrial 
hyperplasia according to both outpatient endometrial Pipelle and uterine histologies at 
hysterectomy. Secondary outcomes included time to disease regression, the proportion of women 
undergoing hysterectomy (histologically indicated or non-histologically indicated) and the 
accuracy of outpatient Pipelle compared to uterine histology at hysterectomy. 
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Statistical analysis  
SPSS version 13 for Windows (Release 13.0, 1 Sep 2004, SPSS Inc.) was used.  The 
significance of different histological subtypes and other covariates on time interval to 
regression was determined by Kaplan-Meier and Cox-regression survival analysis. A P value 
less than 0.05 was considered statistically significant. Sensitivity, Specificity and Likelihood 
Ratios were derived by constructing a 2 by 2 table and using standard techniques
34
. 
RESULTS 
Baseline characteristics 
There were 105 women with endometrial hyperplasia (simple 16, complex 80, atypical 9) 
included in the 5-year study period. A summary of the baseline characteristics and presenting 
symptoms are shown in Table 2.6.  The mean age was 54.5 ± SD 10.1 years (range 37-88). 
The study comprised of 37 premenopausal and 68 postmenopausal women. Most women 
presented with postmenopausal bleeding (n=68). Endometrial polyps were visualised in 
36/105 (34%) cases at hysteroscopy. Hyperplasia in the endometrial polyp, but not in the 
background endometrium, occurred in 16% (17/105) of cases; all remaining cases had 
endometrial hyperplasia identified within the endometrium. 
Endometrial regression at 2 years post LNG-IUS insertion 
Figure 2.2 summarises the outcome of the 105 hyperplasias that received LNG-IUS 
according to pre-treatment and 2-year outpatient endometrial Pipelle histologies. In contrast, 
Table 2.7 summarises the outcome of the study according to histological data derived from 
both outpatient endometrial Pipelle and hysterectomy histologies at 1 and 2 years post LNG-
IUS insertion. The derivation for the data are explained in the footnotes to Figure 2.2 and 
Table 2.7. 
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Table 2.6. Baseline characteristics (n=105) of LNG-IUS treatment of endometrial 
hyperplasia 
Characteristic Size of parameter 
 
Age (years) Mean 54.5   (St Dev 10.1, Range 37-88) 
Weight (kg) Mean 86.0    (St Dev 28.0, Range 50-168 
BMI kg/m
2
 Mean 32.0    (St Dev 8.8. Range 18-67) 
Characteristic  
Percentage of cases in study group (equals number of cases) 
 
Parity 
a
 21% (22)   Parity 0 
43% (45)   Parity 1 or 2 
23%  (24)  Parity 3 or higher 
Mean 1.87; St Dev 1.34, Range 0-5 
Menopausal status 35% (37) Premenopausal; 65% (68) Postmenopausal 
Diabetes 18% (19) 
Hypertension 30%  (31) 
Exogenous HRT 
 
 
Exogenous 
tamoxifen 
21% (22)  
1%   (1)  
Abnormal bleeding 
symptoms on 
presentation 
27% (28)    Premenopausal, abnormal uterine bleeding 
9%   (9)      Premenopausal, unscheduled bleeding with HRT 
51% (54)    Postmenopausal bleeding 
13% (14)    Postmenopausal, unscheduled bleeding with HRT or tamoxifen 
Footnotes 
a
 Missing parity data in 14 cases 
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Table 2.7. Outcome of the study according to histological data derived from outpatient 
endometrial Pipelle and hysterectomy histologies 
 
Endometrial  
Hyperplasia 
(number of 
cases at study 
commencement) 
Total 
number 
of cases 
regressing 
with 
LNG-IUS 
a
 Mean time 
for regression 
(months) and  
95% 
Confidence 
limits 
Proportion 
achieving 
regression 
b  
by 
12 months of 
LNG-IUS 
Proportion 
achieving 
regression 
b
  by 
24 months of 
LNG-IUS 
 
Simple (n=16) 15 (94%) 6.2 (4.4-8.0) 15/16 15/16 
Complex (n=80) 73 (92%) 9.4 (7.0-11.7) 69/80  73/80
  
 
Atypical  (n=9) 6 (67%)   8.2 (5.2-11.3) 6/9  6/9  
Overall group 
(n=105) 
94 (90%) 9.0 (7.0-11.1 ) 
c
 90/105 
c 
94/105
 
 
2. 1 Outcome of study according to histology from Pipelle or hysterectomy 
Footnotes 
a
  There are no statistically significant differences in probabilities of regression 
 over time between simple, complex and atypical hyperplasias [Kaplan-Meier 
 Log Rank Mantel-Cox (p=0.20)). 
b
     Data on histological regression is derived from combined use of outpatient 
 endometrial Pipelle and hysterectomy histologies.  
c
  Two of the 94 cases that shown regression on Pipelle, were subsequently identified to 
have atypical hyperplasia (one case, formerly simple hyperplasia) and ovarian cancer (one 
case, formerly complex hyperplasia). The former case underwent hysterectomy at patient 
request due to troublesome abnormal bleeding side effects with LNG-IUS despite Pipelle 
regression. The latter case underwent hysterectomy as this was indicated through ongoing 
sonographic surveillance for a postmenopausal cyst concurrent with the regressed Pipelle. 
Both cases were identified within one year of LNG-IUS treatment.  
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Figure 2.2.  Outcome of study according to outpatient endometrial Pipelle histology at 
pre-treatment and 2-years following LNG-IUS insertion 
Footnotes 
a
 Of the 10 hysterectomies at patient request from the stayed regressed group, 
histologies from the uteri showed nine regressed uteri and one atypical endometrial 
hyperplasia. This is further explained in Table 2.7, footnote c.  
b
          Of the 7 reverted hyperplasias, all were non-atypical hyperplasias on Pipelle, all were 
offered hysterectomy, five declined hysterectomy in favour of continuing with LNG-IUS. Of 
the 2 indicated hysterectomies performed, histological analysis showed one had regressed and 
one had complex hyperplasia.  
c 
         Of the 11 persisting hyperplasias, all were offered hysterectomy, one declined 
hysterectomy in favour of continuing with LNG-IUS. Of the 10 indicated hysterectomies 
performed, histological analysis showed two had regressed, one simple, four complex, two 
atypical hyperplasias persisted and one case of Stage 1A endometrial cancer.  
LNG-IUS (n=105)
(simple 16, complex 80, atypical 9)
Regressed (n=94)
(simple 15, complex 73, atypical 6)
Persisting hyperplasia (n=11)
(simple 1, complex 7, atypical 3) 
Stayed regressed (n=87)
(simple 14, complex 69, atypical 4)
Reversion of hyperplasia (n=7)
(simple 1, complex 4, atypical 2)
Persisting hyperplasia (n=11)
(simple 1, complex 7, atypical 3)
aStayed regressed (n=87)
68 continue with Mirena
8 continue with Mirena and ERT
1 indicated hysterectomy [ovarian ca]
10 hysterectomy at patient request
bReversion of hyperplasia (n=7)
5 continue with Mirena
2 indicated hysterectomy
cPersisting hyperplasia (n=11)
1 continue with Mirena
10 indicated hysterectomy [of which, 
one case endometrial ca.)
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Outpatient endometrial Pipelle regression was observed in 94/105 cases, and of these, 87/94 
continued to maintain endometrial regression at 2 years follow up (Figure 2.2). Failed 
treatment, indicated by persisting Pipelle hyperplasia or hyperplasia that regressed then 
reverted to hyperplasia, occurred in 18/105 cases (Figure 2.2).  
Overall, 90% (94/105) of the study participants achieved endometrial regression according to 
combined outpatient Pipelle and hysterectomy histologies (Table 2.7). A significant 
proportion (96%, 90/94) had achieved this by one year of LNG-IUS use.  
Survival analysis methods (Kaplan-Meier, Cox proportional hazard) showed there was no 
statistically significant difference between the types of hyperplasia in terms of the time 
interval to regression (Table 2.7). The overall mean interval to regression was 9 months 
(95% CI 7.0-11.1) for the overall group (Table 2.7). Furthermore, survival analysis showed 
no statistically significant association of baseline covariates (age, parity, menopausal status, 
BMI, diabetes, hypertension, exogenous estrogen or tamoxifen use) on the rate of regression. 
Endometrial hyperplasia associated with Hormone Replacement Therapy (HRT) 
Of the 22 cases of HRT associated endometrial hyperplasia and treated subsequently with 
LNG-IUS, 2 stopped HRT, 17 continued with cyclical combined HRT and 3 opted for 
estrogen only HRT.  All were non-atypical hyperplasias (19 complex and 3 simple), and all, 
apart from one case, showed endometrial regression with LNG-IUS therapy. The non-
regressed complex hyperplasia underwent hysterectomy and uterine histology subsequent 
confirmed endometrial regression had in fact occurred. There was a single case of tamoxifen 
associated complex hyperplasia which initially regressed with LNG-IUS then reverted back 
to complex hyperplasia; uterine histology at hysterectomy confirmed complex hyperplasia.  
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Two cases of cancer 
Two cases of cancer were identified. One case was Stage 1B ovarian cancer, which had been 
identified in a complex hyperplasia that had regressed at 3 months with LNG-IUS but had 
been under ultrasonographic surveillance for a persistent postmenopausal ovarian cyst. The 
other case was Stage 1A endometrial cancer, which had been identified in a case of complex 
hyperplasia that had shown non-regression at 12 months with LNG-IUS and therefore 
underwent indicated hysterectomy (Figure 2.2). 
 
Hysterectomy and correlation with endometrial Pipelle 
Hysterectomy occurred in 23/105 women, and a summary of the origin and indication for 
hysterectomy is shown in Figure 2.2.  Most hysterectomies (12/23) were performed for 
persisting hyperplasia and reversion to hyperplasia following initial regression to normal 
histology. However, 10/23 hysterectomies were performed in women with endometrial 
regression on Pipelle histology. The reasons cited included: worsening or persistence of 
abnormal bleeding symptoms (3), patient request (4), patient fear of progression to cancer (1), 
uterine prolapse (1) and concurrent cervical intraepithelial neoplasia (1). In all these cases the 
endometrium was extensively sampled, including the cornual aspects, and showed changes 
secondary to the local progestogen therapy without any evidence of hyperplasia. Using 
histology of the uterus at hysterectomy as the ―gold standard‖ and the preceding endometrial 
Pipelle biopsy as a diagnostic test, then Pipelle had a sensitivity of 83% and specificity of 
73% for identifying endometrial regression (Table 2.8).  
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Table 2.8 Correlation between endometrial Pipelle histology and hysterectomy histology 
(n=23 hysterectomies) 
 Uterine Histology at 
 Hysterectomy 
Regressed  
endometrium 
Not regressed 
endometrium 
Endometrial 
Pipelle 
biopsy 
Test positive: showing  
regression 
10 3 
Test negative: 
showing  
non-regression 
2 8 
Sensitivity 83% 
Specificity 73% 
Likelihood ratio (95% confidence interval) 
LR (positive test) 3.06 (1.23-8.74) 
LR (negative test) 0.23 (0.06-0.70) 
 
DISCUSSION 
LNG-IUS is highly effective at treating endometrial hyperplasia, irrespective of whether non-
atypical or atypical hyperplasia is being treated. Beneficial effects are observed by the 
majority within one year of treatment. Treatment success can be reliably monitored through 
regular 6-monthly outpatient endometrial Pipelle surveillance. Future widespread use of 
LNG-IUS to treat non-atypical hyperplasias is likely to reduce the number of hysterectomies 
performed for this condition, and thereby avoid exposing women to unwarranted surgical 
risks. 
 
This is the largest published series of the use of LNG-IUS to treat endometrial hyperplasia 
24;26;28;35-38
. Furthermore, we believe this is the first study to examine the use of LNG-IUS to 
treat endometrial hyperplasia occurring in HRT users. The prospective design and strict data 
collection proforma used in this study ensured uniform inclusion/exclusion criteria and 
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reliable collection of all outcome measures. The study was designed as a pragmatic measure 
of the effectiveness of LNG-IUS at one and two-years, therefore our results are applicable to 
current clinical practice. 
 
Our study could be criticised for not incorporating a control (expectant management) or 
cohort (e.g. oral progestogens) comparison group. Furthermore, our study is under- powered 
to detect genuine differences in subtypes of endometrial hyperplasia, as well as investigate 
their significance along with other covariates (e.g. diabetes, hypertension, HRT) on the 
likelihood of regression with LNG-IUS treatment.  
 
It has been established that outpatient endometrial biopsy is accurate in diagnosing 
endometrial hyperplasia 
39
. However, we accept there may be uncertainty in our estimations 
of sensitivity and specificity of endometrial Pipelle in correlating to uterine histology. This is 
because we only performed hysterectomy and obtained ‗gold standard‘ uterine histology in 
around a quarter of study participants, and there may be differences in histological criteria 
used by others and our own group. Nonetheless, by finding similar degrees of test accuracy as 
previous authors 
18;40-43
we believe our results are at least consistent with the published 
literature. Furthermore, we minimised the histopathological bias by utilising strict predefined 
histological criteria and limiting the histological interpretation to two experienced 
Histopathologists. 
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Overall, our study‘s 90% (94/105) endometrial regression rate incorporates regression rates 
of 92% (88/96) and 67 % (6/9) for non-atypical and atypical hyperplasias, respectively.  A 
higher regression rate of 95% (19/20) with regression rates of 100% (12/12) and 88%(7/8) for 
non-atypical and atypical hyperplasias had been observed in a recently published long-term 
study 
44
. This difference could be explained by the longer duration of follow up in the 
published study 
45
. Nevertheless, our study‘s non-atypical regression rate is similar to the oral 
progestogen treatment regression rate (93%, n=134) 
46
and exceeds the expectantly managed 
regression rate of 72% (93/129) identified by pooling studies 
16-18. This study‘s atypical 
regression rate does not significantly differ from the expectant regression rate of 54% (15/28) 
identified from the same pooled studies. Importantly, this study suggests a trend for 
intrauterine progestogen therapy to regress non-atypical rather than atypical hyperplasia, 
which is a finding that has also been suggested by other groups 
46-51
. 
 
We would have expected LNG-IUS use in our study to have led to a greater reduction in 
hysterectomy treatment for hyperplasia. However, for a variety of unexpected reasons (e.g. 
personal choice, fear of progression) in addition to those due to failed medical treatment or 
unwanted side-effects with LNG-IUS, women opted for hysterectomy. We were unable to 
further explore how such patient preferences could impact on patient satisfaction, compliance 
and cost-effectiveness of LNG-IUS compared to hysterectomy treatment alternatives.   
Furthermore, as we were dealing with a pre-malignant condition, in an age group not 
requiring to conserve the uterus for fertility, this would lead to an increased risk of favouring 
a hysterectomy decision, irrespective of whether endometrial regression had been successful 
or unsuccessful. 
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Both cases of cancer identified in the study were Stage I tumours, and were readily identified 
within one year of insertion of LNG-IUS. It could be argued that earlier hysterectomy, 
instead of LNG-IUS medical treatment, would have prevented cancer development or 
improved prognosis if cancer was identified earlier. In this context, our study suggests around 
50 hysterectomies would be needed to prevent (NNT) one case of gynaecological cancer in 
women with endometrial hyperplasia.  
 
Oral progestagens and hysterectomy are widely accepted treatment options for endometrial 
hyperplasia 
18;19;52
. Newer therapies under evaluation include endometrial ablation 
53
 and 
aromatase inhibitors
54
. Nonetheless, we believe that the success of this study, utilising LNG-
IUS therapy, should provide an impetus for future robust randomised controlled trials to 
evaluate the effectiveness of medical and surgical treatments in treating endometrial 
hyperplasia. Successful validation of the treatment potential of LNG-IUS for endometrial 
hyperplasia will undoubtedly reduce the number of women undergoing hysterectomies for 
this condition and avoid exposing them to unwarranted surgical risks.
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2. 3. Hospital recovery following Thermachoice ablation is not dependent 
on setting (outpatient or daycase) or rescue analgesia: unexpected result 
 
Background: Thermal balloon endometrial ablation (TBEA) is increasingly being performed 
in the outpatient setting under local anaesthesia (LA) rather than in a daycase setting under 
general anaesthesia (GA).  Our aim was to compare the post operative rescue analgesia 
requirements and duration of hospital say in women undergoing outpatient (LA) and daycase 
(GA) TBEA.   
Methods: Prospective observational study of consecutively recruited women who underwent 
outpatient (LA) TBEA (n=51) and daycase (GA) TBEA (n=50) over the same time period.  
Analgesia that was provided additional to the standard administered analgesic regimen was 
considered rescue analgesia. The main outcome measures were requirement for rescue 
analgesia and duration of hospital stay in both cohorts. 
Result(s): LA compared to GA cohorts had shorter hospital stays (11 hours [95% CI 9-13] 
vs. 17 hours [95% CI 14-20]) and lower analgesia requirements. However, multivariate 
regression, correcting for all known confounders, showed that duration of stay was 
independent of setting for ablation or amount of rescue analgesia. 
Conclusion(s): Duration of hospital stay is not entirely dependent on whether outpatient or 
daycase endometrial ablation is considered. This unexpected preliminary finding deserves to 
be validated in future confirmatory trials that compare outpatient and daycase treatments. We 
also discuss the confounding factors that should be considered when designing such trials. 
Abbreviation(s): TBEA: Thermal Balloon Endometrial Ablation; LA: Local anaesthesia; 
GA: General Anaesthesia; CI: Confidence Interval. 
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INTRODUCTION Menorrhagia has a considerable impact on many women's lives 
55
.  
Endometrial ablation is being increasingly used as a treatment option 
56
 and is endorsed by 
National Institute for Health and Clinical Excellence, NICE, UK 
55
. There is wide variation in 
the preferred endometrial ablation device and whether treatment should be performed in the 
outpatient local anaesthetic (LA) or daycase general anaesthesia (GA) setting 
57-61
. 
 
Outpatient therapy has obvious advantages in terms of safety, convenience and short 
discharge time for the woman, and may be preferred over GA for women with high risk 
medical conditions
62;63
. We 
64
, along with other groups 
65-68
, have had considerable 
experience and success in performing outpatient thermal balloon endometrial ablation 
(TBEA).  We perform local anaesthetic (LA) thermal balloon endometrial ablation in the 
conscious patient without sedation at any time in the menstrual cycle and without prior 
endometrial preparation.  
 
There is considerable heterogeneity in postoperative pain and duration of hospital stay 
reported for LA and GA endometrial ablations. This may be partly explained by differences 
in peri-operative analgesic regimens adopted by such studies. Even if such confounding 
influences are minimized, it remains unclear whether women experience higher levels and/or 
prolonged duration of pain during and after LA TBEA compared to GA TBEA. This 
information would be particularly important when counseling women on their choices 
between LA and GA TBEA. Given the paucity of robust data to answer this concern
64;69;70
, 
we conducted a prospective study to compare rescue analgesia requirement and duration of 
hospital stay in LA and GA TBEA.   
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MATERIALS AND METHODS: 
Patient Population Pre-menopausal women with subjectively defined heavy menstrual 
bleeding were referred by primary care (GP) and / or by secondary care physicians for 
assessment in our menstrual disorders clinic. Our routine practice was to offer a first line trial 
of medical treatments for at least 6 months if there was no clinical suspicion of underlying 
pathology. The medical treatments included Levonorgestrel-releasing intrauterine hormone 
system (LNG-IUS; Mirena®, Schering Health Care), combined oral contraceptive, 
progestogens (oral and long-acting), tranexamic acid and /or mefenamic acid.  
 
All women underwent transvaginal pelvic sonography, hysteroscopy and outpatient 
endometrial Pipelle biopsy (Laboratoire C.C.D, Paris, France) investigations. Any 
significantly sized intrauterine polyps (greater than 2cm in size) were excised by either blind 
polyp forcep avulsion or Versapoint [Gynecare, Ethicon Inc. USA) resection. Women were 
excluded from the study if there were significantly sized uterine fibroids (fibroids greater 
than 3cm size in any uterine location), enlarged uterine size (uterine cavity length greater 
than 10cm), abnormally shaped uterine cavity (e.g. bicornuate uterus), endometrial 
hyperplasia or cancer, or active pelvic infection. 
 
Women with normal sized uteri (less than 10cm cavity size), no underlying structural uterine 
pathology and unresponsive to medical therapy commenced by their GP or secondary care, 
were offered thermal balloon endometrial ablation TBEA (either under LA or GA) and 
hysterectomy as second-line treatments.  Those women who opted for TBEA were given the 
choice of undertaking the procedure under LA or GA. 
 
Chapter 2.3 Outpatient vs. Daycase Thermachoice 
114 
 
Study design Recruitment for the study occurred in a prospective continuous manner 
between June 2003 and June 2005. During this time period, two prospective consecutively 
recruited cohorts were established: LA TBEA and GA TBEA i.e. both cohorts were 
constructed and evaluated over the same time period in parallel. 
Intervention Endometrial ablation was performed using a Thermachoice III (Gynecare®, 
Menlo Park, California, USA) device according to the manufacturer‘s guidance.  
Local  Anaesthetic TBEA This was performed in our ambulatory gynaecological clinic 
according to our previously described protocol 
64
, which included:- 
Pre-procedure analgesic regimen (one to two hours prior to TBEA): 
 All women received diclofenac 100mg rectally, oral co-dydramol 10/500 (two tablets) and 
oral cyclizine 50 mg. Tramadol hydrochloride 100mg was used if non steroidal analgesia was 
contra-indicated.  
Local anaesthetic: The cervix was directly injected in a circumferential manner with three 
2mL cartridges containing 3% prilocaine hydrochloride (30 mg/mL) and felypressin 
0.03 unit/mL (citanest with octapressin®, Dentslply, UK) using a 27G dental syringe.  
Dedicated patient nurse: A particular nurse was allocated to provide continuous supportive 
care to the patient during the procedure. The nurse engaged the patient in conversation 
(‗distraction‘ analgesia effect termed ―vocal local‖) and often held the patient‘s hand 
throughout the procedure.  
Post ablation day case bed stay: All women recovered in a day case bed and were allowed 
home after a minimum stay of 2 hours. A strict protocol of post-procedure pain relief was 
adhered to. A patient information leaflet was provided detailing expected symptoms and 
analgesic advice post LA TBEA.  
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General Anaesthetic TBEA    Women, fasted for at least 6 hours, were admitted to hospital 
on the day of the procedure. In a minority of cases, women with high risk medical disorders 
(e.g. diabetes) were admitted the day before the planned procedure.  TBEA was carried out in 
gynaecology theatres after induction of general anaesthesia.  All women received diclofenac 
100mg and 1g paracetamol rectally (or paracetamol alone if diclofenac was contraindicated) 
just prior to performing TBEA. Infiltration of the cervix with a local anaesthetic was not done 
in these women.  The TBEA surgical procedure, post-procedure analgesia regimen and day 
case bed stay for GA TBEA were identical to the LA TBEA procedure described above. 
 
Outcome measures Initial baseline data recorded were: age, body mass index, menorrhagia 
alone or combined with dysmenorrhoea, menstrual cycle phase, ultrasound and hysteroscopy 
findings and uterine axis. In relationship to TBEA procedure, the following data were 
recorded: mean intrauterine ablation pressure, successful completion of TBEA procedure, 
procedure related complications (e.g. vasovagal episodes for LA TBEA) and duration of 
hospital stay following the TBEA procedure. All women were asked to record the pain they 
experienced immediately following LA TBEA on a graduated Visual Analogue Scale (VAS), 
ranging from 0 (no pain) to 10 (worst imaginable pain), which had been validated in our 
previous study 
64
. 
 
Rescue analgesia This refers to analgesia that was administered post TBEA that was 
additional to the routinely supplied peri-operative analgesia regimen.  Rescue analgesia was 
administered at the request of the woman following nurse-led enquiry. The amount of rescue 
analgesia was determined according to the woman‘s VAS score at the time of enquiry and 
hierarchy of analgesia that was available on a standardised ‗as required‘ drug prescription 
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chart. To quantify the amount of rescue analgesia we utilised a numerical (morphine 
equivalent dose) and an ordinal (mild, moderate, severe) scale was created according to the 
following: 
a) Morphine Equivalent Dose. This is the estimated bioequivalent dose of morphine sulphate 
(in milligrams) that corresponds to the oral analgesic preparations (such as codeine 
phosphate, dihydrocodeine) given according to an accepted validated conversion scale 
71
. 
b) An ordinal ranking scale of none, mild, moderate, strong, very strong rescue analgesia. 
This scale was created by the study authors, and recorded as mild (paracetamol <2g or 
diclofenac  <100mg only), moderate (paracetamol <2g and diclofenac <100mg or low 
morphine equivalent dose <15mg) or strong (paracetamol>2g or diclofenac>100mg or high 
morphine [>15mg] dose) or very strong (paracetamol> 2g and diclofenac>100mg and 
morphine>15mg or high morphine [>30mg] dose) grading for strength of analgesia usage. 
 
Post TBEA procedure (common to both LA and GA TBEA cohorts)  
All women recovered in a daycase bed. Women were discharged home according to a Nurse-
led care plan that required patients to have tolerated oral diet, voided urine, and have 
adequate pain control.  All women were discharged with a patient information leaflet that 
described expected postoperative symptoms and were given instructions to take regular 
analgesics for the first 24 hours (diclofenac 50 mg three times daily and/or co-dydramol 
10/500 two tablets four times daily).  In addition, all women were contacted by telephone at 
home the following day to check on their progress. 
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Statistical analysis:  
Dichotomous data were presented as simple proportions.  SPSS version 13 was used to 
undertake univariate linear regression and multivariate regression analysis and to conduct 
Chi-square and Mann-Whitney U test for comparing the difference between the two groups.  
P < 0.05 was considered statistically significant.   
Sample size & Power calculation  
There was no pilot data of the expected mean and standard deviation values for the amount of  
analgesia used or hospital stay.  Hence, a sample size calculation was not performed a priori 
to study commencement. However, if we assume that a clinically significant difference of the 
mean between two groups is 0.5 Standard Deviations, then the sample size required for an 
alpha of 0.05 and a power of 80% is 64 in each group. Hence, as our study recruited 101 
subjects, it approaches the power required to detect this accepted clinically significant 
difference.  
 
RESULTS: There were 51 and 50 women in LA and GA TBEA cohorts respectively.  
Baseline characteristics are depicted in Table 2.9.  The procedure was completed 
successfully in all women in both cohorts.  There was no serious morbidity in either cohort.  
Individual requirements for different analgesics are shown in Table 2.10.  The strength of 
rescue analgesia was found to be statistically significantly lower in the LA compared to GA 
cohort: 8/51 compared to 47/50 women required moderate to strong analgesia, respectively 
(Table 2.10).   
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On univariate analysis, duration of hospital stay correlated to strength of rescue analgesia and 
type of TBEA; significantly lower in LA (11 hours; 95% CI 9 - 13 hours) compared to GA 
(17 hours; 95% CI 14 - 20 hours) cohorts (Tables 2.10, 2.11 and Figure 2.3). However, 
multivariate regression, correcting for identifiable confounding influences (listed in footnotes 
of Table 2.11), showed that duration of hospital stay was independent of strength of rescue 
analgesia and type of TBEA (Table 2.11). In the LA cohort, there were no postoperative 
complications in 44 (86%) women but 7 (14%) stayed overnight; 2 (4%) due to excessive 
vomiting and 5 (10%) due to pain.  In the GA cohort, there were no postoperative 
complications in 36 (72%) patients but 19 (38%) stayed overnight; 2 (4%) due to excessive 
vomiting, 4 (8%) due to pain, 3 (6%) due to urinary retention, 4 (8%) due to dizziness and 6 
(12%) due to medical reasons unrelated to the ablation procedure (such as hypotension, 
hypertension, transient oxygen requirement). 
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Table 2.9.  Baseline and procedural characteristics of LA vs GA TBEA 
 LA TBEA 
N=51 
GA TBEA 
N=50 
Overall 
N=101 
 
Mean age years (Range) 
 
44.1 (30-54) 
 
42.6  (29-55) 
 
43.4 (29-55) 
Mean BMI (Range) 30.3 (19-55) 27.7 (14-45) 28.9 (14-55) 
Presenting complaint 
Menorrhagia 
Menorrhagia & dysmenorrhoea 
 
46 
5 
 
40 
10 
 
86  
15  
Phase of cycle 
Menstrual 
Proliferative 
Mid-cycle 
Secretory 
 
9 
12 
5 
25 
 
1 
19 
14 
16 
 
10 
31 
19 
41 
Uterine Scan findings 
Normal  
Polyp or fibroid 
 
43 
8 
 
41 
9 
 
84 
17 
Uterine axis 
Anteverted 
Retroverted 
Axial 
 
36 
7 
8 
 
37 
13 
0 
 
73 
20 
8 
Hysteroscopic Uterine findings 
Normal  
Polyp or fibroid 
 
44 
7 
 
47 
3 
 
91 
10 
Intrauterine Ablation pressures (mmHg)  
(95% CI intervals) 
170 
(164-175) 
171 
(168-174) 
170 
(168-173) 
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Table 2.10.  Outcomes of LA vs. GA TBEA 
 LA-TBEA 
N=51 
GA-TBEA 
N=50 
Overall 
N=101 
Difference 
between LA 
and GA 
P value 
 
Mean duration of stay (hours) 
(95% CI intervals) 
 
11 
(9-13) 
 
17 
(14-20) 
 
14 
(12-16) 
 
0.001 
Strength of analgesia 
None 
Mild  
Moderate 
Strong 
Very strong 
 
1 
42 
7 
1 
0 
 
0 
3 
7 
33 
7 
 
1 
45 
14 
34 
7 
 
0.001 
Paracetamol   Used (mean dose, mg) 
                       Not used 
25 (617) 
26 
42 (1760) 
8 
67 (1206) 
34 
0.001 
Diclofenac     Used (mean dose, mg) 
                       Not used 
0 
51 
 44 (101) 
6 
44 (52) 
57 
0.001 
Morphine Mean Equiv.Dose (mg) 
(95% CI intervals) 
13.8 
(11.5-16.1) 
14.2 
(11.0-17.3) 
14.0 
(12.0-15.9) 
0.940 
 
Footnotes 
Statistical tests include Chi-square and Mann-Whitney U test. 
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Table 2.11. Regression analysis 
 Duration of Hospital Stay $ 
LA vs. GA Thermachoice  
Univariate ^ 
Multivariate* 
 
0.001  
0.786 
Strength of Rescue analgesia 
Univariate ^ 
Multivariate* 
 
0.001 
0.303 
Footnotes 
$ Univariate Linear Regression modelling 
* Multivariate Regression corrected for the presence of fixed categorical factors [LA or GA; presenting 
complaint; uterine axis; scan findings; hysteroscopic findings; menstrual phase] and covariates [strength of 
rescue analgesia; intrauterine ablation pressure; uterine length; age; BMI]. 
^ All statistical models were statistically significant (P<0.001) apart from final multivariate regression model.  
 
Figure 2.3.  Correlation of duration of stay with strength of analgesia for combined LA 
and GA TBEA cohort 
 
Statistically significant correlation (Pearson P=0.001; Kendall P=0.001)  
 
 
 
 
 
 
 
 
 
 
 
Footnotes        Central box dot shows Mean.  Error Bars show 95% Confidence Interval of Mean. 
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DISCUSSION: 
This preliminary study suggests that duration of hospital stay is independent of setting 
(outpatient or daycase) of endometrial ablation or amount of rescue analgesia administered. 
Even though on direct observation it appears that there may be shorter post-recovery times 
and lower rescue analgesia with outpatient compared to daycase ablation. This information 
may be useful for preoperative counselling, but its unexpected result deserves to be validated 
in future confirmatory trials. 
 
To date, there is a dearth of evidence comparing outpatient LA and GA daycase 
hysteroscopic based treatments, including endometrial ablation 
55;57-61
. We believe our study 
is the largest sized comparison of LA and GA endometrial ablation, and exceeds the size of 
the recently published RCT comparison of outpatient and daycase Thermachoice 
65
. 
Introduction of study bias was minimized by the prospective continuously recruited cohort 
study design and adopting standardized regimens for perioperative analgesia and post-
operative care. The study was conducted in a pragmatic manner and therefore our findings 
are applicable to current practice.  
 
However, we accept there may be limitations that may make our conclusions less reliable. 
We did not utilise any specific method of reliably identifying women‘s individual pain 
thresholds (e.g. able to either tolerate outpatient endometrial Pipelle or outpatient 
hysteroscopy procedure) prior to ablation and so are uncertain to the prevalence of women 
with low-to-high pain thresholds in our two cohorts. Women who opted for LA TBEA may 
have an inherently higher pain threshold, received more detailed pre-procedure counselling, 
and be more motivated to successfully complete and recover from this procedure, than 
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women who opted for GA TBEA. Likewise, higher analgesia in the GA cohort may relate to 
the higher prevalence of reported dysmenorrhoea and retroverted uterus (possibly indicating 
more significant pathology such as endometriosis) compared to the LA cohort. Alternatively, 
it is conceivable that the local anaesthetic itself induces highly effective peri-operative 
analgesia and its effects are sustained over several hours.  We attempted to correct for this 
confounding using multivariate regression. However, overall, our study is non-randomised 
and likely to be underpowered; the use of regression methodology in such circumstances may 
have led to spurious interpretation. It would have been useful to record patient satisfaction 
with pre-procedure counselling, as well as their original preferences for TBEA setting (even 
if they ultimately had a different TBEA setting) prior to the procedure and explore how these 
factors could impact on both short (post procedure analgesia and recovery time) and long-
term outcomes (e.g. surgical re-intervention rates).   
 
We achieved successful completion of outpatient TBEA in all our cases [100%, 51/51], 
which exceeds that reported by the recently published RCT [87%, 34/39] 
65
. Our mean 
outpatient recovery time of 11 hours (which includes 7/51 overnight admissions) is 
considerably greater than the trial‘s 1 hour 40 minutes 65.  We believe these differences arise 
due to fundamentally differing patient selection criteria and protocols for perioperative 
analgesia and nurse-led discharge.   
 
At first glance, and in agreement with a recent RCT 
65
, we showed that LA may result in a 
lower analgesia requirement and shorter recovery time period, indicating from both a cost-
effective and patient‘s perspective that TBEA should be preferentially performed in the 
outpatient LA rather than currently favoured daycase GA setting. However, our 
―multivariate‖ regression, which corrected for all potential confounders and was not 
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undertaken by the previous trial 
65
, showed that there was no statistically significant 
association between setting (outpatient LA or daycase GA) or amount of rescue analgesia 
upon duration of hospital stay. This contradicts the earlier stated hypotheses that there may be 
inherent differences between LA and GA groups in relation to women‘s pain thresholds or of 
a ―superior‖ analgesic effect induced through use of LA compared to GA technique.  In order 
to define the optimum role for outpatient ablation, we recommend further RCTs directly 
comparing outpatient against daycase treatments. It is important that these trials are 
sufficiently powered, and are able to correct for the confounding influences we have 
discussed earlier. 
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2.4. Outpatient Thermachoice endometrial balloon ablation: long-term, 
prognostic and quality of life measures 
 
STUDY OBJECTIVE: To compare short and long term treatment outcomes of outpatient local 
anaesthetic thermal balloon endometrial ablation (LA-TBEA) and identify any prognostic factors. 
DESIGN: Prospective observational study  
DESIGN CLASSIFICATION: II-2  
SETTING: U.K. teaching hospital. 
PATIENTS: 102 menorrhagic women undergoing LA-TBEA between 2001-2005. 
INTERVENTIONS: Thermachoice I (n=51) and Thermachoice III (n=51) TBEA performed under 
local anaesthesia without conscious sedation. 
MEASUREMENTS: Treatment completion, pain and analgesia, duration of stay (from admission to 
discharge), duration of follow up, need for secondary treatment (repeat ablation, hysterectomy or 
LNG-IUS), menstrual symptoms and amenorrhoea, patient satisfaction, and quality of life.  
RESULTS: TBEA was completed in 97.1% of women. Mean duration of stay was 8.0 hours (95% CI 
6.6-9.3). Mean follow up was 29 months (95% CI 26-32). Secondary treatment occurred in 19/102 
(19%) and was more likely in Thermachoice I (15/51, 29%) than Thermachoice III (4/51, 8%). 
Overall, 50% of surgical re-interventions occurred by 19 months. There were high rates of 
amenorrhoea (29%) and treatment satisfaction (76%). Higher mean intrauterine ablation pressure was 
associated with increased treatment satisfaction.  
CONCLUSION:  Endometrial ablation can be successfully performed in the outpatient setting with 
better success rates achieved with Thermachoice III.  Higher ablation pressures improve long term 
outcomes. 
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INTRODUCTION 
There has been considerable expansion in the establishment of Outpatient ‗One Stop‘ ‗See 
and Treat‘ ambulatory clinics in the management of women with abnormal uterine bleeding 
72
.  Endometrial ablation is being increasingly used as a treatment option 
56
 and is endorsed 
by National Institute for Health and Clinical Excellence, NICE 
55
. Outpatient therapy has 
obvious advantages to the patient in terms of safety, convenience and short discharge time 
after treatment.  The health provider gains by avoidance of costs associated with in patient 
admission and general anaesthesia.  There is wide variation in the preferred endometrial 
ablation device 
73;74
 and whether treatment should be performed in the outpatient (using local 
anaesthetic and/or sedation) or daycase general anaesthesia setting 
69;75
. 
 
We 
64
, along with other groups 
65-68
, have had considerable experience and success in 
performing outpatient thermal balloon endometrial ablation (TBEA).  We perform local 
anaesthetic thermal balloon endometrial ablation (LA-TBEA) in the conscious patient 
without sedation at any time in the menstrual cycle and without prior endometrial 
preparation.  
 
In relation to TBEA, there are particular prognostic factors associated with favourable 
outcome following ablation; these include: anteverted compared to retroverted uterus, older 
age, shorter uterine length, lower (<10ml) intrauterine balloon volumes and higher 
intrauterine pressures 
68;76-79
. Our aim was to compare the short and long term (minimum 12 
months follow-up) treatment outcomes for outpatient LA-TBEA using Thermachoice I and 
Thermachoice III devices and identify any prognostic factors that may influence treatment 
outcome. 
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MATERIALS AND METHODS 
Study population Recruitment for the study occurred prospectively, in a continuous 
manner, between February 2001 and August 2005.  During this time period, we upgraded our 
Thermachoice device: at study commencement we used Thermachoice I (Gynecare®, Menlo 
Park, California, USA) and this was replaced with Thermachoice III (Gynecare®, Menlo 
Park, California, USA) from August 2003 onwards. Thermachoice III contained an impeller 
fan that provided a more even temperature gradient within the balloon and on its surface. 
Accepting that there may be differences in the treatment outcomes between the different 
devices, we have compared outcomes between Thermachoice I and III, as well as reported 
overall combined outcomes. 
 
Pre-menopausal women with subjectively defined heavy menstrual bleeding were referred by 
primary care (GP) and / or by secondary care physicians for assessment in our menstrual 
disorders clinic. In the clinic, all patients are assessed on the need for treatment based on the 
impact of heavy menstrual bleeding (HMB) on the patient‘s quality of life, reported 
menstrual symptoms, presence of gynaecological pathology (all women routinely had pelvic 
ultrasound), fertility requirements, and proven anaemia. Our routine practice was to offer a 
first line trial of medical treatments for at least 6 months if there was no clinical suspicion of 
underlying pathology. The medical treatments included Levonorgestrel-releasing intrauterine 
hormone system (LNG-IUS; Mirena®, Schering Health Care), combined oral contraceptive, 
progestogens (oral and long-acting), tranexamic acid and / or mefenamic acid. This method 
of practice has been endorsed by the National Institute of Clinical Excellence (NICE) 
guideline on HMB 
55
.All women were investigated by transvaginal pelvic sonography, 
outpatient endometrial Pipelle (Laboratoire C.C.D, Paris, France)  and outpatient 
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hysteroscopy. Women with normal sized uteri (less than 10cm cavity size), no underlying 
structural uterine pathology and unresponsive to medical therapy commenced by their GP or 
secondary care, were offered endometrial ablation (either under general anaesthetic or local 
anaesthetic), or hysterectomy as second-line treatments.  Those women who opted for LA-
TBEA were invited to participate and included in this study. This population included women 
with regular and irregular menstrual cycles who expressed a desire for further treatment. No 
specific screening test (e.g. able or unable to tolerate endometrial Pipelle® biopsy without 
local anaesthesia) was undertaken prior to LA-TBEA in order to minimise potential bias in 
patient selection and maintain the pragmatic nature of the study.  
 
Intervention LA-TBEA was undertaken in our ambulatory gynaecological clinic according 
to our previously described treatment protocol 
64
. Essential elements of the protocol include:- 
Timing of TBEA: Ablation was performed at any time during the menstrual cycle and without 
any prior endometrial preparation.  
Pre-medication: All women received diclofenac 100mg rectally, oral co-dydramol 10/500 
(two tablets) and oral cyclizine 50 mg. Tramadol hydrochloride 100mg was used if non 
steroidal analgesia was contra-indicated.  
 Conscious patient: no intravenous cannulation was present.  There was no use of 
sedation. 
 Local anaesthetic: The cervix was directly injected in a circumferential manner with 
three 2mL cartridges containing 3% prilocaine hydrochloride (30 mg/mL) and felypressin 
0.03 unit/mL (citanest with octapressin®, Dentslply, UK) using a 27G dental syringe.  
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 Dedicated patient nurse: A particular nurse was allocated to provide continuous 
supportive care to the patient during the procedure. The nurse engaged the patient in 
conversation (‗distraction‘ analgesia effect termed ―vocal local‖) and often held the patient‘s 
hand throughout the procedure.  
 Pre-ablation hysteroscopy: All women underwent an outpatient hysteroscopy check 
prior to LA-TBEA. An endometrial biopsy had usually been carried out prior to the 
scheduled TBEA. A zero degree microhysteroscope with a 2.5-mm rigid outer sheath (Karl 
Storz, Tuttlingen, Germany) was used. Between 10-100mL of Normal Saline via a nurse 
controlled syringe was used as intrauterine distension medium. Any significantly sized 
intrauterine polyps (greater than 2cm in size) were excised by either blind polyp forcep 
avulsion or Versapoint [Gynecare, Ethicon Inc., Somerville, NJ, USA]) resection prior to LA-
TBEA (Table 2.12). Women were excluded from the study if there were significantly sized 
uterine fibroids (fibroids greater than 3cm size), enlarged uterine size (uterine cavity length 
greater than 10cm), abnormally shaped uterine cavity (e.g. bicornuate uterus), endometrial 
hyperplasia or cancer, or active pelvic infection.  
 Type of Thermachoice device: Thermachoice I (February 2001-July 2003) and 
Thermachoice III (August 2003-August 2005) devices were used. 
 Intrauterine ablation pressure: The manufacturer recommends this is maintained 
between 160mmHg and 180mmHg.  However at the discretion of the operator, the upper 
limit of pressure was controlled in manner so that it did not exceed 195mmHg. This was 
consistently applied in both Thermachoice I and III groups (Table 2.13). 
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Table 2.12. Baseline demographic data for outpatient TBEA 
  Thermachoice 
I    (N=51) 
Thermachoice 
III (N=51) 
Thermachoice 
I and III 
N=102 
P-value 
(Thermachoice 
I vs. III)* 
     
Mean Age   (95% CI; St Dev)  43.4 (41.9-44.8;4.7) 44.1 (42.4-45.7;5.6) 43.7 (42.6-44.8;5.2) 0.118 
Mean BMI  (95% CI; St Dev) 28.8 (26.5-31.1;7.4) 30.3 (28.0-32.6;7.8) 29.6 (28.0-31.2;7.6) 0.318 
Indication for Ablation     
Menorrhagia alone  43 46 89 0.373 
Menorrhagia & severe dysmenorrhoea 8 5 13  
Cycle phase^    0.167 
Proliferative 18  11 29  
Mid-cycle 11  15 26  
Secretory  17  25 42  
Uterine axis^    0.539 
Anteverted 20 36 56  
Axial 2 8 10  
Retroverted 5 7 12  
Ultrasound scan findings    0.029 
Normal 34 45 79  
Polyp 5 1 6  
Fibroid $ 12 5 17  
Hysteroscopy findings     
Normal 44 44 88 0.020 
Polyp 0 5 5  
Fibroid $ 7 2 9  
Median uterine size cm 
And (Range) 
8.0 
(7-10) 
8.0 
(7-13) 
8.0 
(7-13) 
0.964 
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Footnotes 
* Statistical tests include Chi-square, Mann-Whitney U 
^ Data not reported in all cases, calculation based on cases that were reported 
$ Fibroid corresponds to identification of any submucous, intramural or subserosal fibroids 
by either ultrasound or hysteroscopy that are less than 3cm in size 
The comparisons in BOLD are those that are statistically significant with a P value <0.05 .  
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Table 2.13. Peri-procedure outcomes of outpatient TBEA 
Footnotes 
* Statistical tests include Chi-square, Chi-Square trend, Mann-Whitney U 
^ Data not reported in all cases, calculation based on cases that were reported 
$ Excluding 13/102 cases that stayed overnight, the mean duration of hospital stay (minutes) with 95% 
Confidence limits are: 294 [257-330], 364 [326-402] and 329 [303-357; standard deviation 120] for 
Thermachoice I, III and overall combined I and III respectively.  
The comparisons in BOLD are those that are statistically significant with a P value <0.05 .  
 Thermachoice 
I 
Thermachoice 
III 
Thermachoice 
I+III 
P-value 
(Thermachoice 
I vs. III)* 
     
Mean Volume of fluid in mL    
(95% CI; SD) 
24.1  
(16.5-31.8;13.3) 
 
19.2 
(15.8-22.7 ; 11.6) 
20.4 
(17.3-23.5 ; 12.1) 
0.07 
Average Intrauterine pressure  
(95% CI ; SD ) 
157 
(147-166 ; 16) 
169 
(164-176 ; 19) 
167 
(162-172; 19) 
0.004 
Mean hospital stay minutes (hours)$ 
(95% CI; SD in minutes) 
(95% CI; SD in hours) 
433 (7.2h) 
(318-547; 382) 
(5.3-9.1; 6.4) 
522 (8.7h) 
(405-639; 398) 
(6.8-10.7; 6.6) 
478 (8.0h) 
(397-559; 391) 
(6.6-9.3; 6.5) 
0.277 
Mean Visual Analogue Pain  
(95% CI; SD) 
5.6 
(4.7-6.6; 1.6) 
5.9 
(5.1-6.8; 2.9) 
5.8 
(5.2-6.5; 2.7) 
0.541 
Rescue Analgesia ^     
Paracetamol  (frequency) 32 25 57 0.412 
Diclofenac (frequency) 3 0 3 0.074 
Mean Morphine Equivalent Dose (mg)$$ 
 (95% CI; SD) 
4.8 
(3.0-6.5; 6.2) 
13.0 
(10.7-15.3; 8.0) 
8.9  
(7.3-10.5; 8.3) 
0.001 
Overall strength of analgesia $ 
No rescue analgesia 
Mild 
Moderate 
Strong 
 
12 
30 
4 
5 
 
3 
25 
6 
17 
 
15 
55 
10 
22 
 
0.005 
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Post ablation day case bed stay: All women recovered in a day case bed and were allowed 
home after a minimum stay of 2 hours. A strict protocol of post-procedure pain relief was 
adhered to: supplementary analgesia (termed Rescue Analgesia) was provided according to 
the patient‘s pain relief scores and patient request from a standardised ‗as required‘ written 
drug prescription. A patient information leaflet was provided detailing expected symptoms 
and analgesic advice post LA-TBEA. All women were contacted by telephone at home the 
following day to check on their progress. 
Strength of rescue analgesia. To quantify the amount of rescue analgesia utilised a numerical 
(morphine equivalent dose) and ordinal (mild, moderate, severe) scale was created according 
to the following methods:   
a) Morphine Equivalent Dose. This is the estimated bioequivalent dose of morphine 
sulphate (in milligrams) that corresponds to the oral analgesic preparations (such as codeine 
phosphate, dihydrocodeine) given according to an accepted validated conversion scale 
71
. 
b) An ordinal ranking of mild, moderate, severe rescue analgesia. This scale was created 
by the study authors, and recorded as mild (paracetamol or diclofenac only), moderate 
(paracetamol and diclofenac or low morphine equivalent dose) or strong (paracetamol 
/diclofenac / morphine, or high morphine [>15mg] dose) grading for strength of analgesia 
usage.  
 
Outcome measures Initial baseline data recorded were: age, body mass index, menorrhagia 
alone or combined with dysmenorrhoea, menstrual cycle phase, ultrasound and hysteroscopy 
findings, uterine axis and uterine size. Procedure-related data recorded were: types of 
Thermachoice device, total fluid volume used, mean intrauterine ablation pressure, 
completion of TBEA procedure and any complications (e.g. vasovagal episodes).  
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All women were asked to record the pain they experienced immediately following LA-TBEA 
on a graduated Visual Analogue Scale, ranging from 0 (no pain) to 10 (worst imaginable 
pain), which had been validated in our previous study 
64
. Amount and type of patient-initiated 
post procedure analgesia and duration of hospital stay (from initial admission to hospital and 
actual discharge) were also recorded.  
A postal questionnaire was sent to all women post LA-TBEA to determine the effectiveness 
of therapy between July-September 2006. Questionnaire response was maximised by re-
contacting women (by phone and letter) with non-returned forms in accordance with accepted 
practice 
80
. Patient completed data recorded were: menstrual improvement (amenorrhoea, 
lighter periods), menstrual worsening or no change; satisfaction with treatment result or 
dissatisfaction; need for secondary treatment and type (e.g. LNG-IUS, repeat TBEA or 
hysterectomy); usage of HRT; Menorrhagia-specific and generic quality of life measures. 
Both menorrhagia disease-specific (Shaw) 
81
 and generic (EuroQol-5D) 
82
 Quality of Life 
tools were utilised to improve the sensitivity and accuracy in determining this outcome; both 
these tools had been validated in previous related studies 
83;84
. The clinical case records of 
women undergoing hysterectomy secondary treatment were accessed to determine uterine 
histology. Similarly, the case records for women with missing questionnaires were accessed 
to determine if any secondary treatment had been necessary.  
  
Statistical analysis All statistical analysis was performed using SPSS 13.0 statistical 
software (release 1 Sept 2004, ©SPSS Inc., USA). Categorical data was analysed by Chi-
square and Chi-square trend testing. Continuous data was analysed by Mann-Whitney U test. 
A P-value less than 0.05 was considered statistically significant.  Multivariate regression 
(binary logistic, ordinal and linear) was used to explore the significance of various baseline 
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and procedure related factors (i.e. prognostic factors or independent variables) on key 
outcome measures (duration of hospital stay, satisfaction, amenorrhoea and quality of life i.e. 
dependent variables). We accept the risk of increased overall Type I error (the probability of 
incorrectly rejecting a null hypothesis) when performing multiple hypothesis tests in 
multivariate regression. The Bonferroni method lowers the observed significance level 
because of multiple testing and provides a method to achieve an overall study error rate of 
0.05 using a corrected p-value derived by 1- (1-α)1/n, where α=0.05 and n=number of 
hypothesis tests. However, given this was an exploratory statistical analysis, rather than a 
formal confirmatory study, then correcting for multiple testing procedures is not always 
considered necessary 
85;86
. We have therefore reported both uncorrected and Bonferroni 
corrected P-values to enable readers to interpret the true significance of any p<0.05 result in 
line with other factors (e.g. consistency of finding, biological plausibility and clinical 
relevance) 
85;86
. 
 
Ethics A formal application to a Research Ethics Committee was made and they 
recommended that ethics approval was not required as the study was classified as service 
evaluation according to established Central Office for Research Ethics Committees (COREC) 
guidelines. The study was conducted in accordance with basic ethical principles and 
complying with the Data Protection Act 2000 (e.g. informed consent, maintaining patient 
confidentiality, anonymizing patient held data, secure electronic storage of data).  
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RESULTS 
Baseline and peri-procedure outcomes There were no significant differences in the 
baseline characteristics between Thermachoice I (n=51) and Thermachoice III (n=51) cohorts 
apart from differences in ultrasound and hysteroscopic findings (Table 2.12).  Of 105 
consecutively recruited women that underwent planned LA-TBEA, the procedure was 
successfully completed in 102 (97%). Of the 3 failures, two were technical failures (one 
equipment breakdown, one severe cervical stenosis), and due to abandonment of the LA-
TBEA at 3 minutes due to severe patient discomfort. These 3 failures all occurred in the first 
10 cases of Thermachoice I cohort and may therefore be related to a learning curve effect of 
the operator and nursing team (i.e. develop better patient reassurance and analgesic regimes). 
Other complications included: 1 case of severe vasovagal syncope (not requiring atropine), 1 
case of endometritis, 3 cases of severe vomiting, and 9 cases of severe pain requiring 
overnight admission. Fully completed questionnaires were returned by 88/102 participants 
(86%), and partially completed in a further 7 participants (95/102; 93%).  
 
All peri-procedure outcomes are depicted in Table 2.13. The overall (n=102) mean duration 
of hospital stay following Thermachoice I and III was 8.0 hours (95% CI  6.6 to 9.3 hours; 
Standard Deviation 6.5 hours) [Table 2.13].  However, this mean has been skewed due to the 
inclusion of a small proportion of women (n=13/102; 12.8%) who required overnight 
admission. Exclusion of this subgroup (6/51 Thermachoice I, 7/51 Thermachoice III) leads to 
an overall mean duration of stay of 5.5 hours (95% CI 5.1 to 6.0 hours; Standard Deviation 
2.0 hours) [Table 2.13]. Thus, outpatient LA-TBEA was successfully completed as an 
ambulatory day case (under 6 hours hospital stay) procedure in the vast majority.  
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The amount of morphine rescue analgesia used directly correlated to the post ablation VAS 
score and duration of hospital stay (Figure 2.4). Univariate analysis showed that 
Thermachoice III was associated with greater use of rescue analgesia, but was also performed 
at higher mean intrauterine pressure than Thermachoice I (Table 2.13). 
 
Long term outcomes: Table 2.14 shows the long term outcomes in Thermachoice I 
and III procedures (performed between February 2001-July 2003, follow up range 26-54 
months and August 2003-August 2005, follow up range 12-29 months respectively).  Overall, 
despite the majority of women reporting improvement in their menstrual symptoms 
(amenorrhoea 29%, lighter periods 55%; total 84%), not all of these were satisfied (overall 
satisfaction rate 78%).  Further treatment (repeat TBEA, hysterectomy or LNG-IUS) was 
required in 19/102 cases (19%). Of the 14 hysterectomies performed as secondary treatment 
around two-thirds had adenomyosis or fibroids on uterine histopathology.  Satisfied 
compared to dissatisfied women reported higher levels of quality of life and menstrual 
improvement (Table 2.15). Overall, 50% of surgical re-interventions (n=16, 14 
hysterectomies, 2 repeat ablations) occurred by 19 months (Range 10-46 )(Figure 2.5).  
Kaplan-Meier survival analysis suggested a statistically significant trend to earlier surgical 
re-intervention  with Thermachoice III than Thermachoice I (Log Rank Mantel-Cox  
p=0.024). However, Cox regression showed that this was a non-significant (p=0.056) trend 
when corrected for identified confounders (duration of follow up; intrauterine pressures; 
morphine equivalent dose) (Figure 2.5).  
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Figure 2.4. Correlation of morphine usage to post ablation VAS Score and duration of 
hospital stay 
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Footnote: Morphine rescue analgesia directly correlates to VAS score immediately post TBEA 
(Pearson p=0.001, Kendall‘s tau p=0.006). 
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Footnote: Morphine rescue analgesia directly correlates to duration of hospital stay post TBEA 
(Pearson p=0.001, Kendall‘s tau p=0.001), and this relationship remains statistically significant after 
multivariate analysis (see Figure 2.5). 
Chapter 2.4 Outpatient Thermachoice long term outcomes 
139 
 
Table 2.14. Long-term outcomes of outpatient TBEA 
 Thermachoice 
I 
Thermachoice 
III 
Thermachoice 
I+III 
P-value 
(Thermachoice 
I vs. III)* 
Mean follow up time (months) 
(95% CI ; SD) 
41 
(38-43; 8) 
18 
(16-19; 5) 
29 
(26-32; 13) 
0.001 
Further treatment (Repeat ablation, 
Hysterectomy or LNG-IUS)  
No 
Yes 
 
 
36 (70.6%) 
15 (29.4%) 
 
 
47 (92.2%) 
4   (7.8%) 
 
 
83 (81%) 
19 (19%) 
 
 
0.005 
All Types of further treatment 
No further treatment 
LNG-IUS 
Drugs (including HRT) 
Repeat Endometrial Ablation 
Hysterectomy ($$ histology) 
 
30 
3 
6 
1 
11 
 
44 
0 
3 
1 
3 
 
74 (73%) 
3 
9 
2 
14 (14%) 
 
0.024 
Periods at review ^ 
Amenorrhoea 
Lighter 
No change or worse 
 
11 (23%) 
23 (49%) 
13 (28%) 
 
16 (35%) 
28 (61%) 
2 (4%) 
 
27 (29%) 
51 (55%) 
15 (16%) 
 
 
0.009 
Dysmenorrhoea at review ^ 
Pain free or Less 
No change 
Worsening 
 
27 
6 
14 
 
37 
5 
4 
 
64 
11 
18 
 
0.027 
Satisfaction 
Satisfied 
Dissatisfied 
 
35(69%) 
16 (31%) 
 
43 (84%) 
8   (16%) 
 
78 (76%) 
24 (24%) 
 
0.062 
Mean EuroQoL VAS score (95% CI; SD) 76 (69-84; 19) 80 (73-87; 19) 78 (73-83; 19) 0.420 
Mean EuroQoL Index (95% CI; SD) 0.81(0.74-0.88; 
0.19) 
0.87 
(0.80-0.96; 0.21) 
0.84 
(0.79-0.90; 0.20) 
0.022 
Mean Shaw QOL (95% CI; SD) 83 (73-92; 25) 87 (78-96; 24) 84 (78-91; 25) 0.504 
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Footnotes 
* Statistical tests include Chi-square, Chi-Square trend, Mann-Whitney U 
^ Data not reported in all cases, calculation based on cases that were reported 
$$ Histology of the 14 hysterectomies reported adenomyosis, fibroids and normal uterus in 4, 
5 and 5 cases respectively 
The comparisons in BOLD are those that are statistically significant with a P value <0.05 .  
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Table 2.15. Patient satisfaction and its relationship to quality of life and other treatment 
outcomes following endometrial ablation 
Outcomes Satisfied 
N=78 
Dissatisfied 
N=24 
P Value 
Statistical significance $ 
 
No further treatment 
Further treatment 
LNG-IUS 
Drugs (including HRT) 
Repeat Endometrial Ablation 
Hysterectomy  
 
69 
9 
0 
9 
0 
0 
 
5 
19 
3 
0 
2 
14 
 
0.001 
Periods now 
Amenorrhoea 
Lighter  
No change or worsening 
 
25 
43 
1 
 
2 
8 
14 
 
0.001 
Quality of life    
Mean EuroQOL VAS score  
(95% CI ; SD)    
80.5 
(75.8-85.2, 16.8) 
63.1 
(35.5-84.5, 26.5) 
0.077 
Mean EuroQoL Index            
(95% CI ; SD)    
0.89 
(0.86-0.92, 0.13) 
0.50 
(0.22-0.79, 0.31) 
0.001 
Mean Shaw QOL          
(95% CI ; SD)     
87.0 
(80.6-93.3, 22.6) 
68.3 
(37.6-99.0, 33.2) 
0.009 
 
Footnotes 
* Statistical tests include Chi-square, Mann-Whitney U 
The comparisons in BOLD are those that are statistically significant with a P value <0.05.  
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Figure 2.5. Survival analysis for likelihood of surgical re-intervention post TBEA 
 Mean (95% CI; SD) Median (Range) P value 
comparison 
All surgical re-
interventions (n=16) 
21.6 (15.8-27.5; 11.0) 19.0 (10-46) 
 
Not applicable 
Hysterectomy(n=14)  
vs.  
Repeat ablation (n=2) 
20.8 (14.5-27.1) 
vs. 
27.5 
18.5 (10-46) 
vs. 
27.5 (18-37) 
*0.721 
Thermachoice I (n= 12) 
vs.  
Thermachoice III (n=4) 
24.3 (17.9-30.8)  
vs.  
13.5 (10.5-16.5) 
 
23.0 (18.0-28.0)  
vs. 
12.0 (10.0 vs. 14.0) 
*0.024 
 
** 0.056 
*    Log Rank (Mantel-Cox) 
** Cox Regression analysis (corrected for duration of follow up; intrauterine pressures; 
morphine equivalent dose) 
Time (months) from original endometrial 
ablation
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Regression analysis for prognostic factors  
 
Univariate analysis showed that Thermachoice III compared to Thermachoice I was more 
likely to be associated with primary treatment success, menstrual improvement, 
dysmenorrhoea improvement and improved generic Quality of Life (EuroQol-5D index) 
(Table 2.14). However, multivariate regression analysis (Table 2.16; corrected for all 
baseline and peri-procedure characteristics that utilized a P value less than 0.05 as indicative 
of statistical significance) showed:- 
 Morphine dosage in rescue analgesia, but not the overall strength of analgesia 
(combining non-steroidal, Paracetamol and opiates) was independently associated 
with a longer duration of hospital stay. 
 Thermachoice III compared to Thermachoice I increased the likelihood for 
amenorrhoea, but was not associated with increased hospital stay, satisfaction or 
quality of life. 
 Regardless of the type of Thermachoice device, higher mean intrauterine ablation 
pressures and/or higher morphine rescue analgesia correlated to better long term 
patient satisfaction.  
 Neither uterine axis, age nor uterine length was associated with any of the outcomes. 
As previously stated in our methods section, there is an increased risk of identifying a falsely 
positive statistical finding due to multiple testing. For the analysis shown in Table 2.16 the 
Bonferroni corrected p value for a significant factor is 0.001. This meant that only type of 
Thermachoice would be considered statistically significant (p=0.001) amongst all factors 
tested if using Bonferroni correction. 
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Table 2.16. Prognostic outcomes for endometrial ablation (using multivariate regression 
analysis) 
 
Indicator variable Multivariate statistical P values  
of indicator variable in predicting outcome 
Duration of 
Hospital 
Stay$ 
Amenorrhoea~ Satisfaction* EuroQoL 
Index $ 
Age 0.604 0.571 0.078 0.675 
BMI 0.825 0.322 0.778 0.489 
Indication (prior dysmenorrhoea) 0.925 0.526 0.315 0.487 
Cycle phase 0.958 0.982 0.522 0.274 
Uterine axis 0.614 0.234 0.146 0.942 
Ultrasound findings 0.754 0.267 0.169 0.331 
Hysteroscopy findings 0.479 0.742 0.593 0.864 
Uterine size 0.155 0.342 0.918 0.415 
Intrauterine pressure 0.956 0.350 0.014 0.070 
Volume of fluid 0.402 0.425 0.682 0.621 
Post procedure pain VAS 0.792 0.335 0.369 0.064 
Strength of analgesia 0.820 0.791 0.486 0.205 
Morphine dose 0.042 0.595 0.030 0.394 
Type of Thermachoice 0.591 0.001 0.697 0.387 
Is model statistically significant No Yes Yes No 
Footnotes 
* Binary Logistic Regression; $ Univariate Linear Regression ; ~ Ordinal Logistic Regression 
The Bonferroni method lowers the observed significance level because of multiple testing and 
provides a method to achieve an overall study error rate of 0.05 using a corrected p-value derived by 
1- (1-α)1/n, where α=0.05 and n=number of hypothesis tests.  For the entire table (14 by 4 tests, giving 
n=56 and α=0.05) the Bonferroni corrected p value that is 0.001.This means that only type of 
Thermachoice is statistically significant (p=0.001) if using Bonferroni corrected interpretation.  
 
The comparisons in BOLD are those that are statistically significant with a P value <0.05.  
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DISCUSSION 
Local anaesthetic TBEA can be carried out as an outpatient daycase procedure and is an 
effective treatment option. The vast majority (76%) were satisfied with their treatment at a 
mean 2½ years follow up. Upgrading to Thermachoice III, compared to Thermachoice I was 
associated with improved rates of amenorrhoea, although overall, both devices achieved 
similar rates of patient satisfaction and quality of life. We found higher intrauterine ablation 
pressures to be associated with improved long term treatment satisfaction. Overall, 50% of 
surgical re-interventions occurred by around 1½ years.  
This study is an important advancement to the published knowledge in outpatient TBEA 
64-
68;87.  This study‘s principal attribute is that it is of pragmatic design and reflects actual 
clinical management of menorrhagia. We believe this study to be the largest published cohort 
of outpatient TBEA under local anaesthetic without sedation. Apart from two other studies of 
4-6 year follow up 
67;88
, this study represents the longest follow up of outpatient TBEAs 
(mean of 30 months, range of 12 to 54 months). Importantly, this study is the first to utilize 
both menorrhagia-specific 
81
 and generic 
82
 quality of life tools which has been advocated as 
the preferred way to measure these outcomes 
83;84. Furthermore, our study‘s long term 
outcomes are derived from a high response rate (86%) which improves the accuracy of our 
data collection.  
 
We agree there may be caveats when interpreting the results from our prospective study, 
which may lessen the reliability of our conclusions. Our study population may be 
heterogeneous, as we did not use objective criteria to define heavy menstrual bleeding or 
stratify according to differing bleeding patterns. Because of temporal differences between 
Thermachoice I and III cohorts, this has inevitably led to differences in follow up between 
Thermachoice I (mean 41 months) and III cohorts (mean 18 months) at our time of 
Chapter 2.4 Outpatient Thermachoice long term outcomes 
146 
 
questionnaire enquiry. This precluded the reliability of any survival regression analytical 
techniques, although by opting to use regression analysis we have attempted to correct for 
confounding influences. Intrauterine polyp or fibroid removal may have exerted an 
independent curative effect, although their combined proportions were similar in both 
Thermachoice I and III cohorts and thus any distinguishing influence minimized. Our study 
did not collect baseline quality of life data, and therefore we were unable to quantify a change 
in quality of life following LA-TBEA at specified time intervals. Finally, our study is likely 
to be under-powered (Type II error). Based on unpaired student‘s T-test and a minimal 
difference of interest between means of 0.3 Standard Deviations, we estimate a sample of size 
of 178 for each group would be required to show any significant difference in quality of life 
outcomes.  
The mean duration of stay in our study was around 5.5 hours, which is significantly longer 
than an analogous outpatient Thermachoice LA-TBEA study that reported a mean total time 
spent in hospital of 1 hour 40 minutes 
65
. This discrepancy may be partly explained by 
differences in pre- and post-operative analgesia and nursing-led or physician-led discharge 
practices. However, duration of stay is likely to be even more multifactorial than this (see 
Table 2.16), and any attempt to explain such differences would be frank conjecture.  We feel 
that a mean duration of stay shown by our study represents a  realistic recovery period before 
discharge. 
For some outcome measures, the extent of incomplete questionnaire responses or prolonged 
time interval from original treatment may have had a greater effect in over-estimating or 
under-estimating their frequency. This may be particularly pertinent to our reported rates of 
amenorrhoea; if we assume those with missing responses were not truly amenorrhoeic then 
the rates of amenorrhoea for Thermachoice I and III would be 23% and 31% instead of the 
reported 23% and 35%. However, our rates of amenorrhoea are consistent to those reported 
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by other studies 
66-68;88
. Nonetheless, we accept there may be a tendency to under-report 
satisfaction and amenorrhoea rates in Thermachoice I because assessment at longer follow up 
may have enabled women to have regeneration of the endometrial lining and symptomatic 
recurrence. Several studies have explored prognostic factors on TBEA success 
68;76-79
. Unlike 
previous studies, we have shown no adverse prognostic effects due to a retroverted uterus, 
large uterine size or young age 
68;76-79
. However, it is notable that our association of increased 
intrauterine pressure and improved outcome has been consistently identified in other studies 
76-79
.  Furthermore, this study showed associations for amenorrhoea (influenced by type of 
Thermachoice), satisfaction (influenced by intrauterine pressure, rescue morphine usage 
and/or post procedure VAS) and Quality of Life (influenced by intrauterine pressure) 
outcomes. This would reinforce the logical notion that the higher the intrauterine ablation 
pressure, and/or the more painful the TBEA procedure is, perhaps by inducing a greater depth 
uterine ablation, the more likely it is to achieve a successful long term outcome. 
 
This study reports on the safety and effectiveness of outpatient LA-TBEA which is clinically 
relevant to improve patient selection and preoperative counselling. Furthermore, there is 
continued expansion in this area, as evidenced by a growing body of literature which includes 
a randomised trial comparing outpatient and general anaesthetic TBEA 
65
. In order to 
determine the optimum role for outpatient endometrial ablation in treating women with heavy 
periods, further trials are needed to determine the clinical and cost-effectiveness of second 
generation ablation techniques (e.g. microwave, TBEA and radiofrequency ablation devices) 
against each other, against general anaesthetic and local anaesthetic settings, and against 
appropriate treatment alternatives (e.g. LNG-IUS). 
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2.5. Long term outcomes following hysteroscopic myomectomy for 
abnormal uterine bleeding  
 
 
OBJECTIVE: To evaluate the long term effectiveness of hysteroscopic submucous myomectomy for 
women with abnormal uterine bleeding and explore any prognostic factors associated with treatment 
success. 
DESIGN: Prospective observational study. 
SETTING: University teaching hospital in U.K. 
PATIENT(S): 92 women symptomatic of abnormal uterine bleeding with submucous myomas. 
INTERVENTION(S): Hysteroscopic myomectomy performed as outpatient local anaesthetic (38%) 
or daycase general anaesthesia (62%) using Versapoint
TM 
 . 
MAIN OUTCOME MEASURES: Need for secondary surgical or medical re-intervention, 
menstrual improvement and patient satisfaction over a minimum 12 month period. Other outcome 
measures include: successful completion of primary resection, type of secondary treatment and any 
prognostic factors. 
RESULT(S):  Mean follow up was 2.6 years (95% CI 2.3-2.9). Complete fibroid excision and 
removal was achieved in 66%. Secondary surgical re-intervention was required in 27 (29%) of which 
11 (12%) were repeat hysteroscopic myomectomy and 10 (11%) were hysterectomy procedures. 
Multiple uterine fibroids and adenomyosis were identified in 80% of hysterectomies. Overall, 
improved menstrual symptoms and patient satisfaction were reported by 91% and 86% at follow up. 
Size of the submucous fibroid or presence of any intramural or subserosal fibroids were not related to 
treatment success.  
CONCLUSION(S): Women with abnormal uterine bleeding diagnosed with submucous myomas 
may be successfully treated by removing the submucous myoma component, irrespective of co-
existent intramural or subserosal fibroids. This effect is sustained over the long term. 
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INTRODUCTION 
Uterine fibroids are present in 25-40% of women presenting with abnormal uterine bleeding 
89
. Although a direct cause-effect relationship has not been completely established, there is 
sufficient observational data to suggest that shrinkage or removal of any identified uterine 
fibroids is beneficial in alleviating menstrual bleeding abnormalities in most symptomatic 
women. 
Hysteroscopic myomectomy is considered the first-line conservative surgical therapy for the 
management of symptomatic submucous fibroids
89-93
. Data, from mainly observational 
studies, has suggested beneficial effects in treating both menstrual abnormalities and 
infertility with this procedure. The few studies that have reported on long term outcomes for 
fibroid-related menstrual abnormalities, indicate that hysteroscopic myomectomy is 
associated with a 10-35% risk of surgical re-intervention, including repeat myomectomy, 
open myomectomy or hysterectomy
90;92;93
. However, such a high re-intervention rate may 
alter the cost effectiveness of hysteroscopic myomectomy compared to other uterus-
conserving treatment options and hysterectomy. 
Presently, there is insufficient evidence on reliable selection criteria and long term outcomes 
for women with symptomatic fibroids who opt for hysteroscopic myomectomy. This 
knowledge would be particularly important for preoperative counselling and appropriate 
patient selection. We therefore wished to evaluate long term efficacy of this treatment, and 
identify whether there were any adverse (e.g. co-existence of intramural or subserosal 
fibroids) or favourable (e.g. submucous myoma less than 5cm size, completeness of lesion 
excision) peri-operative prognostic factors. 
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MATERIALS AND METHODS: 
Patient Population Women symptomatic of abnormal uterine bleeding (i.e. mainly with 
heavy menstrual bleeding [HMB]) were referred by primary care (GPs) or secondary care to 
our ―One Stop‖ ―See and Treat‖ menstrual disorders clinic. All women underwent 
transvaginal pelvic sonography, outpatient hysteroscopy and endometrial Pipelle biopsy 
(Laboratoire C.C.D, Paris, France) investigations. Women who were considered suitable for 
hysteroscopic myomectomy were included in this study. Women were excluded from the 
study if an abnormally shaped uterine cavity (e.g. bicornuate uterus), endometrial 
hyperplasia, cancer or active pelvic infection were present. 
Study design Prospective patients presenting between June 2003 and November 2006 were 
included in this study.  
Intervention All hysteroscopic myomectomies were performed using Versapoint [Gynecare, 
Ethicon Inc. USA] according to the manufacturer‘s recommended guidance and as previously 
reported by our group 
94;95
. We defined a submucous intracavity fibroid at hysteroscopy as 
having characteristic appearances (sessile or pedunculated, superficial large blood vessels) 
and non-mobility with intrauterine fluid or gentle hysteroscopic tapping of the lesion. In all 
cases, our preoperative suspicion of intracavity fibroid was confirmed on histological analysis 
of the excised lesion.  All women were offered to have the intervention under local 
anaesthetic (LA) outpatient setting or general anaesthetic (GA) daycase setting. Factors that 
influenced the final decision included: patient preference, how she tolerated outpatient 
hysteroscopy, intrauterine location and size of intracavity fibroids. Preoperative preparation 
with a 3 month course of GnRHa prior to myomectomy was deemed necessary in women 
with intracavity fibroids greater than 5cm in size. A patient information leaflet was provided 
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detailing the procedure, expected symptoms and analgesic advice post hysteroscopic 
myomectomy. 
LA hysteroscopic myomectomy This was performed on a ―See and Treat‖ basis with no 
fasting prior to the procedure. Other elements of the treatment included:- 
 Local anaesthetic: The cervix was directly injected in a circumferential manner with 
three 2mL cartridges containing 3% prilocaine hydrochloride (30 mg/mL) and felypressin 
0.03 unit/mL (Dentsply, UK) using a 27G dental syringe.  
 Dedicated patient nurse: A particular nurse was allocated to provide continuous 
supportive care to the patient during the procedure. The nurse engaged the patient in 
conversation (‗distraction‘ analgesia effect termed ―vocal local‖) and often held the patient‘s 
hand throughout the procedure.  
 Post procedure analgesic regimen: All women received diclofenac 100mg rectally 
and oral co-dydramol 10/500 (two tablets). All women were recovered in a dedicated patient 
waiting area and allowed home after a minimum 30 minute stay. A strict protocol of post-
procedure pain relief was adhered to.  
GA hysteroscopic myomectomy:   Women, fasted for at least 6 hours, were admitted to 
hospital on the day of the procedure. In a minority of cases, women with high risk medical 
disorders (e.g. diabetes) were admitted the day before the planned procedure.  Hysteroscopic 
myomectomy was carried out in gynaecology theatres after induction of general anaesthesia.  
All women received diclofenac 100mg and 1g paracetamol rectally (or paracetamol alone if 
diclofenac was contraindicated) just prior to the procedure. Infiltration of the cervix with a 
local anaesthetic was not done in these women.  The hysteroscopic myomectomy surgical 
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procedure, post-procedure analgesia regimen and day case bed stay for GA was identical to 
the LA hysteroscopic myomectomy procedure described above. 
Complete excision, partial excision and devascularisation at hysteroscopic myomectomy 
In all cases, a standardised technique was adopted in order to completely excise and remove 
the fibroid. The submucous fibroid was resected at the junction between the fibroid and 
uterine wall using a shearing technique. To facilitate this it was occasionally necessary to 
bisect, trisect or quadrisect the fibroid lesion to access this fibroid-uterine wall interface.  
Complete excision was achievable in most pedunculated (Type 0) and in those superficially 
myometrially invading (type 1) intracavity fibroids. Occasionally, where the hysteroscopic 
view became obscured following commencement of the procedure, one of two modified 
procedures was performed: 
 Partial excision and removal of the fibroid was performed. The percentage of the fibroid 
removed relative to entire intracavity lesion was clinically estimated and recorded. 
 Devascularisation of the intracavity without its excision. This entailed multiple scoring of 
the fibroid lesion (e.g. trisecting the lesion in a ―hot cross bun‖ technique) at or near its 
vascular attachment base. The percentage of the fibroid devascularised relative to the 
entire intracavity lesion was clinically estimated and recorded. 
 
Outcome measures  Initial baseline data recorded were: age, body mass index, parity, 
menstrual bleeding abnormality, ultrasound and hysteroscopy findings, and use of pre-
procedure GnRHa. The size of the intracavity uterine fibroid selected for myomectomy was 
determined using ultrasound (objective) data in most cases. Where ultrasound had failed to 
identify the intracavity fibroid prior to myomectomy the practitioner recorded their clinical 
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estimate of intracavity fibroid size. In relationship to the hysteroscopic myomectomy 
procedure, the following data were recorded: LA or GA setting, completeness of excision, 
operation length, procedure related complications (e.g. vasovagal episodes) and duration of 
hospital stay. 
A postal questionnaire was sent to all women post procedure between June-November 2007, 
ensuring there was a minimum 12 month follow up period. Questionnaire response was 
maximised by re-contacting women (by phone and letter) with non-returned forms. Patient 
completed data recorded were: need for and nature of any secondary treatment, improvement 
in their menstrual bleeding pattern and dysmenorrhoea (ordinal Likert scales), and patient 
satisfaction at that time (ordinal Likert scale). Secondary treatments were categorised 
according to medical (LNG-IUS, oral progestins, combined oral contraceptive, tranexamic 
acid) and surgical (repeat hysteroscopic myomectomy, open myomectomy, endometrial 
ablation, hysterectomy) interventions. Primary treatment success was defined as the absence 
of any type of medical or surgical secondary treatment following the primary treatment of 
hysteroscopic myomectomy. The case records and histology results of all study participants 
were reviewed and recorded. 
 
Statistical analysis: Dichotomous data were presented as simple proportions.  SPSS version 
13 was used to undertake multivariate regression analysis and to conduct Chi-square tests.  P 
< 0.05 was considered statistically significant.   
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RESULTS 
Ninety-two women participated in the study and their baseline characteristics are depicted in 
Table 2.17.  The characteristics associated with hysteroscopic myomectomy procedure are 
depicted in Table 2.18. Of the 35 (38%) women undergoing LA procedure, none were 
admitted for overnight stay. Of the 57 (62%) women undergoing GA procedure, 20 (35%) 
were admitted for overnight stay. 
In relation to menstrual symptom improvement and patient satisfaction outcomes, only 2 
women (2%) failed to return their questionnaire, representing a 98% follow-up. Examination 
of the clinical case notes and contacting their GPs confirmed that neither of these two women 
had undergone secondary treatment following hysteroscopic myomectomy. The mean follow 
up was 2.6 years (95% CI 2.3-2.9; Range 1-7.3 years; St Dev 1.5).  Overall, greater than, or 
equal to, 12 months, 24 months and 36 months outcome data were available for 90 (98%), 52 
(57% ) and 31 (34%) women.  
The menstrual and secondary treatment outcomes are depicted in Table 2.19. Surgical re-
intervention was necessary in 27 (29%) women, and this involved hysterectomy in 10 cases 
and their characteristics are depicted in Table 2.20. Seven hysterectomies (70%) were 
performed by 12 months of the primary hysteroscopic myomectomy, and of these, 2 
hysterectomies were performed for unexpectedly identified gynaecological pathology (one 
case complex hyperplasia, one case leiomyosarcoma). Adenomyosis and multiple fibroids 
were the commonest histological findings at hysterectomy (8/10 cases).  Multivariate analysis 
of the need for secondary treatment identified no statistically significant prognostic factor 
(Table 2.21).   
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Table 2.17. Baseline characteristics for 92 women undergoing hysteroscopic 
myomectomy 
 
Patient characteristics N=92 
Frequency (Percentage) 
Age 
20-30  years 
30-40 years 
40-50 years 
>50  years 
 
4 (4) 
33 (36) 
42 (46) 
13 (14) 
BMI Mean 28.0 (95% CI 26.4-29.7) 
Range 20-52; St Dev 6.9 
Menopausal status at presentation 
Pre-menopausal 
Post-menopausal 
 
84 (91) 
8 (9) 
Menstrual Bleeding abnormality 
Heavy Menstrual Bleeding (HMB) 
Unscheduled bleeding on HRT 
 
84 (91) 
8   (9) 
Scan findings 
Submucous 
Submucous & Intramural 
Submucous & Intramural & Subserosal 
 
 
41 (45) 
47 (51) 
4   (5) 
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Table 2.18. Characteristics associated with hysteroscopic myomectomy procedure 
 
Procedure setting 
LA Local anaesthetic outpatient 
GA General anaesthetic daycase  
 
35  (38) 
57  (62) 
Preop GnRHa 
Yes 
No 
 
20 (22) 
72 (78) 
Length of operation* 
<30 minutes 
30-60 minutes 
> 60 minutes 
 
77 (84) 
14 (16) 
1 (1) 
Size of uterine fibroid (u/s and by clinical estimation) 
<3cm 
3-5 cm 
>5cm 
 
22 (24) 
53 (58) 
17 (19) 
Primary treatment performed 
Complete excision and removal 
>50% excision and removal 
>50% devascularised and left in situ 
Complete excision and removal and endometrial ablation 
Complete excision and removal and insertion of Mirena 
 
48 (52) 
13 (14) 
18 (20) 
11 (12) 
2 (2) 
Complications 
None 
Bleeding requiring balloon tamponade 
Cervical trauma 
 
83 (90) 
8 (9) 
1 (1) 
Length of hospital stay 
Daycase 
Overnight 
 
72 (78) 
20 (22) 
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Table 2.19 Outcomes after hysteroscopic myomectomy 
Footnotes for Table 2.19          * Missing questionnaire responses for menstrual (2) and 
dysmenorrhoea (2) characteristics and patient satisfaction (2). Case notes and GPs were 
contacted and no secondary treatments were undertaken in the 2 non-returned questionnaire 
responses. 
Outcome measure  Entire cohort, 
including 10 women 
who had 
hysterectomy (n=92) 
Excluding 10 
women who had 
hysterectomy 
(n=82) 
Menstrual bleeding characteristics at enquiry 
Amenorrhoea 
Brown discharge 
Much lighter 
Marginally lighter 
No change 
Heavier  
Unknown 
Overall menstrual symptoms improved 
 
28 (30) 
3 (3) 
40 (43) 
13 (14) 
4 (4) 
2 (2) 
2 (2) 
84 (91) 
 
18 (22) 
3 (4) 
40 (49) 
13 (16) 
4 (5) 
2 (3) 
2 (2) 
74 (90) 
Dysmenorrhoea characteristics at enquiry  
None 
Less 
No change 
Worse 
Unknown 
Overall dysmenorrhoea symptoms improved 
 
50 (54) 
26 (28) 
11 (12) 
3 (3) 
2 (2) 
76 (83) 
 
40 (49) 
26 (31) 
11 (13) 
3 (4) 
2 (2) 
66 (81) 
Degree of satisfaction at enquiry 
Very satisfied  
Satisfied 
Dissatisfied  
Very Dissatisfied  
Unknown 
Overall satisfied 
 
55 (60) 
24 (26) 
6 (7)  
5 (5)  
2 (2) 
79 (86) 
 
54 (66) 
20  (24) 
4 (5) 
2 (2) 
2 (2) 
74 (90) 
Secondary treatment 
Myomectomy (open) 
Thermal Balloon Endometrial Ablation 
LNG-IUS (Mirena) 
Hysterectomy 
Repeat hysteroscopic myomectomy 
Repeat hysteroscopic myomectomy and ablation 
Repeat hysteroscopic myomectomy and  Mirena 
Oral progestins 
No  secondary treatment 
Secondary treatment (all types) required 
No surgical re-intervention 
Overall repeat surgical treatment required 
 
4 (4) 
2 (2) 
7 (8) 
10 (11) 
8 (9) 
1(1) 
2 (2) 
2 (2) 
56/92 (61) 
36/92 (39) 
65/92 (71) 
27/92 (29) 
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Table 2.20 Women (n=10) undergoing hysterectomy following hysteroscopic 
myomectomy 
 
Characteristic Value 
Number of  hysterectomies 10 
Average time to Hysterectomy Mean 14.4  months (95% CI 4.5-24.3) 
Median 9.5 months; Range 1-41 months; St Dev 13.9 
 
Time from procedure and cumulative 
rate of hysterectomy 
 
By 6 months:  4/10 cases   [one for leiomyosarcoma] 
By 12 months: 7/10 cases  [one for complex hyperplasia] 
By 24 months: 8/10 cases 
By 48 months: 10/10 cases  
Very satisfied 
Satisfied 
Dissatisfied 
Very dissatisfied 
Overall satisfied 
Overall dissatisfied 
1 
4  
2 
3  
5 (50%) 
5 (50%)  
Histology  
Adenomyosis and fibroids (multiple) 
Fibroids (multiple) 
Leiomyosarcoma 
Complex Hyperplasia 
 
6 
2  
1 (identified on resection histology and reason for TAH) 
1 (identified at resection histology and reason for TAH) 
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Table 2.21. Multivariate analysis of prognostic factors 
 
 Need for secondary treatment 
 (all types) 
Need for secondary 
surgical re-intervention 
Prognostic factor 
and its  
significance 
(p-value) 
Menstrual pattern  
 
Primary treatment  
 
Scan findings        
 
Size of fibroid  
[p=0.90]  
 
[p=0.10]  
 
[p=0.61]  
 
[p=0.35] 
Menstrual pattern  
 
Primary treatment  
 
Scan findings 
 
Size of fibroid 
 
[p=0.09]  
 
[p=0.12]  
 
[p=0.66]  
 
[p=0.84] 
 
 
 
Footnotes 
 
1. Multivariate regression corrected for the following confounding factors, including: age, 
BMI, parity, menopausal status, type of menstrual bleeding abnormality, scan findings, 
preoperative GnRHa, size of uterine fibroid, type of primary myomectomy treatment. 
 
2. Binary logisitic regression models for secondary treatment and secondary surgical re-
intervention were statistically significant (p<0.001) 
 
 
Chapter 2.5. Hysteroscopic myomectomy: long term outcomes 
160 
 
DISCUSSION 
Women with abnormal uterine bleeding diagnosed with submucous myomas may be 
successfully treated by removing the submucous myoma component, irrespective of co-
existent intramural or subserosal fibroids or size of fibroid that has been resected. The 
beneficial effects of hysteroscopic myomectomy persist long term (mean follow up around 
2½ years), and with the secondary surgical re-intervention rate of 29% this suggests that the 
removal of the submucous component can avoid hysterectomy in 70% of cases.  The majority 
of women who underwent hysterectomy as secondary treatment were identified to have 
adenomyosis and multiple uterine fibroids.  
 
To date,  studies published on hysteroscopic myomectomy have utilised various technical 
approaches, been mainly performed under GA in daycase settings, have mixed retrospective 
and prospective observational designs, and have minimal data on long term follow up, 
particularly patient satisfaction and surgical re-intervention rates
94;96-104
. Our study adds to 
this published literature by exclusively utilising a modern Versapoint bipolar system; has 
been successfully undertaken in both outpatient and daycase setting; has a prospective design; 
has long term follow up incorporating patient satisfaction; has evaluated peri-operative 
features that may have prognostic value; and expands on our previously published work
94
. 
Our surgical re-intervention rate of 29% (over mean 2½ years) was lower than that reported 
by a previous study of 35% (over mean 5 years)
101
. This study has been pragmatic in design, 
ensuring our results are applicable to actual clinical practice.  
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However, we accept our study may have limitations that may make our conclusions less 
reliable. Our study sample size, although at 92 with a low dropout rate (2%), may be 
underpowered to identify all peri-operative prognostic factors. Because our follow up 
intervals varied between patients, there may be a tendency to overestimate or underestimate 
the beneficial effects of hysteroscopic myomectomy at the extremes of follow up. The 
variation in follow up outcome data also precluded our use of survival analysis techniques to 
asses both efficacy and durability of the hysteroscopic procedure.  
 
Given the 29% risk of surgical re-intervention following submucous myomectomy, there is a 
need to identify significant peri-operative prognostic factors that could be usefully employed 
during preoperative counselling. Even though our study did not identify any specific 
prognostic factor previous studies have identified enlarged uterine size, three or more 
intracavity myomas, fibroid size>3cm and increased depth of myometrial penetration to be 
adverse prognostic factors 
100;101
 .  In fact, our study reinforces the widely held opinion that it 
is only the presence of the submucous fibroid itself that appears to be responsible for the 
heavy menstrual bleeding 
92;93
. Furthermore, our study showed that adenomyosis was 
frequently identified in those women who required hysterectomy as secondary treatment. 
There is insufficient evidence on the ultrasonographic criteria predictive of adenomyosis and 
whether adenomyosis should be routinely screened for in women with menstrual 
disorders
105;106
. Future studies are needed to identify the clinical efficacy and optimal patient 
selection criteria for submucous myomectomy, and whether preoperative imaging suspicion 
of adenomyosis may be usefully employed in the treatment decision making process.  
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Chapter 3. SYSTEMATIC REVIEWS AND SYSTEMATIC LITERATURE 
APPRAISAL 
 
Systematic reviews performed for two clinical queries: 
 Do screening-preventative interventions in asymptomatic pregnancies reduce the risk 
of preterm delivery. 
 Is Levonorgestrel-releasing hormone system (LNG-IUS) effective therapy for a 
variety of non-contraceptive indications . 
 
Publications arising from the chapter 
Chapter Manuscript title Reference 
3.1 Do screening-preventative interventions in asymptomatic 
pregnancies reduce the risk of preterm delivery--a critical appraisal 
of the literature. 
 
Antibiotic treatment of bacterial vaginosis in pregnancy: Multiple 
meta-analyses and dilemmas in interpretation 
1
 
 
 
 
2
 
3.2 Non-contraceptive uses of levonorgestrel releasing hormone system 
(LNG-IUS)- a systematic enquiry and overview 
3
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Introduction 
 
Background 
Systematic reviews are considered to provide the definitive evidence-based answer as to 
whether a particular intervention or test is clinically effective and to quantify the strength of 
this effect. The term ―systematic review‖ is widely considered to be synonymous to the 
highest level of evidence-based medicine available for that cited topic. The key strength of 
the research methodology is its ability to produce a more reliable measure of effectiveness 
through mathematically pooling outcomes of clinical trials rather than using an outcome 
ascertained from an individual trial. The methodology is further underpinned through a 
rigorous systematic search, with strict quality control of studies that are eligible to be 
included or excluded in the final meta-analysis stage. 
 
The methodology conforms to established standards which are, by convention, explicity 
stated prior to the systematic review being accepted by peer-reviewed publications or the 
Cochrane collaboration
4;5
.  Hence, systematic reviews, analyzing the same clinical question, 
ought to be consistent and reproducible. Importantly, inherent to the transparency of the 
methods and trial selection process, systematic reviews are relatively easily updated as newer 
trials are published; the process of periodic update is mandatory for all Cochrane reviews and 
ensures the review evidence is continually up-to-date and reliable.  Despite a multitude of 
published systematic reviews, mostly presented through the Cochrane collaboration, there 
remains several unanswered clinical questions within our specialty of obstetrics and 
gynaecology.  
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Aims  
Undertake a systematic review, incorporating the elements of : systematic literature search ; 
appraisal of studies for rejection or inclusion and meta-analyses. This will be performed in 
accordance to standardized methodology as set out by the Cochrane collaboration and 
others
4;5
.  
For each therapeutic intervention, appraise the quality of supporting evidence and assign a 
grade to the strength of recommendation that can be derived according to the evidence by 
using established evidence appraisal tools (Royal College of Obstetricians and 
Gynaecologists guideline development criteria (Table 3i  and GRADE evaluation of 
evidence Table 3ii) 
6;7
.  These appraisal tools will be discussed at greater length in Chapter 
4 (Clinical Guideline Development). 
 
The specific clinical queries that will be used as examples of the systematic review research 
methodology process are: 
1. Do screening-preventative interventions in asymptomatic pregnancies reduce the risk 
of preterm delivery. 
2. Is Levonorgestrel-releasing hormone system (LNG-IUS) effective therapy for a 
variety of non-contraceptive indications . 
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 Table 3i.  Classification of evidence used by RCOG Guideline development (originate 
from US Agency for Health Care Research and Quality)  
Classification of Evidence Levels  
Ia Evidence obtained from meta-analysis of randomised controlled trials.  
Ib Evidence obtained from at least one randomised controlled trial.  
IIa Evidence obtained from at least one well-designed controlled study without 
randomisation.  
IIb Evidence obtained from at least one other type of well-designed quasi-experimental 
study.  
III Evidence obtained from well-designed non-experimental descriptive studies, such as 
comparative studies, correlation studies and case studies.  
IV Evidence obtained from expert committee reports or opinions and/or clinical 
experience of respected authorities.  
Grades of Recommendations  
 
Requires at least one randomised controlled trial as part of a body of literature of 
overall good quality and consistency addressing the specific recommendation. 
(Evidence levels Ia, Ib) 
 
Requires the availability of well controlled clinical studies but no randomised 
clinical trials on the topic of recommendations. (Evidence levels IIa, IIb, III) 
 
Requires evidence obtained from expert committee reports or opinions and/or 
clinical experiences of respected authorities. Indicates an absence of directly 
applicable clinical studies of good quality. (Evidence level IV) 
Good Practice Point    
 
Recommended best practice based on the clinical experience of the guideline  
development group 
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Table 3ii. GRADE approach (http://www.gradeworkinggroup.org/index.htm)  
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
GRADE: Quality of evidence 
The GRADE system classifies
 
the quality of evidence in one of four levels: 
High quality— Further research is very unlikely to change our confidence in the estimate of 
effect 
Moderate quality— Further research is likely to have an important impact on our confidence in 
the
 
estimate of effect and may change the estimate 
Low quality— Further research is very likely to have an important impact on our confidence in 
the estimate of effect and is likely to
 
change the estimate 
Very low quality— Any estimate of effect is very uncertain 
Evidence based on randomised controlled trials begins as high
 
quality evidence, but our 
confidence in the evidence may be
 
decreased for several reasons, including:
 
 
Study limitations
  
Inconsistency of results
 
 
Indirectness
 
of evidence
 
 
Imprecision
 
 
Reporting bias.
 
 
Although observational studies (for example, cohort and case-control
 
studies) start with a "low 
quality" rating, grading upwards
 
may be warranted if the magnitude of the treatment effect is
 
very large,
 
if there is evidence of a dose-response relation or if all plausible
 
biases would 
decrease the magnitude of an apparent treatment
 
effect.
 
 
GRADE: Strength of recommendation 
The GRADE system offers two grades of recommendations: "strong" and "weak" depending 
on whether effects of intervention clearly outweigh the undesirable effects, or clearly do not. If 
trade-offs are less certain—either because of low quality evidence or because evidence 
suggests that desirable and undesirable effects are closely balanced—weak recommendations 
become mandatory. 
Factors that affect the strength of a recommendation  
Factor Examples of strong 
recommendations 
Examples of weak 
recommendations 
Quality of 
evidence 
Many high quality randomised 
trials have shown the benefit of 
inhaled steroids in asthma 
Only case series have examined the 
utility of pleurodesis in 
pneumothorax 
Uncertainty about 
the balance 
Aspirin in myocardial infarction 
reduces mortality with minimal 
Warfarin in low risk patients with 
atrial fibrillation results in small 
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between desirable 
and undesirable 
effects 
toxicity, inconvenience, and cost stroke reduction but increased 
bleeding risk and substantial 
inconvenience 
Uncertainty or 
variability in 
values and 
preferences 
Young patients with lymphoma 
will invariably place a higher 
value on the life prolonging effects 
of chemotherapy than on treatment 
toxicity 
Older patients with lymphoma may 
not place a higher value on the life 
prolonging effects of chemotherapy 
than on treatment toxicity 
Uncertainty about 
whether the 
intervention 
represents a wise 
use of resources 
The low cost of aspirin as 
prophylaxis against stroke in 
patients with transient ischemic 
attacks 
The high cost of clopidogrel and of 
combination dipyridamole and 
aspirin as prophylaxis against stroke 
in patients with transient ischaemic 
attacks 
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3.1. Do screening-preventative interventions in asymptomatic pregnancies 
reduce the risk of preterm delivery: a systematic review and meta-analysis 
 
Background: Recent research has suggested that women who experience preterm delivery (PTD) 
may be identified earlier in pregnancy and before onset of symptoms.   Interventions commenced at 
this earlier asymptomatic stage may offer an opportunity to prevent PTD or lengthen gestation 
sufficiently to reduce adverse perinatal outcome.     
Objectives: To examine the evidence that supports or refutes interventions that prevent PTD. To 
examine whether interventions are effective in all women or only women at high risk of PTD. To 
generate clinical recommendations for each intervention according to evidence appraisal tools 
6;7
.   
Methods: A systematic search, meta-analysis and evidence-based appraisal of the identified literature.  
Results: There is evidence that introducing screening-preventative strategies for asymptomatic 
pregnancies may reduce the rate of PTD.   Evidence for screening and selective treatment exists for : 
asymptomatic bacteriuria in all women; bacterial vaginosis in low-risk population groups; elective 
cervical cerclage in high-risk pregnancies; indicated cervical cerclage in women with short cervical 
length on ultrasound; prophylactic progesterone supplementation in high-risk pregnancies; Smoking 
cessation in all women. However, for most other strategies, such as increased antenatal attendance, or 
routine administration of prophylactic micronutrients, the evidence is inconsistent and conflicting.  
Conclusion: The review suggests an antenatal management plan designed to prevent PTD based on 
current practice and the evidence identified. Data on neonatal outcomes apart from PTD (such as 
serious neonatal morbidity and mortality) were lacking in most studies.  It was therefore not possible 
to establish whether preventing PTD or prolonging gestation would correlate to improved perinatal 
outcome. This lessened the potential clinical usefulness of any proposed preventative strategy. 
Furthermore, no studies were found that evaluated the effectiveness of combining screening-
preventative strategies.  
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INTRODUCTION  
Preterm delivery (PTD) is defined in the UK as delivery after 24 completed weeks‘ gestation 
and before the onset of 37 weeks‘ gestation.   In the United States, the lower limit of PTD is 
20 weeks, which is used for all US Perinatal statistics. PTD affects 6%-15% of deliveries and 
represents a major worldwide health concern 
8
.  PTD has multifactorial aetiology. The causes 
and subgroups associated with PTD include : spontaneous preterm labour (PTL), 31-50%; 
multiple pregnancy, 12-28%; preterm premature rupture of membranes (PPROM), 6%-40%; 
medically indicated (e.g. hypertensive disorders of pregnancy, intrauterine growth restriction, 
antepartum haemorrhage and chorioamnionitis), 20%-25%; miscellaneous (cervical 
incompetence, uterine malformation), 10% 
9
. Some clinicians believe that cervical 
insufficiency and PPROM/chorioamnionitis have moreover similar origins and have 
combined such subgroups when reporting studies of PTD. PTD accounts for 50%-70% of all 
neonatal morbidity and mortality.   Importantly, the earlier the gestation at delivery, the 
greater the risk of adverse perinatal outcome (Table 3.1) 
10
.  Consequently, there is a need to 
prevent PTD and any proposed strategy should ideally aim to target PTDs that occur before 
34 weeks gestation, as this group contributes most to perinatal morbidity and mortality.    
Table 3.1.   Gestation-specific perinatal mortality  
Gestational age (weeks’) Survival (%) 
22-24 5-40 
25-27 55-75 
28-30 80-85 
31-33 95-100 
34-36 100 
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In trying to reduce rates of PTD, the emphasis has been on applying screening-preventative 
interventions to women symptomatic of PTL or PPROM.   However, these have had limited 
efficacy 
11
.   Recent research has suggested that women who experience PTD, PTL and 
PPROM may be identified earlier in pregnancy and before onset of symptoms
12;13
. It has thus 
been suggested that prophylactic and therapeutic interventions commenced at an earlier 
asymptomatic stage of pregnancy, either as specific measures or general measures, may offer 
an opportunity to prevent PTD or lengthen gestation sufficiently to reduce adverse perinatal 
outcome.  We have therefore conducted a systematic search and critical appraisal of the 
literature to identify the evidence that supports or refutes this approach to reducing the rate of 
PTD and related perinatal morbidity and mortality.  In particular, this review considers health 
approaches that address all risk factors that affect the entire population of pregnant women, 
as well as those screening-preventative strategies directed only at high-risk asymptomatic 
women.   The review concludes with a suggested an antenatal management plan designed to 
prevent PTD based on current practice and the evidence presented in this article. 
METHODS An electronic search of MEDLINE (1966- October 2005), EMBASE (1980-
October 2005), and the Cochrane library (2005) was conducted using combinations of 
principle MeSH terms and text words: ―preterm labour‖, ―preterm birth‖, ―preterm labor‖, 
―labor, premature‖, ―infant mortality‖, ―infant premature‖, ―infant, premature, diseases‖, 
―cerclage, cervix‖, ―cervical incompetence‖, ―vaginosis, bacterial‖, ―fibronectins‖, 
―glucocorticoids‖ and ―tocolysis‖.   The reference lists of all known primary, review and 
clinical evidence-based guidelines were also examined to identify cited articles not captured 
by electronic searches.   Articles cited frequently were used in the Science Citation Index to 
identify additional citations. A meta-analysis was conducted to examine whether differences 
in outcome occur when the intervention is applied to high or low risk of PTD study 
populations.
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DEFINITIONS   
Several studies, albeit based on varying population groups and competing risks, have 
consistently shown that women with a previous history of PTD, PPROM, medically indicated 
PTD, delivery of a small-for-gestational-age infant, second trimester pregnancy loss, 
congenital uterine anomalies, or suspected cervical incompetence are at increased risk of 
subsequent PTD 
14-17
.   A selection of these and other risk factors for PTD, with supporting 
odds ratios is depicted in Table 3.2.  Associations for a particular risk factor are supported 
with a single reference citation of a high quality study.   
Unless indicated by the presence of another risk factor,  ‗high-risk‘ groups are defined as 
those asymptomatic pregnancies who are deemed to be at increased risk of PTD because of 
experiencing previous PTD.  The pregnancy is asymptomatic if symptoms of PPROM, PTL 
are absent and there are no overt manifestations of obstetric complications (e.g. multiple 
pregnancy, hypertension, antepartum haemorrhage).  The review is structured by considering 
screening-preventative interventions that may be commenced following routine antenatal care 
or antenatal care combined with specialist investigations, and then elaborate on the evidence 
for the value of strategies in specific high-risk groups as well as population wide health 
strategies.  
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Table 3.2.   Risk factors associated with increased risk of preterm delivery.    
RISK FACTOR Preterm delivery 
under study 
Odds Ratio Reference 
Routine Screening    
Women aged <18 years at delivery 
compared to 18-34 years 
<32 weeks‘ 1.41 (1.02-1.90) 18 
Second birth in women aged 15-19 years 
compared to 20-29 years 
24-32 weeks‘ 2.5 (1.5-4.3) 19 
Previous singleton PTD < 35 weeks‘ 
compared to >35 weeks‘ 
<35 weeks‘ 5.6 (4.5-7.0) 20 
Body mass index<20 <37 weeks‘ 3.96 (2.61-7.09) 21 
Elevated (>90
th
 centile) maternal serum 
alpha- fetoprotein (AFP) 
<35 weeks‘ 3.9 (1.7-8.7) 22 
Singletons following in vitro fertilisation <37 weeks‘ 2.0 (1.7-2.2) 23 
Genital bleeding below 24 weeks‘ <37 weeks‘ 2.5 (1.6-3.8) 15 
Placenta praevia 24-27 weeks‘ 2.90 (2.46-3.42) 24 
Loop electrosurgical excision of cervix 
(matched for smoking status) 
<37 weeks‘ 2.53 (1.42-4.49) 25 
Urinary tract infection <37 weeks‘ 4.4 (1.47-13.34) 21 
Short inter-pregnancy interval     
(<6 months) 
24-32 weeks‘ 4.1 (3.2 -5.3) 26 
Ethnicity- Black Afro-Caribbean 
                 Asian 
         vs.   White Europeans (UK Study) 
<37 weeks‘ 1.33 (1.15-1.56) 
1.45 (1.33-1.56) 
27
 
Alcohol (>7 drinks/week)  <32 weeks‘ 3.26 (0.8-13.24) 28 
Smoking  27-32 weeks‘ 1.7 (1.3-2.2) 29 
Specialist Screening    
Bacterial vaginosis< 16 weeks‘ <37 weeks‘ 7.6 (1.8-31.7) 30 
Positive cervico-vaginal fetal fibronectin  <35 weeks‘ 6.6 (1.7-25.5)  22 
Cervical length ≤25mm <35 weeks‘ 3.9 (1.7-9.2) 22 
Bilateral uterine artery notching <37 weeks‘ 2.38 (1.19-4.75) 31 
Serum granulocyte colony-stimulating 
factor (>75
th
 centile) 
<35 weeks‘ 3.1 (1.4-6.9) 22 
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Evidence for the value of screening-preventative interventions on routine 
antenatal population screening 
 
The components of routine antenatal care will vary according to country and local resources.   
We have used UK‘s NICE guideline as a model for recommended routine antenatal care 
practice 
32
. 
1. Early pregnancy booking and ultrasound dating (10-13 weeks) This provides an 
opportunity to accurately date the pregnancy, identify multiple pregnancies, and categorise 
the pregnancy risk based on obstetric history and routine investigations.   There is no direct 
evidence that this care would decrease PTD.   
2. Psychosocial, work and lifestyle factors There is epidemiological evidence that 
shows that PTD is associated with low maternal weight, poor weight gain during pregnancy, 
and low birth weight 
33
 (Table 3.2).   Two meta-analyses 
34;35
 have shown there is insufficient 
evidence of a beneficial reduction in PTD following increased psychosocial support and 
home visits, preterm delivery education, bed rest, hydration, reducing excess manual labour 
and psychological stress, and ensuring that BMI is greater than 20 before conception.   
Similar results were found for interventions undertaken in both high-risk and low-risk 
pregnancies 
34;35
.  
3. Smoking and drugs avoidanceThe association between smoking or illicit drugs 
(such as heroin or cocaine) and adverse perinatal outcomes is well established.   A Cochrane 
meta-analysis of 16 trials showed a reduction in low birthweight (RR 0.81, 95% CI 0.70 to 
0.94), a reduction in PTD (RR 0.84, 95% CI 0.72 to 0.98), and an increase in mean 
birthweight of 33 g (95% CI 11 g to 55 g) with smoking cessation programs
36
.  Three non-
randomised comparative studies have shown improved neonatal outcomes (but not neonatal 
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mortality) with antenatal drug avoidance programmes 
37-39
, with two of these studies 
suggesting a modest reduction in PTD
38;39
. 
4. Screening and treatment of anaemiaThere is epidemiological evidence to support 
an association between low maternal hemoglobin concentration and low birth weight, as well 
as between low maternal haemoglobin concentration and PTD
40;41
.   However, a meta-
analysis 
42
, and two recent RCTs 
43;44
 have shown that supplementation of anaemic or non-
anaemic pregnant women with iron, folic acid, or both, does not appear to increase either 
birth weight or the duration of gestation.  
5. Screening and treatment of asymptomatic bacteriuria A meta-analysis has shown 
that antibiotic treatment in pregnant women with asymptomatic bacteriuria found on 
antenatal screening is effective in reducing the risk of pyelonephritis (OR 0.24; 95% CI 0.19 - 
0.32), and PTD or low birthweight (OR 0.60; 95% CI 0.45-0.80)
45
, and is thus advocated as 
part of routine antenatal care 
32
 . 
6. Elective prophylactic cervical cerclage for cervical incompetence  A history that 
comprises any combination of: second trimester miscarriage, painless and progressive 
dilatation of the cervix, bulging membranes through the cervix prior to onset of labour, or 
previous cervical surgery (e.g. cone biopsy), may suggest cervical incompetence and an 
increased risk of PTD in the current pregnancy.   This information would normally be 
identified through routine antenatal screening.   Presently, overall evidence suggests that 
elective cervical cerclage (defined in Table 3.3) compared to no cerclage or bed rest is likely 
to reduce the risk of PTD in women considered to be 'at very high-risk' of a second trimester 
miscarriage due to a cervical factor 
46-48‖.  There is no consensus on defining this ―very high-
risk‖ group, but subgroup analyses suggest this mainly comprises of women with three or 
more prior preterm births or second trimester losses.  
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Table 3.3.   Defining elective and indicated types of cervical cerclage 
Elective 
cerclage 
Cerclage is performed before clinical or ultrasonographic evidence of 
cervical dilatation, using McDonald or Shirodkar techniques.   Usually 
performed at 12-16w and based on reproductive history, or other criteria 
suggestive of cervical incompetence.  Also termed as primary cerclage. 
 
Indicated   
(emergency) 
cerclage 
Cerclage is performed following clinical or ultrasonographic evidence of 
cervical dilatation, funneling or shortening.   Also uses McDonald or 
Shirodkar techniques.   Theoretically may be performed at any preterm 
gestation below 32 weeks’, but most often undertaken at midtrimester (18-22 
weeks’) period.  Also termed as secondary cerclage (if scan evidence of 
cervical dilatation) or tertiary cerclage (if clinical evidence of cervical 
dilatation) 
 
Of the three meta-analyses that have clearly distinguished between emergency and elective 
cervical cerclage, one 
47
 has shown no statistically significant reduction in rates of PTD, 
whereas the other two meta-analyses 
46;48
have showed elective cervical cerclage to be 
effective at preventing PTD . Heterogeneity in defining the risk of PTD due to a ―cervical 
factor‖ has contributed to differences in the findings of the meta-analyses. 
 
The largest cervical cerclage trial 
49
 showed that elective cervical cerclage performed 
between 12-16 weeks gestation, in women at risk of cervical incompetence based on clinical 
history, reduced the risk of PTD (<34 weeks‘) but did not reduce perinatal mortality.   It 
found that 24 women (95% CI 10-61) would need to undergo elective cervical cerclage to 
prevent one additional PTD before 34 weeks‘.   Importantly, a quasi-randomisation method 
was adopted, which allowed clinicians to allocate cerclage or no cerclage according to the 
perceived risk of cervical incompetence and only when the clinician felt unsure if such 
cerclage would be beneficial or non-beneficial.   
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Evidence for screening-preventative interventions based on routine antenatal 
care plus specialist investigations 
 
1. Microbiological screening and treatment of the genital tract  
 Bacterial vaginosis (BV) and trichomonas vaginalis (TV): Bacterial vaginosis (BV) 
is found in 9%-23% of pregnant women.   The presence of BV or trichomonas vaginalis (TV) 
in asymptomatic women in the second trimester is associated with PTD independent of other 
known risk factors
50-52
.  Importantly, the earlier in gestation BV is detected, the greater is the 
risk of an adverse outcome.   For example, BV at 26-32 weeks‘ is associated with PTD odds 
ratio (OR) of 1.4 to 2  whereas BV at 7-16 weeks‘ carries an OR of 5 to 7.5 52.     
 
There is evidence that screening and treating BV in unselected low-risk population groups, 
rather than a heterogeneous combination of high-risk population groups, is effective at 
reducing the rate of PTD. When considering the combined screening of both low and high-
risk populations, six meta-analyses 
53-58
have shown that screening and treating asymptomatic 
BV, using either oral metronidazole (majority of trials) or vaginal/oral clindamycin, does not 
reduce the risk of PTD. However, our recently published meta-analysis (Figure 3.1) 
58
 has 
shown that screening and treating BV from a low-risk population does result in a statistically 
significant reduction in PTD (nine trials, RR 0.73; 95% CI 0.55-0.98).  
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Figure 3.1 Meta-analyses for treatment of bacterial vaginosis and reduction in preterm 
delivery 
Screening and treatment of bacterial vaginosis in all population groups (both high and low 
risk) and reduction in preterm delivery 
 
Screening and treatment of bacterial vaginosis in high-risk population and reduction in 
preterm delivery 
 
Screening and treatment of bacterial vaginosis in low risk population and reduction in 
preterm delivery 
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In addition to pregnancy risk stratification, other factors contribute to heterogeneity of the 
trials and methods used by the meta-analyses of screening and treating BV in pregnancy.  
These factors have been highlighted by two recent commentaries
58;59
 and include: antibiotic 
types, dosaging and gestation-specific efficacies; criteria for diagnosing BV; and unexplained 
high therapeutic responses observed from both placebo 
60
 and the screening process itself 
without any antibiotics being administered 
61
. A randomized trial showed that screening and 
treating with metronidazole asymptomatic pregnant women for TV at 16 to 23 weeks‘ did not 
reduce PTD, and rather worryingly increased the risk of PTD (RR 1.8; 95% CI 1.2 to 2.7; 
P=0.004) 
62
.  This is the only trial included in the corresponding Cochrane systematic 
review
63
. 
 
 Chlamydia trachomatis: Chlamydia trachomatis is estimated to infect 2%-37% of 
pregnant women.   Data from the NIH Preterm Prediction Study showed that women with 
Chlamydia trachomatis infection at 24 weeks‘' gestation were twice as likely as uninfected 
women for PTD <37 weeks‘ (OR 2.2; 95% CI 1.03-4.78) and 3 times as likely to have PTD 
<35 weeks‘' gestation (OR, 3.2; 95% CI 1.08-9.57)64.   Only one trial 65 has examined 
screening and treatment for Chlamydia to prevent PTD, and this showed no statistically 
significant reduction.   Information from on-going national opportunistic chlaymdia screening 
programmes may provide further evidence in this area.   
 
 Ureaplasma: Ureaplasma genital tract infection is associated with PTD and PPROM.   
A Cochrane ‗meta-analysis‘ including only one trial, concluded there was insufficient 
evidence to show whether screening and treating women with ureaplasma in the vagina 
would prevent PTD
66
. 
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 Group B streptococcus (GBS): Around 20% of pregnant women have Group B 
streptococcus (GBS) urogenital colonization.   This is associated with an increased risk of 
urinary tract infection, PTL, PPROM, and infectious perinatal transmission
67
.   Only one trial 
was identified, and this showed no reduction in PTD when pregnant women were routinely 
screened and treated (using erythromycin) for GBS in the third trimester 
68
.   Based on this 
trial, and other observational studies, both the RCOG and CDC have stated that routine 
screening and antenatal treatment of women with GBS does not reduce the risk of PTD 
67;69
.  
However, screening of high-risk pregnancy groups is recommended by the UK 
67
, and is 
universally undertaken during the third trimester in United States
69
 and Canada
70
.   This 
facilitates the policy of prophylactic antibiotic treatment to carriers of GBS in labour, which 
has been shown to reduce the incidence of GBS-related neonatal morbidity and mortality 
67;69
. 
 
2. Screening for cervical length by ultrasound or clinically and subsequent 
indicated cervical cerclage There is considerable evidence to show that in the absence of 
uterine contractions transvaginal sonographic measurement of cervical length is an effective 
way of identifying pregnancies at high-risk of PTD, and has greater predictive value than 
other ultrasonographic measurements of the cervix such as dilatation of the internal os or 
funneling of the internal os 
71-78
. A systematic review showed for asymptomatic women at or 
below 20 weeks gestation, a cervical length of 25 mm or less had a test positive likelihood 
ratio of 6.29 (95% CI, 3.29-12.02) and negative test likelihood ratio of 0.79 (95% CI, 0.65-
0.95) for predicting spontaneous PTD before 34 weeks gestation 
76
.    
Cervical cerclage may be performed electively (prophylactic procedure discussed earlier) or 
as an indicated (emergency) procedure (defined in Table 3.3) following clinical or 
ultrasonographic evidence of cervical dilatation, funneling or shortening. 
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 Cerclage vs. no cerclage for short cervical length by ultrasound A meta-analysis has 
showed no statistically significant effect of midtrimester indicated cerclage compared to no 
cerclage on the rates of PTD (four studies) or neonatal mortality (three studies) in women 
with shortened cervical length on transvaginal ultrasound scanning 
79
. However, a meta-
analysis of four trials using individual patient-level data has shown that indicated 
midtrimester cervical cerclage prevents PTD before 35 weeks in women with singleton 
pregnancies and a short cervical length (RR 0.74, 95% CI 0.57-0.96), and this risk reduction 
is greater in singleton gestations with prior PTD or prior second-trimester loss 
80
. This meta-
analysis included two recently published trials 
81;82
 that had individually shown no beneficial 
effect of cerclage, as well as the CIPRACT trial 
83
which was the only trial to show any 
beneficial effect of cerclage on preventing PTD.    
 Emergency cerclage in women with cervical incompetence on physical 
examination In women with cervical incompetence on physical examination, with 
membranes at or beyond a dilated external cervical os, a small RCT (n=23) showed that a 
combination of emergency cerclage, bed rest, antibiotics and indomethacin was more 
effective at reducing PTD <34 weeks than bed rest with antibiotics alone 
84
.  
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3. Elective first trimester cerclage vs. cervical ultrasound surveillance and 
indicated emergency cerclage  Four retrospective comparative studies 
85-88
 have shown no 
difference in obstetric outcomes with either strategy, whereas a recent prospective study 
showed better outcome with cervical surveillance and indicated cerclage 
89
.   Reliable 
interpretation of these studies, as well as comparison with the trials of cerclage (elective and 
indicated) discussed earlier, is markedly hampered due to variation in the definition and 
magnitude of the risk in the population under study. Ultrasonographic cervical length, 
combined with previous obstetric and reproductive history, has been successfully 
incorporated into a risk scoring system for predicting PTD 
90
. However, there is no evidence 
from any robust studies that indicates whether such a pregnancy risk stratification strategy 
followed by indicated cervical cerclage in those at most risk would reduce the rate of PTD.  
The accumulated evidence therefore suggests that a combination of assessment of risk 
factors, obstetric history and serial follow-up of cervical length is more likely to identify the 
group of women who would benefit most from cervical cerclage. 
 
4. Positive fetal fibronectin testing followed by antibiotic treatment Fetal fibronectin 
(fFN) is a basement membrane protein produced by fetal membranes which functions as an 
adhesive factor of the placenta and membranes to the decidua.   It is normally present in 
cervical secretions until 16-20 weeks gestation.    Before testing for the presence of 
cervicovaginal fFN the following criteria must be met: intact amniotic membranes; minimal 
cervical dilatation (<3cm); sampling between 22 and 34 weeks gestation. A meta-analysis of 
cervicovaginal fFN testing in asymptomatic pregnancies to predict PTD before 34 weeks 
showed a test positive likelihood ratio of 4.01, and a test negative likelihood ratio of 0.78 
91
.    
Similar results were found by another meta-analysis
92
, where for the prediction of outcomes 
of delivery <37 and <34 weeks‘' gestation, a positive fFN had overall sensitivity rates of 52% 
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and 53%, and overall specificity rates of 85% and 89%, respectively.   For the outcomes of 
delivery within 7, 14, and 21 days, the sensitivities were 71%, 67%, 59% and specificities 
were 89%, 89% and 92% respectively. 
 
A positive midtrimester fFN test has been associated with an increased risk of subsequently 
diagnosed maternal and fetal infection.    A primary analysis of the trial conducted by MFMU 
showed that metronidazole plus erythromycin treatment of asymptomatic women with a 
positive midtrimester fFN (screened between 21 and 26 weeks‘) did not reduce the risk of 
PTD as hypothesized, but caused a non-statistically significant increase in PTD <37 weeks 
and <32 weeks‘93.   Furthermore, a subgroup analysis in women with previous PTD showed a 
statistically significant increased risk of PTD when the treated group was compared to 
placebo (46.7% versus 23.9%, P =0.039).  Whereas,  a secondary analysis of the MFMU 
study showed that women with both BV or TV and a positive fFN, who were treated with 
metronidazole, had a non-significant reduction in spontaneous PTD from 14.6% to 8.3% 
94
. 
 
If the detection of fFN does not alter the natural history of PTD through earlier antibiotic 
treatment, could there still be a beneficial role for fFN testing in the asymptomatic ‗low‘ or 
‗high‘ risk woman? A positive fFN may have clinical benefit by lowering the threshold for 
admission, or in utero transfer, or administering antenatal corticosteroids.  Conversely, a 
negative fFN may have clinical value in avoiding unnecessary, costly and potentially harmful 
interventions.  However, clinical trials examining improvements in perinatal outcomes 
following such risk assessment with fFN were not identified in the literature.   
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Evidence for the value of screening-preventative strategies in specific high risk 
groups 
 
Multiple Pregnancies Overall, there is a paucity of RCTs that have evaluated screening-
preventative interventions in women with multiple pregnancies.   A retrospective study 
showed no difference in perinatal outcomes between multiple weekly prophylactic 
administration and single course antenatal corticosteroids in women with twin pregnancies 
95
.    
Prophylactic corticosteroids have no proven benefit in twin or higher order multiple 
pregnancies, and may in fact be associated with increased harm such as decreased birthweight 
and increased risk of infection 
96
.   A short cervical length (less than or equal to 25mm), with 
or without funneling, at midtrimester screening is predictive for PTD in twin pregnancy, 
albeit at lower sensitivity than when the same test is applied to singleton pregnancies
97-100
.  A 
meta-analysis of trials using individual patient data 
80
showed a significant increase in PTD 
(RR 2.15, 95% CI 1.15-4.01) at less than 35 weeks when indicated cervical cerclage was 
performed  in twin gestations with short cervical length.  However, a non-randomized 
prospective trial showed that indicated midtrimester cerclage in multiple pregnancies does 
not alter the risks of PTD, PPROM or low birth weight
101
.   One retrospective study showed 
that prophylactic elective cerclage in triplet and higher order multiple pregnancies had no 
beneficial effect on obstetric or perinatal outcome
102
, although this was contradicted by 
another retrospective study
103
. 
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Antiphospholipid syndrome (APLS Antiphospholipid syndrome (APLS) in pregnancy is 
characterized by the presence of autoantibodies (anticardiolipin and/or lupus anticoagulant) in 
association with recurrent fetal loss, maternal thrombocytopenia and other pregnancy 
complications. Systemic lupus erythematosus (SLE), APLS, and thrombophilias have been 
associated with similar pregnancy complications of early and late fetal loss, abruption, pre-
eclampsia and intrauterine growth restriction in three meta-analyses 
104-106
.  Evidence from 
observational studies of rates of PTD in women with SLE, APLS, or thrombophilias is 
conflicting, and the analysis is complicated by complex co-morbidities of maternal disease 
(hypertension, renal impairment), fetal compromise (growth restriction), spontaneous PTL, 
PPROM and medically-indicated PTD. A retrospective study suggested that actively treated 
SLE (requiring prednisone or other immunosuppresants), or the presence of anticardiolipin 
antibodies, are predictive of a higher risk of PTD than inactive disease
107
; implying a 
potential beneficial role in suppressing active SLE disease in pregnancy to reduce the risk of 
PTD. 
 
Systematic reviews of therapeutic trials for treating APLS in pregnancy conclude that there is 
currently only weak evidence for a role of low dose aspirin and low-molecular-weight 
heparin in preventing adverse outcomes 
108;109
, despite this being the recommended treatment.  
However, recent preliminary pilot studies suggests the beneficial effect of such prophylaxis 
has been underestimated, and further research in this area is currently being actively pursued 
105;110;111
.  Current consensus is that thrombophilia screening is recommended for women 
with the following previous complications: fetal loss including three or more first trimester 
loss, two or more second trimester loss, or any stillbirth; early, severe or recurrent 
preeclampsia and severe intrauterine growth restriction 
112
. 
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Pre-eclampsia and uterine artery Doppler There is evidence that women with a previous 
history of pre-eclampsia-related PTD have a greater risk of pre-eclampsia-related PTD in a 
subsequent pregnancy as compared with women with a previous PTD
113;114
.   A systematic 
review showed that low dose aspirin (150mg) reduces the risk of perinatal death, pre-
eclampsia and PTD in women with a history of previous pre-eclampsia, and should therefore 
be strongly advocated 
115
.   The reduction of recurrent pre-eclampsia and perinatal death was 
greater in women with previous severe early-onset (second trimester) pre-eclampsia. There is 
evidence showing an association between impaired midtrimester uterine artery Doppler 
velocimetry and/or uterine artery notching and subsequent pre-eclampsia
116
.  However, there 
are no data from any individual trial or meta-analysis demonstrating any direct reduction in 
PTD following low dose aspirin administration in women with impaired with impaired 
uterine artery Doppler characteristics that have been identified by either selective or 
unselective population Doppler screening
117-121
.  
Gestational Diabetes and Impaired Glucose Tolerance Overall, both gestational diabetes 
(GDM) and impaired glucose tolerance (IGT) affect 3%- 6% of pregnancies, and are 
associated with PTD, PTL, PPROM, and numerous other pregnancy complications.   Once 
identified, women are usually intensively managed with increased obstetric surveillance, 
dietary regulation, insulin therapy and instructed to maintain tight glycaemic control.   
However, evidence to support this intensive treatment is lacking.   Cochrane meta-analyses 
have concluded there is insufficient evidence to determine any beneficial or non-beneficial 
effect of dietary therapy, tight glycaemic control, or other treatments for GDM and IGT, upon 
pregnancy outcomes
122-124
.   A non-randomised comparative study has suggested that 
universal glucose tolerance screening performed at the first antenatal visit compared to later 
screening (24-28 weeks‘) resulted in a reduced risk of PTD and polyhydramnios 125.    
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Evidence for the value of population-wide preventative strategies in high and low 
risk groups 
 
Increased antenatal care and attendance There is conflicting opinion whether increased 
antenatal attendance reduces rates of PTD, and robust RCTs in this area are lacking.   
Nonetheless, lack of antenatal care has been associated with increased rates of PTD in the 
presence, as well as absence, of high-risk conditions 
126
.   In an attempt to reduce PTD, many 
health organizations such as Canada 
127
 and France
128
 have adopted a population wide health 
strategy that integrates disease prevention, health promotion, improvements in socioeconomic 
standards and increased attendance to antenatal care.   Observational studies examining 
variations of this approach have shown modest reduction in rates of PTD when applied to the 
general pregnant population 
128;129
.   However, two meta-analyses 
130;131
 have shown that 
increased antenatal attendance without specific specialist investigations (such as fetal 
biophysical or microbiological surveillance)  does not reduce the risk of PTD, low birth 
weight or perinatal mortality in low-risk women. 
 
Prophylactic micronutrients e.g. fish oil, magnesium, vitamins  
An overview of trials and systematic reviews concluded that there was insufficient evidence 
to show that antenatal prophylactic micronutrient supplementation reduced the risk of PTD in 
either low or high-risk pregnancy groups
42
.   Small studies have shown limited reductions in 
PTD when using fish oil, omega-3 fatty acids, calcium, zinc, magnesium, or multivitamin 
combinations
132-139
, although vitamin C supplementation might even increase the risk of PTD 
140
. These interventions need to be further explored in larger RCTs along with other important 
perinatal outcomes such as growth restriction and pre-eclampsia. 
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Prophylactic tocolytics Three meta-analyses evaluating prophylactic or maintenance oral 
tocolytics (mainly beta-mimetics) in high-risk pregnancies (women with threatened PTL or 
previous PTD) have not shown any reduction in PTD, PTL, perinatal morbidity or perinatal 
mortality
141-143
.   Importantly, newer tocolytics such as nifedipine and atosiban have not 
undergone evaluation in this manner
144
. A recent trial showed no beneficial effect on PTD, 
and a potential harmful effect on fetal renal function and the ductus arteriosus, when 
rofecoxib (a COX-2-specific prostaglandin inhibitor) was administered prophylactically to 
women at high-risk of PTD between 16-32 weeks gestation 
145
. 
 
Prophylactic corticosteroids Meta-analysis has shown maternal antenatal administration of 
a single course of corticosteroids is associated with a significant reduction in perinatal 
mortality (OR 0.60, 95% CI 0.48 to 0.75), respiratory distress syndrome (OR 0.53, 95% CI 
0.44 to 0.63) and intraventricular haemorrhage in preterm infants 
146
.   Consequently, a single 
course of antenatal corticosteroids is recommended in women symptomatic of PTL or 
PPROM or threatening to deliver preterm because of an obstetric disorder 
147
.   No beneficial 
effect has been reported following corticosteroids given before 28 weeks‘ or if infants are 
delivered more than seven days after initiation of treatment.    However, there are no 
prospective trials on the prophylactic use of corticosteroids (single or multiple courses) in 
high-risk asymptomatic pregnancies (e.g. growth restricted fetuses, pre-eclampsia, multiple 
pregnancies, previous recurrent PTD) not at imminent risk of PTD.  Their use in these 
circumstances remains controversial and unproven 
147-150
. In particular, many of these women 
may remain at risk of PTD seven days after the first course, which creates the clinical 
dilemma of whether to administer a repeat course of antenatal corticosteroids.   Repeated 
courses of antenatal corticosteroids may have a lower rate of neonatal lung disease according 
to one meta-analysis 
148
.  However, an extensive review performed by the NIH 
151
 reported 
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that there was insufficient evidence to conclusively show any marked adverse or beneficial 
change with repeated courses of corticosteroids for important neonatal outcomes like small-
for-gestational-age at birth, perinatal death, periventricular haemorrhage, periventricular 
leucomalacia, infectious morbidity, and neonatal lung disease.   Absence of beneficial effect 
of repeated weekly vs. single course antenatal corticosteroids in women at risk of PTD was 
shown in a recently published trial 
152
. Notably, a subgroup analysis of the trial in women 
with PPROM
153
 showed that there was no difference in neonatal morbidity but an increased 
risk of chorioamnionitis in women who received weekly courses of corticosteroids. 
 
Prophylactic antibiotics  A meta-analysis has shown that prophylactic antibiotics given 
during the second and third trimester of pregnancy in unselected pregnancies reduces the risk 
of PPROM (OR 0.32, 95% CI 0.14-0.73) 
154
.  There was a risk reduction in PTD in pregnant 
women with previous PTD associated with bacterial vaginosis (BV) but there was no risk 
reduction of PTD in pregnant women with previous PTD unrelated to BV.   This observation 
complements our meta-analysis 
58
discussed earlier, that showed screening and treating BV in 
unselected low-risk populations was beneficial in reducing PTD. 
 
Prophylactic progesterone Two recently published meta-analyses have shown a beneficial 
role for prophylactic progesterone supplementation in the prevention of PTD 
155;156
. Despite 
differences in the pregnancy risk status of the population included, and the number of 
included trials  [seven trials 
155
 and ten trials 
156
] both meta-analyses have reported similar 
rates of risk reduction of  PTD: OR 0.58, 95% CI 0.48-0.70 
155
 and OR 0.45, 95% CI 0.25-
0.80 
156
 . Based on increasing research in this area, a supportive but cautionary statement was 
released by the ACOG 
157
 in 2004, which recommended that prophylactic progesterone to be 
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used only in women with a history of previous PTD. Two recently published RCTs are 
included in the meta-analysis. One RCT 
158
.   (n=142) showed that daily administration of 
prophylactic vaginal progesterone (100mg) compared to placebo between 24 and 34 weeks‘ 
in high-risk pregnancies (women with previous PTD) reduced the frequency of uterine 
contractions and the rate of PTD (OR 0.40, 95% CI 0.17-0.94).  The other RCT (n=463) 
159
 
showed that women with a history of previous PTD, who received weekly injections of 17 
alpha-hydroxyprogesterone caproate (17P) from recruitment (16-20weeks‘) to 36 weeks‘ 
gestation, had a reduced risk of PTD before 37 weeks‘ (OR 0.66, 95% CI 0.54 to 0.81), 
necrotizing enterocolitis, intraventricular hemorrhage, and need for supplemental oxygen.  A 
secondary analysis of this study showed the risk reduction in PTD is greatest in the subgroup 
of women whose previous PTD was before 34 weeks 
160
. Further research on the correct 
progesterone formulation, mechanism of action, efficacy, and risk-benefit profile is needed 
before prophylactic progesterone may become an accepted clinical intervention in high-risk 
asymptomatic pregnancies. 
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Antenatal management plan and role of specialist antenatal prematurity clinics  
Specialist antenatal clinics for women with multiple pregnancy, diabetes, epilepsy, and 
haematological disorders are widespread and well established.   Likewise, women at high-risk 
of prematurity may also benefit from such specialised antenatal care with individualised risk 
assessment and application of general and specific screening-preventative measures to 
prevent PTD or reduce adverse perinatal outcome.   These clinics are common in many 
university teaching hospitals
161
, although rigorous evaluation of their exact beneficial role in 
reducing PTD is pending.   The exact antenatal design, resources needed, and timing of 
screening interventions remain a controversial issue and have little supporting evidence. 
Nevertheless, we suggest an antenatal management plan (Table 3.4) that may prevent PTD 
based on established practice and evidence presented in this review that may be considered a 
basis for further modification and research. 
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Table 3.4.    Suggested antenatal strategy to prevent preterm delivery 
ANTENATAL 
VISIT AND 
PURPOSE 
Infection 
(Screen and 
treat  
BV, UTI) 
Cervico-
vaginal 
 fFN 
 
Ultrasound 
Abdominal 
and 
Transvaginal 
 
Other interventions to be 
considered 
Pre-pregnancy 
Counselling on recurrence 
risk and any modifiable 
predisposing factors 
Yes 
 
No No Cessation smoking and illicit drugs 
Improve BMI>25 
Thrombophilia screen if history 
suggests 
Optimise control of diabetes, high BP 
Change anticoagulation or 
antihypertensive drugs 
8 weeks’ 
Routine booking bloods 
  
 
Yes  No Dating 
pregnancy 
 
  
 
Thrombophilia screen and commence 
aspirin & LMWH if positive. 
Low dose aspirin if previous pre-
eclampsia (consider use if previous 
stillbirth, abruption, severe IUGR) 
Prophylactic progesterone 
General preterm birth education, 
support, and risk factor avoidance. 
Screen and treat BV, UTIs 
Low threshold for GTT testing 
12, 16, 20, 24, 28 weeks’ 
Nuchal Translucency(12w) 
and/or  Triple Test or msAFP 
(15-18w) 
No No Serial Cervical 
assessments in 
women at high 
risk of PTD 
Emergency or elective (12-16w) 
cervical cerclage based on ultrasound 
findings and/or reproductive history 
Emergency cervical cerclage is not 
indicated if above 32 weeks‘ 
Low threshold for GTT testing 
22 weeks’ Yes  No Detailed fetal 
survey 
Uterine artery 
Doppler 
Low dose aspirin if suspect pre-
eclampsia or IUGR due to uterine 
artery notching and/or previous 
history 
Screen and treat BV and UTIs 
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FootNote: Bacterial vaginosis, BV; BMI, body mass index; BP, blood pressure; fFN, fetal 
fibronectin; GBS, Group B streptococcus; GTT, glucose tolerance test; LMWH, IUGR, 
intrauterine growth restriction; low-molecular weight heparin; msAFP, maternal serum alpha-
fetoprotein; NICU, neonatal intensive care unit; PPROM, preterm premature rupture of 
membranes; PTL, preterm labour; UA, uterine artery; UTI, urinary tract infection. 
24, 28, 32, 36 weeks’ 
GTT at 28 weeks‘ 
No Only if 
symptomati
c 
Fetal growth 
and umbilical 
artery Doppler 
 
Prophylactic corticosteroids, 
antibiotics if symptomatic of PTL or 
PPROM. 
In utero transfer to unit with NICU if 
symptomatic with positive fFN 
 
Labour 
Spontaneous or induced 
Yes  Helps 
confirm 
Likelihood 
of 
PTL, 
PPROM 
Asses fetal well-
being, and 
presentation 
Prophylactic corticosteroids, 
antibiotics (especially GBS 
prophylaxis).    
Tocolytics if in utero transfer to unit 
with NICU is needed. 
Post-partum 
6 week antenatal check 
No No No Review antenatal events and delivery 
Identify modifiable factors for future 
prevention of PTD 
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Discussion 
 
There is evidence that introducing screening-preventative strategies for asymptomatic 
pregnancies may reduce the rate of PTD.   Evidence for screening and selective treatment 
exists for: asymptomatic bacteriuria (meta-analysis: OR 0.60; 95% CI 0.45-0.80); bacterial 
vaginosis in low-risk population groups (meta-analysis: RR 0.73; 95% CI 0.55-0.98, figure 
3.1); elective cervical cerclage in high-risk pregnancies; indicated cervical cerclage in women 
with short cervical length on ultrasound (meta-analysis: RR 0.74, 95% CI 0.57-0.96); 
prophylactic progesterone supplementation in high-risk pregnancies (meta-analysis: OR 0.45, 
95% CI 0.25-0.80). A summary of the quality of evidence and grading of recommendation 
for these interventions are depicted in Table 3.5.  
 
However, for most other strategies, such as increased antenatal attendance, or routine 
administration of prophylactic micronutrients, the evidence is inconsistent and conflicting. 
Information on neonatal outcomes apart from PTD (such as serious neonatal morbidity and 
mortality) was found to be lacking in most studies.  It was therefore not possible to establish 
whether preventing PTD or prolonging gestation would correlate to improved perinatal 
outcome, and so lessened the potential clinical usefulness of any proposed preventative 
strategy. No studies were found that evaluated the effectiveness of combining screening-
preventative strategies. 
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Table 3.5  Summary of screening and preventative strategies that may reduce the risk of 
preterm delivery 
Strategy for preventing preterm 
delivery 
RCOG 
Level of 
Evidence 
GRADE 
Quality 
of 
Evidence 
GRADE 
Strength of 
Recommendation 
Asymptomatic bacteriuria in all women 
 
Ia High Strong 
Bacterial vaginosis in low-risk population 
groups 
Ia, Ib Moderate Weak 
Elective cervical cerclage in high-risk 
pregnancies 
Ib, IIa, 
IIb 
Moderate Strong 
Indicated cervical cerclage in women with 
short cervical length on ultrasound 
Ib, IIa, 
IIb 
Moderate Strong 
Prophylactic progesterone 
supplementation in high-risk pregnancies 
Ia, Ib High Strong 
Smoking cessation in all women IIb, III Very 
Low 
Weak 
 
Reviews discussing screening-preventative interventions for preventing PTD often consider 
both symptomatic (symptoms of PTL or PPROM) and asymptomatic pregnancies.   We have 
focused solely on asymptomatic pregnancies and adopted a rigorous systematic review 
methodology to provide the best possible analysis of the data available.   The review is 
weakened by over-reliance on conclusions drawn from meta-analyses and underpowered 
RCTs. We have identified considerable heterogeneity in the studies and methodologies 
adopted by the meta-analyses, in particular, the groups of women considered to be ‗high‘ and 
low‘ risk of PTD, the magnitude of their risk of PTD, and gestation-specific timing of the 
intervention differs considerably for each trial and meta-analysis (e.g differences in types of 
antibiotic, dosage, method of administration, and gestation when given).  This heterogeneity 
would propagate any potential omission, de-emphasis or misinterpretation of the results of 
RCTs.  
Chapter  3.1: Prevention of preterm delivery 
 195 
The poor clinical efficacy of the proposed screening-preventative strategies is not 
unexpected.   Firstly, current routine antenatal screening is relatively ineffective at identifying 
the majority of pregnancies at risk for PTD, even if combined with specialist investigations.   
Secondly, most of the preventative interventions discussed appear to have, at best, only mild 
efficacy at preventing PTD.  Importantly, adverse effects of increasing the risk of PTD were 
noted for some of the interventions.  Examples include antibiotic treatment for women 
screened to be positive for fFN or trichomonas vaginalis, and inherent surgical risks 
associated with cervical cerclage.   
 
Further trials are needed to identify the optimum gestation and subgroups that may benefit 
most from such screening and therapeutic interventions.   Currently on-going meta-analyses 
of individual patient data 
162;163
 may provided further evidence for the roles of elective and 
indicated cerclage on preventing PTD, and aspirin on the prevention of pre-eclampsia related 
consequences. 
 
It was surprising to show a reduction in PTD following screening and treating BV in the low-
risk (RR 0.73; 95% CI 0.55-0.98) (Figure 3.1) but not the high-risk group, as one would 
normally expect an opposite relationship and treatment to exert greater risk reduction in the 
higher risk group.  The differences in antibiotic sensitivity between high and low risk groups 
may suggest differing causal contributions of the infectious process to PTD. The evidence, 
along with prior knowledge of differing predisposing factors and prognosis between these 
risk groups 
52;164
, supports the hypothesis that PTD in high and low risk pregnant women 
are different entities and not linear extremes of the same syndrome; a view shared by 
others 
8
, and deserving of further confirmatory research. 
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This review has provided a structured approach to addressing the complex issue of preventing 
PTD.  By elaborating on the use of both specific and general measures this review should 
appeal to all health care professionals (General Practitioners, Health Visitors, Midwives, 
Obstetricians) involved in the care of pregnant women, as well as colleagues involved in 
delivering public health care strategies.   We have proposed an antenatal care strategy that 
adopts a gestation-specific approach to assessing risk and intervening as needed (Table 3.4) 
that may be commenced at initial antenatal booking.  However, the efficacy and cost-
effectiveness of these approaches (Tables 3.4 & Table 3.5) needs to be rigorously evaluated 
before routine clinical implementation.  Differences in the prevalence of infection and other 
obstetric and reproductive factors means that any proposed preterm prevention strategy 
should be individualised to the population and health care setting.  Specialist antenatal clinics 
for women deemed at high-risk of PTD may provide an opportunity to carry out this research 
and perform this clinical role.  
 
The recent NICE UK antenatal care guideline 
32
 has stated pregnant women should not be 
offered routine screening for BV, Chlamydia, group B streptococcus, cervical 
ultrasonography, or cervical fFN 
32
.   Our review has presented preliminary evidence that 
some of these strategies may actually be beneficial, and as such, adds to the current debate in 
this important clinical area. 
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Discussion on bacterial vaginosis meta-analyses  
 
Meta-analyses are liable to numerous biases despite quality control measures, and their 
results may not necessarily be trusted 
165;166
.  Concerning screening and treating BV in 
pregnancy, five meta-analyses [Cochrane 
53
, 13 trials; Riggs 
54
, 11 trials; Leitich 
55
, 10 trials; 
Guise 
56
, 7 trials, and Okun 
57
, 11 trials] have been published in the last four years.  All have 
showed no reduction in PTD.  The authors of all five meta-analyses have reported significant 
clinical, methodological and statistical heterogeneity of the included studies, and have 
utilised different fixed or random effects pooling.  Only two meta-analyses 
53;57
 undertook a 
comprehensive investigation of the reasons for heterogeneity or attempted strategies to 
counter this effect.  Nevertheless, without undertaking this process, the summary estimate 
produced by each meta-analysis may not be valid.  Our ―repeat‖ meta-analysis , which 
considered the classification of population risk and therefore addressed the issue of 
heterogeneity to some extent, showed an unexpected beneficial effect of screening in women 
that were at low-risk rather than high risk of PTD .   
 
In summary, we wish to emphasise why it is important to consider the individual primary 
study as well as the methodology criteria adopted by meta-analyses, particularly when 
included trials are underpowered, few in number, and exhibit marked heterogeneity.  These 
factors may contribute to why meta-analyses to date have reported evidence of lack of 
effectiveness, but in fact may be subject to the bias of varying study methodologies, mixing 
high and low risk pregnancies groups, and a confounding effect introduced by the screening 
process itself that is difficult to distinguish from antibiotic treatment of bacterial vaginosis.
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3.2. Non-contraceptive uses of levonorgestrel releasing hormone system 
(LNG-IUS)- a systematic enquiry and overview 
 
Abstract 
Levonorgestrel releasing intrauterine systems (LNG-IUS) were originally developed as a 
method of contraception in the mid 1970‘s.   The only LNG-IUS approved for general public 
use is the Mirena® LNG-IUS, which releases 20mcg of levonorgestrel per day directly in to 
the uterine cavity.  However, new lower dose (10mcg and 14mcg per day) and smaller sized 
LNG-IUS (MLS, FibroPlant-LNG) are currently under clinical development and 
investigation.  Research into the non-contraceptive uses of LNG-IUS is rapidly expanding.  
In the UK, LNG-IUS is licensed for use in menorrhagia and to provide endometrial 
protection to perimenopausal and postmenopausal women on estrogen replacement therapy.  
There is limited evidence to suggest that LNG-IUS may also be beneficial in women with 
endometriosis, adenomyosis, fibroids, endometrial hyperplasia and early stage endometrial 
cancer (where the patient is deemed unfit for primary surgical therapy).  This systematic 
enquiry and overview evaluates the quality of evidence relating to the non-contraceptive 
therapeutic uses of LNG-IUS in gynaecology. 
 
Additional point relating to date listed in tables: For all studies listed in tables, we have 
reported the sample sizes originally recruited by the studies. Where the study drop out rate 
exceeds 10% we have stated this rate to provide the reader with an impression of the number 
of subjects actually evaluated by the study where this drop out rate is exceeded. 
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Introduction 
The only levonorgestrel-releasing intrauterine system (LNG-IUS) approved for general 
public use is the Mirena® (Schering AG), which is a T-shaped plastic intrauterine device 
(IUD) that releases levonorgestrel (20mcg per day) directly into the uterine cavity.  The mean 
systemic levels of levonorgestrel with this LNG-IUS (425pg/mL at 1 month, 330 pg/mL at 6 
months, mean age of subjects was 31 years (range 18-42) 
1
 are less than those achieved with 
therapeutic oral or parenteral doses of progestogens (hence minimizing systemic side effects) 
and exceeds the critical value of 200 pg/mL below which ovulation occurs 
2
.  Mirena was 
first launched in Finland in 1990 and has been marketed in the UK since 1995 as a 
contraceptive device.  Two new lower levonorgestrel dose and smaller sized LNG-IUS 
devices are currently under clinical development and investigation:  FibroPlant™-LNG 
(frameless device, Contrel Research, Belgium) and MLS system, releasing 14mcg and 10mcg 
levonorgestrel per day respectively
3;4
.  
Mirena® LNG-IUS is currently licensed in the UK as a 5-year contraceptive agent (license 
awarded 1995), treatment for idiopathic menorrhagia (license awarded 2001), and to provide 
uterine protection during estrogen replacement therapy in peri- and postmenopausal women 
(license awarded 2005). The latter two applications for Mirena® LNG-IUS are not licensed 
in USA or Canada. The fertility control provided by LNG-IUS is comparable with that of 
female sterilisation, and is completely reversible 
5
.  There are many other non-contraceptive 
beneficial effects of LNG-IUS that have important public health implications.   These have 
been summarized by several reviews 
6-9
 and policy statements 
10
, and incorporated within one 
systematic review examining all types of intrauterine device 
11
.  However, there has since 
been a considerable expansion of publications in this area, many of which have contrasting 
methodological quality and results.  This article expands on past reviews by incorporating 
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these recent advances and performs an up-to-date systematic review focused entirely on 
LNG-IUS.  Furthermore, this review evaluates the quality of supporting evidence, and where 
available, presents information relating to adverse effects, cost-effectiveness, and health 
related quality of life (HRQL) issues. 
 
Materials and Methods  All observational and experimental studies examining the use of 
LNG-IUS in Gynaecology were retrieved from MEDLINE (1996-2005), EMBASE (1996-
2005 week 08), Cochrane Central Register of Controlled Trials, Cochrane Database of 
Systematic Reviews, Database of Abstracts of Reviews of Effects (DARE), The National 
Research Register NRR (http://www.update-software.com/National/), Medical Research 
Council's Clinical Trials Register, and details on reviews in progress collected by the NHS 
Centre for Reviews and Dissemination were searched.  Schering HealthCare (UK) were also 
contacted for further information on licensing and any unpublished controlled clinical trials. 
The following search terms and word variants were used: ‗exp Intrauterine Devices, 
Medicated/‘, ‗levonorgestrel releasing‘, ‗levonorgestrel-releasing‘,‗LNG-IUS‘, ‗LN-IUS‘, 
‗LN-IUD‘, ‗LNG-IUD‘, ‗mirena.tw.‘  ‗Levonorgestrel adj5 (intrauterine or device or coil or 
system). tw, ‗progest$ adj5 (intrauterine or device or coil or system).tw‘, ‗intra-uterine 
progestogen‘  combined with ―AND‖ to ‗gyne$‘, ‗therapy‘ ‗endometriosis‘, 
‗endometrio$.mp‘, ‗genital neoplasms, female‘, ‗dysmenorrhoea‘, ‗pelvic pain‘, ‗estrogen 
replacement therapy‘, ‗hormone replacement therapy‘, or ‗genital diseases, female‘.  The 
search was completed in March 2005.  Obtained data were
 
qualitatively and quantitatively 
analysed. If trials are deemed suitable (similar population groups, trial methodology and 
outcome measures) meta-analysis will be performed. 
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Results  
A summary of the studies identified describing the non-contraceptive therapeutic use of 
LNG-IUS according to the therapeutic indication is shown in Table 3.6.  The associated level 
of evidence and strength of recommendation for each indication is also indicated according to 
accepted criteria 
12
. 
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Table 3.6.  Summary of studies that assess LNG-IUS use in various non-contraceptive 
therapeutic indications as primary study outcome measures 
Therapeutic use of LNG-
IUS 
RCTs Cohort 
Studies 
 
Prospective 
or 
Retrospective 
Observational 
Studies 
Case 
Report 
or small 
case 
series 
**Level 
of 
evidence 
*** 
Strength 
of 
recomme
ndation 
More than 
50 women 
 in 
LNG-IUS 
arm  
of trial 
Less than 
 50 women  
in  
LNG-IUS 
arm 
 of trial 
Menorrhagia 1 9 2 5 0 I, II, III A 
Fibroids/Fibroid related 
menorrhagia 
1# 2# 1 6 1 II, III B 
Endometriosis 0 2 0 3 0 I, III C 
Adenomyosis 1 0 0 1 1 I, III, III C 
Uterine protection with 
estrogen replacement 
therapy in per- and 
postmenopausal women 
3 4 3 7 0 I, II, III A 
Uterine protection with 
tamoxifen in 
postmenopausal women 
1 0 0 1 0 I, III A 
Endometrial hyperplasia 0 0 1 3 2 II, III C 
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Footnotes to Table 3.6 
#
 Trial(s) exist, but therapeutic outcome was not assessed as a priori primary outcome 
measure in the RCT comparison 
 
**Classification of Evidence Levels  
Ia Evidence obtained from meta-analysis of randomised controlled trials.  
Ib Evidence obtained from at least one randomised controlled trial.  
IIa Evidence obtained from at least one well-designed controlled study without 
randomisation.  
IIb Evidence obtained from at least one other type of well-designed quasi-experimental study.  
III Evidence obtained from well-designed non-experimental descriptive studies, such as 
comparative studies, correlation studies and case studies.  
IV Evidence obtained from expert committee reports or opinions and/or clinical experience of 
respected authorities.  
 
***Strength of Recommendation  
A Directly based on category I evidence 
B Directly based on category II evidence or extrapolated recommendation from category 
I evidence 
C Directly based on category III evidence, or extrapolated recommendation from 
category I or II evidence 
GPP Directly based on category IV evidence, or extrapolated recommendation from 
category I, II or III evidence 
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Menorrhagia 
Early RCTs and cohort studies evaluating the contraceptive efficacy of LNG-IUS against Cu-
IUCD showed women who received LNG-IUS reported less dysmenorrhoea and menstrual 
blood loss (MBL)
35;36
.  This provided a basis to examine whether LNG-IUS would also 
decrease menstrual blood loss in women with idiopathic menorrhagia (dysfunctional uterine 
bleeding DUB) and compare its efficacy against established medical and surgical treatments 
for menorrhagia.  In total, approximately 670 women with menorrhagia have used LNG-IUS 
as part of a comparative or non-comparative study (Table 3.7) evaluating the efficacy of 
LNG-IUS in treating menorrhagia. Women using the frameless FibroPlant-LNG™ or 
Femilstrade LNG-IUS (20mcg/24hr) devices for contraception 
33;37
 or treatment of 
menorrhagia 
30-33
 also reported decreased MBL, however study sample sizes were limited 
(n=76 menorrhagia cases) and the devices remain under clinical development.   
 
Two incomplete trials were identified in the search, SMART (Satisfaction with Mirena and 
Ablation: a Randomised Trial) 
38
 and TALIS (Thermo-Ablation versus the Levonorgestrel 
Intrauterine System)
39
. Furthermore, our unit is about to commence the ECLIPSE trial 
(Effectiveness and Cost-effectiveness of Levonorgestrel containing Intrauterine system in 
Primary care against Standard treatment, ISRCTN 86566246) in the UK. 
 
Overall, for all listed studies, LNG-IUS use in women with menorrhagia reduces menstrual 
blood loss by 79% to 97%.  No RCTs have compared LNG-IUS with placebo or no treatment 
in women with menorrhagia.  Importantly, studies have used various outcome measures, 
which precludes pooled meta-analysis.  These include: indirect (pictorial blood loss 
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assessment chart, PBAC) or direct (alkaline haematin method) measures of menstrual blood 
loss (MBL); patient willingness to continue with treatment; or patient preference to abandon 
LNG-IUS treatment in favour of hysterectomy or endometrial resection.  There are 
insufficient participants to show long term therapeutic effect with LNG-IUS, as most studies 
did not extend beyond one year follow up. The total number of participants continuing with 
LNG-IUS by 3-year 
19;34
 and 5-year follow up
14
 was 96 cases. Of the ten trials depicted in 
Table 3.7, seven 
13;16-18;20;23;24
 have been incorporated in two Cochrane reviews 
40;41
 and one 
systematic review 
42
.  Three recent RCTs 
15;21;22
 and two quality cohort studies 
25;26
 not 
included in the prior published meta-analyses have been listed in Table 3.7.  The high patient 
satisfaction (72-94%) and overall continuation rates (65- 88%) obtained in these RCTs are 
consistent with those identified in observational studies of LNG-IUS use for treating 
menorrhagia 
29;43;44
. Interpreting the evidence from Table 3.7, LNG-IUS system is at least 
comparable or more effective than oral progestogens.  Similar rates of patient satisfaction and 
quality of life are reported when comparing LNG-IUS against transcervical endometrial 
resection or balloon ablation.  However, surgical methods are significantly more effective in 
reducing menstrual bleeding or inducing amenorrhoea within one year follow up.  However, 
one trial with longer follow up of three years 
19
 showed no significant difference between the 
LNG-IUS and TCRE in the reduction of menstrual blood loss.   
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Table 3.7. LNG-IUS studies assessing therapeutic effect in women with menorrhagia 
Author Year  
of  
Publication 
Study 
Type 
Sample 
Size of women 
with 
menorrhagia 
Comparison  Outcomes (within one year 
follow up unless stated 
otherwise) 
Hurskainen 
13;14
 2001, 2004 RCT 236 119 LNG-IUS  vs. 
117 hysterectomy  
 
For the LNG-IUS 
group: at one year 
81/119 and at five 
year 57/119 
continued to have 
LNG-IUS in situ 
5 year follow up 
 
Of the LNG-IUS group by one 
year 68% continued with LNG-
IUS and 20% had TAH. 
Both treatments had comparable 
improvements in HRQL 
Soysal 
15
 2002 RCT 72 36 LNG-IUS  
vs.  
36 thermal balloon 
ablation 
 
14% drop out from 
LNG-IUS 
Greater reductions in PBAC with 
ablation than LNG-IUS. 
Comparable improvements in 
haemoglobin 
Ablation group perceived greater 
improved HRQL than LNG-IUS 
Crosignani 
16
 1997 RCT 70 35 LNG-IUS vs.  
35 TCRE 
 
14% drop out from 
LNG-IUS 
Marginally greater reductions in 
PBAC with TCRE 
Comparable satisfaction rates 
Kittelsen 
17
 1998 RCT 60 30 LNG-IUS vs.  
30 TCRE 
 
12% drop out rate 
Comparable reductions in PBAC 
Comparable satisfaction rates 
Istre 
18
 
Rauramo 
19
 
2001,2004 RCT 59 30 LNG-IUS vs.  
29 TCRE 
 
31% drop out rate 
3 year follow up 
 
Greater reductions in PBAC with 
TCRE than LNG-IUS (90% cure 
vs. 67% cure) at one year , but 
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 comparable reductions of MBL 
noted at 3 years. 
Increased haemoglobin and 
ferritin with both treatments 
Lahteenmaki 
20
 1998 RCT 56 28 LNG-IUS vs.  
28 medical 
treatment whilst 
awaiting 
hysterectomy 
 
25% drop out from 
LNG-IUS 
At 6m, 64% LNG-IUS cancelled 
TAH whilst 14% cancelled TAH 
in medical treatment group 
Reid 
21
 2005 RCT 51 25 LNG-IUS vs 26 
mefenamic acid 
 
16% drop out from 
LNG-IUS 
Greater reductions in MBL, 
PBAC and total menstrual fluid 
loss with LNG-IUS (90% vs 
23%) at 6 months. 
Barrington 
22
 2003 RCT 50 25 LNG-IUS vs. 23 
balloon ablation 
 
12% drop out rate 
Comparable reductions in PBAC 
 
Irvine 
23
 
1998 RCT 44 22 LNG-IUS vs. 22 
oral norethisterone 
 
No drop out rate 
Comparable reductions in MBL 
(>90%). Greater satisfaction with 
LNG-IUS 
Milson 
24
 1991 RCT 35 20 LNG-IUS vs.  
15 transexamic acid 
 
20% drop out from 
LNG-IUS 
Greater reduction in MBL with 
LNG-IUS (>90%) 
Romer 
25
 2000 Prospective 
cohort 
30 LNG-IUS vs. roller 
ball endometrial 
ablation 
Comparable reductions in MBL 
and rates of amenorrhoea 
Henshaw 
26
 2002 Retrospecti
ve cohort 
62 LNG-IUS vs. 
microwave 
endometrial 
mean 14 month follow up 
Comparable reductions in MBL 
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ablation 
 
and dysmenorrhoea 
Comparable patient satisfaction 
rates  
Mansour 
27
 1998 Prospective  52  No comparison 
LNG-IUS 
91% of women had improved 
dysmenorrhoea and menorrhagia 
83% continued with treatment 
beyond one year 
Barrington 
28
 1997 Prospective  50  LNG-IUS 
No comparison. 
Women were 
awaiting TCRE or 
hysterectomy 
Reduced PBAC in 82% 
8% amenorrhoea 
No change in haemoglobin or 
ferritin 
Decreased premenstrual 
symptoms in 56% 
Reduced dysmenorrhoea in 80% 
Monteiro 
29
 2002 Prospective  44 LNG-IUS  
No comparison 
Decreased MBL and increased 
haemoglobin 
80% continuation rate at one year 
Wildemeersch 
30
 
31;32
 
2004 Prospective  12 in 2004,  
32 in 2001 
 
No comparison. 
FibroPlant-LNG 
Decreased PBAC (median MBL 
decreased by 90%) 
Decreased dysmenorrhoea 
Wildemeersch 
33
 2005 Prospective 60 women: 
28 normal 
periods, 
32 menorrhagia 
No comparison 
Femilstrade LNG-
IUS 20mcg/24 hr 
Similar reductions in MBL (96-
99%) for both groups 
33% developed amenorrhoea (10 
women in each group) 
Xiao 
34
 2003 Prospective  34 LNG-IUS 
No comparison 
 
3 year follow up 
Decreased MBL at one year 
(84%) and three (85%) years. 
33% amenorrhoea at 6 months. 
Increased Hemoglobin and serum 
ferritin. 
Footnotes FibroPlant-LNG is a frameless low-dose (releasing 14mcg levonorgestrel/day) frameless 
LNG-IUS; HRQL, Health related quality of life assessments; LNG-IUS releasing 20mcg levonorgestrel /day; 
MBL menstrual blood loss; PBAC pictorial blood loss assessment chart; TCRE transcervical endometrial 
resection
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Meta-analyses and RCTs have shown that a significant proportion of women with 
menorrhagia initially treated with either conservative surgery 
45
 or LNG-IUS 
42
 are likely to 
require hysterectomy as a definitive treatment.  However, an RCT (n=236) with five year 
follow up has shown hysterectomy does not improve overall health related quality of life 
significantly more than LNG-IUS and it can cause serious complications 
14
.   Furthermore, 
the same trial showed that LNG-IUS was more cost-effective than hysterectomy at one-year 
13
 (US $ 1530 vs. US $ 4222) and five-years 
14
 follow up (US $ 2817 vs. US $ 4660 per 
participant).  This estimate includes the direct (e.g. operative, costs) and indirect costs (e.g. 
sick leave days) associated with the 42% of the women assigned to the LNG-IUS group who 
eventually underwent hysterectomy. Menorrhagia may arise from inherited bleeding 
disorders (e.g. von Willebrand's Disease).  A prospective study (n=16) has shown reduction 
in menstrual blood loss, improvement in quality of life in women with menorrhagia due to an 
inherited bleeding disorder when treated with LNG-IUS 
46
.   
 
Uterine fibroids and fibroid related menorrhagia One cohort study, five prospective 
observational studies, and one case report have directly assessed the use of LNG-IUS in 
treating fibroids and fibroid related menorrhagia or dysmenorrhoea.  Three RCTs, undertaken 
for other indications, have described decreased incidence of fibroids following LNG-IUS 
insertion 
35;54;55
. All these studies are depicted in Table 3.8.  Apart from one study
35
, study 
duration and follow up did not exceed one year.  Inclusion criteria were clearly stated in two 
studies: women with fibroid uterus below 12 weeks gestational size on pelvic examination or 
380ml uterine volume on pelvic ultrasound 
47;48
. 
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Table 3.8. LNG-IUS studies directly or indirectly assessing therapeutic effect on fibroids 
or fibroid related menorrhagia 
Author Year  
of 
Publication 
Study 
Type 
Sample 
Size 
Comparison  Outcomes (within one year 
follow up unless stated 
otherwise) 
DIRECT STUDIES      
Soysal 
47
 2005  
 
Prospective 
and 
retrospective 
cohort 
64 32 LNG-IUS vs. 
32 thermal 
balloon ablation 
(historical 
matched group) 
Comparable effective reductions 
in PBAC (around 90%) 
Comparable increases in 
haemoglobin 
Fibroid size change not assessed 
Grigorieva 
48
 2003 Prospective 
and 
retrospective  
67  No comparison 
 
Effective reductions in PBAC.  
Improved ferritin and 
haemoglobin 
40% amenorrhoea at 12 months 
Decrease in fibroid size (33%) 
Mercorio 
49
 2003 Prospective  19  No comparison Reduced PBAC, but 14/19 still 
had persistent menorrhagia 
Wildemeersch 
50
 2002 Prospective  14  No comparison 
FibroPlant-LNG 
Reduction in MBL in 13/14 
No reduction in fibroid size 
Starczewski 
51
 2000 Prospective  12  No comparison Reduction in MBL 11/12 cases. 
Amenorrhoea 50% cases 
Improved Haemoglobin 
No change in fibroid size 
Singer 
52
 1994 Prospective  5  No comparison Reduction in MBL 
Reduction in fibroid size 
Follow up to 18 months 
Fong 
53
 1999 Case report 1  No comparison Reduction in MBL and fibroid 
size 
INDIRECT STUDIES      
Gardner 
54
 2000 RCT 122 64 LNG-IUS and 
tamoxifen against 
58 tamoxifen 
13% reduction in fibroids from 
baseline in LNG-IUS group 
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27% drop out rate 
from LNG-IUS 
group 
Inki 
55
 2002 Prospective 
study 
(examine 
one arm of 
RCT) 
38 117 had LNG-
IUS for 
menorrhagia, of 
this 38/119 (32%) 
had uterine 
fibroids 
No ultrasonographic change in 
uterine fibroids, but decreased 
endometrial thickness. 
Increased risk of ovarian cysts 
compared to hysterectomy 
Sivin 
35
 1994  
 
RCT 2226 
recruited, 
1125 had 
LNG-IUS,  
1121 had Cu-
IUCD. 
 
Baseline 
fibroid 
incidence: 
unclear. 
Identified 15 
fibroids at 
end of study 
LNG-IUS vs. Cu-
IUCD (TCu 
380Ag) 
 
Parous women 
aged 18-38, all 
desiring 
contraception. 
 
7 year study 
follow up (3416 
women years in 
LNG-IUS and 
3975 women 
years in Cu-
IUCD) 
 
11.4% drop out 
rate from LNG-
IUS 
7 year follow up 
LNG-IUS compared to Cu-
IUCD has decreased incidence 
of dysmenorrhoea, vaginitis, 
fibroids, but higher rates of 
amenorrhoea, follicular ovarian 
cysts, acne, mastalgia, weight 
gain, and headache. 
 
LNG-IUS: 50% amenorrhoea or 
oligoamenorrhoea by end of 
study, compared to 9% with Cu-
IUCD 
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All studies directly assessing LNG-IUS in women with fibroids reported decreased menstrual 
blood loss (84-90%) and similar increases in haemoglobin of 2-3 g/dl 
47;48;51
. However, there 
was inconsistency on whether LNG-IUS is associated with decreased fibroid size 
48;52;53
 or no 
change in fibroid size 
50;51;55
.  Fibroid size following LNG-IUS was not assessed in one 
cohort study 
47
. Regarding the indirect studies, one large RCT suggested there may be 
decreased incidence of uterine fibroids with LNG-IUS compared to Cu-IUCD 
35
.  A similar 
observation of 13% decreased incidence of fibroids was observed in a RCT comparing LNG-
IUS and tamoxifen against tamoxifen alone 
54
. 
 
Endometriosis  
Two RCTs and three prospective observational studies were identified.  All studies had 
limited sample sizes (range 11 to 39 participants in LNG-IUS arm of study), and their 
features are shown in Table 3.9.  Population groups differed considerably between studies 
and included women with early stage and late stage endometriosis, rectovaginal 
endometriosis, immediately surgically treated endometriosis, prior history of endometriosis 
diagnosis, chronic pelvic pain and/or dysmenorrhoea.  This heterogeneity of population, 
combined with small sample size, limits the strength and validity of the findings. Two studies 
from the same group 
57;60
 report approximately 40% absolute risk reduction in 
dysmenorrhoea by one year with LNG-IUS use. This is consistent with a three year 
prospective study
59
 and a one year RCT 
56
 that reported similar magnitude reductions in 
dysmenorrhoea and chronic pelvic pain . A prospective study reported decreasing severity of 
endometriosis on AFS staging following LNG-IUS insertion 
58
. 
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Table 3.9. LNG-IUS studies assessing therapeutic effect in women with endometriosis 
Author Year  
of  
Publication 
Study 
Type 
Sample 
Size 
Comparison  Outcomes (within one year 
follow up unless stated 
otherwise) 
*Petta 
56
 
*electronic 
publication 
ahead of written 
publication 
2005 RCT 82 with 
endometriosis, 
dysmenorrhoea and 
chronic pelvic pain 
39 LNG-IUS 
vs 43 GnRH 
analogue 
6 months follow up 
Comparable reductions in 
pelvic pain and improved 
quality of life measures. 
Greater amenorrhoea with 
GnRH than LNG-IUS (98% vs 
70%) 
Vercellini 
57
  2003  RCT 40 parous women , 
not desiring fertility, 
with endometriosis 
associated 
dysmenorrhoea and 
receiving 
conservative surgical 
treatment of 
endometriosis 
20 Post 
operative 
LNG-IUS 
and 
endometriotic 
surgery vs. 
20 
endometriotic 
surgery alone 
10% drop out 
from LNG-
IUS group 
Decreased recurrence of 
dysmenorrhoea in LNG-IUS 
vs. surgery alone group (10% 
vs. 45%, p=0.03) 
28% or 50% LNG-IUS users 
had amenorrhoea or 
oligoamenorrhoea 
Comparable levels of patient 
satisfaction (75% and 50%) 
Lockhat 
58;59
 2004,2005 Prospective  34 with symptomatic 
mild-moderate 
endometriosis 
No 
comparison 
(1 yr and 3yr 
follow up) 
Decreased dysmenorrhoea 
and/or non-cyclical pelvic pain 
and AFS staging of 
endometriosis. 
68% continuation rate at one 
year  
56% continuation rate at 3 
years. 
Vercellini 
60
  1999 Prospective 
 
18 
Parous women who 
had history of 
previous 
endometriotic 
surgery and had 
recurrent 
dysmenorrhoea 
 
No 
comparison 
 
Amenorrhoea in 24% 
Oligoamenorrhoea in 47%    
Decreased dysmenorrhoea by  
45% 
Decreased menstrual blood 
loss by 76% 
75% Satisfaction rates 
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Fedele 
61
 2001 Prospective  11 symptomatic 
women with 
rectovaginal 
endometriosis 
No 
comparison 
Decreased pelvic pain, 
dyspareunia, dysmenorrhoea 
related to endometriosis 
Decreased size of 
endometriosis lesions 
(ultrasound) 
 
Adenomyosis  
One non-blinded RCT (n=95), one prospective observational study and one case report were 
identified.   The features of the studies are listed in Table 3.10.  All studies showed a 
reduction in adenomyosis related dysmenorrhoea and menorrhagia, and this effect was 
statistically significant in the RCT 
62
 that compared LNG-IUS against expectant treatment in 
women following TCRE for adenomyosis. However, dysmenorrhoea and menorrhagia 
observed in the trial may not necessarily be due to adenomyosis.  
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Table 3.10. LNG-IUS studies assessing therapeutic effect in women with adenomyosis 
Author Year  
of  
Publication 
Study 
Type 
Sample 
Size 
Comparison  Outcomes within one year 
follow up 
Maia 
62
 2003 
 
 
 
RCT 
Non-blinded 
95 women post TCRE 
for adenomyosis 
53 LNG-IUS 
vs. 42 
expectant 
 
No drop out  
reported. 
19% of expectant group 
needed second treatment for 
uterine bleeding and pain 
compared to none in LNG-IUS 
 
Significantly lower rate of 
dysmenorrhoea in LNG-IUS 
(10%) than expectant (80%) 
group 
 
Significantly higher rate of 
amenorrhoea in LNG-IUS 
group (100% vs. 9%) at one 
year 
Fedele 
63
 1997 Prospective  25 with adenomyosis 
related menorrhagia 
No 
comparison 
For all cases, reduction in 
PBAC, dysmenorrhoea. 
Improved haemoglobin and 
ferritin 
Fong 
64
 1999 Case report 1 enlarged 
adenomyosis uterus 
No 
comparison 
Reduction in uterine size, 
dysmenorrhoea, MBL 
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Endometrial protection during oestrogen replacement therapy or tamoxifen in peri-
menopausal women 
Seven RCTs, three cohort studies, and seven observational studies have described the use of 
LNG-IUS to protect the endometrium from endometrial hyperplasia or malignant 
transformation during exogenous estrogen replacement therapy (ERT) in peri- and 
postmenopausal women.  One RCT 
54
 and one observational study (n=6)
65
 have examined the 
endometrial protective effect of LNG-IUS during tamoxifen therapy in postmenopausal 
women.  The characteristics of these studies are summarised in Table 3.11.  The tamoxifen 
RCT 
54
 showed that 91% women had endometrial suppression (histological decidual or 
atrophic response) in the LNG-IUS and tamoxifen group (n=47) compared to 75% in the 
tamoxifen only group  (n=52) 
54
.   
 
RCTs differed in population subgroups (peri-menopausal and post-menopausal women), 
methods of ERT administration (such as implant, oral, transdermal gel, vaginal ring) 
comparisons (cyclic oral estrogen/progestogen HRT, continuous combined 
estrogen/progestogen HRT, vaginal progestogen, subdermal progestogen, low dose LNG-IUS 
[10mcg or 14mcg systems] vs. higher does LNG-IUS [20mcg]) and methods of assessing 
endometrial suppression outcome (clinical, histological, ultrasonographic, MRI).  A meta-
analysis of discrete groups of studies may be less informative than individually listing the 
study design and outcomes, and was therefore not performed. 
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Table 3.11. LNG-IUS studies assessing use to provide uterine protection during oestrogen 
replacement or tamoxifen therapy 
Author Year  
of 
Publicati
on 
Study 
Type 
Sample 
Size 
Comparison  
group 
Outcomes 
(within one 
year of 
follow up 
unless stated 
otherwise) 
TAMOXIFEN 
STUDIES 
     
Gardner 
54
 2000 
 
RCT Initial 
recruitment of 
122 
Postmenopau
sal breast 
cancer 
women  
 
 
64 LNG-IUS and 
tamoxifen group vs. 58 
tamoxifen group only 
 
27% drop out rate 
from LNG-IUS arm 
All LNG-IUS 
had 
endometrial 
suppression 
(histological 
decidual 
response) 
Decreased 
endometrial 
polyps and 
submucous 
fibroids in 
LNG-IUS 
group 
Turnbull 
65
 1998 Prospectiv
e  
6 
postmenopau
sal breast 
cancer 
women with 
irregular 
thickened 
endometrium 
on tamoxifen 
therapy 
No comparison. 
Inserted LNG-IUS 
No change in 
endometrial 
thickness 
with TV 
ultrasound 
A reduction 
in sub-
endometrial 
cysts and 
endometrial 
volume with 
MRI by 6 
months 
ESTROGEN 
REPLACEME
NT STUDIES 
     
Boon 
66
 2003 RCT 200 
perimenopaus
al women 
 
100 LNG-IUS and 100 
oral estradiol vs. 
cyclic/combined oral 
estrogen and 
progestogen HRT 
(Trisequens) 
2 year follow 
up 
 
endometrial 
suppression 
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18% drop out rate from 
LNG-IUS group 
(atrophic or 
inactive) 
greater with 
LNG-IUS 
than oral 
HRT: 
100% vs 6% 
 
LNG-IUS:  
initial erratic 
bleeding, 
62% 
amenorrhoeic 
by 2 years. 
Cyclic HRT: 
normal 
regular 
monthly 
bleeds in 70-
80% 
Wolter-Sven. 
67
 1997 RCT 112 
Perimenopaus
al women 
symptomatic 
of menopause 
 
 
51 LNG-IUS 10 
mcg/24hr plus estrogen 
(oral/transdermal) vs. 
45 LNG-IUS 
5cmg/24hr plus 
estrogen 
(oral/transdermal) 
 
11% drop out rate 
95/96 cases 
had 
histological 
endometrial 
suppression 
 
Amenorrhoea 
in most cases 
(62% for 
5mcg and 
61% for 
10mcg 
groups) 
 
Satisfactory 
relief of 
menopausal 
vasomotor 
symptoms 
Raudaskoski 
68
 2002 RCT 163  
postmenopau
sal women 
 
Oral estrogen 
Different progestogen 
formulations of HRT 
combining oral 
estradiol with 
High or low dose 
Endometrial 
suppression 
(histologicall
y) and 
amenorrhoea 
in >98% of 
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with: 
 
54  
10mcg/24hr 
LNG-IUS 
(MLS) or 
56 
20mcg/24hr 
LNG-IUS  
or 
53 oral 
progestogen. 
 
LNG-IUS or cyclical 
oral progestogen 
 
7% drop out from 
combined LNG-IUS 
10mcg and 20mcg 
groups 
LNG-IUS 
cases.  
 
Proliferative 
endometrium 
and regular 
withdrawal 
bleeds with 
oral 
progestogen  
Raudaskoski 
69
 1995 RCT 40 
postmenopau
sal 
20 LNG-IUS plus 
transdermal estrogen vs 
20. continuous oral 
estrogen and 
progestogen 
 
12% drop out from 
LNG-IUS group 
Comparable 
endometrial 
suppression 
(histological 
and 
ultrasound) 
 
Comparable 
improvement 
of 
menopausal 
symptoms 
Andersson 
70
 1992 RCT 40 
perimenopaus
al 
 
20 LNG-IUS and oral 
estrogen vs. 
20 Cyclic HRT (oral 
estrogen 3 weeks, oral 
progestogen 1 week) 
83%of LNG-
IUS became 
amenorrhoeic
, but cyclic 
HRT had 
regular 
withdrawal 
bleeds. 
Both groups 
had 
endometrial 
suppression 
Suhonen 
71
 1995 RCT  36 
postmenopau
sal 
16 LNG-IUS and one 
subdermal estrogen 
implant vs 
20 LNG-IUS and three 
subdermal estrogen 
Endometrial 
suppression 
in all cases 
 
72% had 
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implants 
 
No drop out reported 
amenorrhoea 
or spotting by 
three months 
Suhonen 
72
 1995 RCT 19 
postmenopau
sal 
10 oral estrogen and 
LNG-IUS vs. 9 oral 
estrogen and subdermal 
levonorgestrel-
releasing implant  
 
No drop out reported 
Comparable 
endometrial 
suppression 
Suvanto-Luuk. 
73-75
 
1997, 
1998, 
1999 
Prospectiv
e cohort 
 
 
60 
postmenopau
sal women 
 
 
20 received 
LNG-IUS  
 
21 oral 
progesterone 
 
19 vaginal 
progesterone 
 
All received 
transdermal estrogen 
gel 
 
25% drop out rate of 
LNG-IUS group at 5 
years 
5 year  
follow up for 
20 cases in 
LNG-IUS 
group 
 
At one year 
varying 
degrees of 
amenorrhoea: 
80%, LNG-
IUS; 67%, 
oral 
progesterone; 
53% in the 
vaginal 
progesterone. 
 
At five years 
80% 
amenorrhoea 
in LNG-IUS 
 
Endometrial 
suppression 
(histological, 
ultrasound) in 
all LNG-IUS  
cases 
Antoniou 
76
 1997 Prospectiv
e cohort 
56 
postmenopau
sal women 
28 women with LNG-
IUS plus daily 
transdermal estrogen 
Comparable 
endometrial 
suppression 
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with 
urogenital 
symptoms 
vs. 28 women with 
estradiol-releasing 
vaginal ring plus 
vaginal progesterone 
(ultrasound) 
Kalogirou 
77
 1996 Prospectiv
e cohort 
56 
postmenopau
sal  
LNG-IUS and 
transdermal estrogen 
vs. 
Estrogen releasing 
vaginal ring and oral 
progestogen 
Comparable 
endometrial 
suppression 
(ultrasound 
and 
histological) 
Sturdee 
3
 2004 Prospectiv
e  
294 
postmenopau
sal  
 
 
No comparison 
LNG-IUS 10mcg/24hr 
(MLS device) and 
transdermal estrogen 
 
Interim 1 
year results 
from 3 yr 
study 
 
67% 
amenorrheic  
at one year. 
9/294 
discontinued 
because of 
bleeding. 
Wildemeersch 
78
 
2003 Prospectiv
e  
83 
perimenopaus
al and 58 
postmenopau
sal 
 
* Mixed 
group of 
women-
contraception 
needs, 
menorrhagia, 
vasomotor 
symptoms, 
fibroids  
No comparison  
Used FibroPlant-LNG 
with transdermal 
estrogen gel 
 
Up to 3 year 
follow up 
 
All effective 
endometrial 
suppression 
(ultrasound) 
 
64% 
amenorrhoea 
in 
perimenopau
sal group and 
100% in 
postmenopau
sal group 
 
5 cases of 
fibroid 
related 
menorrhagia 
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improved 
 
 
Hampton 
79
 2005 Prospectiv
e 
82 
perimenopaus
al  
No comparison 
Use LNG-IUS with 
oral estrogen 
5 year follow 
up 
96-98% non-
proliferative 
endometrium 
55% 
amenorrhoea 
at one year 
93% 
amenorrhoea 
by fifth year 
 
80 per 100 
women 
continuation 
rate at 5 years 
Varila 
80
 2001 Prospectiv
e 
  
 
40 
postmenopau
sal 
 
 
No comparison 
Used LNG-IUS with 
oral or transdermal 
estrogen 
 
5 year follow 
up 
39 completed 
12 mths 
29 completed 
5 years 
 
All cases had 
endometrial 
suppression 
(histological 
and 
ultrasound) 
51% 
amenorrhoea 
or only 
spotting at 5 
years  
Wildemeersch 
81
 2000 Prospectiv
e  
22 
perimenopaus
al, 8 
postmenopau
19 cases had FibroPlant 
LNG 14mcg/24hr and 
11 cases had 
Up to 2½ 
years follow 
up 
Chapter 3.2. Systematic review of LNG-IUS (Mirena) 
   223 
 
sal 10mcg/24hr doses 
All with transdermal 
estrogen gel 
All effective 
endometrial 
suppression 
(ultrasound) 
 
77% 
amenorrhoea 
in 
perimenopau
sal group and 
100% in 
postmenopau
sal group 
Suhonen 
82
 1997 Prospecti
ve  
 
29 peri- and 
postmenopau
sal women 
No comparison 
LNG-IUS and 
transdermal/subdermal/
oral estrogen 
 
3 year follow 
up 
All cases had 
endometrial 
suppression 
(ultrasound, 
histology)  
79% 
amenorrhoea 
at 3 years 
Wildemeersch 
83
  
2004 Prospectiv
e  
 24 
postmenopau
sal women 
No comparison  
Used FibroPlant-LNG 
with oral estradiol or 
estrogen patches 
 
3 year follow 
up 
All effective 
endometrial 
suppression 
(histologicall
y and 
ultrasound) 
and clinical 
amenorrhoea  
 
 
 Footnotes 
FibroPlant-LNG is a frameless low-dose LNG-IUS (releasing 14mcg levonorgestrel/day)  
MLS is a low dose smaller sized LNG-IUS (releasing 10mcg levonorgestrel/day) 
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Endometrial suppression and symptomatic improvement of menopausal symptoms (e.g. hot 
flushes) was achieved in all studies examining LNG-IUS use in women receiving ERT.  
From the study outcomes, amenorrhoea appeared to be more common in postmenopausal 
women receiving LNG-IUS (studies ranging from 61% to 100% of subjects) than peri-
menopausal women (studies ranging from 38% to 83% of subjects), although this was not 
formally statistically tested due to study heterogeneity.  Seven studies have reported follow 
up beyond one year 
66;75;78-83
, three reported up to a maximum of five-years 
75;79;80
, and one 
study published its interim one year results from a proposed three year study duration 
3
.  
There was no statistically significant difference between LNG-IUS 10mcg and LNG-IUS 
5mcg in one RCT (n=108)
67
. Participants in three separate publications 
78,81,83
 are likely to be 
from the same study cohort. 
  
Endometrial hyperplasia 
No RCTs were identified.  Characteristics of the one cohort, three prospective observational 
studies, and two case reports/case series are shown in Table 3.12.  Most studies examined 
women with non-aypical endometrial hyperplasia, but three studies have included women 
with atypical hyperplasia 
86;87;89
.  Hyperplasia of all types was regressed in all cases treated 
with LNG-IUS. 
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Table 3.12.  LNG-IUS studies assessing therapeutic effect in women with endometrial 
hyperplasia  
Author Year of 
Publication 
Study 
Type 
Sample Size Comparison  Outcomes within one year 
follow up 
Vereide
84
 2003 Retrospecti
ve cohort 
57 endometrial 
hyperplasia 
LNG-IUS vs. oral 
progestogen  
Greater regression with 
LNG-IUS that with oral 
progestogens (100% vs. 
55%) at 3 months 
Scarselli 
85
 1988 Prospective 31 (4 atypical 
types) 
No comparison  Endometrial regression in 
all cases 
Perino 
86
 1987 Prospective 14 (1 case 
atypical type) 
No comparison Endometrial regression in 
29/31 cases at 16 months 
follow up 
Wildemeersch 
87
 
2003 Prospective  12 (non-atypical 
and atypical 
types) 
No comparison Endometrial regression in 
all cases by three years 
Rose 
88
 2001 Case report 1 No comparison Endometrial regression 
Bahamondes 
89
 2003 Case report 1  No comparison Endometrial regression 
 
Endometrial cancer   
The preferred primary treatment for early stage endometrial cancer is surgical hysterectomy, 
with systemic progestins used palliatively or as adjuvant treatments for higher stage cancers.  
A literature review of limited sized case series and cohort studies (n=81 cases, 27 articles) has 
shown safe and effective treatment (overall 76% cure) with systemic progestin therapy in 
women with well differentiated stage 1 endometrial cancer 
90
.  This evidence, although 
limited in quality, establishes a plausible role for LNG-IUS in early stage disease, particularly 
in those women medically unfit for surgical therapy.  One case report describes successful 
reversion of the cancer on endometrial biopsy when using a combination of oral progestogens 
and LNG-IUS in such an indication 
91
.  However, another case series (2 patients) showed no 
regression of the endometrial cancer when treated with LNG-IUS alone in patients awaiting 
definitive surgical treatment 
89
.  A comparative study performed in 14 women with early 
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stage endometrial cancer considered high risk for surgery showed successful reversion of 
cancer on endometrial biopsy in 75% of cases at 12 months 
92
.  However, a case series has 
identified two cases of endometrial carcinoma that were diagnosed following insertion of 
LNG-IUS 
93
.  Clearly, further cases, controlled trials, and longer follow up are required in 
order to obtain more valid conclusions. 
 
Dysmenorrhoea and pain Only one observational study has formally examined the 
therapeutic use of LNG-IUS in women with primary and secondary dysmenorrhoea 
32
. The 
study is of poor quality (limited sample size, n=18, and non-comparative) which makes 
interpretation of the observed beneficial response difficult.  However, reductions in 
dysmenorrhoea have been reported in numerous LNG-IUS trials 
26;35;94-97
 and observational 
studies 
28;98;99
, albeit not being an a priori primary outcome measure in the vast majority. 
An RCT (n=236) that compared LNG-IUS with hysterectomy for women with menorrhagia 
evaluated pain as an outcome using a RAND-36 health survey 
13;14
. The trial showed greater 
improvement in pain by the hysterectomy group than LNG-IUS at one year. However, by five 
years, both LNG-IUS and hysterectomy groups had achieved almost identical reductions in 
pain. Most studies have failed to distinguish dysmenorrhoea from co-existent pelvic pain 
disorders (e.g. endometriosis, chronic pelvic pain, chronic pelvic inflammatory disease) in 
their subgroup analyses. This may cause confounding. However, the fact the association is 
reproducible in so many studies suggests the effect is real even though the magnitude cannot 
be accurately ascertained. 
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 LNG-IUS and effect on pelvic inflammatory disease 
No RCTs have examined whether the incidence of pelvic inflammatory disease (PID) is 
modified following introduction of LNG-IUS as a primary outcome measure.  One RCT 
100
 
and reviews of the early LNG-IUS trials 
101;102
 has suggested a lowering of PID rates when 
using LNG-IUS compared to Cu-IUCD.  Whereas, two early RCTs 
35;103
, a recent 5-year 
study 
104
,  and a systematic review 
105
 of all the contraceptive trials have shown comparable 
rates of PID during the use of the LNG-IUS or a copper IUD. 
 
Other non-contraceptive therapeutic indications Large multicentre studies have not 
detected differences in cervical cytology or breast cancer incidence between copper IUD and 
LNG-IUS users, and non-users 
35;101;102
.  Long-term epidemiological studies are needed to 
confirm this finding, and whether these may represent alternative therapeutic indications.   
 
Adverse effects Irrespective of study design and indication all studies have reported 
adverse side effects following insertion of LNG-IUS, although a direct causal relationship to 
LNG-IUS cannot always be confirmed.  Around 15-20% of LNG-IUS users experience at 
least one or more unwanted side effects
5;106;107
. The most frequent (around 10-15% of users) 
is unscheduled erratic menstrual bleeding, which usually occurs during the first 3-4 months 
following LNG-IUS insertion but tends to subside thereafter. Erratic irregular menstrual 
bleeding is cited by women as the most common reason for discontinuing LNG-IUS 
treatment.  During LNG-IUS use, 17.5% of women had a cyst at 6 months (diameter over 
3cm) and 21.5% at 12 months 
55
. The vast majority of these were asymptomatic and 
functional, and exhibited a high rate (94%) of spontaneous resolution by six months
55
. Other 
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less common side effects include mastalgia, migraine, acne, weight gain, oedema, labile 
mood, abdominal pain, pelvic pain, nausea and coil-related (infection, perforation, 
spontaneous expulsion) complications 
35;101;102
. Nevertheless, the continuation and patient 
satisfaction rates in women using LNG-IUS for contraception remains over 75% 
98;108-111
. 
 
Studies conflict on whether the induction of amenorrhoea is considered a desired effect 
98
 or 
an unwanted side effect 
5;35
 that may lead to LNG-IUS discontinuation. This determination is 
based on the individual‘s clinical symptomology pre-LNG-IUS insertion. Amenorrhoea 
occurs following LNG-IUS insertion in 20-60% of normally menstruating women using the 
device for contraception, between 50-75% in women with menorrhagia, and 61%-100% in 
postmenopausal women using the device to protect the uterus during estrogen replacement 
therapy
9;35;42;75;82;97;107;108;112
.   
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Discussion  
 
Our systematic review has shown strong evidence that LNG-IUS is effective in treating 
women with idiopathic menorrhagia and in providing uterine protection for women receiving 
estrogen replacement therapy or tamoxifen.  There is preliminary evidence that shows LNG-
IUS may be therapeutic in women with fibroids, endometriosis, adenomyosis, endometrial 
hyperplasia, early stage endometrial cancer and dysmenorrhoea, and may reduce the risk of 
pelvic inflammatory disease.  The grading of evidence is depicted in Table 3.6.  The 
incidence of adverse effects, in particular initial period of erratic menstrual bleeding, is 
unaffected by the indication for the use of LNG-IUS.  The incidence of amenorrhoea 
following LNG-IUS insertion appears to be influenced by age and independent of underlying 
gynaecological pathology: the incidence is greater as the woman approaches her menopause.  
 
This review has been original in systematically collecting and presenting the data relating to 
LNG-IUS use in HRT, tamoxifen, endometrial hyperplasia, endometrial cancer, 
endometriosis and adenomyosis. The systematic search strategy employed was 
comprehensive and methodological analysis followed standardized criteria.  This review has 
updated and expanded on studies listed in the Cochrane database  
40;41;113
 and a previous 
related systematic review 
11
.  Our findings complement the recently published Cochrane 
protocol on post-operative LNG-IUS in endometriotic surgery 
113
, and supplements the 
evidence reported in a Cochrane review of pre- and post-operative medical therapy for 
endometriotic surgery which had excluded LNG-IUS usage  
114
.  Our review has included 
recent developments such as data from lower dose LNG-IUS devices currently under 
development (e.g. FibroPlant™-LNG) and health related quality of life assessments for 
women using LNG-IUS
14
.  
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We observed a general paucity of RCTs, varying study methodologies and outcome 
measures, which made the interpretation of study data difficult and prevented us from 
performing a meta-analysis. We had intended to perform a systematic review of LNG-IUS, 
and instead this review is a narrative assimilation of the available literature. Furthermore, our 
systematic search strategy may have missed relevant studies.  However, by maintaining a 
sensitive keyword search, contacting the manufacturer Schering for unpublished studies, and 
checking registered clinical trials databases, we believe this loss has been minimized.  Apart 
from menorrhagia and HRT therapeutic indications, the published literature mainly consists 
of limited sample-sized (below 50 participants in LNG-IUS arm of study) non-controlled 
observational studies with less than one year follow up, which although showing consistent 
trends, are likely to be subject to information and selection biases. Consequently, no firm 
conclusions can be inferred from these studies (evidence grading C).  However, these studies 
may provide a basis to estimate minimum numbers needed to be recruited to demonstrate 
clinically significant results in future therapeutic trials using LNG-IUS. 
There is strong evidence demonstrating the efficacy, cost-effectiveness, and safety of LNG-
IUS in menorrhagia. This evidence has been translated to clinical practice through recent 
licensing (2001) of LNG-IUS for women with menorrhagia.   A similar abundance of RCTs, 
cohort and observational evidence, demonstrating efficacy and endometrial safety, exists for 
the use of LNG-IUS in providing endometrial protection during estrogen replacement 
therapy.   Research in to this modality of HRT has been abundant since its inception in the 
late 1980s
115;116
. However, unlike menorrhagia, the license for HRT use has not been 
forthcoming in many countries, and was only awarded in 2005 by the UK.    
 
The Women‘s Health Initiative and Million Women Study, showed HRT use increased the 
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risk of stroke, pulmonary embolism, and breast cancer, but decreased risk of hip fracture, 
with no effect on coronary heart disease incidence 
117-120
.   Incidence of breast cancer was 
significantly increased for users of hormone replacement therapy containing estrogen only 
(1.30 [1.21-1.40]), estrogen-progestogen (2.00 [1.88-2.12]), and Tibolone (1.45 [1.25-1.68]), 
but the magnitude of the associated risk was substantially greater for estrogen-progestogen 
than for other types of HRT.   The reluctance to use LNG-IUS may be based on concerns that 
stable systemic levels of levonorgestrel (330-350 pg/mL)
1
 may be sufficient through its 
progestogenic effect to promote tumourigenesis in the breast (particularly if given with 
exogenous estrogen) or blunt the anti-tumour effect of tamoxifen on the breast. Similarly, it is 
plausible to extrapolate the endometrial suppression data observed in the perimenopausal 
hormone replacement therapy, tamoxifen and endometrial hyperplasia studies, and 
hypothesize that the risk of endometrial cancer may be reduced in long-term users of LNG-
IUS. However, we found no data relating LNG-IUS use to an increased or decreased risk of 
breast or endometrial cancer risk. However, absence of publications showing association does 
not necessarily indicate a lack of association between LNG-IUS and cancer. We believe this 
to be an important safety issue that remains to be addressed, either through long-term follow 
up and re-analysis of published studies or further prospective trials.  
 
Despite promising findings, further trials are needed to establish efficacy, safety, cost-
effectiveness, and quality of life measures before recommending LNG-IUS in most of the 
non-contraceptive indications discussed.   Studies need to identify which population groups 
benefit most from LNG-IUS use, and this is made difficult due to the varying spectrum of 
disease, co-existence of multiple gynaecological pathology, and whether LNG-IUS is being 
tested as a first line or second line treatment following failed medical or surgical intervention.  
For example, subgroup analysis of trial data has shown that the magnitude of baseline 
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menstrual blood loss was negatively predictive of successful treatment with LNG-IUS
121
. The 
authors and manufacturers of the newer lower-dose and smaller sized LNG-IUS devices 
assert they are easier to insert, have less adverse side effects and greater patient acceptability 
3;67;67;68;83
 than conventional 20mcg/24hr LNG-IUS. However, there is little supporting 
evidence for this assertion, and these devices need to be rigorously evaluated in robust head-
to-head comparisons with conventional LNG-IUS to validate this viewpoint. 
 
There is a paucity of data on patient preference and decision analysis strategies in the use of 
LNG-IUS 
8
.   This research should accompany future trials, particularly given the number of 
competing similar efficacy therapeutic medical and surgical interventions.   A recent 
questionnaire study highlighted how patient‘s choice of treatment is influenced by several 
factors.   These may include the likelihood of whether the treatment will be completely 
successful, prolonged hospital stay and convalescence, and preservation of future fertility.   
The majority of women scheduled for an endometrial ablation or LNG-IUS for menorrhagia 
were inclined to take a risk of 50% likelihood of treatment failure to avoid a hysterectomy 
122
. 
LNG-IUS can no longer just be considered suitable for women with menorrhagia who wish 
reversible contraception.   The fact that so many conditions in Gynaecology are likely to be 
amenable to LNG-IUS underlies the importance of progestogens in the normal and 
pathological female genital tract.   This review‘s findings complement the current resurgence 
of basic science research interest in this area and clinical trials evaluating potential 
therapeutic use of selective progesterone receptor modulators in the conditions discussed in 
this review
123
.   This review has provided a foundation to undertake robust research trials in 
this area that could potentially show greater therapeutic benefit and lesser patient harm when 
using LNG-IUS compared to currently available medical and surgical therapies.    
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Introduction 
 
Clinical guidelines are designed to be educational aids that will promote Good Clinical 
Practice.  Guideline development and practice has become widespread in modern healthcare. 
In the UK, both national bodies (National Institute of Clinical Excellence, Scottish 
Intercollegiate Guideline Network) and specialty based professional organisations (Royal 
College of Obstetricians and Gynaecologists) have active programmes of clinical guideline 
development and publication. There are many clinical topics that lend themselves to 
guideline development, although topics that have the greatest ‗clinical impact‘ are prioritised 
by guideline development bodies (Table 4i). The impetus for the continued proliferation of 
guidelines is the drive to ensure best clinical practice is achieved for both the patient (such as 
desired clinical outcomes, reduction of clinical risk) and health care provider (optimum use of 
healthcare resources and consideration of costs). Furthermore, although not tested, there are 
likely to be medico-legal ramifications in cases where clinical harm has occurred and the 
clinician has not followed established clinical guidelines (either national or at local Trust 
level) or has not clearly justified their rationale for adopting alternative clinical decision 
making. There are established methodologies utilised in the production of clinical guidelines; 
four essential criteria have been defined by the Appraisal of Guidelines for Research and 
Evaluation in Europe (AGREE) guidelines 
7
 and include: 
1. Systematic review of the literature  
2. Graded recommendations with explicit links to the evidence  
3. Input of a multidisciplinary working group  
4. Quality control; for example, input by an independent advisory board or by 
independent peer review.  
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Table  4i.  Assessment criteria for selecting topics for clinical guideline development: 
high clinical impact topics 
Assessment criteria  
 Areas where there are high rates of mortality, morbidity or disability.  
 Areas where improved standards of care would reduce rates of mortality, morbidity or 
disability.  
 Areas where there is uncertainty, as evidenced by a wide variation in clinical practice and 
service delivery.  
 Areas where new high-quality clinical evidence has been published.  
 Areas where there are resource implications: either high cost and low turnover or low cost 
and high turnover.  
 Areas where there are implications across the primary–secondary care interface.  
 Areas where there is a frequent chance of litigation 
 
However, not all clinical guidelines incorporate all of these criteria. Furthermore, concerns 
have been raised on the ‗practical‘ value of clinical guidelines to real life clinical practice. 
Guidelines place considerable weight on the evidence originating from randomised controlled 
trials. Nevertheless, in practice, there is considerable patient heterogeneity, the clinical 
environment is less well controlled, patient compliance is less reliable and resources are more 
restricted. than the trial setting. Consequently,
 
the anticipated benefits of the guideline may 
not be fully realised in an everyday
 
setting. There has been no robust research that has 
demonstrated clear superiority of clinical guideline direct practice over conventional practice. 
Aims of chapter 
 To undertake systematic reviews and develop clinical guidelines in topics in obstetrics 
and gynaecology that are assessed to be of high clinical importance and impact (see earlier 
definition). Case examples selected are: Vaginal Birth after caesarean, Ectopic Pregnancy, 
Laparoscopic entry (Table 4.1). 
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 To explore the value of utilising differing methodological approaches to clinical 
guideline development (RCOG, SIGN, GRADE approaches) (Tables 4ii, 4iii, 4iv). 
7-9
 
 To identify if there are any potential improvements to the guideline development 
process based on appraisal of the guideline methodology. Evidence to justify improvements 
to be acquired through 1) the methodological and practical problems encountered during the 
case examples and 2) any published evidence. 
Table 4ii.  Classification of evidence used by RCOG Guideline development (originate 
from US Agency for Health Care Research and Quality) 
7
 
Classification of Evidence Levels  
Ia Evidence obtained from meta-analysis of randomised controlled trials.  
Ib Evidence obtained from at least one randomised controlled trial.  
IIa Evidence obtained from at least one well-designed controlled study without 
randomisation.  
IIb Evidence obtained from at least one other type of well-designed quasi-experimental study.  
III Evidence obtained from well-designed non-experimental descriptive studies, such as 
comparative studies, correlation studies and case studies.  
IV Evidence obtained from expert committee reports or opinions and/or clinical experience of 
respected authorities 
Grades of Recommendations  
 
Requires at least one randomised controlled trial as part of a body of literature of 
overall good quality and consistency addressing the specific recommendation. 
(Evidence levels Ia, Ib) 
 
Requires the availability of well controlled clinical studies but no randomised 
clinical trials on the topic of recommendations. (Evidence levels IIa, IIb, III) 
 
Requires evidence obtained from expert committee reports or opinions and/or 
clinical experiences of respected authorities. Indicates an absence of directly 
applicable clinical studies of good quality. (Evidence level IV) 
Good Practice Point    
 
Recommended best practice based on the clinical experience of the guideline  
development group 
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Table 4iii.  Classification of evidence used by Scottish Intercollegiate Guidelines 
Network (SIGN) Grading System 
9
 
Levels of evidence 
1++ High quality meta analyses, systematic reviews of RCTs, or RCTs with a very low risk of 
bias 
1+ Well conducted meta analyses, systematic reviews of RCTs, or RCTs with a low risk of 
bias 
1 - Meta analyses, systematic reviews of RCTs, or RCTs with a high risk of bias 
2++ High quality systematic reviews of case-control or cohort studies 
High quality case-control or cohort studies with a very low risk of confounding, bias, or 
chance and a high probability that the relationship is causal 
2+ Well conducted case control or cohort studies with a low risk of confounding, bias, or 
chance and a moderate probability that the relationship is causal 
2 - Case control or cohort studies with a high risk of confounding, bias, or chance and a 
significant risk that the relationship is not causal 
3 Non-analytic studies, e.g. case reports, case series 
4 Expert opinion 
Grades of recommendation 
A At least one meta analysis, systematic review, or RCT rated as 1++, and directly applicable to 
the target population; or 
A systematic review of RCTs or a body of evidence consisting principally of studies rated as 
1+, directly applicable to the target population, and demonstrating consistency of results 
B A body of evidence including studies rated as 2++, directly applicable to the target population, 
and demonstrating overall consistency of results; or 
Extrapolated evidence from studies rated as 1++ or 1+ 
C A body of evidence including studies rated as 2+, directly applicable to the target population 
and demonstrating overall consistency of results; or extrapolated evidence from studies 2++ 
D Evidence level 3 or 4; or Extrapolated evidence from studies 2+ 
GPP Good practice points: Recommended best practice based on the clinical experience of the 
guideline development group 
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Table 4.iv. GRADE approach 
8
 (http://www.gradeworkinggroup.org/index.htm)  
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
GRADE: Quality of evidence 
 The GRADE system classifies the quality of evidence in one of four levels: 
 High quality— Further research is very unlikely to change our confidence in the estimate of effect 
 Moderate quality— Further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate 
 Low quality— Further research is very likely to have an important impact on our confidence in the 
estimate of effect and is likely to
 
change the estimate 
 Very low quality— Any estimate of effect is very uncertain 
Evidence based on randomised controlled trials begins as high
 
quality evidence, but our confidence in 
the evidence may be
 
decreased for several reasons, including:
 
 
 Study limitations  
 Inconsistency of results  
 Indirectness of evidence  
 Imprecision  
 Reporting bias.  
Although observational studies (for example, cohort and case-control
 
studies) start with a "low 
quality" rating, grading upwards
 
may be warranted if the magnitude of the treatment effect is
 
very 
large,
 
if there is evidence of a dose-response relation or if all plausible
 
biases would decrease the 
magnitude of an apparent treatment
 
effect.
 
 
GRADE: Strength of recommendation 
The GRADE system offers two grades of recommendations: "strong" and "weak" depending on 
whether effects of intervention clearly outweigh the undesirable effects, or clearly do not. If trade-offs 
are less certain—either because of low quality evidence or because evidence suggests that desirable 
and undesirable effects are closely balanced—weak recommendations become mandatory. 
Factors that affect the strength of a recommendation  
Factor Examples of strong 
recommendations 
Examples of weak 
recommendations 
Quality of evidence Many high quality randomised 
trials have shown the benefit of 
inhaled steroids in asthma 
Only case series have examined the 
utility of pleurodesis in pneumothorax 
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Uncertainty about the 
balance between 
desirable and 
undesirable effects 
Aspirin in myocardial infarction 
reduces mortality with minimal 
toxicity, inconvenience, and cost 
Warfarin in low risk patients with 
atrial fibrillation results in small 
stroke reduction but increased 
bleeding risk and substantial 
inconvenience 
Uncertainty or 
variability in values and 
preferences 
Young patients with lymphoma 
will invariably place a higher 
value on the life prolonging effects 
of chemotherapy than on treatment 
toxicity 
Older patients with lymphoma may 
not place a higher value on the life 
prolonging effects of chemotherapy 
than on treatment toxicity 
Uncertainty about 
whether the 
intervention represents 
a wise use of resources 
The low cost of aspirin as 
prophylaxis against stroke in 
patients with transient ischemic 
attacks 
The high cost of clopidogrel and of 
combination dipyridamole and aspirin 
as prophylaxis against stroke in 
patients with transient ischaemic 
attacks 
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Tables 4v 
Summary of evidence for each clinical guideline according to RCOG  and 
GRADE guideline development tools 7; 8;9 
All tables exclude recommendations that have been generated from Level IV Evidence (absence of  
directly applicable clinical studies of good quality; evidence generated from committee reports or 
expert opinion). 
Chapter 4.1 Birth after previous caesarean RCOG  
Level of 
Evidence 
GRADE 
Quality of 
Evidence 
GRADE Strength of 
Recommendation 
Women with a single previous caesarean section and 
uncomplicated pregnancy may be offered VBAC 
IIb, III Moderate Weak 
Women with previous uterine rupture, classical 
caesarean, two previous caesarean sections, should not 
be offered VBAC 
III Very Low Weak 
The probability of successful planned VBAC is around 
75% 
IIb Moderate Strong 
The probability of uterine scar rupture during planned 
VBAC labour is around 0.5% 
IIb Moderate  Strong 
Planned VBAC may increase the risk of uterine 
endometritis and requirement for blood transfusion 
IIb Low Weak 
Planned VBAC is associated with a 10 per 10,000 risk of 
antepartum stillbirth beyond 39 weeks and a 4 per 
10,000 risk of delivery related perinatal death 
IIb, III Moderate Weak 
Planned VBAC carries an 8 per 10,000 risk of the infant 
developing hypoxic ischaemic encephalopathy (HIE) 
IIb Low Weak 
Planned VBAC reduces the risk of neonatal respiratory 
after birth: rates are 2 to 3% with planned VBAC and 3 
to 4% with ERCS. 
IIb, III Low Weak 
The risk of subsequent placenta praevia and accreta is 
linearly associated with the number of previous 
caesarean deliveries 
IIb, III Moderate Strong 
In women with previous caesarean delivery, there is a 2 
to 3-fold increased risk of uterine rupture and around 
1.5-fold increased risk of caesarean section in induced 
and/or augmented labours compared to spontaneous 
labours 
IIb, III Very Low Weak 
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Chapter 4.2 Ectopic pregnancy RCOG 
Level of 
Evidence 
GRADE 
Quality of 
Evidence 
GRADE  
Strength of 
Recommendation 
Salpingectomy in women not desiring future 
fertility is beneficial compared to 
salpingotomy or methotrexate in achieving 
primary treatment success 
IIa, IIb Moderate Strong 
Prophylactic methotrexate (systemic) 
following salpingotomy compared to 
salpingotomy alone is beneficial in reducing 
the risk of persistent trophoblast 
Ib, IIa Moderate Strong 
In women desiring future fertility, systemic 
methotrexate (single or multiple dose) and 
salpingotomy achieve similar primary 
treatment success and subsequent fertility 
outcomes 
Ia, Ib, IIa Moderate Strong 
In women desiring future fertility, there is 
marginally improved subsequent fertility rate 
by performing salpingotomy compared to 
salpingectomy 
III Very Low Weak 
Single dose methotrexate may result in higher 
rates of treatment failure in women with 
ectopic pregnancies compared with multiple 
dose regimens.  
Ia, Ib, IIb Low Weak 
In selected cases, expectant management has 
similar primary treatment success and future 
fertility outcomes to salpingectomy or 
salpingotomy 
III Very Low Weak 
Methotrexate plus mifepristone is no more 
effective at increasing treatment success rates 
compared with methotrexate alone but it 
seems this combination may be more effective 
in increasing treatment success rates in women 
with high levels of progesterone. 
  
Ib Moderate Weak 
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Chapter 4.3 Safe Laparoscopic Entry RCOG 
Level of 
Evidence 
GRADE 
Quality of 
Evidence 
GRADE Strength 
of 
Recommendation 
In high risk women (previous abdominal surgery; obesity, 
extremely thin or known abdominal adhesions), an 
alternative to close umbilical entry (e.g. Palmer‘s point or 
open (Hasson) technique) may reduce the risk of 
laparoscopic entry related injury  
IIb,III Very Low Weak 
The Veress needle should be inserted at the deep umbilical 
pit, at 90º to the skin, with or without stabilising or 
elevating the umbilical sheath/fascia or anterior abdominal 
wall.  
IIb, III Low Weak 
A safety check of correct Veress placement is most reliably 
achieved by using a Veress Intra-Abdominal Pressure (IAP) 
of less than 10mmHg. 
IIa Moderate Weak 
A safety check of intra-abdominal pressure of at least 
25mmHg should preceded vertical insertion of the primary 
trocar 
IIa, IIb Moderate Weak 
Secondary trocars should be inserted under direct 
visualisation 
III Moderate Strong 
 
Chapter 4.4 Preventing sterilisation failure RCOG 
Level of 
Evidence 
GRADE 
Quality of 
Evidence 
GRADE Strength 
of 
Recommendation 
Pre-sterilisation pregnancy testing and ensuring the woman 
has taken adequate contraceptive precautions prior to the 
procedure 
III Very low Strong 
Sterilisation performed at the time of abortion or immediate 
post-partum period is associated with increased risk of 
failure and regret compared to interval sterilisation  
III Very low Weak 
Sterilisation performed by laparoscopy is equivalent to 
mini-laparotomy in terms of primary treatment success but 
is superior in terms of patient recovery and shorter 
operative time 
IIb, III Low Weak 
Laparoscopic tubal occlusion using mechanical devices 
have the lowest risk of sterilisation failure. 
Ib, IIa Low Weak 
A second operating surgeon that counter checks the 
sterilisation procedure has been correctly performed may 
reduce the risk of sterilisation failure 
IIb Very Low Weak 
Sterilisation failure occurred significantly earlier in 
negligent than non-negligent failure mechanisms 
IIb Low Weak 
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4.1. Birth after previous caesarean section  
 
Aim  To provide evidence-based information to inform the care of women 
undergoing either planned vaginal birth after previous caesarean section (VBAC) or elective 
repeat caesarean section (ERCS).  
Introduction and background There is widespread public and professional concern 
about the increasing proportion of births by caesarean section 
10
. Increasing rates of primary 
caesarean section have led to an increased proportion of the obstetric population who have a 
history of prior caesarean delivery. Pregnant women with a previous section may be offered 
either planned VBAC or ERCS. The proportion of women who decline VBAC is, in turn, a 
significant determinant of overall rates of caesarean delivery 
11-14
 . New evidence is emerging 
to indicate that VBAC is not as safe as originally thought 
15;16
. These factors, along with 
medico-legal fears, have led to a recent decline in clinicians offering, and women accepting, 
planned VBAC in the UK and North America 
11-14
 . This guideline presents the best available 
evidence to facilitate antenatal counselling in women with prior caesarean delivery and 
intrapartum management of women undergoing planned VBAC. Prior to this guideline, the 
NICE/RCOG Caesarean Section guideline (April 2004) provided the only UK generated 
guidance on the management of childbirth after caesarean 
17
. Our guideline supports the 
recommendations made in the NICE/RCOG Caesarean Section guideline but addresses 
VBAC in more detail. 
Identification and assessment of evidence Electronic searches were performed in 
MEDLINE (Ovid version 1996-October 2006), EMBASE (Ovid version 1996-October 2006) 
using relevant medical subject headings and text words. Evidence based reviews and 
guidance from ACOG 
18;19
, SOGC 
20
 , ARHQ USA 
21
, New Zealand Guidelines Group 
22
 and 
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The Cochrane Library (2006) 
23
 were identified and used in the development of this 
guideline. The definitions of the types of evidence used in this guideline originate from the 
US Agency for Health Care Research and Quality (Table 4.ii)
7
. Where possible, 
recommendations are based on and explicitly linked to the evidence that supports them. Areas 
lacking evidence are highlighted and annotated as ‗Good Practice Points‘. The definition of 
the terms used in this guideline is shown in Tables 4.2 and 4.3. 
Limitations of data used in guideline Presently, there are no published randomised 
controlled trials (RCTs) comparing planned VBAC against planned ERCS.  Evidence for 
these interventions is obtained mainly from retrospective non-randomised studies 
1
 making 
their conclusions less reliable. However, a study by the National Institute of Child Health and 
Human Development (NICHD) Maternal–Fetal Medicine Units Network15 has overcome 
some of the shortcomings of previous studies by combining a large sample size, a prospective 
cohort design and utilisation of standardised definitions for assessing outcomes. Where 
possible, data on various risks and benefits of VBAC and ERCS reported in this chapter 
originate from this study. Further robust data on maternal and infant health outcomes will 
become available following completion of the BAC trial (Birth After Caesarean) 
24
. 
Options for Delivery: VBAC or ERCS Pregnant women with a history of previous 
caesarean section may be offered either planned VBAC (vaginal birth after caesarean) or 
ERCS (elective repeat caesarean section) for their delivery. Such women would have 
consultant-led antenatal care and typically would follow an antenatal strategy that is depicted 
in Figure 4.1. 
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Table 4.2. Definition of obstetric terms 
Planned VBAC 
 
Planned VBAC (vaginal birth after caesarean) refers to 
any woman who has experienced a prior caesarean birth 
who plans to deliver vaginally rather than by elective 
repeat caesarean section (ERCS). 
Successful and unsuccessful 
planned VBAC 
A vaginal delivery (spontaneous or assisted) in a woman 
undergoing planned VBAC indicates a successful VBAC. 
Delivery by emergency caesarean section during the 
labour indicates an unsuccessful VBAC. 
Uterine rupture  
 
Disruption of the uterine muscle extending to and 
involving the uterine serosa or disruption of the uterine 
muscle with extension to the bladder or broad ligament. 
Uterine dehiscence  Disruption of the uterine muscle with intact uterine serosa 
 
Table 4.3. Definition of perinatal terms 
Term perinatal mortality  
 
Combined number of stillbirths (antepartum and 
intrapartum) and neonatal deaths (death of a live born 
infant from birth to age 28 days) per 10,000 live births and 
stillbirths at or beyond 37 weeks gestation. Term perinatal 
mortality rates exclude deaths due to fetal malformation 
unless otherwise stated. 
Term delivery-related perinatal 
death  
Combined number of intrapartum stillbirths and neonatal 
deaths per 10,000 live births and stillbirths at or beyond 
37 weeks gestation. Delivery-related perinatal mortality 
rates exclude antepartum stillbirths and deaths due to fetal 
malformation unless otherwise stated. 
Neonatal respiratory morbidity  
 
Combined rate of transient tachypnoea of the newborn 
(TTN) and respiratory distress syndrome (RDS). 
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Figure 4.1 Plan of care for singleton uncomplicated pregnancy with previous LSCS 
 
Booking Fetal
anomaly scan
39w: ERCS 
36w: assess and 
decide mode of 
delivery
41w and no onset of 
labour: assess and 
decide mode of delivery 
(consider chance of 
VBAC success, priority 
attached to vaginal 
birth and antepartum 
stillbirth risk) 
Placental 
localisation
40w20w 12w -16w
Provide patient 
information 
leaflet on VBAC 
and ERCS 
options
Re-assessment 
of low lying 
placenta
32w 36w 41w
36w to 41w: await
onset of VBAC labour 
41w to 42w:
ERCS or Induction
42w
Determining the mode of delivery For some women, the decision to attempt VBAC may 
be very clear on the basis of their first antenatal visit. In such cases, it may be acceptable, 
following thorough counselling, to have their next review in the consultant clinic post-dates, 
to discuss elective delivery in the event that they do not go into labour spontaneously. For all 
other women, it has been suggested that the final decision on mode of delivery should be 
established at a 36 week gestation antenatal visit. However, it would be prudent to at least 
document an initial preference by the woman at her hospital booking visit (12-16 weeks) 
together with provision of a patient information leaflet detailing VBAC and ERCS options. 
This approach would provide her with the opportunity to consider her options and help guide 
decision making should she go into labour prior to her 36 week review (Figure 4.1).  
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 Suitability for planned VBAC:  
Women with a prior history of one uncomplicated lower segment transverse caesarean 
section, in an otherwise uncomplicated pregnancy at term, with no contraindication for 
vaginal delivery should be able to discuss her options for planned VBAC, and should 
also be offered information about the alternative of a repeat caesarean section (ERCS). 
 
There is limited evidence on whether maternal or neonatal outcomes are significantly 
influenced by the number of prior caesarean deliveries or type of prior uterine scar 
15;25-29
. 
Nonetheless, due to higher absolute risks of uterine rupture or unknown risks, planned VBAC 
is contraindicated in women with:- 
 Previous uterine rupture- risk of recurrent rupture is unknown 27;30. 
 Previous high vertical classical caesarean section (200-900 per 10,000 risk of uterine 
rupture)- where the uterine incision has involved the whole length of the uterine corpus 
27;30
. 
 More than two previous caesarean deliveries (reliable estimate of risks of rupture unknown)
                                              Evidence Levels IIIb, III and IV 
However, it is recognised that in certain extreme circumstances (e.g. miscarriage, intrauterine 
fetal death), for some women in the above groups, the vaginal route (although risky) may not 
necessarily be contraindicated. A number of other variants are associated with an increased 
risk of uterine rupture. These include: women with a prior inverted T or J incision (190 per 
10,000 rupture risk) 
15
 and women with prior low vertical incision (200 per 10,000 rupture 
risk) 
15
.                   Evidence Level IIa 
There is insufficient and conflicting information on whether the risk of uterine rupture is 
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increased in women with previous myomectomy or prior complex uterine surgery
31-33
. 
                   Evidence Level III 
Therefore, women with a previous uterine incision other than an uncomplicated low 
transverse caesarean section incision who wish to consider vaginal birth should be assessed 
by a consultant with full access to the details of the previous surgery.        Evidence Level IV 
 
Women with a prior history of two uncomplicated low transverse caesarean sections, in 
an otherwise uncomplicated pregnancy at term, with no contraindication for vaginal 
delivery who have been carefully counselled and selected, may be considered suitable 
for planned VBAC. This should be a Consultant-led decision.                                
                 
A multivariable analysis of the NICHD study, showed that there was no significant difference 
in the rates of uterine rupture in VBAC with two or more previous caesarean sections (9/975, 
92 per 10,000) compared to women with a single previous caesarean section (115/16,915, 68 
per 10,000) 
34
. However, the rates of hysterectomy (60 per 10,000 vs. 20 per 10,000) and 
transfusion (3.2% vs.1.6%) were increased in the former group 
34
. These findings concur with 
other observational studies, which overall, have shown similar rates of VBAC success with 
two previous caesarean deliveries (VBAC success rates of 62%-75%) and single prior 
caesarean delivery 
26;35-37
 . Therefore, provided the woman has been adequately counselled 
regarding these increased risks and a comprehensive individualised risk analysis of the 
indication for - and the nature of - the previous caesarean sections has been undertaken, then 
planned VBAC may be allowed in women with two previous low transverse caesarean 
deliveries. This counselling process should be Consultant-led.  Evidence Levels IIa,IIb and III 
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Antenatal counselling: 
The antenatal counselling of women with a prior caesarean delivery should be 
documented in the notes. There should be provision of a patient information leaflet with 
the consultation. 
            
All women who have experienced a prior caesarean birth should be counselled about the 
maternal and perinatal risks and benefits of planned VBAC and ERCS when deciding the 
mode of delivery. The trade off between risks and benefits for VBAC and ERCS is highly 
individualised. Women differ in the magnitude of risks they are willing to expose either 
themselves or their unborn child to during delivery 
38
. For example, women who wish to 
minimize the risk of rare, but severe adverse outcome for their child may prefer ERCS in 
preference to VBAC. Conversely, there are many reasons why a woman might prefer to 
attempt vaginal birth and these may lead them to accept a small degree of risk to both 
themselves and their infant during labour and to choose VBAC in preference to ERCS.  
            Evidence Level IV 
 
The risks and benefits should be discussed in the context of the woman's individual 
circumstances, including her personal motivation and preferences to achieve vaginal birth or 
ERCS, her attitudes towards the risk of rare but serious adverse outcomes, her plans for 
future pregnancies and her chance of a successful VBAC (principally whether she has 
previously had a vaginal birth - see below). In addition, where possible, there should be 
review of the operative notes of the previous caesarean to identify the indication, type of 
uterine incision and any peri-operative complications. Decision making should be a shared 
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process between the woman and her obstetrician. Items that should be discussed and 
documented during the consultation are listed in Tables 4.4 and 4.5, and are expanded on 
below. Decision aids and specific patient information literature may facilitate this process 
39
.  
                 Evidence Levels II and IV 
A final decision for mode of delivery should be agreed between the woman and her 
obstetrician before the expected/planned delivery date (ideally by 36 weeks gestation). 
However, as up to 10% of women scheduled for ERCS go into labour before the 39
th
 week, it 
is good practice to have a plan for the event of labour starting prior to the scheduled date
15
.  
                Evidence Level IIa 
Table 4.4. Items to be discussed when determining mode of delivery 
Items  
 
Special considerations 
1 Her understanding of the maternal and 
perinatal risks and benefits of VBAC 
compared to ERCS 
Particularly her attitude towards the risk of rare 
but serious adverse outcomes. 
2 Any contraindications to VBAC 
 
Any complicating obstetric factors e.g. placenta 
praevia, fetal malpresentation, obstructing 
cervical fibroid, maternal medical disorders. 
 
Assessment of previous caesarean delivery and 
any peri-operative complications. A classical scar 
or more than two previous lower segment 
incisions or previous uterine rupture would be 
absolute contraindications to VBAC.  
3 The likelihood of a successful VBAC  
 
Particularly if she has had a previous vaginal 
birth or successful VBAC 
4 Her plans for future pregnancies 
 
 
5 Her personal preference and motivation  
to achieve vaginal birth or ERCS 
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Table 4.5 Risks and Benefits of opting for VBAC or ERCS  
 ^Planned VBAC ERCS at 39 weeks 
 
Mother 
Benefits 
 
72%-76% chance of successful VBAC 
If successful, shorter hospital stay and 
convalescence  
Increases likelihood that future 
pregnancies may be delivered vaginally 
Able to plan to known delivery date 
**Lower risk of blood transfusion (1%) and 
endometritis (1.8%) 
*Essentially zero risk of uterine scar rupture 
No risk of vaginal tears and no worsening of 
pelvic floor support and continence mechanisms 
Able to be surgically sterilised at the same time 
 
 
Mother 
Risks 
 
 
*Around 50 per 10,000 (0.5%) risk of 
uterine scar rupture-if occurs associated 
with maternal morbidity and fetal 
morbidity/mortality 
24-28% chance of emergency caesarean 
10-15% chance of instrumental delivery 
and/or perineal tear requiring suturing 
**Higher risk of blood transfusion (1.7%) 
and endometritis (2.9%) 
0.1%-2% risk of serious surgical complications 
such as injury to bladder 
Longer stay and convalescence   
Future pregnancies would require caesarean 
delivery 
Increased risk of surgical complications with 
each subsequent caesarean delivery due to 
adhesions, placental praevia/accreta 
Infant 
Benefits 
 
1% risk of transient respiratory morbidity 
 
Avoids the 10 per 10,000 prospective risk of 
antepartum stillbirth as delivery is undertaken at 
commencement of 39
th
 week 
1 per 10,000 (0.01%) risk of delivery-related 
perinatal death or hypoxic ischaemic 
encephalopathy (HIE) at delivery 
 
Infant 
Risks 
10 per 10,000 (0.1%) prospective risk of 
antepartum stillbirth beyond 39 weeks 
whilst awaiting spontaneous labour 
4 per 10,000 (0.04%) risk of delivery-
related perinatal death 
$
8 per 10,000 (0.08%) risk of hypoxic 
ischaemic encephalopathy (HIE) during 
labour 
1-3% risk of transient respiratory morbidity 
[6% risk if delivery performed at 38 instead of 39 
weeks] 
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Footnotes Table 4.5 
^ The estimates of risk for adverse maternal or fetal events in VBAC are based on women 
receiving continuous electronic monitoring during their labour. The relative and absolute 
risks of such events in the absence of continuous electronic fetal monitoring are unknown. 
*Uterine rupture in an unscarred uterus is extremely rare at 0.5 to 2 per 10,000 deliveries, and 
this risk is mainly confined to multiparous women in labour 
60
. 
**In the NICHD study there was no statistically significant difference between planned 
VBAC and ERCS groups in relation to hysterectomy (23 per 10,000 vs. 30 per 10,000), 
thromboembolic disease (4 per 10,000 vs. 6 per 10,000) or maternal death (17/100,000 vs. 
44/100,000)
15
 
$
Approximately half of the increased risk of HIE in planned VBAC arises due to the 
additional risk of HIE caused by uterine rupture (4.6 per 10,000)
15
 
 
Women considering their options for birth after a single previous caesarean should be 
counselled that overall, the chances of successful planned VBAC are 72%-76% 
 
Individual studies report success rates of 72%-76% 
15;16;40
 for planned VBAC after a single 
previous caesarean, which concurs with pooled rates derived by systematic and summative 
reviews [Table 4.5]  
41-43
.        Evidence Levels IIa and IIb 
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A number of factors are associated with successful VBAC. Previous vaginal delivery, 
particularly previous VBAC, is the single best predictor for successful VBAC and is 
associated with an approximately 87%-90% planned VBAC success rate 
29;44;45
. Risk factors 
for unsuccessful VBAC are induced labour, no previous vaginal delivery, body mass index 
greater than 30 
46-48
 and previous caesarean for dystocia 
29
. When all these factors are present, 
successful VBAC is achieved in only 40% of cases 
29
. There are numerous other factors 
associated with a decreased likelihood of planned VBAC success 
29;44;49-52
: VBAC at or after 
41 weeks gestation; birth weight >4000g; no epidural anaesthesia; previous preterm 
caesarean delivery; cervical dilatation at admission less than 4cm; less than 2 years from 
previous caesarean delivery; advanced maternal age, non-Caucasian ethnicity, short stature 
and a male infant. Where relevant to the woman‘s circumstances, this information should be 
shared during the antenatal counselling process to enable the woman to make the best 
informed choice.      Evidence Levels IIa, IIb and III 
There is limited and conflicting evidence on whether the cervical dilatation achieved at the 
primary caesarean for dystocia impacts on the subsequent VBAC success rate
53;54
. 
Unfortunately, the NICHD study was unable to address this concern as data relating to the 
labour of the primary caesarean were not collected during the study
29
 
                       Evidence Levels IIb and III 
Several pre-admission and admission based multivariate models have been developed to 
predict the likelihood of VBAC success 
44;53;55-58
 or uterine rupture 
59
 in planned VBAC. 
However, their usefulness in assisting women to make the decision about whether VBAC or 
ERCS is the best choice in their personal situation remains to be determined.  
                  Evidence Level IIb 
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Women considering their options for birth after a previous caesarean should be 
counselled that planned VBAC carries a risk of uterine rupture of 22 to 74 per 10,000. 
There is virtually no risk of uterine rupture in women undergoing ERCS. 
 
Uterine rupture in an unscarred uterus is extremely rare at 0.5 to 2 per 10,000 deliveries, and 
this risk is mainly confined to multiparous women in labour 
60
. The NICHD study reported 
the overall risk for symptomatic uterine rupture at term was 74 per 10,000 planned VBACs 
15
. There was zero risk in women undergoing ERCS 
15
. Studies with differing methodological 
designs and definitions of scar rupture report similar estimates for risk of uterine rupture per 
10,000 planned VBACs: systematic and non-systematic reviews of 39 
43
, 43 
61
 and 62 
41
 ; 
retrospective studies of 22 
62
 , 33 
63
 , 35 
64
 and 65 
40
 per 10,000. For counselling purposes a 
mean uterine rupture risk of 50 per 10,000 may be utilised (as depicted in Table 4.5). 
Although a rare outcome, uterine rupture is associated with significant maternal and perinatal 
morbidity and perinatal mortality (see below).   
Evidence Levels IIa and IIb 
There is limited evidence from a case control study that women who experienced both 
intrapartum and postpartum fever in their prior caesarean delivery were at increased risk of 
uterine rupture in their subsequent planned VBAC labour (OR 4.02; 95% CI 1.04-15.5)
65
 . 
There is conflicting evidence on whether single-layer compared with double-layer uterine 
closure may increase the risk of uterine rupture in subsequent planned VBAC 
17;66
.    
Evidence levels IIb and III 
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Women considering their options for birth after a previous caesarean should be 
counselled that planned VBAC compared to ERCS carries around 1% additional risk 
of either blood transfusion or endometritis. 
            
Women undergoing planned VBAC compared to ERCS are at greater risk of blood 
transfusion requirement (170 per 10,000 vs. 100 per 10,000) and endometritis (289 per 
10,000 vs. 180 per 10,000) )[Table 4.5] 
15
. There was no statistically significant difference 
between planned VBAC and ERCS groups in relation to hysterectomy (23 per 10,000 vs. 30 
per 10,000), thromboembolic disease (4 per 10,000 vs. 6 per 10,000) or maternal death 
(17/100,000 vs. 44/100,000)
15
. The vast majority of cases of maternal death in women with 
prior caesarean section arise due to medical disorders (such as thromboembolism, amniotic 
fluid embolism, pre-eclampsia and surgical complications).                       Evidence Level IIa 
Maternal death due to uterine rupture in planned VBAC occurs in less than 1 in 100,000 
cases in the developed world, and this estimate is based on information from case reports 
40;67
.                     Evidence Level III 
The increased risk of morbidity overall among women attempting VBAC is due to higher 
rates among women who attempt VBAC and are unsuccessful. The NICHD study 
15
 showed 
that unsuccessful planned VBAC compared to successful VBAC is associated with an 
increased risk of uterine rupture (231 per 10,000 vs. 11 per 10,000), uterine dehiscence (210 
per 10,000 vs. 14.5 per 10,000), hysterectomy (46 per 10,000 vs. 14.5 per 10,000), 
transfusion (319 per 10,000 vs. 116 per 10,000) and endometritis (767 per 10,000 vs. 116 per 
10,000). Similar trends were identified in a retrospective study from a Canadian dataset 
40
. 
                    Evidence Level IIa
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Women considering planned VBAC should be counselled that this decision carries a 2 to 
3 per 10,000 additional risk of delivery-related perinatal death compared to ERCS, but 
that the absolute risk of such delivery-related perinatal loss is comparable to the risk for 
women having their first birth. 
 
In the NICHD study 
15
, perinatal mortality at term was significantly greater among women 
having a planned VBAC than ERCS. Overall perinatal mortalities for planned VBAC vs. 
ERCS respectively were 32 per 10,000 vs. 13 per 10,000 (RR 2.40, 95% CI 1.43 to 4.01) and 
perinatal mortalities after excluding fetal malformation were 24 per 10,000 vs. 9.3 per 10,000 
(RR 2.52, 95% CI 1.37-4.62). The increased risk of perinatal mortality is largely attributable 
to the statistically significantly increased risk of antepartum stillbirth beyond 37 weeks in 
planned VBAC compared to ERCS (19.6 per 10,000 vs. 8.0 per 10,000; RR 2.45, 95% CI 
1.27-4.72) in infants without fetal malformation. Approximately 43% of such stillbirths in 
planned VBAC were at or after 39 weeks gestation (approximately 9 per 10,000 women 
delivering at or after 39 weeks), and may have been prevented by ERCS at 39 weeks. A 
similar estimate was identified from analysis of a Scottish data set which showed that the 
absolute risk of antepartum stillbirth at or after 39 weeks among women with one prior 
caesarean section was 10.6 per 10,000 
68
.         
Evidence Level IIa 
In the NICHD study, rates of delivery-related perinatal death were 4 per 10,000 for planned 
VBAC and 1.4 per 10,000 for ERCS 
15
. A report of data for the whole of Scotland 
demonstrated higher overall rates of delivery-related perinatal death associated with 
attempted VBAC of 12.9 per 10,000 whereas the risk of death associated with ERCS was 
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comparable to the US study at 1.1 per 10,000 
16
. The reason for the higher rate of delivery-
related deaths among women attempting VBAC in Scotland may reflect the fact that these 
were population-based data whereas the US data were exclusively from tertiary centres. 
Consistent with this interpretation, a further study of data from Scotland demonstrated a 
lower risk of perinatal death due to uterine rupture in larger centres 
64
.      Evidence Level IIa 
Accepting the limitations of using these observational data, a reasonable summary is that 
planned VBAC is associated with a 10 per 10,000 risk of antepartum stillbirth beyond 
39 weeks and a 4 per 10,000 risk of delivery related perinatal death (if conducted in a 
large centre) [Table 4.5]. It is likely that these risks can be reduced by ERCS at the start of 
the 39
th
 week, but direct evidence to support this is lacking. It may be helpful to emphasise to 
women that the absolute risks of delivery-related perinatal death associated with VBAC are 
comparable to the risks for nulliparous women 
16;69
.           Evidence Level IIa 
Women considering their options for birth after a previous caesarean should be 
counselled that planned VBAC carries an 8 per 10,000 risk of the infant developing 
hypoxic ischaemic encephalopathy (HIE). The effect on the long term outcome of the 
infant upon experiencing HIE is unknown. 
             
The incidence of intrapartum hypoxic ischaemic encephalopathy (HIE) at term is 
significantly greater in planned VBAC (7.8 per 10,000) compared to ERCS (zero rate)[Table 
4.5] 
15
. Approximately half of the increased risk in planned VBAC arises due to the 
additional risk of HIE caused by uterine rupture (4.6 per 10,000)
15
. The definition used and 
distribution of severity of HIE is not stated in the NICHD study 
15
. Severe neonatal metabolic 
acidosis (pH<7.00) occurred in 33% of term uterine ruptures 
15
. There is no information 
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comparing long term outcome, such as cerebral palsy, associated with VBAC and ERCS. 
Given that cerebral palsy following term birth is very rare (approximately 10 per 10,000) and 
only 10% of cases are thought to be related to intrapartum events 
70
, appropriate analysis of 
this question would require a scale involving hundreds of thousands of women. No adequate 
study has currently been reported.               Evidence Level IIa 
Women considering their options for birth after a previous caesarean should be 
counselled that attempting VBAC reduces the risk that their baby will have respiratory 
problems after birth: rates are 2 to 3% with planned VBAC and 3 to 4% with ERCS. 
         
Three observational studies, pooling data from around 90,000 deliveries, have shown an 
increased risk of neonatal respiratory morbidity (defined earlier) among term infants 
delivered by elective caesarean (3.5%-3.7%) compared to vaginal delivery (0.5%-1.4%) 
71-73
. 
The NICHD study 
15
 (n=30,352 deliveries) reported a similar trend in women with prior 
caesarean section, where the incidence of TTN in ERCS vs. planned VBAC was 3.6% vs. 
2.6% (RR 1.40, 95% CI 1.23-1.59; NNT -98)[Table 4.5]. These rates concur with rates of 
TTN derived from a smaller data set that examined women with prior caesarean section (2 
studies, n=4,478 deliveries) of 2.4%-6% vs. 1.3%-3% 
73;74
 for ERCS vs. planned VBAC 
respectively. The NICHD study did not report rates of RDS, however the smaller data set 
reported RDS as 0.4%-0.6% vs. 0%-0.05% for ERCS vs. planned VBAC respectively 
73;74
.    
Evidence Level IIa 
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Women considering ERCS should be counselled that delaying delivery by one week 
from 38 to 39 weeks reduces the risk of respiratory morbidity, but this delay may be 
associated with a 5 per 10,000 risk of antepartum stillbirth. 
 
Evidence from observational studies 
71-73
 and a recently published trial 
75
 has shown a 
beneficial effect on reducing respiratory morbidity by delaying elective caesarean section to 
at least 39 weeks. The trial reported respiratory morbidity was 11.4%, 6.2% and 1.5% at 37, 
38 and 39 weeks gestation respectively 
75
. Thus, delaying delivery by one week from 38 to 39 
weeks enables around a 5 per 100 reduction in the incidence of respiratory morbidity, but this 
delay may be associated with a 5 per 10,000 increase in the risk of antepartum stillbirth 
68;69
 . 
                 Evidence Levels Ib and IIa 
Furthermore, the trial 
75
 demonstrated an approximate 50% reduction in respiratory morbidity 
(for both TTN and RDS components) by administering prophylactic Betamethasone to 
women having elective caesarean deliveries beyond 37 weeks (steroid vs. control; 2.4% vs. 
5.1%; RR 0.46, 95% CI 0.23-0.93), and this treatment effect was still apparent at 39 weeks 
(steroid vs. control; 0.6% vs. 1.5%). However, it has been suggested that even a single course 
of antenatal steroids may have long term consequences for the baby 
76
 and therefore it may be 
safer to delay ERCS until 39 weeks rather than give steroids and deliver at 38 weeks. The 
routine use of prophylactic Betamethasone in ERCS is beyond the scope of this guideline.  
Evidence Level Ib 
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Women considering their options for birth after a previous caesarean should be 
counselled that the risk of anaesthetic complications is extremely low, irrespective of 
whether they opt for planned VBAC or ERCS. 
             
Anaesthetic procedure-related complications are extremely rare 
77
. Of the women undergoing 
caesarean section (emergency and elective) in the NICHD study (n=37,142), 93% received a 
regional anaesthetic and only 3% of regional procedures failed. There was one maternal death 
(2.7 per 100,000) attributed to an anaesthetic problem (failed intubation) 
78
.  
                    Evidence Level IIa 
Women considering their options for birth after a previous caesarean should be 
counselled that ERCS may increase the risk of serious complications in future 
pregnancies.  
          Evidence Levels IIa, IIb & III 
When considering mode of delivery, women should be advised about the effect of their 
decision on future pregnancies. The following risks significantly increase with increasing 
number of previous caesarean deliveries: 
 Placenta praevia. Overall placenta praevia occurs in 0.5% of deliveries. However, 
praevia is present in 0.38%, 0.63% and 0.72% after single vaginal delivery, single 
caesarean, and two consecutive caesareans, respectively 
79
. 
 Placenta accreta. Overall placenta accreta between 0.25-2 per 1000 deliveries80. 
However, accreta is present in 0.24%, 0.31%, 0.57%, 2.13%, 2.33% and 6.74% of women 
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undergoing their first, second, third, fourth, fifth, and sixth or more caesarean deliveries, 
respectively 
81
. The risk that placenta accreta coexists with placenta praevia is 3%, 11%, 
40%, 61%, and 67% for first, second, third, fourth, and fifth or more repeat caesarean 
deliveries, diagnosed to have placenta praevia 
81
. 
 Placental abruption. Overall placenta abruption occurs in 1% of deliveries. However, 
abruption is present in 0.74%, 0.95% and 1.06% after single vaginal delivery, single 
caesarean, and two consecutive caesareans, respectively 
79
. 
 Injury to bladder, bowel or ureter. A retrospective study of approximately 3000 
women from Saudi Arabia showed a linear increase in the risk of bladder injury (0.3%, 
0.8%, 2.4%), with a history of two, three and five caesarean sections, respectively 
82
. 
 Ileus 
 Need for postoperative ventilation 
 Intensive care unit admission 
 Hysterectomy-required in 0.65%, 0.42%, 0.90%, 2.41%, 3.49% and 8.99% of women 
undergoing their first, second, third, fourth, fifth, and sixth or more caesarean deliveries. 
 Blood transfusion (requiring 4 or more units) 
 Duration of operative time and hospital stay. 
Given the high absolute risks of serious complications, caesarean delivery of women with 
high numbers of previous caesarean sections requires the immediate availability of senior 
surgical staff. 
         Evidence levels IIb and III 
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Placenta praevia and accreta: preoperative investigations 
It is widespread practice in the UK, and endorsed by a RCOG guideline
83
, that women 
identified to have low lying placentas at the routine mid-pregnancy fetal anomaly scan should 
be re-scanned in the third trimester. Provided the woman is asymptomatic (not bled), it is 
suggested that re-scan be conducted at 32 or 36 weeks gestation depending on whether the 
mid-pregnancy scan suggested major or minor praevia, respectively (30). However, given the 
strong association between placenta praevia, placenta accreta and prior caesarean birth, and 
the importance of their pre-operative identification, then re-scan and placental localisation 
assessment should commence at 32 weeks (and repeated at 36 weeks) for women with prior 
caesarean delivery. Furthermore, those women identified to have praevia (especially anterior 
placenta praevia) should undergo further antenatal imaging (such as power amplitude 
ultrasonic angiography, MRI or colour flow Doppler) to help clarify the risk of accreta 
83;84
. 
 
Identification of placenta accreta prior to delivery enables instigation of specific management 
strategies to minimise adverse outcome at delivery. These include: consultant anaesthetist and 
obstetrician conducting the delivery; access to crossed matched blood; colleagues from other 
specialties/subspecialties to be on standby to attend as needed; discussing the risk of 
haemorrhage, transfusion and hysterectomy with the women as part of the consent procedure. 
In addition, advance planning and consideration could be given to: prophylactic or 
therapeutic uterine artery embolisation; internal iliac artery ligation at the same time as initial 
surgery; methotrexate treatment following delivery, and expectant management (placenta left 
in place at the end of the caesarean section)
83;84
. 
Evidence Level III and IV 
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Planned VBAC in special circumstances 
Women who are preterm and considering their options for birth after a previous 
caesarean should be counselled that planned preterm VBAC has similar success rates to 
planned term VBAC but with a lower risk of uterine rupture. 
             
A retrospective cohort study showed women who were preterm (24-36 weeks gestation) and 
undergoing planned VBAC had higher success rates when compared with term patients 
undergoing planned VBAC (82% vs. 74%) and non-significantly lower risks of uterine 
rupture 
85
. The prospective NICHD study showed planned VBAC success rates for preterm 
and term pregnancies were similar (72.8% vs. 73.3%), however, the rates of uterine rupture 
(34 per 10,000 vs. 74 per 10,000, respectively) and dehiscence (26 per 10,000 vs. 67 per 
10,000, respectively) were significantly lower in preterm compared with term VBAC 
86
. 
Thromboembolic disease, coagulopathy and transfusion were more common in women 
undergoing preterm than term VBAC, although overall combined absolute risks were less 
than 3% in the preterm VBAC group. Perinatal outcomes were similar with preterm VBAC 
and preterm ERCS 
86
. Therefore, following appropriate counselling and in a carefully 
selected population, planned VBAC may be offered as an option to women undergoing 
preterm delivery with a history of prior caesarean delivery.        Evidence Levels IIa and IIb 
A cautious approach should be adopted when considering planned VBAC in women 
with twin gestation, fetal macrosomia and short inter-delivery interval as there is 
uncertainty in the safety and efficacy of planned VBAC in such situations. 
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Study sample sizes are underpowered to provide reliable evidence suitable for any clinical 
practice recommendation in relation to twin gestation, fetal macrosomia and short inter-
delivery interval.  
 Twin Gestation: The NICHD study 87 (n=186 twins), US retrospective study 88 
(n=535 twins) and a review 
27
 (7 studies, n=233 twins) have reported similar successful rates 
of VBAC in twin pregnancies to that in singleton pregnancies (65%-84%). However, a 
population based study reported a lower VBAC success rate (45%) but a comparable risk of 
uterine rupture (90 per 10,000) 
89
                 Evidence Levels IIa, IIb and III 
 Fetal Macrosomia: A review 27 of four retrospective studies, and the NICHD study 
29
, has reported a significantly decreased likelihood of successful trial of VBAC for 
pregnancies with infants weighing 4000g or more (55-67%) compared to smaller infants (75-
83%). The risk of uterine rupture was reported in one of the retrospective studies to be only 
increased in those who did not have previous vaginal delivery (relative risk, 2.3; P <.001)
90
 . 
A subgroup analysis of the NICHD study showed that women with previous caesarean 
delivery for dystocia, greater birth weight in the subsequent planned VBAC labour relative to 
the first birth weight decreased the likelihood of VBAC success 
91
. However, in reality, birth 
weight cannot be accurately predicted by antenatal ultrasound which limits the clinical 
usefulness of discussing these observations when counselling women for planned VBAC and 
ERCS.        Evidence Levels IIa, IIb and III 
 Short inter-delivery interval: Three observational studies of limited size 92-94 
have shown a two-to-three fold increased risk of uterine scar rupture for women with a short 
inter-delivery interval (below 12-24 months) from their previous caesarean section. In the 
NICHD study, women undergoing planned VBAC whose previous caesarean delivery was 
within 2 years of their labour had an increased risk of caesarean delivery compared to women 
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whose labour was more than 2 years from their previous caesarean (32% vs. 25% 
respectively)
29
 . Although this information is useful antenatally, it should also be shared with 
women postnatally to enable them to plan their preferred spacing intervals for subsequent 
pregnancies.                      Evidence Levels IIa and III 
Intrapartum support and intervention during planned VBAC 
Planned VBAC should be conducted in a suitably staffed and equipped delivery suite, 
with continuous intrapartum care and monitoring, and available resources for 
immediate caesarean section and neonatal resuscitation. 
                   
Obstetric, midwifery, anaesthetic, operating theatre, neonatal and haematological support 
should be continuously available throughout planned VBAC and ERCS.   Evidence Level IV 
A retrospective study of Canadian data showed that the relative risk of uterine rupture when 
comparing planned VBAC with ERCS increased two fold in low-volume obstetric units 
(<500 births per year) than high-volume (>500 births per year) units, even though lower 
volume units had lower-risk obstetric population 
40
. A retrospective study of Scottish data 
showed that planned VBAC in low-volume hospitals (<3000 births/year) was not associated 
with an increased risk of uterine rupture overall but was associated with an increased risk of 
uterine rupture that led to perinatal death 
64
. It is likely that the availability of resources for 
immediate delivery and neonatal resuscitation may reduce the risk of infant morbidity and 
mortality due to uterine rupture.               Evidence Level IIa 
Epidural anaesthesia is not contraindicated in planned VBAC. 
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In the NICHD study, planned VBAC success rates were higher among women receiving 
epidural analgesia than those not receiving epidural analgesia (73.4% vs. 50.4%) 
29
. The 
authors suggested that this difference may relate to the disproportionate use of spinal 
anaesthesia in short planned VBAC labours or opting for non-epidural analgesia in cases with 
non-reassuring fetal well being.                Evidence Level IIa 
A smaller observational study showed comparable rates of unsuccessful VBAC and operative 
delivery in those women receiving epidural analgesia compared to those not receiving 
epidural, even when correcting for oxytocin usage 
95
.             Evidence Level III 
Furthermore, concerns that epidural analgesia might mask the signs and symptoms associated 
with uterine rupture were based on a single case report 
96
, and VBAC is not a 
contraindication for epidural analgesia 
77
. A retrospective comparative study showed that 
within the planned VBAC group, infants of mothers who received epidural analgesia were 
more likely to be subjected to diagnostic tests and therapeutic interventions (including sepsis 
evaluation and antibiotic treatment) compared to infants from a matched no-epidural 
analgesia group 
97
.               Evidence Levels III and IV 
Monitoring in Labour 
Women should be advised to have continuous electronic fetal monitoring following 
onset of uterine contractions for the duration of planned VBAC.  
             
An abnormal CTG is the most consistent finding in uterine rupture and is present in 55%-
87% of these events [Table 4.6] 
61
.                Evidence Level IIb 
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Table 4.6 Clinical features associated with uterine scar rupture 
Abnormal CTG 
Severe abdominal pain, especially if persisting between contractions 
Acute onset scar tenderness 
Abnormal vaginal bleeding or haematuria 
Cessation of previously efficient uterine activity 
Maternal tachycardia, hypotension or shock 
Loss of station of the presenting part 
 
Footnotes Table 4.6. An abnormal CTG is the most consistent finding in uterine scar rupture 
and is present in 55%-87% of these events
61
. 
Moreover, continuous CTG is generally used among women during planned VBAC and thus 
the estimates of risk of both lethal and non-lethal perinatal asphyxia associated with VBAC 
are in this context. The relative and absolute risks of severe adverse events in the absence of 
continuous electronic fetal monitoring are unknown.              Evidence Level IV 
Continuous intrapartum care is necessary to enable prompt identification and 
management of uterine scar rupture. 
                     
Early diagnosis of uterine scar rupture followed by expeditious laparotomy and resuscitation 
is essential to reduce associated morbidity and mortality in mother and infant. There is no 
single pathognomic clinical feature that is indicative of uterine rupture but the presence of 
any of the factors listed in Table 4.6 occurring in the peripartum period should raise the 
concern of the possibility of this event 
30
. The diagnosis is ultimately confirmed at emergency 
caesarean section or postpartum laparotomy.           Evidence Levels III and IV 
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There is insufficient evidence to support the use of intrauterine pressure catheters in the 
early detection of uterine scar rupture 
 
Observational studies, with varying methodology and case mix, have shown intrauterine 
pressure catheters may not always be reliable and are unlikely to add significant additional 
ability to predict uterine rupture over clinical and CTG surveillance 
98-100
. Furthermore, 
intrauterine catheter insertion may be associated with risk 
101
. However, some clinicians may 
prefer to use intrauterine pressure catheters in special circumstances (e.g. in obese women to 
limit the risk of uterine hyper-stimulation) - this should be a Consultant-led decision. 
Evidence Level III 
Induction and Augmentation 
Particular caution should be applied to women requiring induction or augmentation 
with prior caesarean delivery. 
 
Women should be informed of the 2 to 3-fold increased risk of uterine rupture and 
around 1.5-fold increased risk of caesarean section in induced and/or augmented 
labours compared to spontaneous labours.  
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The risks of induction and/or augmentation should be weighed against the advantages 
of a successful VBAC, avoiding the risks that may occur whilst awaiting spontaneous 
labour and avoiding the short and long-term risks of repeat caesarean delivery.  
 
There should be careful serial cervical assessments, preferably by the same person, for 
both augmented and non-augmented labours, to ensure there is adequate cervicometric 
progress thereby allowing the planned VBAC to continue.  
 
The decision to induce, the method chosen, the decision to augment with oxytocin, the 
time intervals for serial vaginal examination, and the selected parameters of progress 
that would necessitate discontinuing VBAC labour, should be Consultant-led decisions. 
 
The risk of adverse maternal and perinatal outcomes are lower among women in spontaneous 
VBAC labour not requiring induction or augmentation (Table 4.7). Although augmentation 
and induction are not contraindicated in women with prior caesarean delivery, there remains 
considerable disagreement amongst clinicians on their use. Systematic reviews 
102-105
 
examining induction and augmentation of labour for women with previous caesarean birth 
have found no RCTs comparing induction/augmentation in planned VBAC against ERCS. In 
the NICHD study, the risks of uterine rupture per 10,000 planned VBACs were 102, 87 and 
36 per 10,000 for induced, augmented and spontaneous labour groups, respectively (Table 
4.7) 
15
. This compares to an overall risk of uterine rupture of 2 per 10,000 in women with 
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unscarred uteri, and this risk includes the combined risks of women undergoing induction, 
augmentation and spontaneous labour 
60
. In the NICHD study, the increased risk of uterine 
rupture after labour induction was found only in women with no prior vaginal delivery
106
. In 
the NICHD study the rates of caesarean section in women undergoing planned VBAC were 
33%, 26% and 19% for induced, augmented and spontaneous labour groups respectively 
(Table 4.7) 
29
.                     Evidence Level IIa 
Prostaglandin vs. Non-Prostaglandin induction methods 
Two studies have expanded on the differences in adverse outcomes between PG and non-PG 
based induction regimens 
15;64
. In the NICHD study, PG induction compared to non-PG 
induction incurred a non-significantly higher rupture risk of uterine (140 per 10,000 vs. 89 
per 10,000; p=0.22) 
15
. In an analysis of nationally collected data from Scotland, PG 
induction compared to non-PG induction was associated with a statistically significantly 
higher uterine rupture risk (87 per 10,000 vs. 29 per 10,000) and a higher risk of perinatal 
death due to uterine rupture (11.2 per 10,000 vs. 4.5 per 10,000) 
64
. This compares to 6 per 
10,000 risk of perinatal death in women with an unscarred uterus induced by prostaglandin 
identified by a Cochrane review 
107
.                 Evidence Level IIa 
Given these risks, and the absence of direct robust evidence, it is important not to exceed the 
safe recommended limit for prostaglandin priming in women with prior caesarean delivery 
102
. Moreover, due consideration could be given to restricting the dosaging and adopting a 
lower threshold of total prostaglandin dose exposure. Importantly, the decision to induce and 
the method chosen (e.g. prostaglandin or non-prostaglandin methods such as intracervical 
Foley catheter) should be Consultant-led.               Evidence Level IV 
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Table 4.7. Risks of planned VBAC labours from NICHD study (N=17,898 planned 
VBACs) 
15;29
 
 Induced Augmented Spontaneous Overall All Planned 
VBAC s 
Uterine 
rupture 
Overall 
102 per 10,000 
(1.0%) 
87 per 10,000 
0.9% 
36 per 10,000 
0.4% 
69 per 10,000 
0.7% 
PG method  
140 per 10,000 
1.4% 
   
 Non-PG method  
89 per 10,000 
0.9% 
   
Caesarean 
section 
33% 26% 19% 27% 
 
Table 4.8. Management of augmentation in established VBAC labour 
 Clinical management issues 
1 The decision for augmentation should follow careful obstetric assessment, maternal 
counselling and be Consultant-led.  
2 Oxytocin augmentation should be titrated such that it should not exceed the 
maximum rate of contractions of 4 in 10 minutes. Particular caution is necessary 
when using high oxytocin augmentation doses as there is a ―"dose response" for 
maximum oxytocin amount and uterine rupture. 
3 Careful serial cervical assessments, preferably by the same person, are necessary to 
show adequate cervicometric progress, thereby allowing augmentation to continue. 
These intervals should not exceed 4 hours. 
4 If there was less than 2 cm progress after 4 hours of oxytocin then caesarean 
section should be considered. A more conservative threshold of inadequate 
progress after 2 hours of augmentation may also justify consideration for caesarean 
section depending on the woman‘s individual circumstances. 
5 If there was 2 cm or more progress, augmentation could be continued and vaginal 
examinations performed 4-hourly. 
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Post dates induction 
The RCOG Induction of labour guideline suggests induction for post dates be offered from 
41weeks as this reduces perinatal mortality without an increase in caesarean section rates. 
There are no adequate data which directly address this issue among women with a previous 
caesarean section. However, there are some specific issues about women with a previous 
caesarean delivery which may influence the decision making process. First, these women are 
at increased risk of antepartum stillbirth 
68;108
. Hence, the reduction in risk of perinatal death 
associated with post-dates elective delivery may be even greater among women with a 
previous caesarean. However, it is also possible that the effect of routine post-dates induction 
on the risk of emergency caesarean section may be different among women with a previous 
caesarean delivery. These women have a higher background risk of emergency intrapartum 
caesarean section and the risk of a failed VBAC is increased both post-dates and with 
induction of labour. These issues lead some women to decide to attempt VBAC if they labour 
spontaneously prior to 41 weeks but to have a planned caesarean section if their pregnancy 
proceeds post-dates. The choice about the method of elective delivery post-dates will also be 
informed by other factors determining the likelihood of a successful VBAC (favourable 
cervix and previous vaginal birth) and by the priority attached to achieving vaginal birth 
(such as plans for many future pregnancies).  
 
There is no direct evidence to recommend what is acceptable or unacceptable cervicometric 
progress in women being augmented with a previous caesarean section 
109-113
. Amongst 
women with unscarred uteri, the NICE Intrapartum guideline defines delay in the established 
first stage of labour as cervical dilatation of less than 2 cm in 4 hours 
114
. For women with 
intact membranes, an amniotomy would then be recommended and repeat vaginal 
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examination performed 2 hours later: if progress was still less than 1cm then diagnosis of 
delay would be confirmed. If there was less than 2 cm progress after 4 hours of oxytocin, 
further obstetric review would be required to consider caesarean section. If there was 2 cm or 
more progress, augmentation could be continued and vaginal examinations performed 4-
hourly.  
If, in the presence of adequate (strength and frequency) uterine contractions, there is a 
slowing down of a previously normally progressing labour, augmentation may increase the 
risk of uterine rupture. A small sized retrospective study suggested that early recognition and 
intervention for labour dystocia (specifically, not exceeding two hours of static cervicometric 
progress) may have prevented a proportion of uterine ruptures among women attempting 
VBAC
113
. Awareness of the increased risk of uterine rupture in scarred uteri, particularly if 
there is labour dystocia, implies that a more conservative threshold to the upper time limit 
(such as 2 hours instead of 4 hours) of oxytocin augmentation without progress may be 
justified. Furthermore, a retrospective multicentre study showed a "dose response" for 
maximum oxytocin amount and uterine rupture, with a uterine rupture rate of 2.07% at the 
highest dosages 
115
. Therefore, particular caution is necessary when using high oxytocin 
augmentation doses. A summary of the key management issues relating to augmented VBAC 
is shown in Table 4.8.  
Evidence Level III 
The key management issues relating to augmented VBAC labour are listed in Table 4.8, and 
although not based on robust evidence, are considered to be helpful in minimising additional 
harmful risks that are consequent to augmentation. When counselling women for induction 
(prostaglandin or non-prostaglandin methods) and/or augmentation clear information should 
be provided on all potential risks and benefits of such a decision and how this may impact on 
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her long term health. For example, women who are contemplating many future pregnancies 
may be prepared to accept the short-term additional risks associated with induction and/or 
augmentation in view of the reduced risk of serious complications in future pregnancies if 
they have a successful VBAC.        
Evidence Level IV 
Auditable standards 
Standards for audit of practice should include the following: 
 Use of continuous electronic fetal monitoring during VBAC labour. 
Standards for audit of documentation could include the following:  
 Documented discussion of risks and benefits of VBAC and ERCS 
 Documentation of Consultant involvement in:  
Deciding to induce or augment labour  
Establishing a plan for induction or augmentation (e.g. preferred vaginal examination 
interval, expected minimal cervicometric progress, and the criteria needed to discontinue 
labour and proceed to emergency caesarean section). 
Future research 
1. Development, validation and pragmatic clinical evaluation of a scoring system to identify 
women at high or low risk of unsuccessful VBAC that is antenatally and/or intrapartum 
based. 
2. The clinical effectiveness of differing induction and augmentation regimens, perhaps 
individualised according to clinical features rather than standardised strategies. 
3. Identify if there are differences in long-term maternal and infant outcomes between 
planned VBAC and ERCS e.g. subfertility, depression, pelvic floor dysfunction, 
incontinence, psychosexual problems, respiratory illness, and neurodevelopmental 
disorders (…this list is not exhaustive). 
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4. Investigate the aetiology and prevention (e.g. specific antenatal monitoring strategies) of 
the increased risk of stillbirth in women with previous caesarean delivery, in the presence 
or absence of other previous complications (e.g. pre-eclampsia, preterm delivery, small 
for gestational age) 
68;116
. 
5. Research in to factors that may explain the regional and unit-based variation in uptake of 
VBAC, and which factors impact most on women accepting or declining VBAC (e.g. 
patient information leaflet, previous childbirth experiences, desired family size, 
understanding the risk analysis during counselling, how to reduce any decisional conflict, 
variation in case mix)
117-127
. 
6. Assess maternal satisfaction 128-130, quality of life measures and health-state utilities in 
women following VBAC and ERCS to undertake robust economic modelling 
assessments. 
Pending relevant trials 
 BAC Birth After Caesarean - Planned vaginal birth or planned caesarean section for 
women at term with a single previous caesarean birth. ISRCTN 53974531, Prof C 
Crowther, University of Adelaide, Australia
24
. 
 The Twin Birth Study- a multicentre RCT comparing planned caesarean section with 
planned vaginal birth for twins at 32-38 weeks gestation, ISRCTN 74420086, Dr J 
Barrett, Toronto, Canada 
 DiAMOND-Decision Aids for Mode Of Next Delivery, ISRCTN 84367722, Dr A 
Montgomery, Bristol, UK 
 CAESAR-Caesarean Section Surgical Techniques, ISRCTN 11849611, Dr P 
Brocklehurst, National Perinatal Epidemiology Unit, Oxford, UK 
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4. 2. What treatments improve outcomes in women with unruptured tubal 
ectopic pregnancy? 
 
SUMMARY OF TREATMENT OPTIONS (see also Tables 4v)  
Beneficial Salpingectomy in women not desiring future fertility 
Likely to be beneficial Prophylactic methotrexate (systemic) following salpingotomy 
 
Systemic methotrexate (single or multiple dose) 
Unknown effectiveness 
 
Expectant management of a subgroup of unruptured ectopic 
pregnancies 
 
Salpingotomy compared to salpingectomy in the presence of a 
healthy contralateral tube for those women desiring future fertility 
 
Salpingotomy in women with contralateral tubal disease who 
desire future fertility 
Unlikely to be 
beneficial 
Systemic methotrexate combined with mifepristone versus 
systemic methotrexate alone 
 
KEY POINTS Approximately one in a hundred pregnancies are ectopic, with the 
conceptus usually implanting in the fallopian tube. Some ectopic pregnancies can resolve 
spontaneously, but others continue to grow and lead to rupture of the tube. 
Risks are higher in women with damage to the fallopian tubes due to pelvic infections, 
surgery, or previous ectopic pregnancy or abortion, and in smokers. The intrauterine 
contraceptive device does not increase the absolute risk, but a pregnancy that does occur with 
IUD use is more likely to be ectopic than intrauterine. 
Expectant management of unruptured ectopic pregnancies may lead to similar subsequent 
intrauterine pregnancy rates compared with surgery, but few studies have been done. 
Ongoing surveillance is required as part of expectant management, but tubal rupture can 
occur despite falling beta hCG levels. 
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Methotrexate , as single or multiple dose regimens, seems to be as likely as salpingotomy to 
remove trophoblast material and leave a patent fallopian tube in women with non-invasive, 
small ectopic pregnancies with no tubal rupture or bleeding, no sign of fetal cardiac activity 
and low beta human chorionic gonadotrophin (hCG) levels. About 15–40% of ectopic 
pregnancies may be suitable for such non-surgical management.  
Systemic or intratubal methotrexate may also reduce persistent trophoblast after 
salpingotomy.Adding mifepristone to systemic methotrexate seems unlikely to increase 
treatment success compared with methotrexate alone, other than in women with higher 
progesterone levels. 
 
DEFINITION Ectopic pregnancy is defined as a conceptus implanting outside the uterine 
endometrium. The most common implantation site is within the fallopian tube (95.5%), 
followed by ovarian (3.2%) and abdominal (1.3%) sites. The sites of tubal implantation in 
descending order of frequency are ampulla (73.3%), isthmus (12.5%), fimbrial (11.6%), and 
interstitial (2.6%).
131
 Population: In this systematic review, we will consider 
haemodynamically stable women with unruptured tubal ectopic pregnancy, diagnosed by 
non-invasive or invasive techniques. All terms used in this chapter are defined and  listed in 
Table 4.9 
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Table 4.9 Glossary of terms used in ectopic pregnancy guideline 
βhCG is the pregnancy hormone beta-human chorionic gonadotrophin. 
Contralateral tube denotes the opposite tube to that affected by the ectopic pregnancy. 
Compare with homolateral or ipsilateral tube. 
Discriminatory zone denotes a serum hCG level at which it is assumed that all intrauterine 
pregnancies will be visualised by transvaginal ultrasound. This may vary according to 
sonographic expertise but is often between 1000 and 1500 IU/L. 
Expectant management is where ectopic pregnancy treatment involves a watch and wait 
policy in conjunction with close clinical, ultrasonographic, and serum hCG surveillance. 
Fecundity rate ratio (FRR) The fecundity rate represents the probability of spontaneous 
intrauterine pregnancy (IUP) per time unit elapsed derived from analysing the cumulative 
probability of pregnancy over the study duration. Only women trying to conceive are 
included in the calculation, and women who have conceived using additional treatments (e.g. 
IVF) are excluded up and till the start of their additional treatment. The fecundity rate ratio 
(FRR) is the ratio of fecundity between the test treatment (e.g. salpingotomy) against the 
reference treatment (e.g. salpingectomy). A significant treatment difference between 
salpingotomy compared to salpingectomy is indicated if 1 is not included in the 95% CI for 
the FRR of salpingotomy compared to salpingectomy. Thus a FRR of 1.9 for intrauterine 
pregnancy indicates that the probability of intrauterine pregnancy is 90% higher with 
salpingotomy than salpingectomy. 
Fertility outcome reports the rates of subsequent intrauterine pregnancy, repeat ectopic 
pregnancy, and live birth rate. Such pregnancies may either be spontaneous or achieved 
through assisted reproductive technology, and this should be stated clearly in the fertility 
outcome. Furthermore, fertility outcome rates differ according to the ectopic pregnancy 
associated reproductive and pathological characteristics, and treatment method chosen. The 
denominator will differ in those women who desire future fertility and who are trying to 
conceive compared to those women taking contraceptive measures. 
Homolateral or ipsilateral tube denotes the tube that is affected by the ectopic pregnancy. 
Compare with contralateral tube. 
Persistent trophoblast is defined as suboptimal falling, increasing, or plateauing serum 
hCG concentrations following initial ectopic pregnancy treatment for which additional 
treatment (surgical or medical) is needed. This rarely occurs following salpingectomy, but 
may arise following salpingotomy, methotrexate, or expectant management. 
Pregnancy of unknown location is defined as absence of pregnancy localisation (either 
intrauterine or extrauterine) by transvaginal sonography when serum hCG levels are below 
the discriminatory zone (1000–1500 IU/L). If there is an absence of pregnancy localisation 
with the serum βhCG above the discriminatory zone then this, along with other clinical, 
ultrasonographic, and serum βhCG features increases the likelihood of ectopic pregnancy. 
Primary treatment success is defined as progressive decline of serum hCG to undetectable 
levels following initial treatment without reintervention (surgical or medical) for persistent 
trophoblast or supervening clinical sequelae (e.g. tubal rupture or worsening clinical 
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symptoms). 
Salpingotomy is where the ectopic conceptus is removed from the affected tube through a 
linear incision of the tube overlying the ectopic. This incision is not surgically closed and is 
allowed to heal through secondary intention. This surgical treatment conserves the affected 
tube. 
Treatment failure denotes the sum of the reintervention rates for persistent trophoblast and 
supervening clinical sequelae (e.g. tubal rupture or worsening clinical symptoms). 
Tubal excision or salpingectomy is defined as the surgical removal of the tube affected by 
the ectopic pregnancy. 
Tubal preservation is a treatment approach designed to preserve the tube affected by the 
ectopic. This involves expectant, medical (e.g. systemic methotrexate) or salpingotomy 
treatment approaches. 
Tubal patency examines the homolateral tube for the passage of dye at hysterosalpingogram, 
or at second look laparoscopy, or the passage of contrast media at transvaginal ultrasound. 
Only those cases that have been managed by tubal preservation, rather than salpingectomy, 
are eligible for tubal patency testing. 
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INCIDENCE/PREVALENCE  Around 10,000 ectopic pregnancies are 
diagnosed annually in the UK. The incidence of ectopic pregnancy in the UK (11.0 per 1000 
pregnancies) is similar to other countries like Norway (14.9 per 1000) and Australia (16.2 per 
1000).
132-134
 Since 1994, the overall rate of ectopic pregnancy and mortality rate (0.4 per 
1000 ectopic pregnancies) has been static in the UK. 
134
 Until recently, most epidemiological 
studies have failed to distinguish between ectopic pregnancies occurring in women who did 
not use contraception (reproductive failure) and women who used contraception 
(contraceptive failure). 
135;136
 A French population study undertaken from 1992 to 2002 
found that, over the duration of the study, the rate of reproductive failure ectopic pregnancies 
increased by 17%, whilst the rate of contraceptive failure ectopic pregnancies decreased by 
29%.
136
 Increasing rates of Chlamydia infection, smoking, and assisted reproductive 
technology usage may have contributed to the disproportionate increase in reproductive 
failure ectopic pregnancy rate over contraceptive failure ectopic pregnancy rate. Widespread 
use of dedicated early pregnancy assessment units and non-invasive diagnostic algorithms are 
likely to have contributed to increasing rates of ectopic pregnancy diagnosis.
137;138
 
 
AETIOLOGY/RISK FACTORS  The aetiology of ectopic pregnancy is unclear. 
Ectopic pregnancy arising from reproductive failure or contraceptive failure should be 
considered separate entities with differing aetiology, risk factors and reproductive outcomes. 
135;136;139
The main risk factors for reproductive failure are a history of pelvic inflammatory 
disease, previous ectopic pregnancy, pelvic and tubal surgery, infertility, smoking, and 
assisted conception. 
135;140
The main risk factor for contraceptive failure ectopic is intrauterine 
contraceptive device (IUD) failure. IUDs do not increase the absolute risk of ectopic 
pregnancy, but a pregnancy occurring with IUD is more likely to be ectopic than intrauterine. 
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Other risk factors for ectopic include prior spontaneous abortion, prior induced abortion, 
endometriosis, uterotubal anomalies, and prior in utero exposure to diethylstilbestrol. 
However, less than half of the ectopic pregnancies diagnosed are associated with risk factors. 
141
 
PROGNOSIS OF ECTOPIC PREGNANCIES  As the pregnancy advances, tubal 
pregnancies may either diminish in size and spontaneously resolve, or increase in size and 
eventually lead to tubal rupture with consequent maternal morbidity and mortality. There are 
no reliable clinical, sonographic or biological markers (e.g. serum hCG or serum 
progesterone) that can predict rupture of tubal ectopic pregnancy.
142;143
 Maternal mortality 
following ectopic pregnancy is an uncommon short-term outcome in developed countries. 
The recent UK Confidential Enquiry into Maternal Deaths cited ectopic pregnancy as a cause 
of 11 maternal deaths (0.4 per 1000 ectopic pregnancies). 
134
 Short-term maternal morbidity 
relates to pain, transfusion requirement and operative complications.  
Primary treatment success and long-term fertility outcomes depend on the clinical 
characteristics of the ectopic pregnancy (e.g. whether the ectopic occurred in a woman using 
contraception or not, tubal rupture or not, contralateral tubal disease) and the type of surgical 
or medical treatment chosen. A ten-year follow up of ectopic pregnancies showed the rate of 
repeat ectopic pregnancy was much higher in women who had a IUD at the time of the index 
ectopic pregnancy compared to women whose ectopic was not associated with IUD use. In 
contrast, the rate of intrauterine pregnancy was 1.7-fold higher (Fecundity Rate Ratio 1.7, 
95% CI 1.3-2.3) in women who had a IUD at the time of the index EP compared to women 
whose index ectopic was not associated with IUD use.
139
Short and long-term consequences 
on health-related quality of life and psychological issues (e.g. bereavement) are also 
important, but are rarely quantified.  
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PREGNANCIES OF UNKNOWN LOCATION  Pregnancy of unknown location is 
defined as the absence of pregnancy localisation (either intrauterine or extrauterine) by 
transvaginal sonography when serum hCG levels are below the discriminatory zone (1000–
1500IU/L).  An observational study of pregnancies of unknown location has shown 55% 
spontaneously resolve, 34% are subsequently diagnosed as viable, and 11% are subsequently 
diagnosed as ectopic pregnancies. 
144
  
 
AIMS OF INTERVENTION 
Short-term: primary treatment success; to reduce maternal morbidity and mortality related to 
ectopic pregnancy (tubal rupture and haemorrhage) and/or treatment method used (e.g. 
surgical complications, medical drug toxicity).  
Long-term (all women): to reduce risk of recurrent ectopic pregnancy.  
Long-term (for subgroup of women desiring future fertility): to maximise chance of 
future intrauterine pregnancy and live birth rate from unassisted spontaneous conception, or 
following use of assisted reproductive technology techniques (e.g. in vitro fertilisation). 
 
OUTCOMES 
Primary outcomes: primary treatment success (eradication of the ectopic pregnancy without 
the need for secondary treatment arising from persisting trophoblast and/or tubal rupture 
and/or worsening clinical symptoms and signs); persistent trophoblast.  
Secondary outcomes: future fertility-spontaneous intrauterine pregnancy, live birth rate, and 
repeat ectopic pregnancy in women desiring future fertility (this should ideally be expressed 
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as fecundity rate ratios over specific time intervals corrected for known confounders [e.g. 
history of infertility and contraception usage at time of index ectopic pregnancy]).  
Other outcome measures: tubal rupture; ipsilateral tubal patency following tubal preserving 
treatment (salpingotomy, methotrexate, or expectant management); maternal morbidity and 
mortality (prior to ectopic treatment [natural history of ectopic pregnancy] and following 
treatment alternatives); harms of treatment alternatives; complications of surgery [injury, 
infection, thromboembolism]; drug toxicity; health-related quality of life assessments. 
 
METHODS 
Clinical Evidence search and appraisal June 2006. Given that there are limitations in 
performing RCTs comparing medical and surgical ectopic pregnancy treatments, and limited 
trial numbers, the search was extended to incorporate large sample sized quality cohort 
studies (either prospective or retrospective, with control or comparison treatment groups). 
Where appropriate, evidence from quality observational studies is utilised, when RCT 
evidence is lacking. The following databases were used to identify studies for this chapter: 
Medline 1966 to June 2006; Embase 1980 to June 2006; and The Cochrane Library 2006, 
issue 2. Additional searches were carried out using the 
following websites: NHS Centre for Reviews and Dissemination (CRD), Database of 
Abstracts of Reviews of Effects (DARE), Health Technology Assessment (HTA), Turning 
Research into Practice (TRIP), and National Institute of Health and Clinical Excellence 
(NICE) guidance. Abstracts of the studies retrieved were assessed independently by two 
information specialists using predetermined criteria to identify relevant studies. Design 
criteria included: study types — published systematic reviews, meta-analysis, RCTs, 
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controlled clinical trials, cohort studies with a control or comparison group, or case-control 
studies in any language; open or blinded studies acceptable; studies had to contain 20 or more 
individuals. There was no maximum loss to follow up or minimum length of follow up. 
Fecundity rate ratios have been calculated by the Clinical Evidence author, except where 
indicated. A GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) 
8
 approach and evaluation of the quality of evidence for interventions is included 
in this review (see Introduction to Chapter 4 ; Table 4.iv; Table 4v).  
TREATMENT OPTION: SALPINGECTOMY 
Treatment failure (persistent trophoblast) 
Compared with salpingotomy: salpingectomy may be more effective at reducing initial 
treatment failure rates compared with salpingotomy. (moderate quality evidence) 
Compared with methotrexate: Salpingectomy may be more effective at reducing initial 
treatment failure rates compared with methotrexate . (moderate quality evidence) 
Subsequent pregnancy rates 
Compared with salpingotomy: we don't know whether salpingectomy may result in lower 
rates of subsequent intrauterine pregnancies or recurrent ectopic pregnancy rates compared 
with salpingotomy.       (very low quality evidence) 
Compared with expectant management: Salpingectomy may be no more effective at 
increasing subsequent pregnancy rates in women with ectopic pregnancies compared with 
expectant management.      (very low quality evidence)  
 
SALPINGECTOMY BENEFITS 
Salpingectomy versus salpingotomy:  We found no systematic review or RCTs. We found 
one non-systematic review and four cohort studies (and related single follow up publication) 
that compared salpingectomy versus salpingotomy (see Table 4.10). 
139;145-149
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Table. 4.10. Comparison of fertility outcomes of salpingotomy versus salpingectomy  
Study Sample size  
 
 
(sum of salpingectomy and 
salpingotomy cases unless 
otherwise stated) 
Salpingotomy compared with salpingectomy as 
the reference 
treatment 
Crude spontaneous 
intrauterine 
pregnancy (IUP) rates 
and/or 
Fecundity Rate 
Ratios* (FRR) 
 (95% CI) 
Crude repeat ectopic 
pregnancy (REP) rates 
and/or  
Fecundity Rate Ratios* 
(FRR) 
 (95% CI) 
Non-systematic 
review 
149
  
 
1774 women (in 9 cohort studies) 
undergoing salpingotomy or 
salpingectomy for ectopic 
pregnancy and desiring future 
fertility 
 
176 women (in 18 cohort studies) 
with cTD after salpingotomy 
(corresponding results for 
salpingectomy not reported) 
280/528 (53%) with 
salpingotomy v 
614/1246 (49%) with 
salpingectomy 
 
 Crude FRRs 
$
 
1.08 (0.97 to 1.19) 
 
Salpingotomy in 
women with cTD then 
IUP is 96/176 (55%) 
78/528 (15%) v 123/1246 
(10%) 
 
Crude FRRs 
$
 
1.50 (1.15 to 1.95) 
 
 
Salpingotomy in women 
with cTD then REP is 
36/176 (21%)  
Prospective 
cohort 
148
 
86 women undergoing 
laparoscopic surgery for ectopic 
pregnancy and were attempting 
conception. 
cTD present in 33/60 
salpingotomy and 15/26 
salpingectomy cases 
 
36/60 (60%) with 
salpingotomy v 14/26 
with salpingectomy 
(53.9%) 
FRR 1.11 (0.77 to 
1.76)* 
Irrespective of the type 
of surgery performed if 
cTD then crude FRR 
0.53 (0.36 to 0.75) 
 (based on 20/50, 40% 
pregnant with cTD vs. 
27/34, 79.4% not 
pregnant with cTD)  
11/60 (18.3%) v 2/26 
(7.7%) 
FRR 2.38 (0.67 to 9.30) 
Retrospective 
cohort 
147
 
135 women undergoing 
laparoscopy or laparotomy for 
62% v 38% at 18 
months (numbers not 
28% v 23% at 3 years 
(numbers not reported) 
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ectopic pregnancy. 
cTD present in 15/56 
salpingotomy and 38/79 
salpingectomy cases 
reported) 
FRR 1.9 (0.91 to 3.8)  
 
If cTD, FRR 0.80 (0.13 
to 4.9) 
If bilateral tubal 
pathology, FRR 1.4 
(0.13 to 16) 
 
Irrespective of the type 
of surgery performed:  
If cTD then FRR 0.48 
(0.18 to 1.2) 
FRR 2.4 (0.57 to 11) 
 
 
 
 
 
 
Irrespective of the type of 
surgery performed:  
If cTD, FRR 0.79 (0.18 to 
3.4) 
Retrospective 
cohort 
145
 
276 women undergoing 
salpingotomy or salpingectomy 
(by laparoscopy or laparotomy) 
for their first ectopic pregnancy. 
cTD present in 30/208 
salpingotomy and 17/68 
salpingectomy cases 
89% v 66% at 7 years 
(numbers not reported); 
P<0.05 
FRR 1.58 (1.06 to 
2.38)* 
Irrespective of the type 
of surgery performed: 
If cTD, FRR 0.46 (0.26 
to 0.82) 
If previous fertility 
surgery,  
FRR 0.74 (0.34 to 1.60) 
17% v 16% at 2 years 
(numbers not reported; 
reported as not significant) 
FRR 1.28 (0.57 to 2.87)* 
Irrespective of the type of 
surgery performed: 
If cTD, FRR 2.25 (1.11 to 
4.531) 
If previous fertility 
surgery,  
FRR 2.51 (1.002 to 6.31) 
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Cohort 
139;146
 
  
476 women with tubal ectopic 
pregnancy who were not using 
contraception at conception. 
Salpingotomy (262, cTD in 
236/262 cases); Salpingectomy 
(178, cTD in 159/178 cases); 
Methotrexate (36, cTD in 8/36 
cases) 
 
Salpingotomy vs. 
Salpingectomy vs. 
Methotrexate 
73% vs. 57% vs. 80%. 
 
Irrespective of the type 
of surgery performed: 
If cTD, FRR 0.53 (0.33 
to 0.83) 
Women with infertility 
factors: 
Salpingotomy vs. 
Salpingectomy FRR 
1.67 (1 to 2.78) 
Methotrexate vs. 
Salpingectomy FRR 2.5 
(1.95 to 8.33) 
Women with no 
infertility factors: 
Salpingotomy vs. 
salpingectomy FRR 
1.18 (0.63 to 2.22) 
Methotrexate vs. 
Salpingectomy FRR 
2.12 (0.49 to 9.78) 
Salpingotomy vs. 
Salpingectomy vs. 
Methotrexate 
25% vs. 27% vs. 41% (no 
significant difference 
between groups, p=0.55) 
 
Salpingotomy vs. 
Salpingectomy FRR 0.93 
(0.76 to 3.5) 
Methotrexate vs. 
Salpingectomy FRR 1.51 
(0.25 to 7.08) 
139
 
1595 women with ectopic 
pregnancy. 
Salpingotomy (798); 
Salpingectomy (654); 
Methotrexate (143) 
Numbers of cases with cTD for 
each treatment is unstated 
 
Salpingotomy vs. 
Salpingectomy 
FRR 1.25 (1 to 1.67) 
Methotrexate vs. 
Salpingectomy 
FRR 1.25 (0.7 to 2.33) 
Irrespective of the type 
of surgery performed: 
If cTD, FRR 0.83 (0.67 
to 1.0) 
Salpingotomy vs. 
Salpingectomy 
FRR 1.25 (0.67 to 2) 
Methotrexate vs. 
Salpingectomy 
FRR 2.25 (0.6 to 7.4) 
Irrespective of the type of 
surgery performed: 
If cTD, FRR 1 (0.5 to 2.0) 
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Footnotes  
cTD contralateral tubal disease. This may be absent or occluded or distorted by pathology 
(hydrosalpinges, adhesions) 
Asterisked FRRs – calculated by author 
*Fecundity Rate Ratio-See glossary. 
FRR are stated for salpingotomy compared to salpingectomy as the reference unless 
otherwise stated. FRRs are also stated for the presence relative to absence of confounding 
factors (e.g. cTD or infertility) disregarding the type of surgery (either salpingotomy or 
salpingectomy) that was performed. Where studies have calculated FRR using salpingotomy 
as the reference standard the reciprocal of this FRR has been quoted as this provides the FRR 
of salpingotomy compared to salpingectomy as the reference standard.  
Crude FRRs
$ 
We report an FRR based on the results reported in the meta-analysis. However, 
due to study heterogeneity and non-adoption of survival analysis techniques by included 
studies within the meta-analysis, a pooled FRR as we have reported is likely to be crude and 
subject to bias. 
 
Primary treatment success: Salpingectomy compared to salpingotomy has higher primary 
treatment success and a lower risk of persistent trophoblast. Primary treatment success rate of 
salpingectomy is almost 100%, with the risk of persistent trophoblast less than 1%. 
146;149
 
Primary treatment success rate of salpingotomy ranges from 72%-98% 
150;151
, with a 3-20% 
risk of persistent trophoblast.
145;146;149;152;153
  
Subsequent pregnancy rates in salpingectomy versus salpingotomy (see Table 4.10): 
Subsequent spontaneous intrauterine pregnancy rates following salpingotomy (range 53%-
89%) did not significantly differ from those following salpingectomy (range 38-66%) apart 
from one cohort study 
145
  that showed an improved fecundity with salpingotomy [89% vs. 
66%, FRR 1.58 (1.06-2.38)]. A similar trend of no difference between salpingotomy (range 
10%-28%) and salpingectomy (range 8%-23%) was observed for rates of repeat ectopic 
pregnancy.  
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Contralateral tubal disease and infertility factors (see Table 4.10): In the presence of 
contralateral tubal disease (hydrosalpinx, peritubal adhesions or absent tube) or infertility 
factors (e.g. previous ectopic, previous tubal surgery, previous pelvic inflammatory disease, 
infertility factors) there is a trend to decreased subsequent intrauterine pregnancy and 
increased risk of ectopic pregnancy irrespective of whether salpingotomy or salpingectomy is 
performed. 
145-148;154-156
. In the presence of such factors, salpingotomy provides a greater 
probability of subsequent intrauterine pregnancy than salpingectomy; however this does not 
achieve statistical significance.  
Salpingectomy versus methotrexate: We found no RCTs or observational studies of 
sufficient quality. 
Salpingectomy versus methotrexate (systemic): One cohort study, and its follow up 
publication, compared three interventions: salpingotomy, salpingectomy, and methotrexate. 
139;146
  It found that the rate of treatment failure with salpingectomy was similar to 
salpingotomy, but less than methotrexate. The study showed no significant difference 
between salpingectomy and salpingotomy in rates of subsequent intrauterine pregnancy or 
subsequent ectopic pregnancy. 
Salpingectomy versus expectant management: see benefits of expectant management. 
SALPINGECTOMY HARMS 
Salpingectomy versus salpingotomy: The non-systematic review and cohort studies listed in 
(see Table 4.10) did not report on harms.  
Salpingectomy versus methotrexate: We found no RCTs or observational studies of 
sufficient quality.  
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Salpingectomy versus salpingotomy or methotrexate management (systemic): We found 
no RCTs or observational studies of sufficient quality. The cohort study gave no information 
on adverse effects. 
139;146
  One cost-effectiveness meta-analysis found rates of 0–22% (mean 
10%) for minor complications (e.g. drug side effects), and 0–11% (mean 7%) for serious 
complications (e.g. ruptured ectopic, or other symptoms of persistent trophoblast) in women 
who had methotrexate. 
151
 It also found intraoperative complications of 0–8% (mean 2%) and 
postoperative complications of 0–15% (mean 9%) for laparoscopy (either salpingectomy or 
salpingotomy). 
COMMENTS ON SALPINGECTOMY EVIDENCE:  All comparisons included here 
have been based on retrospective or prospective observational cohort designs in women with 
unruptured tubal ectopic pregnancies (see Table 4.10).  Few studies have considered the 
impact of infertility factors (known infertility, contralateral tubal disease) on treatment choice 
(conservative salpingotomy or radical salpingectomy) and future fertility outcome. 
Differences in such prognostic factors may not be adequately clarified when comparing 
salpingotomy with salpingectomy, even when adopting multivariate analysis techniques. 
However, further information may be provided by an RCT comparing salpingotomy with 
salpingectomy that is currently recruiting. This is the ESEP (European Surgery in Ectopic 
Pregnancy) study, which represents an international multi-centre Dutch–Swedish–British 
collaboration. Importantly, any potential benefits of improved intrauterine pregnancy rate 
with salpingotomy compared with salpingectomy appear to be small, and possibly restricted 
to subgroups with contralateral tubal disease. This effect and its magnitude should be verified 
by RCTs comparing salpingotomy with salpingectomy. 
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TREATMENT OPTION: PROPHYLACTIC METHOTREXATE AFTER 
SALPINGOTOMY 
Treatment failure (persistent trophoblast) 
Compared with no salpingotomy alone: A single prophylactic dose of methotrexate after 
salpingotomy is more effective at reducing persistent trophoblast compared with 
salpingotomy alone.       (moderate quality evidence) 
 
BENEFITS PROPHYLACTIC METHOTREXATE AFTER SALPINGOTOMY 
Salpingotomy plus single systemic dose methotrexate versus salpingotomy alone: One 
RCT found that adding a single prophylactic dose of systemic methotrexate (1 mg/kg im) 
after salpingotomy (by laparoscopy or laparotomy) significantly reduced the incidence of 
persistent trophoblast compared with salpingotomy alone (1/54 [2%] v 9/62 [15%]; RR 0.13, 
95% CI 0.02 to 0.74; NNT 8, 95% CI 4 to 33). 
153
 
HARMS AND COMMENTS ON PROPHYLACTIC METHOTREXATE AFTER 
SALPINGOTOMY.   See under methotrexate section. 
TREATMENT OPTION: SYSTEMIC METHOTREXATE 
Treatment failure 
Single dose methotrexate compared with multiple dose regimens: Single dose methotrexate 
may result in higher rates of treatment failure in women with ectopic pregnancies compared 
with multiple dose regimens.       (low quality evidence) 
Compared with salpingectomy: Methotrexate may be less effective at reducing initial 
treatment failure rates compared with salpingectomy.       (moderate quality evidence) 
Single dose methotrexate compared with salpingotomy: Single dose methotrexate is no 
different at increasing primary treatment success rates in women with small unruptured tubal 
pregnancies compared with salpingotomy by laparoscopy.  (moderate quality evidence) 
Multiple dose methotrexate compared with salpingotomy: Multiple dose methotrexate is no 
different at increasing primary treatment success rates in women with confirmed unruptured 
tubal pregnancy compared with salpingotomy by laparoscopy. (moderate quality evidence) 
Subsequent pregnancy rates 
Single or multiple dose methotrexate compared with salpingotomy: Single dose methotrexate 
is no   different at increasing tubal patency, subsequent intrauterine or ectopic pregancy rates 
in women with small unruptured tubal pregnancies compared with salpingotomy. 
                     (moderate quality evidence) 
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SYSTEMIC METHOTREXATE BENEFITS 
Systemic single dose versus multiple dose methotrexate regimens: We found one 
systematic review (3 RCTs, 23 observational studies, 1327 women with ectopic 
pregnancy)
157
, one RCT (108 women)
158
 and one cohort study (643 women). 
159
 The 
systematic review found that single dose methotrexate had significantly higher primary 
treatment failure than multiple dose methotrexate (absolute numbers not reported; OR 1.71, 
95% CI 1.04 to 2.82). The review also found a significant difference for the studies 
considered high quality (high quality according to the authors‘ own rating system; absolute 
numbers not reported; OR 1.96, 95% CI 1.07 to 3.60) and for studies that controlled 
confounding factors (βhCG and fetal cardiac activity: OR 4.74, 95% CI 1.77 to 12.62) 
Systemic methotrexate (single or multiple dose) versus salpingotomy: We found one 
systematic review (search date 2004, 4 RCTs, 307 women; see Table 4.11).
150
 The review (3 
RCTs, 207 haemodynamically stable women with a small unruptured tubal pregnancy) found 
that single dose methotrexate was significantly less effective than salpingotomy (by 
laparoscopy) in primary treatment success (elimination of tubal pregnancy), but found no 
significant difference in tubal patency, subsequent intrauterine pregnancy, and repeat ectopic 
pregnancy rates. The systematic review also found no significant difference between multiple 
dose methotrexate (1 RCT, 100 haemodynamically stable women with a laparoscopically 
confirmed unruptured tubal pregnancy) compared with salpingotomy (by laparoscopy) in 
primary treatment success or tubal patency (see Table 4.11). One RCT identified by the 
review found that physical functioning (measured as part of SF-36, 0 = worst, 1 = best) was 
significantly better with single dose methotrexate compared with salpingotomy at 4 and 10 
days (4 days: 73 with methotrexate v 43 with salpingotomy, P = 0.001; 10 days: 93 v 70; P = 
0.006). 
160
 Another RCT identified by the review found that a variety of scores of quality of 
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life were significantly lower with multiple dose methotrexate compared with salpingotomy at 
2 weeks (Medical Outcomes Study, 0 = worst, 100 = best; role function: 29 v 51; social 
function: 45 v 68; health perceptions: 52 v 63; P < 0.05 for all comparisons). 
161
 
Methotrexate (systemic) versus salpingectomy or salpingotomy: See Table 4.11  
Systemic methotrexate versus expectant management: We found no RCTs. 
 
Table 4.11. RCTs and meta-analyses of surgical and surgical versus medical treatments 
in the management of ectopic pregnancy. 
150
 
Type of comparison No 
Of  
RCTs 
Sample 
size 
Trial 
/ including longer 
follow up of trial in 
separate publication 
Meta-analysis of trials 
as reported by Cochrane review 
150
 
Primary 
treatment 
success 
Relative risk 
(95% CI) 
Tubal 
patency 
in those 
desiring 
future 
fertility 
Relative risk 
(95% CI) 
Subsequent 
intrauterine 
pregnancy 
rate 
Relative risk 
(95% CI) 
Repeat 
ectopic 
pregnancy 
rate 
Relative risk 
(95% CI) 
Laparoscopic 
salpingotomy vs. 
laparotomy 
salpingotomy
194;200-
202
.  
 
3 105 
63 
60 
Lundorff 1991/1992 
Murphy 1992 
Vermesh 1989  
91/104 (88%) 
v 121.124 
(98%) 
(RR 0.90, 
95% CI 0.83 
to 0.97; NNT 
10, 95% CI 6 
to 27) 
78% v 87% 
(0.89, 0.74 to 
1.1) 
61% v 53% 
(1.20, 0.88 to 
1.15) 
6% v 15% 
(0.43, 0.15 to 
1.2) 
Systemic MTX 
multiple dose i.m. 
vs. laparoscopic 
salpingotomy
203;204
 
1  
 
100 Hajenius 1997/ 
Dias Pereira 1999 
 
82% v 72% 
(1.15, 0.93 to 
1.4) 
55% v 59% 
(0.93, 0.64 to 
1.4) 
36% v 43% 
(0.89, 0.42 to 
1.9) 
9% v 10% 
(0.77, 0.17 to 
3.4) 
Systemic MTX 
single-dose i.m vs. 
laparoscopic 
salpingotomy.
160;205-
207
 
3 71 
74 
62 
Fernandez 1998  
Saraj 1998  
Sowter 2001/ 
Sowter 2001  
71% v 88% 
(0.83, 0.71 to 
0.97) 
60% v 57% 
(1.1, 0.74 to 
1.5) 
37% v 47% 
(0.99, 0.55 to 
1.8) 
0% v 17% 
(0.27, 0.02 to 
4.5) 
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SYSTEMIC METHOTREXATE HARMS 
Systemic single dose versus multiple dose methotrexate regimens: One systematic review 
found significantly lower rates of adverse effects (including nausea, vomiting, alopecia) in 
women who had single dose compared with multiple dose methotrexate (31% v 41% 
[absolute numbers not reported]; OR 0.44, 95% CI 0.31 to 0.63). However, it found no 
significant difference between regimens when it adjusted for serum βhCG (OR 0.79, 95% CI 
0.21 to 3.01). 
157
  It also found no significant difference between regimens for abdominal pain 
or hospital admission (abdominal pain: 22% v 26%; OR 0.80, 95% CI 0.53 to 1.19; hospital 
admission: 12% v 11%; OR 1.11, 95% CI 0.83 to 1.47).  
Systemic methotrexate (single or multiple dose) versus salpingotomy: 
The systematic review gave no information on adverse effects. 
150
 The first RCT found that 
women who received single dose methotrexate had significantly longer vaginal bleeding than 
did those who underwent salpingotomy (7.5 days v 3 days; P < 0.001). 
160
  The second RCT 
found that pain was greater with multiple dose methotrexate over 16 weeks compared with 
salpingotomy (results presented graphically; significance assessment not reported). 
161
 
Salpingotomy plus single systemic dose methotrexate versus salpingotomy alone: The 
RCT reported that there were no ―clinically significant‖ adverse effects in people who had 
methotrexate. It also reported that there was no significant difference in laboratory values 
(white blood cell count, haemoglobin, haematocrit, serum creatinine, and transaminase) 
between groups at 7 days after surgery (reported at non-significant; P value not reported). 
153
 
Systemic methotrexate versus expectant management: We found no RCTs or 
observational studies of sufficient quality. 
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COMMENTS ON SYSTEMIC METHOTREXATE EVIDENCE: The primary treatment 
success rate of systemic methotrexate (single or multiple dose regimens) in treating ectopic 
pregnancies has been reported by meta-analyses as 87% (range 75%-90%) 
151
, 84%
162
and 
89%. 
157
 The risk of persistent trophoblast is 18% (range 6%-31%). 
150
 Despite the term 
single dose methotrexate regimen, repeat doses are permitted every 7 days if there is 
inadequate hCG fall and a meta-analysis has shown two or more doses are required in 13.5% 
women undergoing single dose regimens. 
157
A retrospective study (n=93) has shown two-
year subsequent cumulative intrauterine pregnancy rates of 67% and repeat ectopic 
pregnancy rates of 24%
163
, which correlates to fertility outcomes obtained by RCTs included 
in the meta-analysis (see Table 4.11). 
150
 
Clinical guide: Multiple dose systemic methotrexate involves a regime of once daily 
methotrexate 1mg/kg i.m on alternate days (days 1, 3, 5, 7), and leucovorin 0.1mg/kg i.m.on 
alternate days (days 2, 4, 6, 8). The regimen is continued unless βhCG falls by more than 
15% in 48 hours or until four doses of methotrexate are given. A repeat course can be given if 
βhCG is not less than 40% of its initial value by day 14.Single dose systemic methotrexate 
regime involves a single dose of methotrexate i.m. (50mg/m2). The dose is repeated if βhCG 
has not fallen by at least 15% between day 4 and day 7 of treatment. Up to four doses can be 
given if βhCG does not decline by 15% every week. Prospective studies suggest around 25-
40% of non-invasively diagnosed ectopic pregnancies are suitable for non-surgical (expectant 
or methotrexate) management 
160;164-166
.The criteria necessary for methotrexate treatment 
have been agreed by the RCOG and includes: non-invasive diagnosis of ectopic pregnancy; 
haemodynamically stability with no signs of tubal rupture; ectopic mass is less than 3.5cm in 
diameter and there is no fetal cardiac activity;  hCG does not exceed 3000 IU/L; no medical 
contraindications to methotrexate usage; woman consents to frequent outpatient follow up. 
167
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Observational (prospective and retrospective) studies have shown higher primary treatment 
success of methotrexate with ectopics that have: low pre-treatment βhCG  (preferably < 1000 
IU/l); 
160;168-174
absent fetal cardiac activity 
170;175
 or absent yolk sac identified by sonography; 
176;177
;no prior history of treated ectopic; 
175
no pelvic pain; 
172
;no previous history of 
infertility.
163
 Therefore, treatment outcomes of methotrexate should be compared against the 
other tubal conserving methods (salpingotomy and expectant management).  
Adverse effects: The frequency of methotrexate complications is similar to that associated 
with laparoscopy.
151
 However, the nature of the complications differs, with serious 
complications of laparoscopy having greater morbidity and mortality than those related to 
methotrexate. Women who experienced side effects were more likely to have successful 
treatment regardless of single or multiple dose methotrexate regimen.
157
 Drug adverse effects, 
although prevalent, are usually self-limiting and relatively minor and include: nausea, 
vomiting, gastritis, diarrhoea, abdominal pain, oral mucositis, pneumonitis, bone marrow 
suppression and abnormal liver function. Case reports have described other rare but serious 
complications: life-threatening neutropenia and fever,
178
anaphylaxis, 
179
 haematosalpinx and 
pelvic haematocoele, 
180
and death due to multi-organ failure.
181
 A meta-analysis of single 
dose methotrexate showed side-effects in 24% (95% CI 9% to 47%) and 10% (95% CI 7% to 
14%) had a ruptured ectopic pregnancy. 
162
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TREATMENT OPTION: EXPECTANT MANAGEMENT 
Subsequent pregnancy rates 
Compared with surgery: Expectant management may lead to similar subsequent pregnancy 
rates in women with nonviable embryos (non-invasive with declining hCG levels) compared 
with salpingectomy or salpingotomy.      (very low quality evidence) 
 
Note: We found no clinically important results about expectant management compared with 
methotrexate in women with ectopic pregnancies. 
EXPECTANT MANAGEMENT BENEFITS    
We found no systematic review or RCTs.  
Expectant management versus salpingectomy or salpingotomy:  
One retrospective cohort study (180 women with ectopic pregnancy) found similar rates of 
expectant management and salpingectomy or salpingotomy in subsequent intrauterine 
conception rate (19/37 [51%] with expectant management v 31/49 [63%] with surgery). 
182
 
The study did not report on success of treatment or report separate data by type of surgery. 
We found one small prospective observational study that compared expectant (16 women) 
versus systemic methotrexate (26 women) versus salpingotomy/salpingectomy (46 women); 
interpretation of outcomes was biased by case selection. 
183
 The study also only reported 
treatment success for women who had methotrexate.  
Expectant management versus methotrexate: We found no RCTs or observational studies 
of sufficient quality.  
Expectant management in studies with no control group: We found one non-systematic 
review (15 prospective cohort studies, 482 women with ectopic pregnancy who were 
described as ―stable‖ or ―well‖) which found a mean rate of 67% (range 47–82%) for 
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successful management of ectopic pregnancy by expectant management. 
184
 The review also 
reported that rates of tubal patency were 57/74 (77%), subsequent intrauterine pregnancy 
42/62 (68%), and repeat ectopic pregnancy 6/47 (13%). One prospective cohort study (107 
women who were clinically stable with non-viable pregnancies and no signs of 
haematoperitoneum) found that 75/107 (70%) of ectopic pregnancies resolved spontaneously. 
166
 Another prospective cohort study (30 women who wanted to become pregnant again) 
found tubal patency in 28/30 (93%) of women, subsequent intrauterine pregnancy in 21/24 
(88%), and repeat ectopic pregnancy in 1/24 (4%).
185
 
 
EXPECTANT MANAGEMENT HARMS 
Expectant management versus salpingectomy or salpingotomy: The retrospective cohort 
study did not report on harms. 
182
  
Expectant management versus methotrexate: We found no RCTs or observational studies 
of sufficient quality.  
Expectant management in studies with no control group: The meta-analysis reported that 
2.5% of women had a tubal rupture in one of the cohort studies. 
184
 The two cohort studies 
did not report on harms. 
166;185
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COMMENTS ON EXPECTANT MANAGEMENT EVIDENCE: Expectant management 
was confined to a selected subgroup of unruptured ectopic pregnancies. We found no RCTs 
that compared expectant management with laparoscopic surgery or systemic methotrexate. 
Data for expectant management are derived from retrospective studies with different 
inclusion criteria (e.g. ectopic size, serum βhCG, presence of fetal cardiac activity) that 
contribute to methodological bias and preclude effective statistical comparison. There is 
limited evidence that expectant management has similar primary treatment success and future 
fertility outcomes to surgically treated ectopic pregnancy.  
Clinical guide on expectant management Cases considered suitable for expectant 
management should conform to strict criteria: non-invasive diagnosis of ectopic pregnancy, 
unruptured ectopic, woman is haemodynamically stable, less than 100 mL of fluid in Pouch 
of Douglas, initial βhCG is below 1000 IU/L (when the success rate increases to 80% 184 ), 
consecutive serial serum hCG levels show spontaneous decline, no worsening of symptoms 
(especially abdominal pain, vaginal bleeding) during this interval, and woman understands 
the need for ongoing surveillance. 
167
These factors have been verified as favourable 
prognostic signs in observational studies. 
184
Prospective and retrospective observational 
studies have shown that low serum progesterone (< 20 nmol/L) and increased rate of βhCG 
decline to be important predictor of successful expectant management in pregnancies of 
unknown location. 
144;186-189
 . There is no quantifiable harm in expectant management as 
intervention is absent. However, harm would arise should primary treatment fail or tubal 
rupture ensues. Expectant management necessitates regular surveillance until normalisation 
of clinical, ultrasound, and hCG variables. The risks of tubal rupture and persistent 
trophoblast remain despite adequately declining serum hCG concentrations. Tubal rupture 
has been reported with serum hCG levels below 50 IU/L.190;191 
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TREATMENT OPTION: SALPINGOTOMY 
Treatment failure (persistent trophoblast) 
Salpingotomy by laparoscopy compared with salpingotomy by laparotomy: Salpingotomy by 
laparoscopy is less effective at increasing primary treatment success rates compared with 
salpingotomy by laparotomy.                    (high quality evidence) 
Compared with salpingectomy: Salpingotomy may be less effective at reducing initial 
treatment failure rates compared with salpingectomy        (moderate quality evidence) 
Compared with single or multiple dose methotrexate Salpingotomy is no different at 
increasing primary treatment success rates compared with single or multiple dose 
methotrexate                                                                                  (moderate quality evidence) 
Subsequent pregnancy rates 
Salpingotomy by laparoscopy compared with salpingotomy by laparotomy: Salpingotomy by 
laparoscopy is as effective at increasing tubal patencies, subsequent intrauterine pregnancy 
rates, and decreasing subsequent ectopic pregnancies compared with salpingotomy by 
laparotomy.                      (high quality evidence) 
Compared with salpingectomy: We don't know whether salpingotomy may result in lower 
rates of subsequent intrauterine pregnancies or recurrent ectopic pregnancies compared with 
salpingectomy.              (very low quality evidence) 
Compared with expectant management: Salpingotomy may be no more effective at increasing 
subsequent pregnancy rates in women with ectopic pregnancies compared with expectant 
management.               (very low quality evidence) 
Compared with single or multiple dose methotrexate: Salpingotomy by laparoscopy is no 
different at increasing tubal patency, subsequent intrauterine or ectopic pregancy rates in 
women with small unruptured tubal pregnancies compared with single dose methotrexate. 
                  (high quality evidence) 
 
SALPINGOTOMY BENEFITS 
Salpingotomy (via laparoscopy) versus salpingotomy (via laparotomy):  
We found one systematic review (search date 2004, 3 RCTs, 228 women haemodynamically 
stable women with a small unruptured tubal pregnancy) that compared laparoscopic 
salpingotomy with laparotomy salpingotomy (see Table 4.11). 
150
 It found that significantly 
fewer women have primary treatment success with salpingotomy by laparoscopy compared 
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with salpingotomy by laparotomy (see Table 4.11) due to a higher rate of persistent 
trophoblast (RR 3.6, 95% CI 0.63 to 21), but found no difference in tubal patency (see Table 
4.11). In those women desiring future fertility (145/228 [64%]), there was no significant 
difference between salpingotomy by laparoscopy and salpingotomy by laparotomy in 
intrauterine pregnancy rate and rate of repeat ectopic pregnancies (see Table 4.11).  
Salpingotomy versus salpingectomy: See benefits of salpingectomy. 
Salpingotomy versus expectant management: See benefits of expectant management.  
 
SALPINGOTOMY HARMS 
Salpingotomy (by laparoscopy) versus salpingotomy (by laparotomy): The systematic 
review gave no information on adverse effects.
150
 
Salpingotomy versus salpingectomy: See harms of salpingectomy.  
Salpingotomy versus expectant management: We found no RCTs or observational studies 
of sufficient quality.  
COMMENTS ON SALPINGOTOMY EVIDENCE: 
The surgeon‘s preference and operative experience, as well as patient related factors (e.g. 
obesity, previous abdominal surgery, known pelvic adhesions, haemodynamic instability) 
dictates whether laparoscopy or laparotomy is preferred. These confounding factors may lead 
to an overestimation of laparotomy related complications in high operative risk groups.
192
 See 
also comment on salpingectomy. 
Laparoscopy or laparotomy surgical treatment of ectopic pregnancy  Evaluation of these 
trials showed that laparoscopy compared with laparotomy treatment of ectopic pregnancy 
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incurs less blood loss and analgesic requirement, and has a shorter duration of operation time, 
hospital stay, and convalescence time.
150
 A reduced prevalence of pelvic adhesions has been 
suggested as a mechanism for the potential higher future fertility rate observed with 
laparoscopy compared to laparotomy. 
193;194
 A multicentre observational study reported major 
surgical complication rates of 2.7/1000 for diagnostic laparoscopic procedures, and 17.9/1000 
for operative laparoscopy.
195
 The major complications arise following laparoscopic bowel 
(0.4-0.7/1000 cases) and major vessel (0.2/1000 cases) injury.
196
 Apart from possible 
differences in primary treatment success and future fertility, there are no additional maternal 
harms between laparoscopic salpingotomy and laparoscopic salpingectomy. 
 
TREATMENT OPTION: METHOTREXATE (SYSTEMIC) PLUS MIFEPRISTONE 
Treatment failure 
Compared with methotrexate alone: Methotrexate plus mifepristone is no more effective at 
increasing treatment success rates compared with methotrexate alone but it seems this 
combination may be more effective in increasing treatment success rates in women with high 
levels of progesterone.           (moderate quality evidence) 
 
METHOTREXATE (SYSTEMIC) PLUS MIFEPRISTONE BENEFITS 
Systemic methotrexate plus mifepristone versus systemic methotrexate alone: 
One RCT found no significant difference between methotrexate plus mifepristone and 
methotrexate in the number of women who had initial treatment success (22/25 [88.0%] v 
18/25 [72.0%]; OR 2.85, 95% CI 0.54 to 19.17). 
197
  However, the median time to resolution 
of the ectopic pregnancy was quicker with the combined treatment (14 days v 21 days; 
significance assessment not reported). A second RCT also found no significant difference 
between methotrexate plus mifepristone and methotrexate in the number of women who had 
initial treatment success (90/113 [79.7%] v 72/97 [74.0%]; RR 1.07, 95% CI 0.92 to 1.25). 
198
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For women with higher levels of progesterone (greater than or equal to 10nmol/L), it found 
that treatment success was significantly more successful with the combined treatment than 
with methotrexate alone (15/18 [83.3%] v 5/13 [38.5%]; RR 2.16, 95% CI 1.06 to 4.44). One 
prospective cohort study found that there were less treatment failures with methotrexate plus 
mifepristone compared with methotrexate alone (1/30 [3.3%] with methotrexate plus 
mifepristone v 11/42 [26.2%] with methotrexate). 
199
 
METHOTREXATE (SYSTEMIC) PLUS MIFEPRISTONE HARMS 
Systemic methotrexate plus mifepristone versus systemic methotrexate alone: 
The first RCT found that two women in each group reported mild nausea. 
197
 The second 
RCT found the same rate of gastritis in both groups (34/113 [30.1%] v 30/99 [30.3%]; P = 
1.00). 
198
  The cohort study gave no information on adverse effects. 
199
 
COMMENTS ON EVIDENCE: See comment under methotrexate. 
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4. 3. Laparoscopic entry techniques: clinical guideline, national survey and 
medicolegal ramifications 
 
INTRODUCTION Although complications associated with laparoscopic surgery are 
fortunately rare, a significant proportion of these occur at the time of laparoscopic abdominal 
wall entry 
208-233
.Meta-analyses and large multicentre centre studies have provided pooled 
risks of vascular and bowel injury at the time of laparoscopic entry as 0.2 per 1000 and 0.4 
per 1000 respectively 
208;226;234-245
. Such complications may incur serious morbidity and 
mortality, and this is compounded if such injuries are not detected at the time of original 
surgery, particularly in the case of bowel injury 
208;212;246-254
. 
Two laparoscopic entry methods are principally used in gynaecology and general surgery 
respectively: 
 Closed entry and creation of a pneumoperitoneum at the umbilicus (or Palmer‘s 
point). 
 Open laparoscopy (Hasson) 255-257. 
Other techniques, used less frequently and with limited supporting evidence
213
, are direct  
entry 
258-266
, optical access trocars 
267-277
 and radially expanding trocars 
278-283
.  
On current evidence, mainly based on observational studies, no one laparoscopic entry 
method has demonstrated clear superiority over another. This has led to wide variation 
amongst clinicians as to which entry method should be recommended 
213;284;285
. It has been 
suggested that open (Hasson)  entry is superior as vascular injury is less likely to occur 
compared to closed entry techniques 
235;239;256;257;264;284;286-296
, although this viewpoint has 
been challenged 
235
.  
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There is significant variation in laparoscopic entry practice in the UK 
297-300
 and International  
locations 
234;301;302
. In an attempt to minimise the risks of laparoscopy and unify clinical 
practice, several international bodies [International Middlesbrough Consensus 
303
, RCOG 
(draft version only)
304
 , SOGC 
285
, RANZCOG 
305
, EAES 
306
, SAGES 
307
, French society of 
Endoscopic Gynecology 
308
, Netherlands 
309
] and experts 
310-312
 have recommended specific 
―safe laparoscopic entry‖ principles. In fact, several small-sized studies 313-315 have shown 
that adopting a recommended technique 
285;303
 can reduce the incidence of laparoscopic entry 
related complications.  
We wanted to evaluate the status of gynaecological laparoscopic entry in the UK, bearing in 
mind that litigated cases normally consider both what should be (published 
recommendations) and what is (questionnaire enquiries) occurring in clinical practice. To 
achieve this we planned to:  
1. Establish evidence based criteria for safe laparoscopic entry through a systematic 
literature search and critical appraisal of the literature. 
2. Currently identify what laparoscopic entry techniques are used in the UK, and explore 
any factors that may influence the preference for a particular technique. This was 
determined through a UK wide questionnaire survey. 
3. Identify the current judicial viewpoint on laparoscopic entry injuries from the published 
literature. 
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METHODS 
Establish criteria for safe laparoscopic entry: Electronic searches were performed in 
MEDLINE (Ovid version 1996-December 2007), EMBASE (Ovid version 1996-December 
2007) using relevant combinations of medical subject headings (laparoscopy; gynecological 
surgical procedures; intraoperative complications; postoperative complications; 
pneumoperitoneum, artificial; malpractice; risk assessment; legal liability; judicial role; 
jurisprudence) and text words. International guidelines were identified by interrogating 
specialised electronic repositories (e.g. national guideline clearinghouse, national electronic 
library for health, OMNI, TRIP database, E guidelines and GFMER databases) and searching 
national Collegiate (e.g. RCOG, ACOG, RANZCOG, SOGC) and specialist international 
laparoscopy organisation websites (e.g. AAGL, SLS, ISGE, BSGE, SAGES, EAES, 
ASERNIP-S). Literature was critically appraised according to established evidence-based 
criteria [see Scottish Intercollegiate Guidelines Network (SIGN) recommendations Table 4.ii-
4iv 
7;316
] to generate a list of key steps necessary for safe laparoscopic entry (see Table 4.v 
and 4.12).  For each step, we denoted a level of evidence and grade of recommendation and 
discussed their derivation from the supporting literature. 
 
Chapter 4.3. Safe Laparoscopic entry 
307 
 
Table 4.12:  Evidence-based criteria for safe laparoscopic entry: 10 steps 
Step Intervention 
Level of evidence and 
Grade of 
recommendation  
Supporting 
references 
1 
Suitability criteria: Consider alternative to close umbilical entry 
(e.g. Palmer‘s point or open (Hasson) technique) in patients with 
risk factors such as: previous abdominal surgery; obesity, 
extremely thin or known abdominal adhesions. 
2++, B Adhesion risks: 
 
324-344
 
2 
Safety Criteria: Patient should be lying flat with an empty 
bladder. Palpation for the abdominal aorta, any masses and check 
Veress needle for spring action and gas patency. 
4, GPP  
3 
Incision: 10mm vertical intra-umbilical incision starting deep 
inside the umbilicus pit extending caudally.  
4, GPP  
4 
Insertion of Veress: At the deep umbilical pit, at 90º to the skin, 
with or without stabilising or elevating the umbilical sheath/fascia 
or anterior abdominal wall,  and in a controlled manner with 
insertion of less than 2cm of the Veress needle tip 
2+, 2-, C 
(Indirect evidence from 
knowledge of abdominal 
anatomy) 
258;317-319;351-355
 
5 
No movement of the Veress needle following insertion - avoid 
converting a possible needlepoint injury into a large complex tear 
4, GPP  
6 
Safety Abdominal pressure check of Veress placement: Most 
reliably achieved by using a Veress Intra-Abdominal Pressure 
(IAP) of less than 10mmHg.  
2+, C 
315;356-358
 
7 
Safety Abdominal pressure check for Primary trocar: The 
intra-abdominal pressure should be 25mmHg to achieve the 
maximum safe distance between anterior abdominal wall and 
underlying abdominal contents. 
2+, C 
315;359-363
 
8 
Vertical Primary Trocar insertion: 
Inserted in a controlled two-handed screwing manner, vertically at 
90° to the skin, with only the tip of the trocar inserted through the 
abdominal wall.   
2+, C 
317-319;351-353
 
9 
Injury check: An initial 360º laparoscopic check for intra-
peritoneal organ injury is performed 
4, GPP  
10 
No Epigastric for Secondary trocar(s) insertion 
Inserted under direct vision in a controlled two-handed manner at 
90° to the skin, avoiding inferior Epigastric vessels. 
2+, C 
(Indirect evidence from 
knowledge of abdominal 
anatomy) 
364-368
. 
Footnotes:We suggest an acronym, SCIIN  SAVE SAVING, for the 10 steps: Suitability, Criteria, Incision, 
Insertion, No movement, Safety Abdominal VEress, Safety Abdominal pressure (Trocar), Vertical trocar, Injury 
check, No epiGastrics. 
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Questionnaire survey: The questionnaire was developed in collaboration with the 
British Society of Gynaecological Endoscopy (BSGE) which recorded:  
1. Clinician grade 
2. Method of entry in the uncomplicated woman and the high-risk woman (defined as any 
woman with previous suprapubic or midline laparotomy, very thin or obese)   
3. Angle of entry for Veress needle and primary trocar 
4. Criteria used to test for correct placement of Veress and adequacy of CO2 
pneumoperitoneum prior to primary trocar insertion.   
5. Whether the clinician routinely inspected the abdomen for laparoscopic injury at the 
beginning or end of the laparoscopy procedure  
6. Whether the clinician had experienced (personally or through witnessing) any 
laparoscopic entry-related bowel or vascular injury. 
7. Awareness of Middlesbrough Consensus and RCOG sourced information on 
recommended laparoscopic entry practice. 
In contrast to previous questionnaire studies, we wished to compare practice amongst trainee 
grades as well as consultant specialists. The study population comprised of three groups. 
1. Registered BSGE members at May 2006. The questionnaire (and pre-paid postage reply 
envelope) was included in the BSGE May 2006 quarterly newsletter, which was sent to all 
180 registered BSGE members. 
2. Specialist Registrar trainees. The questionnaire was distributed to all trainees who 
attended regional study days at Birmingham Women‘s Hospital, UK.  
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3. Attendees at the joint RCOG/BSGE conference held on Friday 8th December 2006 at 
Royal College of Obstetricians and Gynaecologists, London, UK where a questionnaire 
through an electronic-audience participation format was used. Audience members responded 
through handheld devices and instantaneous feedback on the entire audience was 
electronically displayed after each question.  
RESULTS 
A. Evidence based criteria for safe laparoscopic entry  
 
The original systematic literature review identified 276 primary studies relating to 
laparoscopic techniques and complications, 21 secondary studies (13 meta-analyses and 8 
clinical guidelines) and 12 citations relating to medicolegal aspects of laparoscopy entry 
related complications. A further 17 relevant citations were identified through the bibliography 
of primary and secondary (clinical guidelines, reviews) studies. Through a process of critical 
appraisal of the literature a 10 step evidence-based criteria for safe closed umbilical 
laparoscopic entry was constructed and shown in Table 4.12. The level of evidence 
justifying each step is outlined below. 
Suitability criteria (Step 1):  Women who are extremely thin 
317-319
 or obese 
320-323
 or known 
to have abdominal adhesions are at increased risk of laparoscopic entry related injury at the 
umbilical entry point. The estimated risks of umbilical and/or anterior abdominal wall 
adhesions in women with no prior laparoscopic surgery, previous suprapubic laparotomy and 
previous midline laparotomy are 0-5%, 20%-30% and 50-65%, respectively 
324-344
.  
Prospective observational studies suggest the risk of laparoscopic entry related injury may be 
considerably reduced by adopting alternative entry (e.g. left upper quadrant Palmer‘s point or 
open Hasson technique) in women with such risk factors.  However, the actual relative risk 
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reduction is not quantified as the studies have no comparator. Left upper quadrant Palmer‘s 
laparoscopic entry could also be considered if there has been failure to achieve 
pneumoperitoneum at the umbilicus. Of significance, there is limited evidence that testing for 
reduced (<1cm) visceral slide (ultrasound-visualised movement of the underlying bowel or 
omentum) may be helpful in detecting sub-umbilical adhesions, thereby allowing 
consideration of an alternative laparoscopic entry strategy 
345-350
.    
Supine patient positioning, safety checks and umbilical incision (Steps 2 and 3): Reliable 
data on appropriate patient positioning and location/type of umbilical incision were not 
identified. Consequently, we suggest the patient should be laid flat at commencement of 
laparoscopy to avoid the theoretical risk that ―pelvic‖ bowel being displaced towards the 
umbilicus, thereby exposing the bowel to entry related injury. On a similar stance, adopting 
an alternative entry technique is advisable if a prominent abdominal aorta pulsation is 
identified in close proximity to the undersurface of the umbilicus.  Current consensus among 
clinicians is for a 10mm vertical intra-umbilical incision extending caudally. 
 
Controlled vertical (90 degree) Veress needle entry (Steps 4 and 5):  There are no 
comparative studies assessing the optimum angle of Veress needle entry. The fusion of the 
parietal peritoneum and linea alba at the pit of the umbilicus logically dictates that a vertical 
(90 degree to the horizontal abdomen) Veress insertion represents the shortest skin-to-
peritoneum anatomical distance to enable direct peritoneal entry. According to CT abdominal 
mapping 
317;318;351
 and actual laparoscopy 
319;352;353
, this skin-to-peritoneum distance at the 
umbilical pit is consistently no greater than 2cm, irrespective of abdominal obesity. 
Nevertheless,  it has been suggested that the Veress angle of entry should vary (45 degrees in 
non-obese women and 90 degrees in obese women) as CT abdominal imaging 
318
, and 
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visualisation at laparoscopy 
319
, has shown that the location of the underlying aortic 
bifurcation (which may be prone to Veress injury) tends to be directly under or 2-3cm caudal 
to the umbilicus in non-obese and obese women, respectively. The umbilicus pit (and 
underlying parietal peritoneum) may also be stabilised and/or successfully elevated away 
(either by grasping the lower abdominal wall or by applying tissue forceps/towel clips within 
2cm from the umbilicus) from underlying abdominal viscera during Veress insertion 
258;353-
355
. However, a reasonable summary of the indirect evidence stated is that, traversing the 
thinnest portion of the abdomen by controlled 90 degree vertical entry, with insertion of no 
greater than 2cm of the Veress needle tip, with selective umbilical stabilisation/elevation, is 
likely to be safest route of Veress insertion for the vast majority of women, regardless of any 
caudal displacement of their umbilicus. 
 
Less than 10mmHg IAP safety test for correct Veress placement (Step 6): A variety of 
safety tests for correct intra-peritoneal placement of the Veress needle are employed in 
clinical practice, and include: double-click, aspiration, and hanging drop tests. Prospective 
studies in women undergoing laparoscopy have shown that a Veress intra-abdominal pressure 
(IAP) less than, or equal to, 10 mm Hg, reliably indicates correct Veress placement at 
umbilical 
315;356;357
 and Palmer‘s point entry 358 locations. The Veress IAP pressure correlates 
positively with the weight and BMI and negatively with the parity of women 
357
. 
 
Controlled vertical (90 degree) primary trocar insertion at 25mmHg IAP (Steps 7, 8, 9): 
Prospective observational studies have shown higher intra-abdominal CO2 insufflated 
pressures achieve greater anterior abdominal wall splinting and intra-abdominal CO2 gas 
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bubble space 
315;359-361
. An IAP of 25mmHg has been shown to achieve a maximum safe 
distance between anterior abdominal wall and underlying abdominal contents, without 
compromising cardio-respiratory function 
362;363
. A two-handed screwing manner controlled 
vertical (90 degree) entry of only the primary trocar tip utilises the safe CO2 bubble depth 
afforded through an IAP of 25mmHg and is highly unlikely to injure underlying vessels 
based on actual laparoscopy 
319;352;353
 and abdominal vasculature CT mapping studies 
317;318;351
.  Although there is no direct supporting evidence, an initial check for bowel and 
vascular injury, immediately after primary trocar insertion, is recommended to avoid missing 
this complication and exposing the women to serious morbidity. 
Controlled insertion of secondary trocars under direct vision (Step 10):   Epigastric 
vessels can be reliably identified through a combination of direct visualisation [vessels lie 1-2 
cm lateral to the medial umbilical ligaments (obliterated umbilical arteries)], 
transillumination and external anatomical landmarks 
364-368
. In most women, a useful and safe 
point of insertion is 2 cm from the anterior superior iliac crest along an imaginary line 
connecting the iliac crest to the umbilicus.  The controlled insertion, at a 90 degree angle to 
the skin, using a two-handed screwing manner of the secondary trocar (analogous to that used 
to insert the primary trocar), should be observed under direct vision to ensure no inadvertent 
injury of abdominal organs. 
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B. Questionnaire survey 
 
There was a 62% (n=112) response rate from the postal questionnaire, and 100% response 
rates from SpR registrars (n=82) and attendees at the RCOG/BSGE meeting (n=32). Analysis 
was performed on all 226 total respondents. 
Entry technique in uncomplicated vs. high risk women: The vast majority would perform 
a closed umbilical laparoscopic entry in uncomplicated women and a Hasson or Palmer‘s 
point entry in women with previous midline laparotomy (Table 4.13).  However, there was 
inconsistency when selecting entry technique in women with previous suprapubic 
laparotomy, obesity, or who were extremely thin (Table 4.13). 
Veress and primary trocar entry: Only 18% would use the recommended 90º/90º Veress 
and primary trocar entry method (Table 4.14). Safety checks performed to ensure correct 
Veress placement and prior to primary trocar insertion are depicted in Tables 4.15 and 4.16, 
respectively. The proportion of respondents aware of evidence-based guidance, or who have 
previous experience of laparoscopic injury, is depicted in Table 4.17. 
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Table 4.13 Laparoscopic entry technique in uncomplicated vs.  high-risk women 
  
Veress entry technique Uncomplicat
ed women 
High risk women 
Women 
with 
Previous 
Suprapubi
c 
laparotomy 
Women 
with 
previous 
midline 
laparotom
y 
Women 
with obesity 
Women 
who are 
extremely 
thin 
Closed umbilical (umb.) 213 (94%) 193 (85%) 37 (16%) 179 (79%) 189 (84%) 
Open (Hasson)  5 (2%) 14 (6%) 49 (22%) 13 (6%) 15 (7%) 
Palmer's point 1 (<1%) 8 (4%) 102 (45%) 4 (2%) 2 (<1%) 
Suprapubic point 3 (1%) 1 (<1%) 4 (2%) 9 (4%) 6 (3%) 
Direct entry 3 (1%) 2 (<1%) 0 3 (1%) 2 (<1%) 
transvaginal culdoscopy  1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 
Closed umb.  or suprapubic 0 0 1 (<1%) 4 (2%) 1 (<1%) 
Hasson or Palmer's 0 3 (1%) 23 (10%) 0 1 (<1%) 
Closed umb. or Palmer's 0 2 (<1%) 5 (2%) 0 4 (2%) 
Closed umb. or Hasson or 
Palmer‘s 
0 0 3 (1%) 1 (<1%) 0 
Closed umb. or Hasson  0 2 (<1%) 1 (<1%) 9 (4%) 6 (3%) 
 
Footnotes 
Umb. Refers to umbilical 
Direct entry would be gasless direct primary trocar abdominal entry and would not utilise 
Veress. 
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Table 4.14 Frequency of angle of entry for Veress and Primary Trocar 
 
  Angle of Primary Trocar entry [Count] Total 
  90  60  45  30  Z angle 
b
   
Angle of 
Veress 
entry 
[Count] 
90  40 
(18%) 
28 
(12%) 
24 
(11%) 
1 1 94 
60  6 34 
(15%) 
9 0 2 51 
45  1 11 57 
(25%) 
1 3 73 
30  0 1 1 0 0 2 
Not used 
a
 3 1 1 1 0 6 
Total 50 75 92 3 6 226 
 
Footnotes 
a 
Veress angle not determined as practitioner prefers to use either Hasson or direct entry 
method for insertion of primary trocar. 
b
 Z angle system corresponds to initial shallow angle <30 then a steeper angle >60. 
The five most frequent Veress/Primary trocar combinations are shaded in grey and bolded 
font. 
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Table 4.15. Safety checks performed to ensure correct Veress placement 
 
TESTS  SpR 1-3 
n=63 
Count 
SpR 4-5 
n=41 
Count 
Consultant 
n=122 
Count 
Total 
Count (%) 
Pressure & saline aspiration & two Veress clicks  14 11 28 53 (23%) 
Pressure & saline aspiration 13 11 24 48 (21%) 
Saline aspiration 20 6 10 36 (16%) 
Pressure & two Veress clicks 6 5 21 32 (14%) 
Pressure  3 4 14 21 (9%) 
Saline aspiration & two Veress clicks 6 1 4 11 (5%) 
Pressure & freely moving Veress & two Veress 
clicks  
0 0 7 7 (3%) 
Two Veress clicks 1 1 3 5 (2%) 
Freely moving Veress & two Veress clicks 0 1 2 3 (1%) 
Pressure and freely moving Veress 0 0 3 3 (1%) 
Freely moving Veress 0 0 2 2 (<1%) 
Not use Veress  0 1 4 5 (2%) 
 
Footnotes 
Pressure refers to pre-insufflation intra-abdominal pressure recorded as below 8mmHg 
Two Veress clicks refers to the audible or tactile impression of two Veress clicks on 
abdominal insertion 
Saline aspiration refers to the four-component saline aspiration, injection, aspiration, drop test 
commonly known as Palmer‘s test. 
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Table 4.16. Safety checks performed prior to primary trocar insertion 
 
TESTS SpR 1-3 SpR 4-5 Consultan
t 
Total 
Count (%) 
IAP 25mmHg 29 22 48 99 (44%) 
Distension and  IAP 25mmHg 20 6 14 40 (18%) 
Distension and IAP 12-15mmHg 4 0 21 25 (11%) 
Distension 2 4 13 19 (8%) 
IAP 12-15mmHg 4 4 8 16 (7%) 
Distension,   >3L CO2 , IAP 12-15mmHg 1 3 6 10 (4%) 
Distension,   >3L CO2, IAP 25mmHg 2 2 6 10 (4%) 
Distension, >3L CO2 0 0 5 5 (2%) 
CO2 >3 litres  1 0 1 2 (<1%) 
 
Footnotes 
IAP refers to intra-abdominal pressure 
Distension refers to clinical abdominal wall distension 
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Table 4.17. Awareness of evidence-based guidance and previous experience of 
laparoscopic injury  
 
 SpR 1-3 
n=63 
Count 
SpR 4-5 
n=41 
Count 
a 
Consultant 
n=122 
Count 
Total 
n=226 
Count (%) 
Awareness of Middlesbrough Consensus  
Yes 
 
27 
 
22 
 
100 
 
149 (66%) 
No 36 19 22 77 (34%) 
Awareness of RCOG Guidance  
Yes 
 
55 
 
33 
 
90 
 
178 (79%) 
No 8 8 32 48 (21%) 
Previous experience laparoscopic injury  
Yes, bowel injury 
 
14 
 
13 
 
57 
 
84 (37%) 
Yes, vascular injury 7 4 7 18 (8%) 
Yes, both vascular and bowel injury 4 5 32 41 (18%) 
No 38 19 26 83 (37%) 
Routine Inspection of abdomen  
Yes 
 
48 
 
38 
 
110 
 
196 (87%) 
No 15 3 12 30 (13%) 
 
 
Footnotes 
a 
Consultant category includes 4 Staff Grades, 5 Associate Specialists and 113 Consultants.  
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C. Medico-legal ramifications  
 
The civil standard of law is used in UK medico-legal litigation. This means it is the 
responsibility of the claimant (woman patient) to prove that, it is more likely than not (greater 
than 51% probability), that the injury she incurred arose through a negligently performed 
rather than non-negligently performed surgical technique by the defendant (Surgeon). 
Laparoscopic entry related complications have contributed significantly to medical litigation 
in gynaecological surgery 
233;247;248;369-376
. Until recently, there had been inconsistency in the 
judicial viewpoint in awarding negligent or non-negligent verdicts. However, the case of 
Palmer v Cardiff & Vale NHS Trust 
377
 has now set judicial guidance in this area. The court 
ruled that the likelihood of laparoscopic related bowel injury occurring in an uncomplicated 
case if there had been good surgical technique, was highly unlikely. If there was no 
alternative plausible non-negligent explanation for the complication then the defendant was 
liable - complying with the legal maxim res ipsa loquitir (―the thing speaks for itself‖). This 
overruled the defendant‘s viewpoint that injury was a recognized complication of 
laparoscopy and therefore its occurrence was not proof of negligence per se. The judicial 
guidance accepted that given a woman without risk factors, and a surgeon following a safe 
technique (i.e. correctly inserting Veress needle, it‘s position checked, insufflation of the 
peritoneal cavity to 25mmHg, controlled insertion of the primary trocar with penetration of 
the cavity by just the trocar tip), then the risk of injury was highly improbable. Thus the 
occurrence of any injury under these circumstances would imply a negligent technique. 
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Discussion 
 
Based on our systematic literature search, critical appraisal of the published literature and 
available guidelines, we have constructed a ten step evidence based guideline necessary for 
safe closed laparoscopic entry. Our findings are analogous to Semm‘s original 11 safety steps 
312
.  However, we have updated these steps in line with current evidence-based literature and 
have ascribed the level of evidence to each step supported by the literature citation(s) for that 
step. We feel that these 10 steps represent the current most up to date evidence to enable 
clinicians to practice safe closed laparoscopic entry (Table 4.12). 
Our national questionnaire study revealed considerable heterogeneity in laparoscopic entry 
practice despite widespread awareness of the Middlesbrough Consensus or RCOG sourced 
guidance. The inconsistency was inherent throughout every step of the laparoscopic entry 
procedure, and has been identified by previous UK based surveys 
297-300
. Fundamentally, 
there was a failure to appreciate risk factors that would justify a change in entry technique, as 
well as not adopting the correct safety checks following Veress insertion and prior to primary 
trocar insertion. Even if there was authoritative guidance on safe laparoscopic entry technique 
it is unclear how many practitioners would actually change their clinical practice accordingly.  
However an Australian based questionnaire study suggests that this would be supported by 
the majority of minimally invasive surgeons 
301
.  
We acknowledge that we have a limited sample size and have surveyed a highly selected 
group. On one hand it is reassuring that we have shown no real differences between trainees 
and specialists. However, it is of great concern that even in the ―expert‖ specialist group there 
is such a wide variation in entry technique.  It is possible that a survey of general 
gynaecologists may identify an even wider and more alarming variation in practice. 
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We strongly feel that safe laparoscopic entry guidance should be disseminated widely such as 
the 10 steps shown in Table 4.12.  However, we accept that following such guidance would 
not necessarily negate the risk of laparoscopic entry related injury nor would it protect the 
clinician against any negligent ruling should a complication occur. We believe that written 
guidance should be reinforced through simulated training 
378;379
, structured formal assessment 
and consistent clinical direction by specialists. Unless practice concurs with recommended 
guidance, women undergoing laparoscopy will be exposed to increased unnecessary 
operative risk.   
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4.4.  Minimising the Risk of Sterilisation Failure-an evidence-based 
approach 
 
Introduction Female sterilization is one of the commonest procedures performed 
worldwide. In 1999 around 50,000 female sterilisations were performed in England in the 
NHS and charitable sectors 
380
 .  The procedure is performed on mainly healthy women at 
their request, and the intention is to occlude each fallopian tube. This may be achieved 
through tubal surgical excision, application of a mechanical device or electrocautery 
coagulation (Table 4.18). Where resources permit, the preference, and most widely 
established technique, is laparoscopic tubal occlusion, which has moreover replaced the 
earlier technique of performing female sterilisation via mini-laparotomy. In the UK, the 
RCOG 
380
 recommends that laparoscopic sterilisation should be performed using either 
Filshie clip or ring. Tubal excision and separation and related techniques (e.g. Pomeroy 
procedure) are preferred if sterilisation is performed at caesarean delivery.  
 
Hysteroscopic sterilisation may be considered a non-incisional, non-surgical form of 
permanent contraception, and is a promising alternative to laparoscopic tubal occlusion. The 
procedure involves the insertion of a small flexible titanium microinsert into each of the 
fallopian tubes through the cervix using a guidewire and a hysteroscope (ESSURE®, 
Conceptus Inc.).  The procedure is usually performed under local anaesthesia and/or 
intravenous sedation. Despite being licensed in the UK, NICE considers hysteroscopic 
sterilisation to still be under evaluation and should only be performed in accordance with 
specific NICE guidance (particularly on patient consent and coordinated follow up.
381
 This is 
mainly because there is insufficient evidence on long term efficacy (single case report of 
failure
382
 and tubal perforation
383
) and safety of hysteroscopic sterilisation, with the 
manufacturer reporting 99.8% effectiveness at preventing pregnancy at 2 year follow up 
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(http://www.essure.co.uk). 
384-386
Furthermore, there are no published randomised controlled 
trials comparing ESSURE directly with commonly used female tubal occlusion methods.
387
 
Table 4.18: Female surgical sterilisation techniques 
Method Techniques Comments 
Ligating tube with 
partial or complete 
tubal excision 
Pomeroy 
Fimbriectomy 
Salpingectomy 
Preferred option at  mini-
laparotomy, but laparoscopic 
salpingectomy is an alternative 
 
Mechanical occlusion 
of the tubal lumen 
Filshie clip 
Hulka-Clemens clip 
Falope ring  
Silastic ring 
Less of the tube is damaged 
increasing the chance of 
reversibility 
 
 
Coagulation induced 
tubal closure 
Unipolar diathermy 
Bipolar diathermy 
Not recommended as the first line 
method in the UK by the RCOG 
 
Hysteroscopic tubal 
occlusion 
Expanding metal tubal 
micro-insert implant 
(ESSURE) 
Licensed in UK and under 
evaluation. Guidance for usage in 
accordance to NICE.  
Virtually no possibility of reversal. 
Contraceptive precautions to 
continue for at least 3 months post 
procedure and X-Ray HSG 
confirmation of tubal occlusion 
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Rates of sterilisation failure  Conception occurring after sterilisation is termed 
sterilisation failure, and can occur several years after the procedure. Publications have 
reported differences in rates in sterilisation failure rates, even amongst the same sterilisation 
method. Such variation is due to differences in: the characteristics of the women undergoing 
sterilisation; operator experience; operating centre workload; sterilisation method chosen, and 
the time interval to resuming sexual activity post sterilisation and its frequency.
5
 
 
The two largest studies that have examined failed sterilisation have reported the ten-year 
cumulative probability of pregnancy of 18.5 per 1000 procedures  (US CREST study) 
388
 and 
8 per 1000 procedures (Canada) 
389
 . The reason for the lower sterilisation failure rate in the 
Canadian study compared to the US CREST study may be due to predominant use of the 
Filshie clip and incorporation of non-teaching hospitals in the Canadian dataset.  However, 
both studies were also significant in: 
 Utilizing the superior and preferred life table analysis method (cumulative probability of 
pregnancy at serial time intervals since sterilisation) for reporting sterilisation failure, 
rather than the less accurate crude failure or Pearl index outcomes that were reported by 
previous studies.  
 Obtaining follow up data for at least 5 to 15 years following the sterilisation 
This concept of cumulative risk of pregnancy is particularly important for those women 
sterilized at a young age (who will be exposed to a risk of pregnancy for a greater time 
period) and who have been sterilisation by methods of low short and long term efficacy 
(because such methods, over certain time frames, will acquire a greater percentage of total 
failures than other more effective methods). 
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Both US and Canadian dataset studies 
388;389
 validated this concept of cumulative risk of 
pregnancy. In the Canadian dataset 
389
 the cumulative probability of pregnancy increased 
from 0.3% at 1 year, to 0.7% by 5 years and 0.9% by 15 years.
389
  This is depicted in Figure 
1.  It is therefore important to quote women a 10 year risk of sterilisation failure, 
individualised to each method and patient age, when counselling them for the sterilisation 
procedure.  Bearing in mind that as long as a woman is fertile, and sexually active, she may 
continue to be at risk for sterilization failure.The RCOG has recommended a 10-year 
sterilisation failure rate of 2-3 per 1000 procedures be used for the Filshie clip method. 
However, this rate is predominantly drawn from a retrospective questionnaire study, of 5 year 
follow up, with an exaggerated denominator.
390
 Given this information, and considering the 
other reported Filshie clip studies (listed in Table 4.19), 2-3 per 1000 risk is more likely to 
correspond to the first year or even annual non-cumulated absolute risk of sterilisation failure.  
4.4 Preventing Sterilisation Failure 
326 
 
Table 4.19.  Filshie Clip: reported sterilisation failure rates  
Study Period 
data are 
collected 
from 
Sterilisations  
Performed 
Sterilisation 
method 
Outcome Type of  
study 
Peterson
388
 
US Collaborative 
review of 
Sterilisation 
(CREST) 
1978-1986 
 
10,685 
Filshie clip was 
not used- as it 
was not 
licensed in 
USA until 1996 
392
 
Various methods. 
Hulka spring clip 
(1595) 
Silicone Rubber 
band (3329) 
Overall 18.5 per 1000 
over 10 years 
Hulka 36.5 per 1000 
Silicone rubber band 
17.7 per 1000 
Prospective cohort 
multicentre 
Trussell 
389
 1980-1999 311,960 Mainly 
Laparoscopic 
Filshie clip  
 
8 per 1000 
[2496 failures] 
Retrospective 
multicentre  
Kovacs 
390
 1994-1998 30,000 
(estimate) 
All Filshie 2.4 per 1000 
[73 failures]
a
 
Retrospective 
multicentre 
Filshie 
424
 1982-1992 First 202 
responders 
from a series of 
434 
All Filshie 2.3 per 1000  
[1 failure at 6 months] 
Case series 
Birdsall 
415
 1988-1989 1094  Mainly 
Laparoscopic 
Filshie clip  
12 per 1000 at 12 
months 
b 
 
Case series 
Sokal 
423
 1984-1990 2746 Filshie clips vs. 
Rings 
[2 in each group 
became pregnant] 
1.7 per 1000 for both 
Ring and Filshie clip 
groups at 12 months 
RCT 
Dominik 
422
 1984-1990 2126 Filshie clips vs. 
Hulka clips 
[11 pregnancies 
occurred:  
9 Hulka, 2 Filshie] 
At 12 months 
1.1 per 1000 for Filshie 
Clip  
6.9 per 1000 for Hulka 
Clip group.  
At 24 months, 9.7 per 
1000 for Filshie and 
28.1 per 1000 for Hulka 
RCT 
Footnotes  
a
   Kovacs: Of the 73 failures, 14 cases were due to operator error, 29 were properly applied clips and 30 cases 
had unknown reason for failure   
b    
Birdsall: Registrars had a 1.3% failure rate, consultants 1.9% and when both a consultant and registrar 
performed the procedure a failure rate was 0.7%. Eighty-six percent (6/7) of failed sterilisations were due to 
operator error (wrong structure, initial non-occlusion). 
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Key factors [excluding operator error] identified to alter cumulative probability of 
pregnancy 
The failure rate for each sterilisation method tends to stabilize over the long term and may 
thus be represented as a constant lifetime risk of sterilisation failure (1 in 200 is quoted for 
the Filshie clip
380
). However, a more precise estimate would also be based upon her age at 
sterilisation and the subsequent number of fertile years during which she is at risk of 
pregnancy. The Canadian dataset 
389
 showed that  sterilisation of young women (< 30years of 
age) compared to older women (>35 years age) was associated with an overall increased 
absolute risk of pregnancy after sterilisation (1.5% vs. 0.4% ), and that this cumulative risk 
stabilized later in the younger age group. This is depicted in Figure 4.2. Multivariate 
regression analysis of the CREST study 
388
 showed the following factors were associated 
with an increased risk of sterilisation failure: 
 Sterilisation method used. Most effective were postpartum partial salpingectomy and 
laparoscopic unipolar coagulation at 7.5 pregnancies per 1000 procedures, but 
laparoscopic spring clip application had the highest risk of failure at 36.5 pregnancies per 
1000 procedures (see Figure 4.3) 
 Age at sterilisation. The probability of failure for women sterilized at ages <28 years is 
greater than that for women sterilized at ages >34 years for all methods of sterilization 
except interval partial salpingectomy. 
 Race-ethnicity. Black, non-Hispanic women were at significantly greater risk for 
sterilization failure than were white, non-Hispanic women. 
 Operating centre. Substantial differences in procedure specific failure rates between 
sites, likely representing variation in operator experience, requirements to teach juniors 
and volume of sterilisation operations. 
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Figure 4.2: Clinico-pathological mechanisms proposed in sterilisation failure based on 
Canadian dataset 
389
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Figure 4.3.  Cumulative risk of pregnancy by method from US CREST study 
388
 and 
Filshie clip references 
 
Years since 
sterilisation  
  
Cumulative risk of pregnancy per 1000 sterilisation procedures 
 
Bipolar Unipolar Silicone 
Band 
Hulka 
clip 
post partum 
salpingectomy 
Filshie 
clip 
(estimate 
only) 
1 2.3 0.7 5.9 18.2 0.6 2.5 
2 4.6 2.3 7.6 23.8 3.9 2.5 
3 6.7 2.3 8.3 29.1 4.6 2.5 
4 13.1 2.3 9 30.7 5.4 2.5 
5 16.5 2.3 10 31.7 6.3 2.5 
6 18.3 2.3 10 31.7 6.3 2.5 
7 20.7 2.3 13 31.7 6.3 2.5 
8 22 2.3 16.1 31.7 6.3 2.5 
9 23.3 4 16.1 34 7.5 2.5 
10 24.8 7.5 17.7 36.5 7.5 2.5 
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Notably, the US Crest study showed no statistically significant associations between risk of 
sterilisation failure and a history of pelvic inflammatory disease, history of previous 
abdominal or pelvic surgery, or presence of any adhesions recorded at sterilization. Although 
these factors have been assumed empirically by practitioners to affect the risk of sterilisation 
failure.  
Sterilisation failure and subsequent intrauterine or ectopic pregnancy 
Overall, for all sterilisation methods, studies have shown ectopic pregnancy may occur in  
4.3–76.0% of failed sterilisations.380 The relative risk of intrauterine to ectopic pregnancy 
occurrence in failed sterilisation varies according to the sterilisation method and time interval 
from the sterilisation procedure. Women who have been sterilized have a considerably lower 
absolute risk of an ectopic pregnancy compared to non-sterilised fertile women (as 
sterilisation protects against both intrauterine and ectopic pregnancies). However, should 
pregnancy occur, the relative risk of it being ectopic rather than intrauterine is higher in 
pregnant women who have been sterilized. Women should be counselled about such risks 
when deciding the method of sterilisation. 
 
There were 47 ectopic pregnancies in the 10,685 sterilised women in the US CREST study, 
which equates to a 10-year cumulative probability of ectopic pregnancy for all sterilisation 
methods combined of 7.3 per 1000 procedures. 
391
 Women sterilized by bipolar tubal 
coagulation before the age of 30 years had a probability of ectopic pregnancy that was 27 
times as high as that among women of similar age who underwent postpartum partial 
salpingectomy (31.9 vs. 1.2 ectopic pregnancies per 1000 procedures).
391
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Classification of causes of sterilisation failures: the role of operator error [negligent 
mechanism] 
The mechanism of failure should be identified through a systematic assessment of fallopian 
tube histology, X-ray hysterosalpingography and direct pelvic visual inspection. Neither of 
the major observational studies on sterilisation failure reported on  the underlying mechanism 
of sterilisation failure.
388;389
 Our systematic review identified only 81 cases in the world 
literature where the mechanism of sterilisation failure had been confirmed by such systematic 
methodology. 
5
 Sterilisation failure may be classified as arising from negligent or non-
negligent mechanisms, which may be dependent or independent of the sterilisation method 
utilised (Table 4.20).  If the mechanism of failure is due to ‗tubal non-occlusion‘ or ‗wrong 
structure sterilisation ‘, these are considered negligent mechanisms, whereas ‗spontaneous 
tubal recanalisation‘ or ‗fistula formation‘ mechanisms of failure are considered non-
negligent. 
Several studies have shown operator error to represent a significant (if not the major) cause of 
sterilisation failure. One summative review showed that the overall ten year failure rate for 
worldwide Filshie clip sterilisations was 0.56% in 10,000 women, but fell significantly to 
0.2% when cases caused by operator error were excluded.
392
 A questionnaire based study 
examining Filshie clip use in Australia showed of the 73 sterilisation failures from 30,000 
procedures, 14 were due to operator error, 30 unknown reason and 29 occurred in the 
presence of a ‗properly applied clip‘.390 Another study, which incorporated participants of the 
US CREST study, reported that all 20 sterilisation failures using spring clip and silicone 
rubber band arose to improper application of the occlusive devices.
393;394
 Of  the 81 
sterilisation failures reported in our systematic review of published literature 
5
, 57 cases were 
due to operator error ( wrong structured ‗sterilised‘ and initial tubal non-occlusion, ) and 24 
not due to operator error (fistula formation or recanalisation). We have recently published an 
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analysis of 131 cases of sterilisation failure, incorporating our systematic review, where 88 
were negligent and 43 non-negligent sterilisation failures (see Chapter 2 and reference 
395
). 
Table 4.20. Classification system for mechanism of sterilisation failure 
DEPENDENT ON THE STERILISATION METHOD 
Negligent 
Initial tubal non-occlusion (poor operator technique) e.g. slippage or overclosure of 
Filshie clip (see Figure 3). 
Wrong structured ‗sterilised‘  
Improperly maintained equipment (e.g. non-calibrated/serviced Filshie clip applicator) 
which contributed to initial tubal non-occlusion. 
 
Non negligent 
Initial tubal non-occlusion  (true method failure)- this is reported extremely rarely 
and occurs despite correctly applied technique 
the ends of the fallopian tube can reconnect spontaneously (recanalisation) 
a fistula can develop at the occluded portion of the tube 
INDEPENDENT OF THE STERILISATION METHOD* 
Already conceived in the cycle prior to sterilisation 
Or in the case of Filshie clip, conceives following sterilisation in the remainder of the 
menstrual cycle because the ovulatory ovum is proximal to tubal sterilisation point 
(luteal-phase pregnancy) 
Or in the case of Hysteroscopic sterilisation, conceives within the 3 month interval 
post sterilisation and/or prior to confirmation of effective sterilisation by HSG or 
ultrasound. 
*Most studies on sterilisation failure have excluded such pregnancies from their 
reported final analysis 
Mechanical tubal occlusive methods have lower rates of tuboperitoneal fistula formation than 
coagulation based techniques.
396-398
  This may be because mechanical occlusion methods 
destroy much less tube (approximately 4 mm for clips and 2 cm for rings) than 
electrocoagulation methods (3-4 cm).  However the exact aetiology of tubal lumen 
regeneration remains unclear. Other factors such as individual‘s tubal ‗healing‘ response, pre-
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existing proliferative tubal disease (e.g. endosalpingiosis), degree of tubal avascularity and 
interval from operation are likely to modify tubal lumen regeneration ability.
396;399-403
  
Presently there is no evidence to suggest that operator fault in sterilisation technique 
predisposes to tubal lumen regeneration, and therefore this mechanism of sterilisation failure 
would be considered to be non-negligent and independent of operator error. 
Medico legal consequences  The psychological and physical morbidity following failed 
sterilisation often leads to litigation.
404
 A gynaecologist has a duty to inform women of the 
risk of failure, to carry out the operation in accordance with accepted good medical practice 
and to avoid foreseeable complications. Women who have undergone sterilisation performed 
negligently are entitled to recover damages according to:  
 Wrongful conception: In addition, an action in contract may also arise if the sterilisation 
procedure was performed outside the NHS in the private sector. 
 Negligence: A breach of duty arises when an operation is not carried out in accordance 
with practice accepted as proper by a reasonable body of gynaecologists (Bolam test).  
Negligence also occurs when there is omission in appropriate pre-operative counselling.  
 Wrongful birth: The negligent act deprived the mother of the possibility to prevent the 
conception of a disabled child or to have a lawful abortion.  
Women are entitled to recover general damages for pain and suffering during pregnancy and 
delivery, and loss of earnings during pregnancy. A recent judgment in the Australian High 
Court 
405
  led the Australian government to amend the Civil Liberty Act to restrict the amount 
of damages that could be awarded in such situations. In the majority of failed sterilisation 
cases, even those in the advanced stages of litigation, the mechanism of failure remains 
unknown as there is no uniform requirement for such cases to undergo systematic enquiry or 
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to be reported to any supervisory national registry. The RCOG should consider this 
requirement at the time of the sterilisation guideline review in 2006. 
380
 Thus, a common 
scenario in the legal setting is to cast judgment on the likelihood of negligence or non-
negligence in cases with unknown mechanism of sterilisation failure. Based on pooling the 81 
cases of sterilisation failure with documented interval to pregnancy and mechanism of failure 
we proposed: 
That a greater proportion of early (within 12 months from operation) than late (after 12 
months from operation) sterilisation failures occurred by a negligent mechanism. Thus, the 
time interval to sterilisation failure may be predictive of negligence. In our recent publication 
of 131 cases of sterilisation failure
395
, we showed sterilisation failure occurred significantly 
earlier in negligent than non-negligent failure mechanisms (mean failure intervals 7.5 vs. 14.2 
months; Hazard Ratio 2.35 [95% CI 1.31-4.21]). 
Initial tubal non-occlusion is more likely to lead to early sterilisation failure (within one 
year), and as it is less likely to damage the tube, the resulting pregnancy is more likely to be 
intrauterine than ectopic. Conversely, late sterilisation failure arising from tubal re-
canalisation or fistula formation is more likely to result in an abnormal lumen predisposing to 
a decreased risk of pregnancy, but should it occur there would be an increased risk of ectopic 
pregnancy.  This is graphically illustrated in figure 1.   
Identification and assessment of evidence  
MEDLINE 1966-2006, the Cochrane library, 2006, Royal College of Obstetricians and 
Gynaecologists (RCOG, UK) were searched for relevant randomised controlled trials, 
systematic reviews, meta-analyses, and evidence-based guidelines relating to sterilisation. 
The searches were performed using the relevant MeSH terms including: sterilization, tubal; 
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sterilization; sterilization sexual; surgical instruments; electrocautery; cautery; liability, legal; 
jurisprudence; malpractice; medical errors; treatment failure; risk factors. The majority of 
publications were retrospective observational studies, case reports and reviews, with a 
paucity of prospective controlled trials or meta-analyses.
5;380;406
 The definitions of the types 
of evidence used in this chapter are as denoted in the RCOG Clinical Governance advice.
407
 
Where possible, recommendations on strategies to minimise sterilisation failure are annotated 
with the level of evidence that supports them (A, B, C or GPP) as indicated ( Table 4.2ii). 
Data generated was incorporated in our recently published systematic review in failed 
sterilisation 
5
 and utilised for this chapter to generate a best evidence based guideline 
6
. 
Clinical Guideline: Minimising the risks of sterilisation failure 
 
1. Patient Selection                    Level GPP 
There is limited evidence that pre-existing gynaecological pathology, in addition to 
increasing the technical difficulty of performing the sterilisation procedure, independently 
predisposes to sterilisation failure. Factors such as pre-existing tubal disease, history of 
abdominal or pelvic surgery, history of pelvic inflammatory disease previous ectopic 
pregnancy, pregnancy or post-partum state,, obesity, prior use of an intrauterine contraceptive 
device, previous induced abortion, congenital uterine anomalies, fibroids, endometriosis, 
endosalpingoblastosis and adenomyosis.
388;389;397;408-412
  The myth that sterilisation protects 
against pelvic inflammatory disease has recently been challenged.
413
 
2. Pre-sterilisation pregnancy testing and timing of sterilisation        Level C 
Both hysteroscopic and laparoscopic tubal occlusion may be performed at any time during 
the menstrual cycle provided that the clinician is certain that the woman has used effective 
contraception up until the day of the operation. It is recommended practice that all women 
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should have a urine pregnancy test prior to sterilisation. Routine pre-operative same day 
pregnancy testing has been shown to reduce the incidence of pregnancies discovered after the 
sterilisation procedure that have been falsely attributed to presumed negligent sterilisation 
procedure.
414
  However, such a test may still be falsely negative in a very early pregnancy. A 
serum hCG pre-operatively may be considered, however, if there is any doubt, then the 
sterilisation should be deferred until the follicular phase of a subsequent cycle.  
3. Pre-procedure contraception and the need to continue until onset of next menstrual 
cycle (reduce risk of luteal pregnancy)                 Level GPP 
Contraception is immediately effective if using the combined pill (if commenced between 
day 1 and day 5 of period) and Mirena IUS. However, with laparoscopic tubal occlusion, 
contraception is only likely to be completely effective by the onset of the next menses. 
Therefore, for this method, pre-procedure contraception measures should be continued until 
the onset of next menses to prevent ―luteal phase‖ pregnancy failure (Table 4.20). This is 
where sterilisation has occurred just after ovulation, and the ovum is already ‗proximal‘ to the 
tubal occlusion, enabling pregnancy to occur in this luteal phase through post sterilisation 
‗unprotected‘ intercourse. Studies have identified luteal pregnancy occurring in 0.32% to 
0.6% of sterilisation cases.
388;415;416
 Women selecting hysteroscopic sterilisation (ESSURE) 
need to continue with contraceptive precautions for at least three months post procedure and 
may resume ‗unprotected‘ sexual intercourse only after there is confirmation of satisfactory 
tubal occlusion (e.g. by X Ray hysterosalpingogram). 
4. Timing the operation - Interval preferred          Level B 
Wherever possible, tubal occlusion should be performed at an appropriate interval following 
pregnancy. Sterilisation can be performed in the immedate post-partum period (combined 
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with caesarean section or via minilaparotomy) or post-abortion.  However this period is 
associated with higher rates of failure and regret by the woman
416
 
417
, and this should be 
incorporated into the counselling and documentation prior to the procedure. In terms of post-
partum sterilisation, salpingectomy and Filshie clip have similar rates of failure (7.5 and 8.8 
per 1000 respectively).
388
 
416
 
5. Selection of technique- Laparoscopy preferred over laparotomy       Level B 
Each sterilisation method has specific advantages, disadvantages and individualised failure 
rates according to the sterilisation method and patient characteristics. This information should 
be conveyed during the counseling process. A meta-analysis 
418
, and large population study 
419
, has shown no significant difference in failure rate or major operative morbidity between 
mini-laparotomy and laparoscopy methods of sterilisation. However, laparoscopic methods 
have lower minor operative morbidity and are preferred for interval sterilisations as it offers 
obvious advantages in terms of shorter operative time, same day hospital discharge and 
shorter convalescence period. 
6. Selection of technique- Modified Pomeroy at caesarean section       Level B 
A modified Pomeroy procedure rather than Filshie clip application may be preferable for 
postpartum sterilisation performed by mini-laparotomy or at the time of caesarean section, as 
this leads to lower failure rates.
388;416;420
, although both procedures are equally popular 
choices with surgeons.
421
 
7. Selection of technique- Filshie clip sterilisation is preferred method       Level B 
Two small RCTs 
422;423
 and observational studies
390;424
 have shown Filshie clip to have the 
lowest failure rate for interval sterilisation failure and has therefore been recommended by 
the RCOG 
380
 as the preferred method at laparoscopic tubal occlusion (Table 4.19). Ring 
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methods have also been recommended by the RCOG, and appear to have equal contraceptive 
efficacy to Filshie clip. However, ring methods tend to be technically more difficult to apply 
to the fallopian tubes and have gradually become less popular in UK clinical practice.  
8. Operative technique for Filshie clip:                Levels C and GPP 
a) Care should be taken to ensure the Filshie clip is applied to the optimal mid-isthmic tubal 
position (1cm to 3cm from the uterine cornu) and this structure not be mistaken for an 
adjacent structure e.g. the round ligament or a fold of peritoneum.
425
 
b) The Filshie clip should be applied in a manner to completely encapsulate the tube and 
lumen, be fully locked with the upper jaw compressed, completely flattened and its end 
adequately secured under the under the latch which ‗locks‘ the clip jaw (Figure 4.4).  The 
clip should flatten the whole tube portion within the clip without leaving any unflattened 
tubal ‗knuckles‘ without transecting the tube.  Finally, the clip should sit perpendicular to the 
long axis of the tube. 
425
 facilitated by stretching the isthmic portion with hinge placed on the 
antimesenteric aspect of the tube.  
c) Excessive forceful clip applicator overclosure (Figure 4.4) or underclosure may lead to 
tubal transection and subsequent sterilisation failure through luminal regeneration (i.e. tubal 
fistula or re-canalisation) or incomplete tubal occlusion. 
425
 
Figure 4.4: Filshie clip under-closure due to operator fault          
Despite the clip appearing locked, on 
closer inspection the upper jaw of the 
clip will be noted to be incompletely 
compressed, rounded rather than 
flattened, and the end insufficiently 
secured under the under the latch for 
the upper jaw. Most causes of clip 
under-closure are due to operator 
fault. 
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A predisposing factor to improper closure is a ‗faulty‘ Filshie clip applicator. However, this is 
rare, as it is a legal requirement that device applicators are well maintained and adequately 
checked to ensure optimum function.  In the case of the Filshie clip, both the manufacturer 
(Femcare, UK www.femcare.co.uk) and MDA strongly recommend that all single Filshie clip 
applicators are serviced and re-adjusted at least once a year or after every 100 procedures.  
Furthermore, a closing checking gauge should be used prior to every sterilisation procedure 
to ensure the applicator functions correctly.  There is only one published case of failed 
sterilisation, which proposes Filshie clip under-closure as the most likely mechanism of 
sterilisation failure.  Therefore this cause of failure should be considered rare.
426
  
d) Applying two mechanical clips adjacent to each other on the tube does not decrease the 
failure rate, but may even increase it if they are applied too closely together.
425;427-429
 
e) Following clip application there should be a systematic checking procedure to ensure the 
correct structure and both sides of the tube have been satisfactorily occluded, and this should 
be documented. Although not a legal requirement in the UK, we recommend: 
e) Taking clinical photographs or operative videos of the sterilised structures 
identifying them as fallopian tubes. However photographs may be unhelpful in confidently 
excluding other negligent causes of incomplete tubal occlusion e.g. protruding knuckle of 
tube inadequate locking of clip jaws, clip under-closure, or tubal transection (partial or 
complete)  
f) Presence of second operating surgeon for counter-checking.  A recent study 
involving 1094 sterilisations from 1988-1989 showed that Registrars had a 1.3% failure rate, 
Consultants 1.9% and when both a Consultant and Registrar performed the procedure a 
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failure rate of 0.7% was recorded.
415
  A medical witness to concur the sterilisation procedure 
is a legal requirement in some countries.
430
 
9. True method failure. There is evidence that anatomical tubal patency can occur 
following a correctly undertaken sterilisation (true method failure), and has been reported 
following correctly applied Filshie clips in three cases of Filshie clip failure (table 4.19)
431
 
and is implied to have occurred in the 29/73 correctly applied clip sterilisation failures 
reported by an observational study. 
390
However, persisting anatomical tubal patency does not 
necessarily imply sterilisation failure, as tubal patency rates of 1-2% at three months and 16% 
at five years have been noted following correctly applied tubal ligation, with the actual 
pregnancy occurrence of 1-2% over this time period. 
400
.  Even so, true method failure is rare 
and difficult to prove; nonetheless three possible mechanisms of true method failure are 
suggested: 
 A partially non-occluded segment of tubal lumen has formed within the clip. This tubal 
‗knuckle‘, with a patent lumen, can exist within the completely flattened tube portion 
inside the clip identifiable only at microscopy.  
 Pre-existing utero-tubal structural abnormalities such as accessory fallopian tube, uterine 
didelphys 
432
, and utero-tubal fistulas 
Mechanical failure of the Filshie clip.  Manufacturers for Filshie clip have not reported 
spontaneous mechanical failure as a possibility for sterilisation failure, and this concurs with 
an absence of such cases in the published literature.  Nevertheless, there remains at least a 
theoretical possibility of mechanical material failure, and manufacturers like FEMCARE® 
offer an examination of the Filshie clips in failed sterilisation to exclude the possibility of this 
failure mechanism (Femcare - personal communication). 
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10. Operator experience and training                     Levels C and GPP 
Improper application of tubal occlusive
 
devices by inexperienced surgeons is frequently 
reported in cases of sterilisation failure.
394;433;434
  Furthermore, operator preference is likely to 
have an impact on method related failure rates. The CREST study showed failure rates of 7.1 
to 78.0 per 1000 for the Hulka clip and 0 to 42.5 per 1000 for the silicone ring - dependent on 
the operating centres being surveyed.
388
 Higher failure rates were more common in centres 
with performing fewer annual procedures. RCOG recommends that trainees should perform 
at least 25 supervised laparoscopic tubal occlusions before operating without supervision. 
380
 
11. Follow up required if uncertainty in tubal occlusion               Level GPP 
Following a complicated sterilisation good clinical practice (rather than a legal requirement) 
dictates testing of tubal patency.
394;435-438
  However, a negative dye spill post sterilisation 
HSG does not completely preclude the possibility of pregnancy at a later stage.
439
  
12.  Other issues: Clip Migration and dropped ‘lost’ Filshie clips       Level C 
Good clinical practice dictates that proof of tubal occlusion (X-ray HSG or tubal dye 
insufflation or histology of salpingectomy) should be undertaken once missing clips are 
identified, not only when examining failed sterilisation cases, but also at laparoscopy or 
laparotomy for other reasons.
425;440
  However, missing clips do not necessarily indicate failed 
application or imminent pregnancy failure, as over time there is a tendency for clips to 
migrate and even be expelled without resulting in clinical morbidity.
390;423;441-449
 There are no 
reports of this leading to sterilisation failures.
441
 It is estimated that over 25% of women will 
experience a migration of one or more Filshie clips.
441
  The tissue between the Filshie clip 
jaws normally undergoes avascular necrosis and fibrosis, leaving two healed stumps, which 
tend to separate, permitting clip displacement. Filshie clips may be inadvertently dropped 
4.4 Preventing Sterilisation Failure 
342 
 
during laparoscopic sterilisation. If possible the clip should be laparoscopically removed 
upon completion of the sterilisation procedure. However, if the clip is irretrievable, either 
open or closed, it should be left.   Performing a laparotomy would subject the woman to 
greater operative morbidity risk than leaving the lost clip in the abdomen.  To date, there have 
been no reports of any serious morbidity or mortality consequent to a lost clip. Women 
should be informed of the lost clip and reassured accordingly.
425
 
Conclusion and Further research  
Overall, the level of evidence supporting any screening-preventative measures to reduce the 
risk of sterilisation failure remains poor. There appears to be a propensity for negligent rather 
than non-negligent sterilisation failures. However, this can only be verified by establishment 
of a national register of failed sterilisations (as recommended by the RCOG
380
)  that have 
been subjected to systematic enquiry to establish the mechanism of failure. Like other 
Confidential Enquiries, such a registry could identify areas of substandard care that could be 
used as an impetus to improve research and medical training in sterilisation procedures and 
help design effective clinical risk prevention strategies. The introduction of an operative 
checklist or proforma, similar to the pre-operative counseling checklist recommended by the 
RCOG
380
 and used in another study 
450
, may result in reduced numbers of negligently 
performed sterilisations.  
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Figure 5.1. Ascension of a research pyramid of research methodologies to benefit 
clinical practice 
Audit
Clinical 
Guidelines
Systematic 
reviews & RCTs
Cohort studies
Descriptive studies 
Elucidating aetiopathogenesis
molecular  in vitro &  in vivo models
Molecular & epidemiological associations
 
 
Footnotes 
RCT randomised controlled clinical trials 
Audit refers to clinical audit to assess impact of clinical guidelines 
 
 
Thesis Précis 
The central aim of this PhD thesis was to produce research that could inform and benefit 
clinical practice. Each chapter of this thesis has achieved this aim, within the limits of the 
research methodology applied The chapters have been ordered to follow a stepwise ascension 
of a research methodological pyramid (Figure 5.1). 
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5.1. Experimental investigation of endometriosis 
 
The experimental data explored whether there was a causal link for endometriosis as a 
neoplastic precursor to ovarian cancer. The chapter was original in adopting distinctive, yet 
complimentary, approaches to testing this hypothesis through clinical epidemiology 
(Bradford Hill causality criteria
1
), histopathology, immunohistochemistry, genetic and 
molecular approaches. The chapter reported the largest EAOC series to be subjected to 
clinico-epidemiological and LOH mapping for the entire length of chromosome 9 (20 
markers) and chromosome 11 (27 markers).  Furthermore, this chapter includes the first study 
to apply SNP 100K genome wide genotyping to endometriosis
2
. 
Epidemiological and causality literature analysis showed: 
 No strong evidence to support a causal link between endometriosis and ovarian cancer3-5. 
 However, there was moderate quality evidence that endometriosis may display similar 
properties to a cancer cell (Hanahan‘s Hallmarks of cancer6). There are numerous anti-
cancer therapies that target the specific molecular properties of the ‗cancer cell‘. Hence it 
is conceivable, that anti-endometriosis therapies may also be designed around such cancer 
cell-like molecular targets (Table 5.1). 
Experimental analysis showed: 
 A prognostic association of the LOH (loss of heterozygosity) identified at 9q34.3 and 
11q23.3 chromosomal regions suggesting that these regions may harbour genes that 
impact on malignant transformation and progression of cancer.  
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 Decreased glycodelin immunohistochemical expression in endometriosis adjacent to 
ovarian cancer compared to endometriosis distant from ovarian cancer- hence a possible 
role for glycodelin as a TSG responsible for development for ―malignant‖ endometriosis. 
 Ovarian endometriosis harbours micro-regions of LOH through Affymetrix genome-wide 
100k SNP microarray. However, to confirm and validate the location of these multiple 
micro-regions of LOH analysis further customised microsatellite markers analysis is 
required. 
2;5
 
Future directions  
High throughput molecular technologies (as used in this chapter) allow parallel genomic, 
transcriptomic and proteomic evaluation of diseases, at the genome-wide level. Such 
approaches could be used to elucidate the multigene pathways involved in aetiopathogenesis 
of endometriosis (Figure 5.2, Table 5.2), as well as numerous other diseases. Application of 
techniques in cancer biology may also facilitate the research and development of therapies for 
endometriosis (Tables 5.1 and 5.3).  A key future goal would be the identification of 
characteristic endometriotic ‗genetic‘ or ‗proteomic‘ signatures that could form the basis of 
an early screening-preventative testing strategy from women‘s urine, menstrual endometrium 
or blood. Furthermore, a similar genomic/transcriptomic/proteomic approach may be 
considered for the investigation of analogous gynaecological disorders (such as adenomyosis 
and fibroids) and explore whether genetic alterations are focal or widespread in a diseased 
reproductive tract. 
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Table. 5.1. Individualise therapeutic approach to endometriosis according to cancer cell 
hallmarks 
6
 
 CANCER 
CELL 
HALLMARKS 
TARGETS UNDER 
EVALUATION IN 
ENDOMETRIOSIS BASED ON 
AGENTS USED IN CANCER 
TRIALS 
TARGETS/ PUTATIVE TARGETS UNDER 
INVESTIGATION IN CANCER  
1 Self-sufficiency in 
growth signals 
Aromatase inhibitors, Selective 
oestrogen (e.g. Arzoxifene) and 
progesterone receptor modulators, 
Mirena Coil, Gonadotrophin releasing 
hormone antagonists (e.g. Cetrorelix) 
Inhibitors of: Mitogen-activated protein kinase inhibitors, 
HER-2 receptor (trastuzumab), IGF-1 receptor, EGFR 
(erbitux), EGFR tyrosine kinase (gefitinib) farneysl 
transferase, Bcr-Abl tyrosine kinase (imatinib mesylate) 
2 Insensitivity to 
antiproliferative 
signals 
 Proteasome inhibitors (bortezomib), cdk inhibitors 
(flavopiridol) 
3 Resistance to 
Apoptosis 
Angiostatin gene transfer; transfection 
with pro-apoptotic (e.g. BAX) gene 
COX-2 inhibitors 
 
 
COX-2 inhibitor (celecoxib), thalidomide, apoptosis inducers 
(exisulind inhibits cGMP). 
 
Immunotherapy by genetically modified tumour vaccines 
(e.g. HER-2 peptide vaccination) or humoral factors (e.g. 
immunokines like IL-12, TNF antagonists; monoclonal 
antibody to CA-125 [ovarex], recombinant immunotoxin to 
mesothelin) 
4 Limitless 
replicative 
potential 
 Telomerase modifiers 
5 Sustained 
angiogenesis 
Anti-VEGF monoclonal antibody 
(bevacizumab), VEGF receptor 
tyrosine kinase inhibitors 
Angiozyme (cleaves mRNA for Flt-1, the main receptor for 
VEGF), Protein kinase C-beta inhibitor (LY317615), COX-2 
inhibitor, thalidomide, lysophosphatidic acid inhibitors 
 
6 Tissue invasion 
and metastasis 
 Inhibit/modify Catenin/Cadherin signaling, Selective MMP 
inhibitors 
7 Genomic instability  Gene therapy to deliver therapeutic or corrective gene to alter 
oncogenes/TSG balance. Genes may be delivered by 
infectious (adenovirus) or non-infectious (liposome) vectors. 
Examples: 
Adenoviral E1A (oppose HE-2/neu oncogene), 
Adenovirus transfection of wild-type p53 (restore TSG) 
Transfect viral suicide genes like HSV-thymidine kinase 
(sensitizes to ganciclovir cytotoxicity) 
Antisense oligonucletoides (targeting proto-oncogenes, 
oncogenes like c-myc, protein kinase C-alpha [affinitak]) 
Tribozymes (cleave oncogenes transcripts) 
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Footnotes  Consequent to endometriosis heterogeneity, the exact contribution of each 
hallmark component may vary between individuals and clinical symptoms. Nevertheless, 
therapies can be designed to target predominant categories following endometriosis 
molecular classification (expression signature). 
 
Figure 5.2. Evaluating, in parallel, differences between genomic, transcriptomic and 
proteomic array platforms to identify candidate molecular pathways 
 
Integrating microarrays 
into endometriosis gene 
identification strategies
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Table 5.2. Summary of studies comparing genomic, transcriptomic and proteomic 
profiling of endometriosis using high-through put microarray technology 
 
GENOMIC TRANSCRIPTOMIC PROTEOMIC 
Comparative Genomic 
Hybridisation (CGH)  
7-9
  
 
Human endometriosis  
(ectopic vs. eutopic 
endometrium) 
10-24
 
 
DNA originating from blood 
(lymphocyte sourced ) of 
women with endometriosis 
25
  
 
Animal model endometriosis 
26;27
  
Endometriosis: protein tissue 
microarrays 
28;29
 
 
Endometriosis: surface-
enhanced laser 
desorption/ionization time-
of-flight mass spectrometry 
protein chip array 
30
 
 
 
Single nucleotide 
polymorphisms (SNP) 
microarray based chips 
 
None identified for 
endometriosis (apart from 
data presented in this thesis) 
 
SNP microarrays in other 
disorders 
Adenomyosis 
31
 
Bladder cancer 
32
 
Prostate cancer 
33
 
Expression microarrays in 
other disorders 
Endometrial cancer  
Normal endometrium
34
 
Proteomics in other related 
disorders 
Adenomyosis and 
leiomyomas: protein tissue 
microarrays 
35
 
 
 
 
Footnotes 
Most studies have compared endometriosis (ectopic endometrium) with matched eutopic 
endometrium. 
CGH) studies have been undertaken in endometriosis, but could only detect relatively large-
scale deletions or duplications. 
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Table 5.3. Implications of thesis findings and future research directions for 
endometriosis 
Key overall themes 
Establish biological tissue bank- biological samples (e.g. endometriosis, endometriosis associated 
ovarian cancer, matched eutopic endometrium and ovarian surface epithelium and blood) should be 
considered in conjunction with originating patient clinical epidemiological outcome data 
Establish international coordinating body to pursue biological tissue bank, basic science and clinical 
endometriosis research 
Implications for genetic epidemiology  
Meta-analysis of genetic association studies 
Meta-analysis of multiple gene expression analyses to validate candidate genes 
Interrogate accessible bioinformatic tissue expression databases to cross tabulate and identify 
candidate genes-combine this with above meta-analyses. 
Implications for basic science research 
Compare and contrast molecular profiles from endometriosis and matched eutopic 
endometrium/ovarian surface/peritoneum/blood using genomic, transcriptomic and proteomic 
technology IN parallel. 
Evaluate clinical prognostic value of nuclear morphometry in evaluation of endometriosis 
Utilise animal models of endometriosis (e.g. baboon) to study molecular profiling (compare with 
human studies) and evaluate novel medical therapies 
Implications for clinical trials 
Standardize methodology (e.g. inclusion, exclusion and diagnostic criteria, fertility and 
endometriosis-specific quality of life outcomes)  
Introduce temporality in studies (i.e. long term follow up) as cost-effectiveness between medical and 
surgical treatments may depend on rates of re-treatment or persistence of impaired quality of life 
outcomes. 
Consider assessing from duration of onset of symptoms rather than from time of diagnosis of 
endometriosis (delayed onset of presentation)-factor this in to epidemiological associations and 
quality of life outcomes of new endometriosis cases or individualised retrospective analysis of cases 
with known endometriosis onset and duration  
Aim to identify early biomarkers (urine, blood, menstrual flow) which correlate to disease onset to 
enable early therapy (medical or surgical).  
RCTs to evaluate medical vs. surgical treatments for specific anatomical or clinical presentations of 
endometriosis i.e. consider endometriosis as multiple differing clinical entities 
Consider (or evaluate the need) for long term follow up of early onset severe  or atypical 
endometriosis  in view of increased risk of ovarian cancer 
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5.2. Observational Analytical Studies 
 
The observational analytical cohort studies have ascertained the incidence, natural history and 
treatment outcomes of common encountered gynaecological disorders such as heavy 
menstrual bleeding and endometrial hyperplasia 
36-39
 (Table 5.4). Furthermore, the cohort 
design has been employed to identify prognostic factors associated with the rare outcome of 
failed female sterilisation
40
.  
The results of each study are immediately transferable to clinical practice and are likely to 
improve health care outcomes as outlined in Table 5.4 Improvements will mainly arise 
through improved pre-operative patient counselling, better patient selection, consideration of 
outpatient rather than inpatient treatment modalities and adopting treatments that would 
reduce rates of hysterectomy for menorrhagia. 
Although observational analytical studies (for example, cohort and case-control studies) start 
with a "low quality" rating of evidence (Table 5.5 Level of Evidence; Table 5.6 GRADE 
quality of evidence), grading upwards may be warranted if the magnitude of the treatment 
effect is very large, if there is evidence of a dose-response relation or if all plausible biases 
would decrease the magnitude of an apparent treatment effect. Further confirmatory 
randomised controlled trials (RCTs) would be needed to validate the observations noted in 
the menorrhagia studies cited in this chapter. However, a larger prospective data set( perhaps 
multicentre or national), with defined inclusion/exclusion criteria, may be provide a study 
population that minimises biases, and be of sufficient power to generate data of a standard 
that approaches a RCT. Hence a future goal would be the creation of large linked 
prospectively collected patient datasets that could be flexibly used by both clinical and 
research organisations e.g. NHS electronic patient record.  
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Table 5.4. Improved health care resulting from analytical observational studies. 
Chapter  
and 
Reference 
Study Beneficial health care outcome 
2.1 
40
 
Predicting 
negligence in female 
sterilization failure  
Early sterilisation failure is suggestive of a negligent rather 
than non-negligent mechanism of failure.  
Result increases awareness of need for adequate surgical 
training in sterilisation procedure 
Result also has medico-legal implications 
2.2 
37
 
Effectiveness of a 
Mirena in the 
treatment of 
endometrial 
hyperplasia 
Mirena is highly effective in treating non-atypical endometrial 
hyperplasia 
Use of Mirena will reduce the rate of hysterectomy for women 
with non-atypical endometrial hyperplasia 
2.3 
 
38
 
Outpatient vs. 
Daycase 
Thermachoice 
ablation 
Thermachoice balloon ablation may be successfully carried out 
in outpatient local anaesthetic setting 
Outpatient Thermachoice population utilise less analgesia than 
day case Thermachoice population 
Duration of hospital stay is not entirely dependent on whether 
outpatient or daycase endometrial ablation is considered 
Consider patient suitability criteria (e.g. pain thresholds) when 
offering outpatient vs daycase ablation 
2.4 
39
 
Long term outcome 
of outpatient 
Thermachoice 
endometrial balloon 
ablation 
Thermachoice balloon ablation may be successfully carried out 
in outpatient local anaesthetic setting 
Ablation reduces the rate of hysterectomy for women with 
menorrhagia that is unresponsive to medical therapy 
Higher intrauterine ablation pressures correlate to better long 
term outcome 
2.5 
36
 
Long term outcomes 
following 
hysteroscopic 
myomectomy  
Removal of the intracavity component of the fibroid is 
effective in reducing abnormal uterine bleeding. 
This effect is independent of the size of the fibroid removed, 
uterine cavity size and presence of other intramural/subserous 
fibroids 
Widespread adoption of this minimally invasive surgical 
technique will improve patient quality of life and reduce the 
need for hysterectomy 
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Table 5.5.  Classification of evidence used by RCOG Guideline development (originate 
from US Agency for Health Care Research and Quality) 
41
 
Classification of Evidence Levels  
Ia Evidence obtained from meta-analysis of randomised controlled trials.  
Ib Evidence obtained from at least one randomised controlled trial.  
IIa Evidence obtained from at least one well-designed controlled study without 
randomisation.  
IIb Evidence obtained from at least one other type of well-designed quasi-experimental 
study.  
III Evidence obtained from well-designed non-experimental descriptive studies, such as 
comparative studies, correlation studies and case studies.  
IV Evidence obtained from expert committee reports or opinions and/or clinical 
experience of respected authorities.  
Grades of Recommendations  
 
Requires at least one randomised controlled trial as part of a body of literature of 
overall good quality and consistency addressing the specific recommendation. 
(Evidence levels Ia, Ib) 
 
Requires the availability of well controlled clinical studies but no randomised 
clinical trials on the topic of recommendations. (Evidence levels IIa, IIb, III) 
 
Requires evidence obtained from expert committee reports or opinions and/or 
clinical experiences of respected authorities. Indicates an absence of directly 
applicable clinical studies of good quality. (Evidence level IV) 
Good Practice Point    
 
Recommended best practice based on the clinical experience of the guideline  
development group 
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Table 5.6. GRADE approach 
42
 (http://www.gradeworkinggroup.org/index.htm)  
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
GRADE: Quality of evidence 
The GRADE system classifies
 
the quality of evidence in one of four levels: 
High quality— Further research is very unlikely to change our confidence in the estimate of 
effect 
Moderate quality— Further research is likely to have an important impact on our confidence in 
the
 
estimate of effect and may change the estimate 
Low quality— Further research is very likely to have an important impact on our confidence in 
the estimate of effect and is likely to
 
change the estimate 
Very low quality— Any estimate of effect is very uncertain 
Evidence based on randomised controlled trials begins as high
 
quality evidence, but our 
confidence in the evidence may be
 
decreased for several reasons, including:
 
 
 Study limitations  
 Inconsistency of results  
 Indirectness of evidence  
 Imprecision  
 Reporting bias.  
Although observational studies (for example, cohort and case-control
 
studies) start with a "low 
quality" rating, grading upwards
 
may be warranted if the magnitude of the treatment effect is
 
very large,
 
if there is evidence of a dose-response relation or if all plausible
 
biases would 
decrease the magnitude of an apparent treatment
 
effect.
 
 
GRADE: Strength of recommendation 
The GRADE system offers two grades of recommendations: "strong" and "weak" depending 
on whether effects of intervention clearly outweigh the undesirable effects, or clearly do not. If 
trade-offs are less certain—either because of low quality evidence or because evidence 
suggests that desirable and undesirable effects are closely balanced—weak recommendations 
become mandatory. 
Factors that affect the strength of a recommendation  
Factor Examples of strong 
recommendations 
Examples of weak 
recommendations 
Quality of 
evidence 
Many high quality randomised 
trials have shown the benefit of 
inhaled steroids in asthma 
Only case series have examined the 
utility of pleurodesis in 
pneumothorax 
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Uncertainty about 
the balance 
between desirable 
and undesirable 
effects 
Aspirin in myocardial infarction 
reduces mortality with minimal 
toxicity, inconvenience, and cost 
Warfarin in low risk patients with 
atrial fibrillation results in small 
stroke reduction but increased 
bleeding risk and substantial 
inconvenience 
Uncertainty or 
variability in 
values and 
preferences 
Young patients with lymphoma 
will invariably place a higher 
value on the life prolonging effects 
of chemotherapy than on treatment 
toxicity 
Older patients with lymphoma may 
not place a higher value on the life 
prolonging effects of chemotherapy 
than on treatment toxicity 
Uncertainty about 
whether the 
intervention 
represents a wise 
use of resources 
The low cost of aspirin as 
prophylaxis against stroke in 
patients with transient ischemic 
attacks 
The high cost of clopidogrel and of 
combination dipyridamole and 
aspirin as prophylaxis against stroke 
in patients with transient ischaemic 
attacks 
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5.3. Systematic reviews 
 
The systematic review in chapter 3 has utilised robust methodology (systematic search, meta-
analysis, grading of evidence) to assimilate the published literature relating to the screening 
and prevention of preterm labour
43;44
. A similar approach has been applied to the systematic 
review of the clinical use of levonorgestrel-releasing intrauterine system (LNG-IUS) 
45
. 
However, for the LNG-IUS study, meta-analysis was precluded due to extensive study 
heterogeneity and paucity of suitable clinical trials.  
Included in each review is an appraisal of the quality of evidence for each therapeutic 
intervention according to standardised criteria (RCOG, GRADE; Table 5.5, Table 5.6). In 
relation to the screening-prevention of preterm labour, tables listing the evidence appraisal 
(Table 5.7) and resulting care algorithm (Table 5.8) are shown below. The algorithm for 
managing a women at high risk of preterm labour exemplifies how this evaluated research 
evidence may be effectively applied in the clinical setting.  
Furthermore, both reviews have identified areas where future research is likely to be 
clinically advantageous, but where the evidence is currently lacking. The generation of 
hypotheses that require further confirmatory validation is another important end-product of 
systematic reviews, and has been considered an essential pre-requisite by most research 
funding councils when seeking funding to conduct the confirmatory clinical trials 
46
.  
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Table 5.7  Screening and preventative strategies that may reduce the risk of preterm 
delivery 
Strategy for preventing preterm 
delivery 
RCOG 
Level of 
Evidence 
GRADE 
Quality 
of 
Evidence 
GRADE 
Strength of 
Recommendation 
Asymptomatic bacteriuria in all women Ia High Strong 
Bacterial vaginosis in low-risk population 
groups 
Ia, Ib Moderate Weak 
Elective cervical cerclage in high-risk 
pregnancies 
Ib, IIa, 
IIb 
Moderate Strong 
Indicated cervical cerclage in women with 
short cervical length on ultrasound 
Ib, IIa, 
IIb 
Moderate Strong 
Prophylactic progesterone 
supplementation in high-risk pregnancies 
Ia, Ib High Strong 
Smoking cessation in all women IIb, III Very 
Low 
Weak 
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ANTENATAL 
VISIT AND 
PURPOSE 
Infection 
(Screen and 
treat  
BV, UTI) 
Cervico-
vaginal 
 fFN 
 
Ultrasound 
Abdominal 
and 
Transvaginal 
 
Other interventions to be considered 
Pre-pregnancy 
Counselling on recurrence risk 
and any modifiable predisposing 
factors 
Yes 
 
No No Cessation smoking and illicit drugs 
Improve BMI>25 
Thrombophilia screen if history suggests 
Optimise control of diabetes, high BP 
Change anticoagulation or 
antihypertensive drugs 
8 weeks’ 
Routine booking bloods 
  
 
Yes  No Dating pregnancy 
 
  
 
Thrombophilia screen and commence 
aspirin & LMWH if positive. 
Low dose aspirin if previous pre-
eclampsia (consider use if previous 
stillbirth, abruption, severe IUGR) 
Prophylactic progesterone 
General preterm birth education, support, 
and risk factor avoidance. 
Screen and treat BV, UTIs 
Low threshold for GTT testing 
12, 16, 20, 24, 28 weeks’ 
Nuchal Translucency(12w) 
and/or  Triple Test or msAFP 
(15-18w) 
No No Serial Cervical 
assessments in 
women at high 
risk of PTD 
Emergency or elective (12-16w) cervical 
cerclage based on ultrasound findings 
and/or reproductive history 
Emergency cervical cerclage is not 
indicated if above 32 weeks‘ 
Low threshold for GTT testing 
22 weeks’ Yes  No Detailed fetal 
survey 
Uterine artery 
Doppler 
Low dose aspirin if suspect pre-
eclampsia or IUGR due to uterine artery 
notching and/or previous history 
Screen and treat BV and UTIs 
24, 28, 32, 36 weeks’ 
GTT at 28 weeks‘ 
No Only if 
symptomatic 
Fetal growth and 
umbilical artery 
Doppler 
 
Prophylactic corticosteroids, antibiotics 
if symptomatic of PTL or PPROM. 
In utero transfer to unit with NICU if 
symptomatic with positive fFN 
 
Labour 
Spontaneous or induced 
Yes  Helps 
confirm 
Likelihood 
of 
PTL, PPROM 
Asses fetal well-
being, and 
presentation 
Prophylactic corticosteroids, antibiotics 
(especially GBS prophylaxis).    
Tocolytics if in utero transfer to unit with 
NICU is needed. 
Post-partum 
6 week antenatal check 
No No No Review antenatal events and delivery 
Identify modifiable factors for future 
prevention of PTD 
Table 5.8    Suggested antenatal strategy to prevent preterm delivery 
 
FootNote: Bacterial vaginosis, BV; BMI, body mass index; BP, blood pressure; fFN, fetal 
fibronectin; GBS, Group B streptococcus; GTT, glucose tolerance test; LMWH, IUGR, 
intrauterine growth restriction; low-molecular weight heparin; msAFP, maternal serum alpha-
fetoprotein; NICU, neonatal intensive care unit; PPROM, preterm premature rupture of 
membranes; PTL, preterm labour; UA, uterine artery; UTI, urinary tract infection.
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5.4. Clinical guideline development 
 
There are established methodologies utilised in the production of clinical guidelines (depicted 
in Figure 5.3). Four essential criteria have been defined by the Appraisal of Guidelines for 
Research and Evaluation in Europe (AGREE) guidelines 
41
  and include: 
 Systematic review of the literature  
 Graded recommendations with explicit links to the evidence (Tables 4v in Chapter 4) 
 Input of a multidisciplinary working group  
 Quality control; for example, input by an independent advisory board or by independent 
peer review.  
All guidelines developed in this chapter comply with the four essential AGREE criteria 
41
.   
Figure 5.3 Derivation of clinical guidelines 
Quality Control (Peer review) 
Published clinical guideline
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The publications of the clinical guidelines in chapter 4 are likely to have immediate and 
maximal benefit on clinical practice. Hospital clinical guidelines are normally developed 
from guidelines published by professional bodies (e.g. RCOG
47
; chapter 4), specialist 
evidence-based resources (e.g. BMJ Clinical evidence
48
; chapter 4) and peer-reviewed 
publications (e.g. Surgical Endoscopy
49
; chapter 4). Clinical governance demands the 
utilisation of best up-to-date evidence, as indicated by such clinical guidelines, to ensure 
patient receive excellence in their clinical care
50
. 
The work performed in the production of this research thesis has also identified potential 
drawbacks in the research methodologies utilised. Given that the aim of research is to inform 
and benefit clinical practice, due consideration should be given to strategies that may 
augment the research methodological approaches considered in this thesis in order to achieve 
this goal. These include: 
Quality control. For example, input by an independent advisory board or by independent 
peer review. In relation to the VBAC guideline 
47
, the RCOG Guidelines Development Group 
invited peer review from British Maternal Fetal Medicine Society, National Childbirth Trust, 
Obstetric anaesthetists, Midwifery supervisors, Obstetricians, and Neonatologists; this served 
as a the multidisciplinary component of the guideline development process. No specific 
multidisciplinary working groups were employed by the other chapter guidelines
48;49;51
, 
although all had at least three external peer reviewers in addition to the journal‘s editor in 
chief. 
Grading the evidence base of the recommendation. The guidelines produced in this 
chapter have highlighted the significant change in how evidence is now valued for guideline 
development. The traditional and most common approach has been to value the research 
study evidence alone using the SIGN classification 
52
 or amendments from this (Table 5.5); 
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the SIGN classification had been derived from earlier work by U.S. Preventive Services Task 
Force 
53;54
. This was used by RCOG VBAC, safe laparoscopic entry and failed sterilisation 
guidelines. However, this system neglects: the study‘s relevance for particular patients and 
settings; inconsistencies amongst studies examining the same interventions; potential impact 
of health care resource limitations. The newer approach, using the GRADE system
42
, applied 
in the ectopic pregnancy guideline
48
, considers all these components when evaluating the 
study by using a strict framework  (Table 5.6). Grading judgments are expressed in a clear 
and simple manner as either high, moderate, low, or very low levels of supporting evidence 
and these are incorporated in the allocation of either strong or weak recommendations for 
each intervention (Table 5.9 provides an example for how ectopic pregnancy guideline was 
appraised). However, it has not been proven that this grading system is significantly superior 
to the traditional grading system in pragmatic clinical decision-making. Nonetheless, the 
GRADE system
42
 is advantageous in clearly identifying areas where there is uncertainty in 
the level of evidence.  
 
Evaluating the quality of clinical guidelines. Concern has been raised that guidelines 
published by both professional medical bodies and peer-reviewed journals :lack sufficient 
reliability; are scientifically inaccurate;  fail to clarify what influence the level of health care 
resources may have on guideline practice; and should be critically reviewed by ‗experts‘ in 
guideline development prior to publication if not produced by ‗experts ‗(such as SIGN or 
NICE)
55-59
. Such criticism is harsh, but it is true that no guideline can ever achieve complete 
coverage and applicability in every health care setting. 
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Table 5.9.Ectopic pregnancy evidence appraised using RCOG and GRADE criteria 
Chapter 4.2 Ectopic pregnancy RCOG 
Level of 
Evidence 
GRADE 
Quality of 
Evidence 
GRADE  
Strength of 
Recommendation 
Salpingectomy in women not desiring 
future fertility is beneficial compared to 
salpingotomy or methotrexate in achieving 
primary treatment success 
IIa, IIb Moderate Strong 
Prophylactic methotrexate (systemic) 
following salpingotomy compared to 
salpingotomy alone is beneficial in 
reducing the risk of persistent trophoblast 
Ib, IIa Moderate Strong 
In women desiring future fertility, 
systemic methotrexate (single or multiple 
dose) and salpingotomy achieve similar 
primary treatment success and subsequent 
fertility outcomes 
Ia, Ib, IIa Moderate Strong 
In women desiring future fertility, there is 
marginally improved subsequent fertility 
rate by performing salpingotomy 
compared to salpingectomy 
III Very Low Weak 
Single dose methotrexate may result in 
higher rates of treatment failure in women 
with ectopic pregnancies compared with 
multiple dose regimens.  
Ia, Ib, IIb Low Weak 
In selected cases, expectant management 
has similar primary treatment success and 
future fertility outcomes to salpingectomy 
or salpingotomy 
III Very Low Weak 
Methotrexate plus mifepristone is no more 
effective at increasing treatment success 
rates compared with methotrexate alone 
but it seems this combination may be more 
effective in increasing treatment success 
rates in women with high levels of 
progesterone.   
Ib Moderate Weak 
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Future directions in guideline development 
It is clear that strategies are needed, above and beyond new developments in grading 
evidence, in order to maintain guideline quality, consistency and applicability across all 
health care settings for all health care interventions. Apart from adopting the GRADE criteria 
42
 to grade the level of evidence, one possibility is that guidelines should go through a formal 
appraisal process using validated tools, such as AGREE tool ( Appraisal of Guidelines, 
Research, and Evaluation in Europe (AGREE)
60
 based on the Cluzeau instrument 
59
prior to 
publication. Alternatively, a ―second‖ expert consensus panel peer review should be 
undertaken prior to publication; these could be representatives of SIGN, NICE or Cochrane 
group. Importantly, consideration should be given to producing a more time efficient means 
of guideline development, with fewer group meetings and a shorter time frame; the RCOG 
VBAC guideline took the author nine months to complete from commencement to final peer-
reviewed amended draft submission. Finally, there needs to be periodic review of the clinical 
guideline (such as every 2 years) to ensure the guideline remains valid and up-to-date with 
the latest research evidence.  
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5.5. Future research themes arising from Thesis 
 
The remainder of this chapter suggests future research themes that may augment the research 
methodological approaches evaluated in this thesis in order to benefit clinical practice. 
Integrating genomic, transcriptomic and proteomic high throughput technology 
The Affymetrix Single Nucleotide Polymorphism (SNP) DNA microarray chip technology 
has been validated 
61and its raison d‘etre of obtaining genome wide association data are now 
becoming fulfilled across many health conditions
62
. The Affymetrix SNP microarray chip 
technology has been successfully applied to the investigation of endometriosis (in this thesis), 
bladder cancer 
32
, and prostate cancer 
33
. The integration of genomic, transcriptomic and 
proteomic microarray technology is likely to yield greater discovery of genetic and molecular 
aetiopathology 
63-65
.  Table 5.2 lists the published studies that utilised either genomic, 
transcriptomic or proteomic approaches to investigate endometriosis (and related 
adenomyosis). Given this consensus opinion, and the established knowledge relating to the 
difficulty of identifying endometriosis polymorphisms (that are likely to be multiple and 
highly variably expressed across the population)  using traditional candidate gene 
investigative approaches
66
, future research should now be focused on adopting this high 
throughput combinatorial approach (Table 5.2, Figure 5.2). 
Anatomical and molecular re-classification of endometriosis Genomic, 
transcriptomic and proteomic profiling (Table 5.2, Figure 5.2) should provide a better 
understanding of the temporo-spatial relationship of endometriosis in relation to location 
within the female reproductive tract, nature during menstrual cycle phase, nature during 
pelvic pain and infertility. Novel therapies should target the aberrant process at the molecular 
level, rather than focussing solely on endometriotic lesion eradication. Examples of strategies 
Chapter 5.5 Future research themes arising from Thesis 
364 
 
using the cancer hallmark model (Table 5.1) are other approaches (Table 5.3) are discussed 
earlier.  
Tissue banks for endometriosis (and other important diseases) Our host institution 
provided a unique tissue bank of endometriosis-associated ovarian cancer, but shared 
biological tissue banks, matched with clinical epidemiological outcome data, would enable 
greater research throughput and encourage collaboration. These aims are postulated bthey UK  
67;68
 and European bodies
69
, but various restrictions (particularly  Human Tissue Act 2004, 
implemented September 2006) have hindered the creation of biological libraries. Given the 
significant burden of endometriosis on worldwide health, a central international body to 
coordinate endometriosis tissue banking and scientific research is justified and urgently 
needed. 
Developing and utilising animal models of disease There may be a significant 
difference between a pharmacological agent that is effective in vtiro on a fundamental 
cellular process and one that is disease-specific and safe in vivo. Animal models could be 
useful experimental tools, although opinion is divided as to their correlation to human 
disease
70
. Nonetheless, several animal models for endometriosis exist (mouse
71;72
, rat
73
, 
baboon
74
) , and these have been successfully used to test pathophysiology (such as molecular 
profiling 
26
 and capacity for malignant transformation
75
) and novel pharmacological 
therapies
76
.  
Improved basic science and clinical science collaboration There appears to be 
virtually no collaboration between clinical trialists and basic scientists. This is undoubtedly a 
missed opportunity, as clinical trials could be designed to recover both biological specimens 
and clinical outcome measures. The effort and expense in generating a specific patient 
population may thus be used for greater benefit, particularly as quality biological sample 
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resources are scarce. However, when designing the clinical trial, due consideration should be 
given to ensure that the trial is adequately powered for both primary clinical and translational 
research endpoints. 
The need to increase translational potential of basic science research Translational 
research has been defined as research that considers and supports the transition of findings 
from research setting to benefit clinical practice. Importantly, the concept also includes 
feedback of findings from the practice to research setting to ensure that the originating 
research remains applicable and appropriate; a concept that is frequently neglected. There has 
been concern that academic basic science research has not achieved its full potential. 
Consequently, there has been renewed impetus to support and create translational research 
partnerships, with significant financial grants tendered by National Institute for Health 
Research (NIHR) and Medical Research Council (joint strategy), Wellcome Trust and Cancer 
Research UK. 
Co-ordinated research programmes and commitment from Government funded 
research bodies Endometriosis research has been relatively neglected despite having a 
major burden of disease worldwide. It is entirely justified that a central worldwide 
coordinating body of endometriosis research should be created given the importance of the 
condition. Funding should be at government, European Parliament 
69
or international (such as 
WHO) level, particularly given the expense involved in high throughput molecular 
technology . In contrast, integrated clinical care and a common research strategy are 
fundamental components of the successful National Cancer Institute (NCI), the Gynecologic 
Oncology Group (GOG) and the Specialized Programs of Research Excellence (SPOREs) 
collaboration in the North American approach to ovarian cancer
77
. 
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Utilising and developing high quality clinical datasets The ―gold standard‖ research 
methodology that provides the highest level of evidence on interventions is the randomised 
controlled clinical trial (RCT). However, it is unrealistic to assume the RCT design may be 
achievable for all disorders. Particularly, as many of the main outcomes of interest are 
relatively uncommon or tend to occur over several years. Furthermore, randomisation may be 
considered unethical in certain conditions, such as randomising between planned VBAC and 
elective caesarean as discussed in chapter 4
78
.  
The alternative is to utilise a lower level of evidence in the form of the non-randomised 
cohort study. The optimum components of such a cohort study would be large sample size, 
long term follow up, standardised definitions for recruiting and assessing outcome and ability 
to compare against matched non-intervention participants.  The Scottish Linked Maternity 
dataset represents such a cohort dataset based on routinely collected obstetric and neonatal 
data; the interrogation of the dataset yielded publications 
79;80
 utilised by the VBAC clinical 
guideline (Chapter 4). However, there is considerable heterogeneity in which disorders are 
being monitored through such data repositories 
81
. Inevitably, most clinical guidelines 
conclude a need to establish national database registries for important outcomes (such as 
hypoxic ischaemic encephalopathy by NICE Intrapartum guideline
82
), but there is no 
agreement on which body should coordinate the data collection. 
Fortunately, there appears to be a realisation that such datasets are urgently needed, both by 
Department  of Health (NHS Connecting for Health-NHS Care record service is one of many 
components
83
) and medical research organisations (e.g. MRC
67
 ). However, there needs to be 
stringent quality assurance to ensure that the electronic health record contains accurate data, a 
concern that has been raised by those establishing the analogous United States National 
Health Information Infrastructure (NHII) project
84
. 
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Nevertheless, there are immense clinical and biomedical research opportunities by creating 
such datasets and sharing these amongst interested public and commercial stakeholders, that 
have thus far, been relatively underplayed by the UK National Programme for Information 
Technology
85
.  It is feasible that given the large sample size within the dataset and utilisation 
of individual patient data meta-analysis techniques, the clinical results generated are at least 
as reliable (if not more robust) than RCT derived data, even though the primary data are non-
randomised. Furthermore, the exchange of biological clinical samples, linked with patient 
epidemiological outcome, facilitates translational basic science research. 
Caution with over-reliance on meta-analyses: value according to the quality and 
methodology of the RCTs included Despite adherence to rigorous quality standards for 
RCTs
86
, systematic reviews and meta-analyses may provide misleading results or be of poor 
quality
87
. Greater bias is likely in meta-analyses that pool underpowered trials, fewer trials, or 
exhibit marked heterogeneity
86;88;89
. The latter factor was identified by the meta-analysis in 
Chapter 3 which demonstrated a statistically significant pooled result if the study population 
were divided into high or low risk of preterm delivery
43
. Methods for assessment of 
methodological quality by systematic reviews are still in their infancy, but there is likely to be 
substantial room for improvement
86
. When interpreting meta-analysis, careful consideration 
should be given to the relevance, quality and robustness of the individual primary study in 
addition to the methodology used by the systematic review
90
. 
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Ensure that clinical guidelines and their utilisation adds value to clinical practice 
There is a concerted development to expand the programme of guideline development though 
professional medical bodies (such as RCOG) and national policy drivers (principally National 
Institute of Clinical Excellence, UK) to fulfil the remit of delivering excellence in clinical 
care. However, clinical guidelines are not necessarily transferable to current clinical 
practice
91;92. Guidelines are mainly based on data derived from the ―perfect‖ population and 
health care resource setting because of the weighting it affords to RCTs. In contrast, the 
actual clinical population and environment tends to be heterogeneous and ―imperfect‖. 
Furthermore, such evidence-based health care policy will be practiced in a mainly non-
evidence-based health care system.  
Importantly, there is a dearth of evidence that has conclusively shown that the introduction of 
clinical guidelines has actually improved clinical practice
93;94
.  This research is vitally 
important, as it not only justifies continuing with the guideline but also provides feedback to 
guideline developers to enable improvements to content to maintain guideline validity, 
applicability and overall effectiveness
95;96
. A national audit represents the best study design 
for evaluation and feedback of clinical guideline-led practice; examples of such audits are the 
long-established perinatal and maternal mortality reports produced by CEMACH 
(Confidential Enquiry into Maternal and Child Health, www.cemach.org.uk ). Alternatively, 
instead of establishing numerous discrete national audits, data on multiple health outcomes 
could be retrieved and processed from the proposed national electronic linked patient records 
system
83
. Again, the problem lies in creating a national coordinating audit body that could 
validate the effectiveness of guidelines, perhaps allied to the professional medical colleges. 
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